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Ref.no Title
 Biomarkers and Imaging
001 A metagenomics study of the elbow of psoriasis subjects and their healthy relatives
 Clinical phenotypes
002 Nail disorders in patients with Psoriasis vulgaris
003 Psoriasis hidden in Gottron’s papules
 Comorbidities
004 Characteristics of psoriasis in obese patients versus non-obese patients; a multicenter study
005 Psoriasis and comorbidity
006 Risk of periodontal disease in patients with chronic plaque psoriasis
007 Splenomegaly and Psoriasis - A case report
008 Psoriasis as predictor for cardiovascular and metabolic comorbidity in middle-aged women
009 A Case of Concurrent Psoriasis and Vitiligo
010 Successful long-term double disease control by adalimumab in a patient with psoriasis vulgaris and hidradenitis suppurativa
011 Clinical and epidemiological caracterization of psoriasis and psoriatic arthritis on a multidisciplinary assesment model.
012 Alcohol and Psoriasis- a Prospective Swedish Study
013 ¨Psoriasis and Cancer. Retrospective study in the Psoriasis sector of the Dermatology Service at Ramos Mejia Hospital¨
014 Hematological disorders in the patient with psoriatic arthritis treated with methotrexate and tumor necrosis alpha (TNFalpha) inhibitor
015 The relationship between psoriasis, comorbidities, and depression onset: A nationwide observational control study
 Current and new therapeutic modalities
016	 Efficacy	of	Adalimumab	plus	Methotrexate	in	Patients	with	Moderate	to	Severe	Plaque	Psoriasis
018 Attainment of remission and minimal disease activity after starting methotrexate subcutaneous therap
019 Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
020 Ixekizumab improves impact of genital psoriasis on sexual activity: Results from a Phase 3b study
021 Dose optimization of Secukinumab in subjects with moderate to severe plaque psoriasis: OPTIMISE study
022 Inhibition of anti-TNF-alpha cytokine in the treatment of psoriasis and the analysis of infectious complications
023 Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis in Scandinavia
024 First Patient-Reported Insights From a Multinational, Retrospective, Cross-Sectional Study of Real-World Experience of Psoriasis Patients 
Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE)
025 Physician- and Patient-Reported Outcomes With Apremilast for Patients With Plaque Psoriasis During Routine Dermatology Care in 
Germany: A Second Interim Analysis
026 Improvements in Work Productivity With Up to 104 Weeks of Apremilast Monotherapy: Results From a Phase 3b, Randomized, Controlled 
Study in Biologic-Naive Subjects With Active Psoriatic Arthritis
027 Examining Disease Severity and Symptom Improvement With Patient and Physician Assessments: Results From a Phase IV Analysis of 
Apremilast in Patients With Moderate Plaque Psoriasis
028 Hemoglobin A1c and Weight Changes With Apremilast in Patients With Psoriasis and Psoriatic Arthritis: Pooled Laboratory Analysis of 
the Phase 3 ESTEEM and PALACE Trials
029 Canadian Humira Post-Marketing Observational Epidemiological Study Assessing the Effectiveness of Adalimumab vs Non-Biologic 
DMARDs in Psoriatic Arthritis (Complete-PsA): 12-Month Effectiveness Data
030	 Secukinumab	Efficacy	in	Patients	with	Active	Psoriatic	Arthritis:	Meta-analysis	of	4	Phase	3	Trials
031 Impact of adalimumab vs. non-biologic treatments on skin outcomes of psoriatic arthritis patients: real-world data from the COMPLETE Study
032 Ixekizumab Improves Nail and Skin Psoriasis through 52 Weeks of Treatment in Patients with Active Psoriatic Arthritis: Results from Two 
Randomized, Double-Blind, Phase 3, Clinical Trials (SPIRIT-P1 and SPIRIT-P2)
034 Ixekizumab Makes Therapeutic Thresholds Possible in Active Psoriatic Arthritis Patients: Results from SPIRIT Trials
035	 The	macrophage	modulator	MP1032	shows	safety	and	efficacy	in	a	human	phase	IIa	study	for	the	treatment	of	moderate-to-severe	plaque	
psoriasis
036 Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: Results from a Phase 3 Study, FUTURE 5
037	 Incidence	of	Inflammatory	Bowel	Disease	In	Patients	Treated	With	Secukinumab:	Pooled	Analysis	of	21	Randomised	Controlled	Phase	
3/4 Clinical Trials of Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
038 Analysis of the position of the fumaric acid esters in current European psoriasis guidelines
039 Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies, 
FUTURE 2 and FUTURE 3
041 Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated 
Analysis in 29,987 Patients Representing 56,951 Patient-years
042 Clinical response after guselkumab treatment among adalimumab PASI 90 non- responders: Results from the VOYAGE 1 and 2 trials
043 Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 
2 trials
044 Impact of Clinical Specialty Setting on Disease Management in Patients with Psoriatic Arthritis
045 Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24 
from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials
046 Safety of Certolizumab Pegol over 48 Weeks in Chronic Plaque Psoriasis Phase 3 Trials
047 Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis 
(DAPSA): 2-year Results from a Phase 3 Study
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048 Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis
049	 Long-term	efficacy	of	guselkumab	treatment	after	drug	withdrawal	and	retreatment	in	patients	with	moderate-severe	plaque	psoriasis:	
results from VOYAGE 2
050 Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab
051	 Efficacy	and	Safety	of	Ixekizumab	in	Patients	with	Active	Psoriatic	Arthritis:	Three	Year	Results	from	a	Phase	3	Study	(SPIRIT-P1)
052 Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis
053 Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
054	 Relationships	Between	Tildrakizumab	Dose,	Exposure,	Efficacy	and	Safety	in	Psoriasis	Phase	3	Studies
055	 Long-Term	Safety	and	Efficacy	of	Adalimumab	from	the	Phase	3	Randomized,	Placebo-Controlled	Trial	in	Patients	with	Nail	and	Skin	
Psoriasis
056 Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis
057 Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials
058	 Primary	Efficacy	and	Safety	of	Adalimumab	in	Nail	Psoriasis	From	the	First	26	Weeks	of	a	Phase-3,	Randomized,	Placebo-Controlled	
Trial With Subanalysis in Patients With and Without Psoriatic Arthritis
059 Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups
060 Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort
061 Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis
062	 Efficacy	and	Safety	of	Risankizumab:	Results	from	Two	Double-Blind,	Placebo-	and	Ustekinumab-Controlled,	Phase	3	Trials	in	Moderate-
to-Severe Plaque Psoriasis
063	 Efficacy	and	safety	of	guselkumab	administered	with	a	novel	self-injection	device	for	the	treatment	of	moderate-to-severe	psoriasis:	Results	
from the Phase III ORION self-dose study through Week 16
064	 Efficacy	of	Tildrakizumab	in	Etanercept	Partial	Responders	or	Nonresponders
065	 Efficacy	of	Tildrakizumab	in	Moderate	to	Severe	Psoriasis	Patients	With	Prior	Exposure	to	Apremilast
066	 Risankizumab	Efficacy/Safety	in	Moderate-to-Severe	Plaque	Psoriasis:	16-Week	Results	from	IMMhance
067	 Disease	Severity	and	Efficacy	Insights:	Patient-Level	PASI	Scores	in	Tildrakizumab	Psoriasis	Trials
068	 Sustained	and	Improved	Efficacy	of	Tildrakizumab	from	Week	28	to	Week	52	in	Treating	Moderate-to-Severe	Plaque	Psoriasis
070 Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab
071 Statistic review of psoriasis systematic therapies in North Greece
073 Pharmakovigilance of systemic antipsoritic drugs: an update from routine care
074 The Impact of Patient Requests on Psoriatic Arthritis Treatment
 Epidemiology
075 The Risk Of KC In Psoriasis Patients Receiving Biologics Compared To Conventional Systemic Therapies
076 Patient perceptions of psoriasis severity in Sweden, Norway, and Denmark
077 Patient expectations and satisfaction in psoriasis treatment: A survey from Europe and Canada
078 Socioeconomic determinants of paediatric psoriasis
079 Obesity and the risk of psoriasis: A Korean nationwide, population-based study
080 Clinical characterization of Psoriatic Arthritis in a multidisciplinary care model of patients with Psoriasis
081 Triggering factors in childhood psoriasis
082 Quality of care for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany
083 Global Psoriasis Atlas – Work Stream 2
084 Global Burden of Disease: A Systematic Literature Review on Disability Weights for Skin Diseases
 Genetics
085 MIR-499 polymorphism is associated with susceptibility to psoriatic arthritis – preliminary study
086	 Association	between	inflammasome-related	polymorphisms	and	clinical	phenotypes	of	Psoriatic	arthritis
 Health Economics and Health Policies
088 Frequency of Inadequate Response to Treatment among Psoriasis Patients on First-Line Biologics
089 Barriers of guideline-compliant care for psoriasis in Germany – Results of the European study PsoBarrier
 Interesting Clinical Cases
090 Individualised Therapy for Psoriasis - Case series
091 A Unique Clinical Case of Psoriatic Arthritis and Relapsing Polychondritis
092 Spiny follicular hyperkeratosis in a psoriasis patient treated with ustekinumab
093 Combination therapy of apremilast and biological product in a patient with psoriasis.
094 Psoriasis worst-case scenarios: A series of 3 case reports
095	 Successful	switching	to	biosimilar	in	psoriatic	patient	with	severe	drug	reaction	to	infliximab.	A	case	report
096 Safety of Apremilast in the treatment of a psoriasis patient with chronic Hepatitis B
 Pathophysiology and immunobiology
098 IL-22 induces keratinocytes hyperproliferation in psoriasis via miR-21 and miR-31 upregulation
099 Serum concentracion of IFN-gamma in patients with psoriasis: correlation with clinical type and severity of disease
100 Immunological memory exists in the recurrent lesion and nonrecurrent skin after remission in psoriatic patients
101	 Investigating	systemic	inflammation	as	the	common	link	between	depression,	Psoriasis,	and	Psoriatic	arthritis	in	US	Veterans.
102 The Immune-phenotype of Small Plaque Psoriasis
4www.medicaljournals.se/acta
5th World Psoriasis & Psoriatic Arthritis Conference 2018
104 Serum Glucocorticoid-inducible Kinase-1(SGK1) Levels in Patients with Psoriatic Arthritis
105 Differential NH2-terminal autoantigen trimming may explain epistasis between HLA-C*06:02 and ERAP1 variants in psoriasis risk
106 Environmental triggers of an HLA-C*06:02-restricted autoimmune response in psoriasis
107 A skewed pool of resident T cells triggers disease-associated tissue responses in never- lesional psoriasis
 Psoriasis and Psoriatic Arthritis relationship
108 Nail involvement in psoriasis; is it a predictor of psoriatic arthritis?
109 Absolute and relative PASI improvements with ixekizumab treatment: Results at Week 12 from IXORA-P
110 Prevalence and sex differences of psoriatic arthritis in patients with severe plaque psoriasis.
111 Skin Lesion Severity In Early Axial and Peripheral Psoriatic Arthritis Patients
112 Gastrointestinal symptoms are common in U.S. patients with moderate-severe psoriasis
113 Secukinumab’s Long-Term Safety Remains Favorable up to 5 Years of Treatment
114 Impact of Improvement in Skin and Joint on Quality of Life in Active Psoriatic Arthritis Patients
115	 Secukinumab	Shows	High	and	Sustained	Efficacy	in	Subjects	with	Moderate	to	Severe	Palmoplantar	Psoriasis:	2.5-Year	Results	From	the	
GESTURE Study
116	 Secukinumab	Shows	High	and	Sustained	Efficacy	in	Nail	Psoriasis:	2.5-Year	TRANSFIGURE	Study	Results
117 The obesity and prevalence psoriatic arthritis in patients with plaque psoriasis: dermatological real-setting data.
118 Diagnosis of Psoriatic Arthritis in Patients with Moderate to Severe Chronic Plaque Psoriasis Treated with Secukinumab vs. Other Treat-
ments in the PURE Registry: Indication of Selection Preferences and Underdiagnosis
119	 Efficacy	and	Safety	Results	of	Guselkumab	in	Patients	with	Active	Psoriatic	Arthritis	over	56	Weeks
120	 Tildrakizumab	efficacy	over	time	by	week	28	response	levels	in	two	Phase	3	clinical	trials	in	patients	with	chronic	plaque	psoriasis
122 Potential Disconnect: Co-Management of Patients with Psoriatic Arthritis Between Rheumatologists and Dermatologists
123 The Use of Tumor Necrosis Factor Inhibitors (TNF) in the Second-Line Biologic/Small Molecule Setting: A Cross-Specialty Comparison
124 Impact of Guselkumab versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in 
VOYAGE 2
 Quality of Life
125 The Dermatology Life Quality Index in Russian patients with psoriasis and psoriatic arthritis.
126 Effects of mindfulness-based cognitive therapy on self-reported psoriasis and psychological symptoms
127 A mixed methods study exploring the impact of mindfulness on psoriasis, anxiety, depression and QoL
128 A link between quality of patient-physician communication and patient healthcare needs in PsA
129 Psoriasis Patients Point of View: What bare we Missing when Managing Them?
130 The impact of psoriasis and psoriatic arthritis on quality of life and career in Scandinavia
131 Quality of life of patients with psoriasis in Khartoum dermatology hospital, December 2017
132	 Mirikizumab	Significantly	Improves	Self-Reported	Disease	Severity	and	General	Health	Status	in	Patients	with	Moderate-to-Severe	Pso-
riasis
133 Effect of Tildrakizumab on Personal Relationships in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
134 Pruritus severity assessment and correlation with baseline characteristics of patients with psoriasis vulgaris: an exploratory analysis of the 
Phase IIIb, PSORITUS study
135 Quality of life and psychosocial implications in patients with psoriasis
136 Swedish psoriatic patients’ perspective of their disease. Results from an observational patient survey.
137	 Ixekizumab	Provides	Greater	Cumulative	Benefits	versus	Ustekinumab	over	24	Weeks	for	Patients	with	Moderate-to-Severe	Psoriasis	in	
a Randomized, Double-Blind Phase 3b Clinical Trial
138 Coach@Home: A Support Program for Patients Treated With Certolizumab Pegol
139 A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis
140 The Psychosocial Impact of Psoriasis: Differential Experiences of Men and Women in Early Adulthood
141 Certolizumab Pegol Improves Patient-Reported Outcomes in Chronic Plaque Psoriasis Over 1 Year
142 Translating WHO resolution into the public: the German program against stigmatization of people with chronic visible skin diseases
143 The Global Research on the Impact of Dermatological Diseases (GRIDD)
 Young scientists (born on or after January 1, 1983)
144 Treatment of Nail Psoriasis with Different Pulse Durations of Pulsed Dye Laser
145	 Neutropenia	in	a	psoriasis	patient:	Secukinumab	or	micronutrient	deficiency?
146	 Establishment	of	a	Psoriatic	Skin	Model	for	α-Irradiation
147 The History of Psoriasis
148 Comorbidities and treatments in patients with inverse psoriasis
 Late Breakers
150 Development of the “PsO Sleepy-Q” and the “PsA Sleepy-Q”: two questionnaires to characterize sleep in patients with psoriatic disease
151 Unstable forms of psoriasis – indicator of an intermediate state of systemic disease
152 Could biological agents foster suicide through its potential antidepressant mechanism? A Psychodermatological approach. 
153 Treating the pain, not the problem? Results from a Swedish online survey on psoriatic arthritis and psoriasis with joint pain.
154	 An	International	Delphi	survey	to	define	screening	for	psoriatic	arthritis	and	measurement	of	psoriatic	arthritis	symptoms	in	psoriasis	
clinical trials
155 The impact of a diagnosis on the patients’ perception of treatment and care. Results from an online survey on psoriatic arthritis and psoriasis 
with joint pain.
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P001
A METAGENOMICS STUDY OF THE ELBOW OF PSORIA­
SIS SUBJECTS AND THEIR HEALTHY RELATIVES
Hailun Wang1, Michael Ni1, Japio Fung1, Kang Yan1, Xiaoxin Yao1, 
Yinpeng Wang1, Martin Kriegel2, Henry Chan1, Herbert Pang1
1The University of Hong Kong, and 2Yale University
Introduction: Psoriasis is a multifaceted immune-mediated skin 
disease and has been associated with other comorbidities. Previous 
studies in psoriasis reported the abundance of microbial taxa above 
the species rank (family Firmicutes and genus Staphylococcus), 
or the combined abundance of multiple taxa (Corynebacterium, 
Propionibacterium, Staphylococcus, and Streptococcus) were 
associated with psoriasis [1–3]. Characterizing the skin micro-
biome of psoriasis subjects and family controls can further our 
understanding of microbiota’s role in this disease.
Objectives: This study aims to reveal the difference of skin mi-
crobiome between skin lesion area and normal area of the elbow 
as well as family controls. 
Methods: DNA samples was extracted from 21 elbow-skin. 14 of 
21 were from 7 psoriasis subjects’ lesion side and normal side. 
The rest were from a healthy family member whom the subject 
lives with. Shotgun metagenomic sequencing was adapted to 
resolute the skin microbiota. Partially overlapping t-test was used 
to investigate differentially abundant taxa. PERMANOVA was 
used to test the difference of microbial community composition 
influenced	by	psoriasis	and	sampling	families.
Results: Bacteria phyla Proteobacteria, Actinobacteria, and Bac-
teroidetes were three most abundant microbial taxa in both lesion 
and normal skin. Bacteria phyla Cyanobacteria and Candidatus 
Parcubacteria, family Hymenobacteraceae were less abundant 
on lesion skin than normal skin (p < 0.05). Sampling families 
had	significantly	different	elbow-skin	microbial	composition	for	
bacterial	genus	level	profile	(p = 0.001).
Conclusions: Several bacterial taxa different from those previously 
discovered are more abundant on normal skin than lesion skin in 
the elbow.
References:
[1] Unexplored diversity and strain-level structure of the skin microbiome 
associated	with	psoriasis.	NPJ	Biofilms	Microbiomes.	3,14	(2017).
[2] Statnikov, A. et al. Microbiomic signatures of psoriasis: feasibility and 
methodology comparison. Sci. Rep. 3, 2620 (2013).
[3] Alekseyenko, A. V. et al. Community differentiation of the cutaneous 
microbiota in psoriasis. Microbiome. 1, 31 (2013).
P002
NAIL DISORDERS IN PATIENTS WITH PSORIASIS 
VULGARIS
Jasmina Muhovic
University Clinical Centre Sarajevo
Introduction: Psoriasis	vulgaris	is	a	chronic	inflammatory	skin	
disease characterized by T-cell-mediated hyperpfoliferation of 
keratinocytes in the skin. Approximately, 10–78% of patients 
with psoriasis have concurrent nail psoriasis while isolated nail 
involvement is seen in 5–10% of patients. Affected nail plates often 
thicken and crumble and because they are very visible patients 
tend to avoid normal day-to-day activities and social interactions. 
Importantly, 70–80% of patients with psoriatic arthritis have nail 
psoriasis. In this overview, we review the clinical manifestations 
of psoriasis affecting the nails.
Objectives: To correlate frequency of certain nail dissorders 
in patients with psoriasis vulgaris. The observed dissorders 
were:onicholysis, subungual hyperkeratosis, oil spots, and pitting 
in both male and female patients aged 15–75 and combined with 
psoriatic arthritis. 
Methods: A total of 60 patients who were treated in our Inpatients 
Service with diagnosis of Psoriasis vulgaris from January 2017 
to July 2017 at Dermatology Department, University Clinical of 
Sarajevo.We	searched	for	specific	nail	dissorders.	
Results: A total number of 60 patients with Psoriasis vulgaris, 
both male and female aged 15–75 werw examined. Out of that 
number,	43	patients	reported	to	have	specific	nail	dissorders	and/
or psoriatic arthritis, and 17 of them were without any nail diss-
orders or psoriatic arthritis. Among the number of 43 examined 
psoriatis patients with nail dissorders, there were 23 female and 
20 male patients, all of them aged between 45–60. Seven female 
and eight male patients had previously diagnosed psoriatic arthritis 
combined with psoriasis and nail disorders, while the rest of them, 
28 patients, only had psoriasis followed by progressive changes 
on their nails, but without any signs of psoriatic arthritis. The 
presented nail dissorders in all patients included in these two 
groups were: subungual hyperkeratosis, onicolysis and pitting 
all combined in 14 patients, only subungual hyperkeratosis in 10 
patients, pitting in 7 patients, 7 of them showed only onycholysis 
on both hands and 6 patients had oil spotting and pitting together. 
In patients without psoriatic arthritis the prevalence of dissorders 
in all affected groups was in male patients. 
Conclusion: Nail psoriasis engenders both physical and psycho-
logical	handicap,	leading	to	significant	negative	repercussions	in	
the quolity of life. The presence of nail disease in a patient with 
psoriasis may indicate a severe form of the disease and must be 
taken into account when selecting a treatment otion, with an aim to 
reduce pain, functional impairment as well as emotional distress.
P003
PSORIASIS HIDDEN IN GOTTRON’S PAPULES
Florentina Berianu, Juan J. Maya
Mayo Clinic Florida
Introduction: Patients with Dermatomyositis (DM) present with 
rashes in a photosensitive distribution and occasionally a scaly 
rash over elbows, knees and scalp can resemble psoriasis. The 
biopsy of such lesions shows interface dermatitis which is highly 
distinguishing for DM. In rare occasions, patients can suffer 
from both DM and psoriasis (Ps). Objectives: To report a case of 
Dermatomyositis and Psoriatic arthritis 
Method: 45 years old female presented with a red, itchy rash with 
diffuse swelling over the entire body associated with swallowing 
difficulties	and	weakness	affecting	mainly	the	proximal	muscles	
of upper and lower extremities. She has pain and stiffness in her 
hands	and	feet.	DM	was	confirmed	based	on	specific	findings	on	
skin biopsy, EMG with myopathic features and a muscle biopsy 
that	confirmed	the	myopathy.	Patient	had	insulin	dependent	dia-
betes and IVIG was the initial choice of therapy to avoid steroid 
use. Patient responded excellent in regards to generalized rash 
and had reported improvement in regards to proximal muscle 
weakness	and	swallowing	difficulties	but	she	had	persistence	of	
the scaly rash over elbows, knees and developed what resembled 
dactylitis	along	with	worsened	asymmetric	inflammatory	arthritis	
of ankle, hand and feet joints. Based on her presentation, Ps and 
psoriatic arthritis (PsA) were diagnosed. Methotrexate was added 
and	patient	had	improved	in	skin	psoriasis	along	with	inflammatory	
arthritis. Results: Ps and PsA were associated with DM in this 
patient. These are distinct diseases that have parallel courses and 
require different therapeutic approaches. 
Conclusion: Ps has been reported in association with Connective 
Tissue Diseases. Gotron’s papules can resemble Ps in patients 
with DM but rare case reports have described concomitant DM 
and Ps. The association of DM, Ps and PsA was even more rarely 
described.
References:
1. Tselios K, Yap KS, Pakchotanon R et al. Psoriasis in systemic lu-
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pus erythematosus: a single-center experience. Clin Rheumatol. 2017 
Apr;36(4):879-884.
2. Inkeles MS, No D, Wu JJ. Clinical improvement of a patient with both 
amyopathic dermatomyositis and psoriasis following treatment with 
cyclosporine. Dermatol Online J. 2017 Aug 15;23(8)
3. Kato Y, Yamamoto T . Development of psoriasis with relapse of 
dermatomyositis-associated interstitial lung disease. Int J Rheum Dis. 
2017 May;20(5):660-661.
4. Ueno T, Kanzaki A et al. Association of psoriasis with Hashimoto’s 
thyroiditis, Sjögren’s syndrome and dermatomyositis. J Dermatol. 2016 
Jun;43(6):711-2.
P004
CHARACTERISTICS OF PSORIASIS IN OBESE 
PATIENTS VERSUS NON­OBESE PATIENTS; A 
MULTICENTER STUDY
Omid Zargari1, Seyyede Zeinab Azimi2, Tara Barat1, Vahideh La-
jevardi3, Ehsan Kazemnejad4, Mohamad Shahidi Dadras1
1Department of Dermatology, Skin Research Center, Shahid Beheshti Uni-
versity of Medical Sciences, Tehran, 2Department of Dermatology and 4De-
partment of Biostatistics, Guilan University of Medical Sciences, Rasht, 
and 3Department of Dermatology, Tehran University of Medical Sciences, 
Tehran, Iran
Introduction:	Psoriasis	is	a	common	chronic	inflammatory	skin	
disease,	which	is	gradually	being	recognized	as	a	systemic	inflam-
matory disorder. Psoriasis and obesity are strongly linked, but 
there is not enough data whether obese psoriatic patients present 
differently from non-obese psoriatic patients.
Objective: To compare the phenotype, clinical features, severity, 
baseline	comorbidities	and	laboratory	findings	among	psoriatic	
patients with/without obesity.
Methods: All the psoriatic patients, from three centers, who were 
receiving systemic therapy were included in the study. Patients 
were divided into two groups: those with obesity and those with-
out obesity.
Results: We included 497 patients: 154 (31%) patients were obese 
and 343 (69%) were non-obese. Obese patients had more comorbi-
dities, particularly hyperlipidemia, followed by hypertension and 
diabetes.	Fasting	blood	sugar	and	serum	lipids	were	significantly	
higher among obese subjects. 
Conclusions: Given the differences between obese patients and 
non-obese patients, the former group should be followed and 
managed	more	closely	and	with	specific	attention.
References:
1. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ et al. National 
Psoriasis Foundation clinical consensus on psoriasis comorbidities and re-
commendations for screening. J Am Acad Dermatol. 2008; 58(6):1031-42.
2. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence 
of the metabolic syndrome in psoriasis: results from the National Health 
and Nutrition Examination Survey, 2003–2006. Arch Dermatol. 2011; 
147(4):419-24
P005
PSORIASIS AND COMORBIDITY
Veranika Liubiankova, Sviatlana Makarava
Mogilev Regional Centre of Dermatology and Venerology
Introduction. In recent years special attention has been paid not 
only to the systemic nature of the process in psoriasis, but also 
to its association with comorbidities. Comorbidity is a regular 
combination of various diseases or conditions in one patient, it 
occurs	in	many	inflammatory	processes.
Objectives: The study of the incidence of concomitant diseases in 
patients with psoriasis in relation to patients with allergic contact 
dermatitis, analysis by age group.
Methods: A retrospective analysis of data of 804 patients, who 
were treated in 2016–2017 in Mogilev Regional Dermatology and 
Venerology Centre with different forms of psoriasis, was conduc-
ted. 492 males, 312 females. The mean age was 43.05 years. The 
control group consisted of patients with allergic contact dermatitis, 
comparable in age and sex, in an amount of 397 people.
Results: Specific	gravity	and	incidence	of	comorbidity	in	patients	
with psoriasis: cardiovascular damage 41% (331), gastrointestinal 
tract - 30.4% (245), endocrine system - 22.7% (183), metabolic 
syndrome - 28.2% (227), chronic otorhinolaryngological diseases 
- 11.4% (92), diseases of urinary system - 6.2% (50), respiratory 
system	-	4.7%	(38).	Significant	differences	between	the	groups	
were obtained for all the comorbidity except respiratory diseases. 
Psoriatic polyarthritis were observed in 219 patients (27.3%), nail 
psoriasis – in 117 patients (14.6%). The average body mass index 
in the psoriasis group was 27.2, in the allergic contact dermatitis 
group	 -	 25.3.	Significant	 differences	between	 the	 groups	were	
obtained for all the laboratory test changes except the general 
bilirubin, C-reactive protein and urinalysis. The percentage of di-
seases changed with increasing age: diseases of the cardiovascular 
system from 10% to 87%, gastrointestinal diseases from 20% to 
61%, endocrine system diseases - from 14.5% to 38%, metabolic 
syndrome - from 11% to 34%, otorhinolaryngological diseases - 
from 15% to 8.5%, diseases of the urinary system - from 1.8% to 
8.5%, respiratory system diseases – from 1.8% to 13%.
Conclusions: The analysis showed that in patients with psoriasis 
the most frequent comorbidity are: cardiovascular and gastroin-
testinal diseases, endocrine disorders, polyarthritis, nail psoriasis 
and metabolic syndrome. A rather high risk of comorbidity is 
established, in comparison with the population, which can directly 
affects the severity of the course of the disease, the effectiveness 
of the therapy and life expectancy.
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RISK OF PERIODONTAL DISEASE IN PATIENTS WITH 
CHRONIC PLAQUE PSORIASIS
Veronica Lopez Castillo, Inmaculada Lopez Castillo, Pedro Rodri-
guez, Jose Maria Ricart Vaya
Introduction: Psoriasis	 is	 a	 common,	 chronic,	 inflammatory,	
multisystem disease affecting approximately 2% of population. It 
has been associated with certain diseases and there is a strong link 
between metabolic syndrome and psoriasis. Chronic periodontitis 
is	an	infectious	disease	resulting	in	inflammation	within	the	sup-
porting tissues of the teeth, progressive attachment loss, and bone 
resorption and clinically characterized by pocket formation and/
or gingival recession. Psoriasis and chronic periodontitis share 
common risk factors and co-morbidities.
Objective: The aim of our study was to determine how frequently 
chronic periodontitis is associated with patients with psoriasis 
compared to systemic healthy subjects and if its presence is as-
sociated to severity of psoriatic lesions.
Methods: Baseline demographic data including sex, age, smoking 
habits, family history of psoriasis or periodontal disease was 
recorded in 40 psoriasis subjects and 40 healthy subjects. Infor-
mation on comorbidities and pharmacological treatment, daily 
tooth brushing, the presence of gingival bleeding, location of skin 
lesions, weight and height were also evaluated. The periodontal 
clinical parameters probing depth, periodontal attachment level, 
plaque index and presence or absence of radiographic bone loss 
were recorded. The severity of psoriasis was assessed by Psoriasis 
Area and Severity Index. A complete blood test was asked for all 
subjects included in the study.
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Results: During the study enrolment period 40 patients with 
psoriasis and 40 age- and gender-matched controls were included 
in this study. Probing depth and periodontal attachment level 
showed	significant	higher	values	in	psoriasis	group	compared	to	
healthy subjects.
Conclusions: We found evidence of a psoriasis-associated in-
creased risk of periodontitis. Thus, dermatologists should be 
aware of this comorbidity because these patients should be closely 
followed-up by a dentist for the adequate and early treatment of 
periodontitis. Periodontitis may be associated with psoriasis but 
further studies are needed to elucidate their relationship.
References:
1. Egeberg A, Mallbris L, Gislason G et al. Risk of periodontitis in patients 
with psoriasis and psoriatic arthritis. JEADV 2017, 31: 288-293.
2. Ungprasert P, Wijampreecha K, Wetter DA. Periodontitis and risk of pso-
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SPLENOMEGALY AND PSORIASIS ­ A CASE REPORT
Suzana Ozanic Bulic
Department of Dermatovenerology, KBC Sestre milosrdnice, Zagreb, 
Croatia
Psoriasis	is	a	chronic,	systemic,	inflammatory	disease	associated	
with numerous comorbidities that have been well documented in 
the literature. Comorbidities often become clinically evident years 
after the onset of psoriasis and are related to persistent low-grade 
inflammation	with	 secretion	 of	 proinflamamtory	 cytokines,	 as	
seen in metabolic syndrome(1). Nevertheless, the evidence shows 
new emerging comorbidities that share link with psoriasis. Hjuler 
et	al.	observed	 increased	splenic	 inflammation	 in	patients	with	
moderate-to-severe psoriasis (2). They also showed that splenic 
activity	was	correlating	with	aortic	wall	inflammation	in	psoriasis	
patients, explaining the increased risk of heart disease (2).
A 56-year old patient with chronic plaque psoriasis (Fig 1) for 
more than thirty years, presented with splenomegaly, diabetes 
type two, arterial hypertension, chronic kidney disease stage III, 
obesity, with BMI  > 40,	and	depression.	Psoriasis	severely	flared	
up in 2012, and on workup up for cataract operation, enlarged 
lymph	nodes	were	observed	and	further	confirmed	on	CT	scans	in	
axillae, inguinum, mediastinum and upper abdomen. Patient was 
hospitalized at haematology department and reactive lymphade-
nopathy	due	to	skin	inflammation	was	diagnosed.	Acitretin	was	
started and stopped after a week for worsening of pancytopenia, 
and Methotrexate was stopped after two weeks for triple increase 
in liver enzymes, although the dose was of only 5 mg weekly. In 
August 2017, repeated blood tests were normal and abdominal 
US showed no progression in hepato-splenomegaly, with spleen 
measuring 23 cm. Psoriasis was severe, with PASI 36, BSA 31% 
and DLQI 19. Ustekinumab 90 mg was started in October 2017 
with PASI75 achieved after 12 weeks of treatment. Patient has 
been closely monitored with no haematological side-effects on 
last assessment.
Significant	splenomegaly	and	lymphadenopathy	with	no	underly-
ing haematological disease has not been described as a comorbidity 
of psoriasis. The treatment with biologics was delayed in our 
patient as underlying haematological malignancy was suspected. 
The	untreated	severe	psoriasis	flared	up	in	the	mean	time	the	whole	
spectrum of comorbidities, led by depression. Ustekinumab has 
significantly	improved	his	psoriasis	(Fig	2),	with	improvement	in	
depression that was best observed in patient’s motivation to lose 
weight and be referred for gastric bypass.
Effective control of psoriasis and associated conditions requires not 
only appropriate treatment, but also management of comorbidities, 
including screening and treatment by various specialists, as disease 
is known for its cumulative impairment over patient’s lifetime (3).
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PSORIASIS AS PREDICTOR FOR CARDIOVASCULAR 
AND METABOLIC COMORBIDITY IN MIDDLE­AGED 
WOMEN
Christoffer Blegvad1, Anne-Marie Nybo Andersen2, Abdulfatah 
Adam2, Claus Zachariae1, Lone Skov1
1Copenhagen Research Group for Inflammatory Skin (CORGIS), Depart-
ment of Dermatology and Allergy, Herlev and Gentofte Hospital, Univer-
sity of Copenhagen, Copenhagen, 2Section of Epidemiology, Department of 
Public Health, University of Copenhagen, Denmark
Introduction: Cardiovascular and metabolic comorbidities such as 
ischemic heart disease and diabetes are known to be associated 
with psoriasis. However, it is less clear whether this is due to com-
mon life-style related risk factors such as overweight and smoking.
Objectives: We wished to investigate the association between 
psoriasis and cardiovascular and metabolic comorbidity in a cohort 
of middle-aged women, and at the same time taking the effect of 
body mass index (BMI) and smoking into account.
Methods: The study population consisted of expectant mothers 
in a large nationwide birth cohort established between 1996 and 
2002. During pregnancy, the women were asked whether they 
have ever had any skin diseases including psoriasis, and whether 
the disease was diagnosed by a physician. The relation to self-
reported cardiovascular and metabolic comorbidity 11 years 
after giving birth was assessed by multiple logistic regression. 
Furthermore, we performed an analysis where the cohort was 
followed up for hospital-diagnosed comorbidity including cardiac 
death until 31st December 2014. Here the risk was assessed by 
Cox proportional hazards regression. All analyses were adjusted 
for age, pre-pregnant BMI, and smoking status collected at time 
of inclusion during pregnancy.
Results:	We	 identified	2,435	(2.90%)	women	with	a	history	of	
psoriasis and 81,388 women without psoriasis. The women with 
and without psoriasis were on average respectively 30.4 (SD 
4.5) and 29.9 (SD 4.3) years old at time of inclusion in the study. 
Women with psoriasis had slightly higher BMI and smoked mar-
kedly more than women without psoriasis (38.1% vs. 26.4%). A 
history	of	psoriasis	was	significantly	associated	with	self-reported	
hypercholesterolemia (adjusted odds ratio 1.31; 1.01–1.70) and 
hospital-diagnosed hypertension (adjusted hazard ratio 1.33; 
1.08–1.65). A positive association was also found with respectively 
hospital-diagnosed ischaemic heart disease, type 2 diabetes, and 
hypercholesterolemia,	 however,	 these	findings	were	 not	 statis-
tically	significant.	No	associations	were	found	for	self-reported	
hypertension, thrombosis, or type 2 diabetes.
Conclusions: Women with psoriasis are at increased risk of 
developing cardiovascular and metabolic comorbidity in early 
adult life. This may suggest an importance of awareness of these 
comorbidities also in younger patients with early screening for 
hypertension, hyperglycemia, and hypercholesterolemia.
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A CASE OF CONCURRENT PSORIASIS AND VITILIGO
Selma Poparic
Dermatology Department University Clinical Center of Ssrajevo
Introduction: Psoriasis and vitiligo are common dermatoses that 
affect 1~3% (psoriasis) and 0.5% (vitiligo) of the general popula-
tion, respectively. Yet the pathogenesis of the association between 
these two dermatoses is still unknown.
Case report: We report a case of a 52-year-old patient who was 
admitted to our department with a 6-month history of squamous 
papules and plaques on his right elbow region and both right and 
left lower leg. He was also noticed with hypopigmented patches 
on his right and left wrist. Anamnestic questionnaire revealed that 
his mother has had similar discolorations on her skin, but never 
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underwent any diagnostic procedure, nor treatment. Clinical and 
hystopathological diagnosis of erythematosquamous areas on the 
patients right elbow and right and left lower leg was a plaque pso-
riasis, while hypopigmented patches on his wrists were diagnosed 
as vitiligo. Blood work up and T3, fT4, TSH, ANA laboratory tests 
were within normal ranges.
Conclusion: Psoriasis and vitiligo, although seemingly unrelated 
skin disorders, have a lot in common. Causes, incidence, and even 
distribution seem to strongly correlate between these two.
P010
SUCCESSFUL LONG­TERM DOUBLE DISEASE 
CONTROL BY ADALIMUMAB IN A PATIENT WITH 
PSORIASIS VULGARIS AND HIDRADENITIS 
SUPPURATIVA
Melita Vuksic Polic1, Zlatica Jukic1, Andrea Krnic1, Renata Vuka-
din1, Ivana Patrk2
1Osijek University Hospital: Faculty of Medicine Osijek, 2Privat dermato-
venerological clinic dr Ivana Patrk, Zadar
Introduction:	Psoriasis	vulgaris	/PV/	is	a	chronic	inflammatory	
skin disease1. Studies have shown the role of genes important for 
the	transcription	of	inflammatory	citokines,	such	as	TNF	alpha	
and IL-23, which play main role in the patoghenesis of psoriasis2. 
Hidradenitis	suppurativa	 /HS/	 is	chronic	 inflammatory	skin	di-
sease3, in which pathogenesis are IL-23 and TNF alpha, supporting 
the theory of the immunologic disease4. Adalimumab is human 
monoclonal	antibody	that	has	a	great	affinity	for	the	membrane	of	
TNF alpha5. We report the case of a 44-year-old Caucasian woman 
with a history of PV and HS, both diseases are in remission during 
the therapy with adalimumab.
Case report: We report the case of a 44-year-old Caucasian woman 
with a history of PV and HS that started adalimumab therapy 3 
years	ago.	PV	started	14	years	ago	and	was	verified	by	skin	biopsy.	
Initially, the clinical course of psoriasis was mild and later she took 
course to moderate psoriasis with PASI 10. Psoriasis was treated 
only with local therapy. HS started when she was 38-years-old in 
her left groin, as swelling and pain on palpation and in movement. 
Skin changes started to develop also on the right groin and perianal 
region	as	painful	nodules,	with	pus	draining,	and	fistula	tracts.	
Skin	 biopsy	 confirmed	HS.Chest	X-ray	 and	 gastroenterology	
examination were performed to exclude any additional illnesses 
and she also did a psychologcal testing. She was treated with dif-
ferent antibiotics also prednisone and isotretinoin at a dose 1mg/
kg/day. Topical therapy was consisting of antibiotics, antiseptics 
and hydrocolloid dressings. She had 3 surgical interventions. In 
2015, she started adalimumab according to the scheme. On the 
day of the initial aplication of adalimumab, patient had 4 absces-
ses,	13	nodules	and	16	fistula	tracts.	She	had	successful	clinical	
response to the drug and is without psoriatic symptoms or HS 
active lesions. Both diseases are successfuly controled and quality 
of life has improved.
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CLINICAL AND EPIDEMIOLOGICAL 
CARACTERIZATION OF PSORIASIS AND PSORIATIC 
ARTHRITIS ON A MULTIDISCIPLINARY ASSESMENT 
MODEL
Karla Del Rocio Macias-Garcia, Dalila Alejandra Lopez Rodri-
guez
Dermatologico Country
Introduction: Presentation and clinical course in Psoriasis are 
heterogeneos. A multidisciplinary assessment model was designed 
by	five	specialties:	dermatology,	rheumatology,	internal	medicine,	
nutrition and psychiatry, to evaluate at the same time and place, 
patients with psoriasis.
Objetive: To ascertain frequency of comorbilities in psoriatic pa-
tients and conduct a clinical and epidemiological characterization.
Methods: Prospective study, from August 2016 to february 2018, 
patients attending to Multidisciplinary Clinic for psoriasis in 
Dermatologico Country were included.
Results: 53 patients were included. Median age was 42 years old 
and 62.3% were female. Family history of psoriasis was found 
in 26.4% patients and 19.4% had spodyloarthropathy family 
history. Most common comorbidities found obesity, metabolic 
syndrome, diabetes mellitus, dyslipidemia, hypertension and fatty 
liver. Affective assessment was found for 49.1% met criteria for 
anxiety. Psoriasis found 96.2% with psoriasis in skin and 56.6% 
in nails. Most common presentation of psoriasis, was plaque 
psoriasis in 66%. PASI score showed 50.9% with mild disease, 
15.1% moderate, and 34% had severe. NAPSI score was from 0 
to 61, with a median of 3 (0.13). DLQI indicated that only 13.2% 
had no condition in life quality, meanwhile 86.8% patients had 
impaired quality of life. Psoriatic arthritis, and identify 58.5% 
patients that met CASPAR criteria, axial disease was present in 
51.6%, peripheral joint disease in 71% and in 13.2% both were 
present. 54.8%(17) patients had enthesitis and 16.1% had dactilitis. 
DAS28 was performed, and showed 45.2% with severe activity. 
Total number of subjects with peripheral disease 100%, did not 
met criteria for MDA. HAQ score to assess PsA patients quality 
of life, revealed a median of 1.38 (1.10, 2.25).
Conclusions: we found that more than half of the patients presented 
a	severe	form	of	psoriasis	with	significant	quality	of	life	impair-
ment. The number of psoriatic arthritis was higher than expected 
with both axial and peripheral manifestations. We have found a 
high proportion of patients with comorbidities such as metabolic 
syndrome, diabetes mellitus, hypertension, dyslipidemia and 
obesity. We also found a high frequency of psychiatric illness. 
The limitations of our study are the small sample to highlight 
if comorbidities had an impact on the severity of skin and joint 
disease.	This	multidisciplinary	model	has	identified	psoriasis	as	
a disease with an unpredictable course, which requires several 
evaluations by a multidisciplinary model, with a group of experts 
beyond Dermatologist and Rheumatologist.
P012
ALCOHOL AND PSORIASIS­ A PROSPECTIVE SWEDISH 
STUDY
Caroline Svanström1, Sol-Britt Lonne-Rahm1, Ebru Bircan2, Knut 
Stokkeland3, Johan Franck4, Klas Nordlind5
1Department of Dermatology, Mälarsjukhuset, Eskilstuna, 2Department 
of Medicine, Solna, Dermatology and Venereology Unit, Karolinska Insti-
tutet, 3Department of Medicine, Gastroenterology and Hepatology Unit, 
Karolinska Institutet, 4Department of Clinical Neuroscience, Division of 
Psychiatry, Karolinska Institutet, Stockholm, and Department of Medicine, 
Visby Hospital, Visby, 5Department of Medicine, Solna, Dermatology and 
Venereology Unit, Karolinska Institutet, Stockholm, Sweden
Background: We have earlier in a limited cross-sectional study 
shown a correlation in females for alcohol consumption and extent 
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of psoriasis. There are few prospective studies on the relation of 
alcohol with the extent of psoriasis.
Objectives: The purpose of this prospective study was to further 
investigate how alcohol affects psoriasis in female patients.
Methods: Twenty-two female psoriasis patients with light to 
moderate psoriasis, with only local treatment and with a regular 
alcohol intake, were recruited. The study was run for three years, 
starting in 2014. We used Christmas and New Year, as intervention 
period, when the amount of alcohol is expected to exceed normal 
consumption. The total study period was 8 weeks. During the study 
period,	the	alcohol	intake	was	measured	by	the	patients	filling	a	
calendar, specifying the alcohol intake per day, moreover, the de-
gree of severity of psoriasis, degree of pruritus, and of perceived 
stress, using a visual analog scale. In addition, the patients once a 
week determined Self-Administered Psoriasis Area and Severity 
Index (SAPASI).
Results: The alcohol intake, which was generally low to moderate, 
increased during Christmas and New Year, reaching its maximum 
during week 52 (Christmas week). There was a marginal increase 
in the extent of psoriasis, determined by SAPASI, during week 52. 
There was no correlation with alcohol intake nor pruritus. The level 
of perceived stress decreased shortly after week 52, and reached 
its lowest value during week 1, after that increasing. 
Conclusion: Even if there is an increased alcohol consumption 
during Christmas and New Year, there is no evident worsening 
of psoriasis.
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PSORIASIS AND CANCER. RETROSPECTIVE STUDY 
IN THE PSORIASIS SECTOR OF THE DERMATOLOGY 
SERVICE AT RAMOS MEJIA HOSPITAL
Jennifer Kreimer, Alejandra Crespo, Elena Chaparro, Daniela 
Gonzalez, Veira Rosana, Kogan Nora
Introduction: Psoriasis is a chronic, systemic, immune-mediated 
inflammatory	disease	 that	 compromises	 the	 skin,	 attachments,	
semi-mucosal, mucous membranes and joints. There are different 
clinical forms that can vary in the same patient at different times 
of life. It is accompanied by comorbidities that affect the quality 
and survival of patients. Within the comorbidities associated with 
psoriasis, malignancies constitute a prominent and controversial 
group. In the review of the current literature, there would be 
evidence of a relationship between psoriasis and cancer, given 
the existence of structural and molecular similarities between the 
two pathologies. Objectives: To assess the prevalence of cancer 
development in patients with psoriasis in our population.
Methods: A retrospective epidemiological analysis of the total 
population of 1969 patients with psoriasis is carried out, attended 
in the psoriasis sector of the dermatology service of Ramos Mejía 
Hospital in the period between January 2008 and January 2018. 
Results: We	identified	56	patients	who	presented	coexistence	of	
oncological pathology and psoriasis of different severity: 38 se-
vere, 14 moderate and 4 mild. The population was divided equally 
between both sexes. Of these 56 patients, 61 tumors were detected 
(non-melanoma skin cancer, solid tumors and lymphomas). The 
oncological manifestations are the following: table 1.
Table 1. Oncological manifestations Oncological manifestations 
Tumor	quantification	Total	%	Cutaneous	Squamous	Cell	Carci-
noma 4 7% Basal Cell Carcinoma 12 20% Breast Cancer 9 15% 
Prostate Cancer 12 20% Thyroid Cancer 6 10% Endometrial 
Cancer 3 5% Lung Cancer 1 2% Colon Cancer 4 7% Lymphoma 
No Hodgkin 1 2% Cervical Cancer 2 3% Kidney Cancer 1 2% 
Multiple Myeloma 1 2% Testicular Cancer 2 3% Tumoral Micosis 
Fungoide 1 2% Acute Myeloid Leukemia 1 2% Bladder Cancer 1 
2% TOTAL 61 100% The epidemiological analysis of this group 
of patients showed an incidence for all types of malignancies of 
3.098% in this population. The diagnosis of psoriasis preceded the 
oncological diagnosis in 50 of the patients studied.
Conclusions: The incidence of cancer in the general population 
in Argentina, according to the Ministry of Health is 172.3–242.9 
per 100,000 inhabitants. In our study population, we found an 
incidence of 3.098%, which would support the hypothesis of an 
increased risk of developing cancer in patients with psoriasis. The 
risk was identical in both sexes and directly proportional to the 
degree of severity of the psoriasis.
Reference:
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HEMATOLOGICAL DISORDERS IN THE PATIENT 
WITH PSORIATIC ARTHRITIS TREATED WITH 
METHOTREXATE AND TUMOR NECROSIS ALPHA 
(TNFALPHA) INHIBITOR
Renata Sokolik1, Aleksandra Butrym2, Grzegorz Mazur2, Piotr Wi-
land1
1Department and Clinic of Rheumatology and Internal Medicine, 2Depart-
ment and Clinic of Internal and Occupational Diseases and Hypertension, 
Wroclaw Medical University, Wroclaw Poland
Introduction: Non-Hodgkin lymphomas are a heterogenous group 
of neoplastic disorders characterized by clonal limphoid cell 
proliferation. They rank sixth among the cancers in terms of the 
frequency of occurrence in adults. Waldenstrom macroglobuline-
mia is lymphoplasmic hyperplasia with excessive production of 
monoclonal M-protein. According to literature data, patients with 
psoriasis have more frequent lymphomas than healthy population. 
The real risk of lymphoproliferative disease in psoriatic arthritis 
patients	has	not	yet	been	defined.
Objectives: The aim of the study was to describe a case of a patient 
with psoriatic arthritis and concurent monoclonal gammopathy, 
who did not respond to treatment with TNFalpha inhibitor in 
combination with methotrexate.
Methods: A 57 year old woman with psoriasis and psoriatic arthritis 
diagnosed in 2012 (presence of HLA B27 antigen, arthritis of the 
sacroiliac joints, peripheral arthritis) with monoclonal gammopa-
thy	of	undeterminated	significance,	was	treated	with	non-steroid	
anti-inflammatory	drugs,	methotrexate	(20	mg	once	a	week),	folic	
acid 15 mg and inhibitor of TNFalpha.
At the beginning of biological therapy she presented with labora-
tory results: ESR 126, total protein 8 g/dl, abnormal IgM 11.6 g/l 
(normal range 0.4–2.3 g/l), IgG 2.25 g/l (normal range 7–16g/l), 
IgA	0.32	g/l	(normal	range	0.7–4	g/l).	Immunofixation	test	revea-
led possitivity for IgM kappa monoclonal protein. There were no 
abnormalities in the bone marrow aspiration biopsy, no lympha-
denopathy was observed. She complained of general weakness 
and	polineuropathy.	Analysis	of	spino-cerebral	fluid	showed	type	
V of oligoclonal band.
Results: In 2017, after 2 years of TNFalpha inhibitor combi-
ned with methotrexate therapy, the diagnosis of Waldenstrom 
macroglobulinemia has been done. The patient presented with 
high ESR 103 and monoclonal IgM 33 g/l. Repeated aspiration 
bone marrow biopsy showed 3% of plasmocytes and 21% of 
lymphocytes.
Conclusions: The patient started standard RCD chemotherapy 
regimen (rituximab, cyclophosphamide, dexamethason) with good 
clinical response to therapy.
P015
THE RELATIONSHIP BETWEEN PSORIASIS, 
COMORBIDITIES, AND DEPRESSION ONSET: A 
NATIONWIDE OBSERVATIONAL CONTROL STUDY
Kirk Geale1, Martin Henriksson2, Jussi Jokinen3, Marcus Schmitt-
Egenolf1
1Dermatology, Department of Public Health and Clinical Medicine, Umeå 
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University, Linköping, 3Department of Clinical Neuroscience, Karolinska 
Institutet, Stockholm, Sweden
Introduction: Psoriasis is a complex, systemic disease associated 
with comorbidities extending beyond the skin, often affecting 
psychological well-being which may manifest as clinical depres-
sion. Psoriasis can be viewed narrowly by focusing on the skin, 
or holistically to include associated comorbidities. To date, the 
complex interplay between psoriasis, comorbidities, and depres-
sion has not been adequately described, and an innovative approach 
is necessary to understand interrelationship between them. 
Objectives: Calculate incidence rates of depression in psoriasis 
patients compared to the general population and subsequently ex-
plore the risk factors associated with depression onset. Determine 
the	contributions	of	comorbidities	compared	to	narrowly	defined,	
psoriasis-only symptoms. 
Methods: 96,666 psoriasis patients were matched to 15 controls 
and followed from psoriasis onset until incident depression di-
agnosis or censoring using population-based routine care data. 
Incidence of depression was calculated using Poisson regres-
sion	models.	Risk	of	depression	onset	using	a	narrow	definition	
of	psoriasis	was	compared	 to	a	holistic	definition	 including	all	
comorbidities using a Cox proportional hazards model, with ad-
ditional adjustment for sociodemographic factors. Comorbidities 
were represented by ICD chapters with more than 5% correlation 
with psoriasis. Sensitivity analysis examined the role of psoriatic 
arthropathy,	alternative	depression	definitions,	and	searched	for	
unobserved confounding. 
Results: Patients with psoriasis have a higher incidence of clinical 
depression than those without the disease. Holistically, psoriasis 
was associated with an increased risk of depression onset of 40% 
(HR = 1.404, p < 0.001), compared to 12% increase (HR = 1.115, 
p < 0.001)	when	narrowly	defined.	The	proportional	hazards	as-
sumption appeared to hold in each survival analysis. A substantial 
portion, but not all, of psoriasis patients’ risk of depression onset 
was attributable to comorbidities, and sociodemographic factors 
did not appear to affect the estimates of association between 
depression and psoriasis. Major differences were found between 
antidepressant-	 and	 diagnosis-based	 definitions	 of	 depression,	
while inclusion of psoriatic arthropathy did not affect the results. 
No	unmeasured	confounding	was	identified.	
Conclusions: Due to the elevated risk of depression in psoriasis 
patients, treating physicians should ensure patients’ psychologi-
cal well-being is addressed, especially in those presenting with 
additional risk factors, to break the cyclical relationship between 
depression and psoriasis and improve patients’ quality of life. 
Contemporary, holistic management of psoriasis patients should 
encourage routine screening for depression.
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EFFICACY OF ADALIMUMAB PLUS METHOTREXATE 
IN PATIENTS WITH MODERATE TO SEVERE PLAQUE 
PSORIASIS
Ghasem Rahmatpour Rokni, Mohamad Goldust
Mazandaran University of Medical Sciences
Background:	Adalimumab,	a	high-affinity	monoclonal	antibody	
that	selectively	targets	tumor	necrosis	factor	alpha,	is	efficacious	
in treating moderate-to-severe plaque psoriasis. Currently there 
are some reports regarding drug resistance to adalimumab (1,2). 
Objective:	This	 study	 aimed	 at	 evaluating	 the	 efficacy	of	 ada-
limumab plus methotrexate in patients with moderate to severe 
plaque psoriasis.
Methods: In this cross sectional study, 23 patients suffering from 
moderate to severe psoriasis were recruited. Patients received 
adalimumab 80 mg week 0, 1 and then 40 mg every 2 weeks and 
methotrexate up to 25 mg/week. The primary outcome measure 
was the difference in Psoriasis area and severity index (PASI-
75) response after 12 weeks. The secondary outcomes included 
PASI 75 at week 6 (onset of action) and week 12, Investigator’s 
Global Assessment (IGA), Patient Global Assessment, impact on 
quality of life (Skindex-17 and SF-36), Treatment Satisfaction 
Questionnaire of Medication, duration of remission, maintenance 
treatment and safety.
Results: In the study group, 86.9% (20 out of 23 patients) reached 
PASI-75 at week 12. The longitudinal analysis showed a PASI 
reduction of 6.42% per week. The onset of action was achieved 
in 65.2%. At week 12, IGA ‘clear or almost clear’ was observed 
in 91.3% (p < 0·01).	Skindex-17	symptom	score	was	significant	
with combination therapy (p < 0·01). Maintenance treatment ac-
hieved PASI 75 for 82.6% (p < 0·01). Mild adverse events were 
reported in 79.5%.
Conclusion: Combination therapy of adalimumab plus methotrex-
ate is a highly effective, well-tolerated, maintenance therapy in 
patients with moderate to severe plaque psoriasis.
References:
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Placebo for Psoriatic Arthritis. N Engl J Med 2017 Oct 19. 377;1537-1550.
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ATTAINMENT OF REMISSION AND MINIMAL DISEASE 
ACTIVITY AFTER STARTING METHOTREXATE 
SUBCUTANEOUS THERAPY
Elena Loginova, Tatiana Korotaeva, Elena Gubar, Svetlana Gluk-
hova, Eugeny Nasonov
Nasonova Research Institute of Rheumatology, Moscow
Introduction:	Methotrexate	(MTX)	is	the	first-choice	therapy	in	
psoriatic	arthritis	(PsA).	There	is	limited	data	concerning	efficacy	
of early administration and rapidly dose escalation of MTX sub-
cutaneous (s/c) in early (E) PsA patients (pts).
Objective: to study attainment of remission (REM) or minimal 
disease activity (MDA) after starting MTX s/c therapy in EPsA 
pts treated according to treat-to-target (T2T) strategy. 
Methods: 77 (M-37/F-40) pts with active EPsA, according to the 
CASPAR criteria were included. Mean age 37.4±10.8 years (yrs.), 
PsA duration 11±10 months (mon.), psoriasis duration 86±96.1 
mon., DAPSA 32.45±12.7. At baseline all pts started MTX s/c 
therapy. The dose of MTX s/c was escalated by 5 mg every 2 
weeks from 10 mg/wk to appropriate dose 20–25 mg/wk according 
to the drug intolerance. If the patient did not achieve remission 
or MDA on MTX mono-therapy, biological (b)DMARDs was 
added. At baseline and every 3 mon. of study (till 24 mon.) all 
pts underwent assessment of PsA activity by DAPSA and MDA 
criteria (tender joint count ≤ 1, swollen joint count ≤ 1, PASI ≤ 1 or 
BSA ≤ 3, patient pain global assessment VAS ≤ 15, patient´s global 
disease activity VAS ≤ 20, HAQ ≤ 0.5, enthesitis count ≤ 1). The 
proportion of pts who achieved REM by DAPSA ≤ 4 and MDA (5 
of 7 cutpoints), the timing of REM/MDA, the mean dose of MTX 
during the study were performed. M±SD, Me [Q75; Q50], (%), 
W-test were calculated. All p < 0.05 were considered to indicate 
statistical	significance.	
Results: 36 out of 77 pts (46.75%) did not achieve REM or MDA in 
MTX therapy within 7±5 mon. and bDMARDs were added. 5 out 
of 77 pts (6.5%) stopped MTX therapy due to intolerance within 
6±2 mon. 36 out of 77 pts (46.75%) went on taking MTX-mono-
therapy. In 22 out of 36 pts, who had mean DAPSA 27.7±10.0 at 
baseline, data was available by the 24 mon. of study. At baseline 
median dose of MTX s/c was 15 [10;20], Min 10–Max 20 mg/
wk. At the third mon. of study median dose of MTX s/c was 
escalated to 20 [20;20], Min 0–Max 25 mg/wk. After attainment 
of REM/MDA the dose of MTX was decreased. At the end of the 
study median dose of MTX s/c was 7.5 [0;15], Min 0–Max 20 
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mg/wk	(fig.1).	After	 starting	MTX	disease	activity	by	DAPSA	
significantly	decreased	by	the	third	mon.	and	maintained	till	the	
end	of	 the	study	 (fig.2).	DAPSA-REM	and	МDA	was	 reached	
within 9.7±7.7 and 13.7±7.6 mon. accordingly. By the 24 mon. 
of therapy stable REM by DAPSA and MDA was seen in 10 out 
of 22 pts (45.5%) and in 16 out of 22 pts (72.7%) accordingly.
Conclusions: In half of EPsA pts early administration of MTX 
s/c and rapidly dose escalation is effective and well tolerated. 
After achieving REM or MDA, a decrease of the dose of MTX is 
possible in most cases.
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SECUKINUMAB IN PREGNANCY: OUTCOMES IN 
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DATABASE
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Introduction: Secukinumab, a fully human monoclonal antibody 
selectively	targeting	IL-17A,	is	highly	efficacious	in	the	treatment	
of moderate to severe psoriasis, psoriatic arthritis (PsA) and an-
kylosing	spondylitis	(AS),	with	sustained	efficacy	and	favorable	
safety	profile.	Long	term	treatment	with	targeted	therapies	such	
as secukinumab may be necessary in women of childbearing 
age. Pre-clinical animal studies with secukinumab, which can 
cross the placenta, do not indicate harmful effects with respect to 
pregnancy, embryonic/fetal development, parturition or postnatal 
development, however only limited data has been reported on 
human pregnancies.
Objectives: Using the Novartis global safety database, we analyzed 
the outcome of pregnancies where there was maternal or paternal 
exposure to secukinumab.
Methods: The Novartis global safety database (covering all 
secukinumab indications and including clinical trial and post-
marketing data) was searched for cases reporting pregnancy and 
neonatal topics. All pregnancies where there was either maternal 
or paternal exposure to secukinumab were included in the sys-
tematic, independently validated analysis. The cut-off date was 
25th June, 2017.
Results: Of 292 pregnancies reported, 141 (48.3%) came from 
clinical trials, 79 (27.1%) were spontaneous reports and 72 
(24.7%) were from post-marketing surveillance, with 238 cases 
of maternal and 54 cases of paternal exposure. 175 patients recei-
ved secukinumab for psoriasis, 38 for PsA, 15 for AS and 62 for 
other/unknown indications. The majority of patients discontinued 
secukinumab	in	the	first	trimester	of	pregnancy;	18	did	not	discon-
tinue. Of 153 cases where the outcome was known, there were 73 
full term normal neonates and 37 elective terminations. Rates of 
spontaneous abortions were 30/292, 10.3% overall (30/153 known 
outcomes, 19.6%). These are in line with previously reported rates 
(15–20%) for the general population with maternal age of 30.6 
(study mean). No still births ( > 20 weeks) were reported. Three 
congenital abnormalities were reported following maternal and 
1 paternal exposure, with no repeated pattern of abnormality. At 
data cut-off, 32 pregnancies were ongoing.
Conclusions: There was no evidence for increased rates of adverse 
pregnancy outcomes across indications with secukinumab in this 
review of the safety database. Given the limited exposure repor-
ted to date, the safe continuous use of secukinumab throughout 
pregnancy requires further research.
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IXEKIZUMAB IMPROVES IMPACT OF GENITAL 
PSORIASIS ON SEXUAL ACTIVITY: RESULTS FROM A 
PHASE 3B STUDY
Jennifer Clay Cather1, Kim Meeuwis2, Russel Burge3, Alison Potts 
Bleakman3, Chen-Yen Lin3, Alice Gottlieb4, Catriona Ryan5
1Modern Dermatology and Modern Research Associates, Dallas, TX, USA, 
2Radboud University Medical Center, Nijmegen, The Netherlands, 3Eli Lilly 
and Company, Indianapolis, IN, USA, 4Department of Dermatology, New 
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Vincent’s University Hospital, Dublin, Ireland
Introduction: Genital psoriasis (GP) is often associated with impai-
red	sexual	health.	Ixekizumab	(IXE)	is	a	high-affinity	monoclonal	
antibody that selectively targets interleukin-17A.
Objective: To evaluate the effect of IXE on the impact of GP on 
sexual activity during 12 weeks of treatment compared to placebo 
(PBO) in patients with moderate-to-severe GP.
Methods: In this double-blind, placebo-controlled study, patients 
(n = 149) with moderate-to-severe GP were randomized (1:1) to 
receive PBO or 80 mg IXE every 2 weeks following an initial 
dose of PBO or 160 mg IXE. The impact of GP on sexual activity 
was	measured	by	pre-specified	patient-reported	outcomes	inclu-
ding the Genital Psoriasis Sexual Impact Scale (GPSIS), which 
is composed of the Sexual Activity Avoidance (Avoidance) and 
Impact of Sexual Activity on Genital Psoriasis Symptoms (Impact) 
subscales, the Sexual Frequency Questionnaire (SFQ) item 2, and 
the Dermatology Life Quality Index (DLQI) item 9. Of patients 
with	a	baseline	SFQ	item	2	score	≥2,	the	percentage	of	patients	
whose frequency of sexual activity was never (0) or rarely (1) 
limited by GP (SFQ item 2 0/1) was examined. Among patients 
with	respective	GPSIS	subscale	scores	≥3	at	baseline,	response	
was measured as the percentage of patients whose frequency of 
avoiding sexual activity was never (1) or rarely (2) impacted by GP 
(GPSIS-Avoidance 1/2) and whose GP symptom worsening after 
sexual activity was very low/none at all (1) or low (2) (GPSIS-
Impact 1/2). DLQI item 9 response was measured as the percentage 
of patients with no (0) or a little (1) impairment of sexual activity. 
Treatment comparisons were made using a logistic regression 
model with missing values imputed by non-responder imputation.
Results: IXE treatment reduced the impact of GP on sexual activity 
at Week 12 versus PBO as assessed by SFQ item 2 0/1 (IXE 78.4%, 
PBO 21.4%; p < 0.001), GPSIS-Avoidance 1/2 (IXE 76.7%, PBO 
25.7%; p < 0.001), and DLQI item 9 0/1 (IXE 92.0%, PBO 56.8%; 
p < 0.001). IXE was superior to PBO as early as Week 1 for SFQ 
item 2 0/1 (p < 0.05), Week 2 for DLQI item 9 0/1 (p < 0.001), 
and Week 4 for GPSIS-Avoidance 1/2 (p < 0.01). GPSIS-Impact 
1/2 response rates suggested a trend of reduced impact of sexual 
activity on GP symptoms (IXE 85.7%, PBO 52.9%; p = 0.062).
Conclusions: During 12 weeks of treatment, IXE resulted in a rapid 
and	significant	decrease	in	the	impact	of	GP	on	sexual	activity,	
including how often GP limited sexual frequency among patients 
with moderate-to-severe GP.
Cather J, Meeuwis K, Burge R, Bleakman AP, Lin C-Y, Ryan C. Ixeki-
zumab Provides Greater Improvement Versus Placebo on the Impact of 
Genital Psoriasis on Sexual Activity for Patients with Moderate-to-Severe 
Genital Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial. 
American Academy of Dermatology-76th Annual Meeting 2018. 
P021
DOSE OPTIMIZATION OF SECUKINUMAB IN 
SUBJECTS WITH MODERATE TO SEVERE PLAQUE 
PSORIASIS: OPTIMISE STUDY
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12
www.medicaljournals.se/acta
5th World Psoriasis & Psoriatic Arthritis Conference 2018
Michael Rissler5, Christian Sieder6, Roberto Orsenigo7, Kamel 
Chaouche-Teyara5
1SCIderm Research Institute Hamburg and Dermatologikum Berlin, Ger-
many, 2Department of Dermatology, Hospital de la Santa Creu I Sant Pau, 
Barcelona, Spain, 3Department of Dermatology, Venereology and Allergo-
logy, Wroclaw Medical University, Wroclaw, Poland, 4Department of Der-
matology, Larrey University Hospital, Toulouse, France, 5Novartis Pharma 
AG, Basel, Switzerland, 6Novartis Pharma GmbH, Nuernberg, Germany, 
7Novartis Farma S.p.A, Origgio, Italy
Introduction: Secukinumab is a fully human monoclonal antibody 
that selectively neutralizes IL-17A, a key cytokine involved in 
the development of psoriasis. Heterogeneity in clinical response 
to targeted therapies such as secukinumab may be addressed by 
flexible	dosing.
Objectives: To compare downtitration of PASI90 responders to 
6-weekly	and	uptitration	of	PASI≥75	to	 < 90 responders to two-
weekly secukinumab dosing with standard 4-weekly dosing.
Methods: OPTIMISE was a randomized, multicenter, open-label, 
rater blinded Phase 3b study. 1647 subjects received secukinumab 
300 mg at baseline, Weeks 1, 2, 3 and 4 then 4-weekly to Week 24. 
At Week 24, PASI90 responders were randomized to secukinumab 
300 mg q4w (n = 644) or q6w (n = 662)	 to	Week	52;	PASI≥75	
to  < 90 responders were randomized to secukinumab 300 mg q4w 
(n = 114) or 2-weekly (q2w) (n = 92) to Week 52. Groups were 
stratified	by	body	weight	( < 90kg,	≥90kg).
Results: PASI90 response was maintained at Week 52 by 85.7% 
subjects with q4w dosing vs 74.9% with q6w dosing; OR 1.91 
(95% CI 1.44, 2.55). The primary endpoint, non-inferiority of q6w 
vs	q4w	dosing	in	PASI90	responders,	was	not	met.	In	PASI≥75	
to  < 90 responders, 46.5% of subjects achieved PASI90 response 
by Week 52 with q4w dosing. PASI90 response at Week 52 was 
numerically higher for q2w compared to q4w dosing (56.5% vs. 
46.5%),	but	this	difference	did	not	reach	statistical	significance	
(p = 0.1013).	This	 numerical	 benefit	 of	 q2w	dosing	was	 even	
higher	in	subjects	weighing	≥	90	kg	(n = 49; 57.1% vs. 39.6%; 
p = 0.1053). No new or unexpected safety signals were observed.
Conclusions: Non-inferiority of q6w vs. q4w dosing cannot be 
claimed in maintaining PASI90 response achieved at Week 24. 
Around	half	 of	PASI≥75	 to	  < 90 responders at 24 weeks, can 
achieve PASI90 response with continued q4w dosing. Subjects 
with	higher	body	weight	may	benefit	from	the	q2w	dosing.
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INHIBITION OF ANTI­TNF­ALPHA CYTOKINE IN THE 
TREATMENT OF PSORIASIS AND THE ANALYSIS OF 
INFECTIOUS COMPLICATIONS
Tatiana Péčová, Karolína Vorčáková1, Marián Grendár2, Juraj 
Péč1
1Department of Dermatovenereology, 2Biomedical Center Martin, Jesse-
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Introduction: TNF-alpha cytokine plays an important role in the 
regulation of activation, proliferation, differentiation and apoptosis 
of the immune cells. It is an important therapeutical target in the 
treatment of chronic plaque psoriasis. From its other roles, it plays 
key part in formation and maintenance of granuloma through the 
increased fagocytic capacity of macrophages and eradication of 
intracellular pathogens, therefore its inhibitors pose a risk for 
granulomatous infections and reactivation of latent tuberculosis.
Objectives: The main focus was to assess the infectious compli-
cations of biologic anti-TNF-alpha treatment of chronic plaque 
psoriasis with focus on the tuberculosis and reactivation of its 
latent form. Moreover, the authors tried to establish possible risk 
factors on the reactivation of latent tuberculosis.
Methods: The authors analyzed the group of 190 patients from 
Middle-European population treated with TNF-alpha inhibitors, 
as compared to other biologics, for the occurence of infectious 
complications. Interferon-gamma release assay (IGRA) test was 
performed before the start of the treatment and then every year, 
in accordance with The Tuberculosis Network European Trials 
Group (TBNET) consensus. Statistical analysis was performed 
on the results.
Results: 3% of patients had permanently positive IGRA test (before 
and after beginning of the treatmet) and in 28% of patients treated 
by TNF inhibitors, conversion of IGRA test appeared with nega-
tive test before treatment and positive test after administration of 
biologics. No active tuberculosis was detected. The average time 
of IGRA conversion was 3 years after beginning of treatment. The 
only	statistically	significant	predictor	was	age,	with	an	increase	
of age by one year associated with the 5.8% increase of risk of 
IGRA conversion. Regarding other infectious complications, the 
most common infections in patients treated with biologics were 
respiratory and HPV infections. No severe infection leading to the 
permanent discontinuation of treatment was observed.
Conclusions: Treatment with TNF-alpha inhibitors was associated 
with	statistically	significant	risk	of	IGRA	test	conversion.	The	only	
established	predictor	of	risk	was	age	of	patient,	with	no	influence	of	
previous or concomittant systemic tretament. However, the limita-
tion was size of group of patients. The most common infections 
were common respiratory infections and viral HPV infections.
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PATIENTS WITH PSORIASIS AND PSORIATIC 
ARTHRITIS IN SCANDINAVIA
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Introduction: Patients’ perspectives on psoriasis (PsO) and pso-
riatic arthritis (PsA) treatment are important in establishing better 
approaches to their care.
Objectives: To assess treatment use and satisfaction among patients 
with PsO/PsA in Scandinavia.
Methods: NORPAPP was an on-line survey carried out in Nov/
Dec 2015 using YouGov panels in Sweden, Denmark, and Norway. 
Adults with physician-diagnosed PsO or PsA (n = 1221), answered 
questions about contact with the healthcare system, and treatment 
experience and satisfaction. Self-perceived disease severity was 
dichotomised to severe (responses of “quite severe”, “very severe” 
or “extremely severe”) and non-severe (“not particularly severe” 
or “not severe at all”).
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Results: Among respondents with PsO alone 38.9% had seen a 
dermatologist in the past year, and 10.7% had never seen a derma-
tologist; 60.9% of those with PsA±PsO had seen a rheumatologist 
in the past year; 14.3% had never seen a rheumatologist. Systemic 
treatments had been used by 14.6% of respondents with PsO alone 
and 58.5% with PsA±PsO. Respondents with self-perceived severe 
symptoms and patient organization members (POMs) were more 
likely than those with non-severe symptoms or non-members, to 
have discussed systemic treatments with their physician and to 
have used the treatments; however, 35.2% of respondents with 
self-perceived severe symptoms had never discussed systemic 
treatment with their physician. Asked about long-term health risks 
of systemic treatments, 18–44 year-olds and POMs were less likely 
to answer “don’t know” than 45–74 year-olds (47.7%–49.1% vs 
66.7%–72.9%) or non-members (26.1%–30.7% vs 66.8%–70.4%). 
Biologics had been used by 40.7% of POMs vs 6.9% of non-
members, and 21.5% of 18–44 year-olds vs 8.1% of 45–74 year-
olds. Among respondents using oral/injectable methotrexate 30.5% 
were	dissatisfied,	60.2%	citing	side-effects	as	the	reason;	22.9%	
of	biologics	users	were	dissatisfied,	28.9%	citing	lack	of	effect	
and 28.1% citing side-effects.
Conclusion: In Scandinavia POMs and young patients are more 
likely to receive systemic treatment. A high proportion of patients 
are	dissatisfied	with	their	treatment	because	of	side	effects.
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Introduction: Patient (pt)-centered care is gaining traction in 
long-term disease management. We report on a multinational, 
retrospective, cross-sectional study in psoriasis pts treated with 
apremilast (APR), an oral phosphodiesterase 4 inhibitor, in a real-
world clinical setting. 
Objectives: The study aims to identify important pt needs and 
therapeutic	benefits	of	APR.
Methods: Consecutive pts with chronic plaque psoriasis treated 
according to routine clinical practice who could be contacted 
6±1 mo after APR initiation were enrolled. Medical chart review, 
standardized pt-reported outcome tools (PBI, TSQM-9), and pt/
physician	questionnaires	were	used.	An	interim	analysis	of	the	first	
104 pts from 40 sites in Germany (42), UK (31), and Sweden (31) 
was	performed	using	predefined	descriptive	statistics.
Results: 102 pt questionnaires were analyzed (98%). At 6±1 mo, 
74 pts (71%) continued APR; 30 (29%) had discontinued APR 
(lack	of	efficacy	[14%],	safety/tolerability	[11%],	other	[4%]).	
Assessment of pts’ main needs from a therapy (quite/very im-
portant on the PBI) revealed the importance pts attributed to skin 
involvement	(93%	of	responders),	confidence	in	healing	(92%),	
being itch free (85%), fewer side effects (84%), being able to lead 
a normal everyday life (83%), and needing less time for daily 
treatment (80%). Based on a clinically meaningful PBI score 
≥1,	78%	of	pts	achieved	a	benefit	with	APR	after	6	mo.	Mean	
(SD) PBI score was 2.2 (1.3) and increased to 2.5 (1.2) for pts 
on continued APR at 6 mo vs 1.6 (1.3) for pts who discontinued 
APR.	Pts	achieved	benefit	 related	 to	 skin	 involvement	 (60%),	
confidence	in	healing	(70%),	itch	(69%),	side	effects	(60%),	be-
ing able to lead a normal everyday life (72%), and needing less 
time for daily treatment (65%). Consistent with phase 3 studies, 
most frequently reported AEs were diarrhea (19.2%), nausea 
(16.4%), and headache (11.5%); 25% of pts reported weight loss 
(no change, 71%; gain, 4%). 
Conclusions: This interim analysis indicates main pt needs from a 
therapy extend beyond skin improvement. Findings indicate APR 
may address diverse pt needs.
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PHYSICIAN­ AND PATIENT­REPORTED OUTCOMES 
WITH APREMILAST FOR PATIENTS WITH PLAQUE 
PSORIASIS DURING ROUTINE DERMATOLOGY CARE 
IN GERMANY: A SECOND INTERIM ANALYSIS
Kristian Reich1, Stefanie Bomas2, Bernhard Korge3, Uwe Schwich-
tenberg4, Hannah Mentz5, Kathrin Groegel5, Natalie Núnez Gómez5
1Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, 
2Praxis Dr. med. S. Rotterdam, Gelsenkirchen-Feldmark, 3Priv. Doz. Dr. 
med. Korge, Düren, 4Derma Nord Hautarztpraxen Dr. med. Schwichten-
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Introduction: LAPIS-PSO is an ongoing, 52-week, prospective, 
multicenter, observational cohort study in real-world dermatology 
clinical settings in Germany.
Objectives: To present a 4-month interim analysis of patient (pt)-
reported	outcomes	and	efficacy	assessments	of	apremilast	(APR)	
among pts (n = 294; full analysis set [FAS], n = 196) who were 
continuing APR at 4 mo.
Methods: Physician- and pt-reported outcomes for QOL, treatment 
effectiveness, and treatment satisfaction were evaluated in pts with 
psoriasis vulgaris during long-term APR treatment. The primary 
endpoint at Visit 2 (~4 mo after baseline [BL]) is the proportion 
of pts who achieve DLQI score  ≤ 5 or improvement from BL in 
DLQI	score	≥5	points.
Results: At BL, mean (SD) age was 51.7 (13.20) years in the FAS; 
90 pts (45.9%) were female. At APR initiation, 171 pts (87.3%) 
had Physician’s Global Assessment of disease severity (PGA) 
≥3	and	174	(89.2%)	had	Patient’s	Global	Assessment	of	disease	
severity	(PaGA)	≥3;	mean	psoriasis-involved	BSA	was	22.2%,	
mean pruritus VAS score was 56.6 mm, and mean DLQI score 
was	14.1.	In	all,	62.7%	of	pts	had	scalp	PGA	(ScPGA)	≥3;	42.5%	
had	palmoplantar	PGA	(PPPGA)	≥3.	Among	pts	continuing	APR	
at 4 mo, 120/181 (66.3%) achieved DLQI score  ≤ 5 or reduction 
by	≥5	points.	Mean	(SD)	improvement	in	BSA	was	−9.5%	(14.91)	
and mean (SD) percentage improvement in pruritus VAS score 
was	−47.3%	 (32.29).	A	 total	 of	32.1%	of	pts	 achieved	PGA	0	
(clear) or 1 (minimal); 32.6% achieved PaGA 0 or 1. NAPSI-50 
was achieved by 62.4% (53/85) of pts. In all, 58.4% (87/149) of 
pts achieved ScPGA 0 or 1 and 69.0% (29/42) had PPPGA 0 or 
1.	AEs	were	 consistent	with	 the	known	 safety	profile	of	APR.	
Eighty	pts	(27.8%)	reported	≥1	AE;	1	AE	occurred	in	≥5%	of	pts	
(diarrhea, n = 21 [7.3%]).
Conclusion: In routine clinical care in Germany, APR treatment 
outcomes	for	pts	with	psoriasis	vulgaris,	including	difficult-to-treat	
locations	such	as	the	nails,	scalp,	palms,	and	soles,	confirm	the	
broad	efficacy	of	APR	observed	in	clinical	trials.
Prior Presentation: AAD 2018
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IMPROVEMENTS IN WORK PRODUCTIVITY WITH 
UP TO 104 WEEKS OF APREMILAST MONOTHERAPY: 
RESULTS FROM A PHASE 3B, RANDOMIZED, 
CONTROLLED STUDY IN BIOLOGIC­NAIVE SUBJECTS 
WITH ACTIVE PSORIATIC ARTHRITIS
Philip J. Mease1, Dafna D. Gladman2, Eric K. Davenport3, Xiaolei 
Zhou3, Benoit Guerette4, Lichen Teng4, Satyin Kaura4, Peter Nash5
1Swedish Medical Center and University of Washington School of Medi-
cine, Seattle, WA, USA, 2Krembil Research Institute, Toronto Western 
Hospital, Toronto, ON, Canada, 3RTI Health Solutions, Research Triangle 
Park, NC, USA, 4Celgene Corporation, Summit, NJ, USA, 5University of 
Queensland, Brisbane, Australia
Introduction: PsA patients may have impaired functioning in home 
or	work	activities.	The	phase	3b	ACTIVE	study	assessed	efficacy	
of apremilast (APR) monotherapy in biologic-naive subjects 
with active PsA who may have had exposure to 1 conventional 
DMARD.
Objectives: Assess work productivity through Wk104.
Methods: Subjects were randomized (1:1) to APR 30 mg BID or 
placebo	(PBO).	Subjects	whose	SJC/TJC	did	not	improve	≥10%	
at Wk16 were eligible for early escape. At Wk24, remaining 
PBO subjects switched to APR. Work productivity and activity 
impairment were assessed at baseline (BL) and Wk16 using the 
WPAI:PsA; WPAI:PsA Absenteeism, Presenteeism, Work Pro-
ductivity Loss, and Activity Impairment subscale scores range 
from 0% to 100%; higher scores indicate greater impairment. 
Work-related subscales were assessed in employed subjects; ac-
tivity impairment was assessed in all subjects. Correlations were 
examined at Wk16 between WPAI:PsA subscale and SF-36v2 
domain scores (Physical Functioning [PF], Bodily Pain [Pain], 
and Vitality [VIT]) associations with ACR20 response. Work 
productivity improvement was assessed to Wk104.
Results: BL characteristics were similar between groups. At Wk16, 
APR improved work productivity and ability to carry out daily 
activities vs PBO, with greater mean improvements in overall 
Work Productivity Loss (p = 0.001) and Activity Impairment 
(p < 0.001). Estimated mean change in Absenteeism score was 
similar with APR vs PBO (p = 0.679). The Presenteeism score 
showed	significant	improvement	with	APR	vs	worsening	with	PBO	
(−10.8%	vs	4.1%;	P = 0.002).	At	Wk16,	statistically	significant	
correlations were observed between WPAI:PsA subscale (except 
Absenteeism) and SF-36v2 domain scores, as were associations 
with ACR20 response. In subjects randomized to APR at BL, 
Wk16 improvements were generally maintained to Wk104 in 
those continuing APR.
Conclusions: In biologic-naive subjects with PsA, APR contri-
buted to overall improvement in work productivity at Wk16, 
which correlated with SF-36v2 PF, Pain, and VIT scores and was 
associated with ACR20 response; improvements in WPAI:PsA 
subscale scores were generally maintained to Wk104.
Prior Presentation: EULAR 2018
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EXAMINING DISEASE SEVERITY AND SYMPTOM 
IMPROVEMENT WITH PATIENT AND PHYSICIAN 
ASSESSMENTS: RESULTS FROM A PHASE IV ANALYSIS 
OF APREMILAST IN PATIENTS WITH MODERATE 
PLAQUE PSORIASIS
Mark Lebwohl1, J. Mark Jackson2, Jerry Bagel3, Eugenia Levi4, 
Jerry Weaver4, Linda Stein Gold5, Ali Alikhan6, Seth Forman7, Ben-
jamin Lockshin8, Kristina Callis Duffin9
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Introduction: UNVEIL	is	the	first	study	of	apremilast	in	patients	
(pts) with moderate psoriasis (BSA 5%-10%) naive to biologic 
and systemic therapy.
Objectives: Improvements on physician and pt assessments over 
52wks are described.
Methods: Pts with chronic moderate plaque psoriasis (BSA 5%-
10%; sPGA = 3 [0–5 scale]) were randomized (2:1) to apremilast 
30 mg BID (APR) or placebo (PBO) for 16wks. Pts continued APR 
(APR/APR) or switched from PBO to APR (PBO/APR) through 
Wk52 (open-label treatment). Physician assessments were product 
of sPGA and BSA (PGAxBSA), proportion of pts who achieved 
sPGA	score	0	(clear)	or	1	(almost	clear)	and	PGAxBSA-75	(≥75%	
improvement from baseline [BL]). Pt assessments were Derma-
tology Life Quality Index (DLQI), pruritus VAS (0–100 mm), 
Treatment Satisfaction Questionnaire for Medication (TSQM), 
and Pt’s Global Assessment (PtGA [0–4 scale]).
Results: In randomized pts (PBO n = 73; APR n = 148), mean BL 
BSA was 7.2%, PGAxBSA was 21.8, DLQI was 11.0, and pruritus 
VAS was 56.6mm. At Wk16, mean improvement in PGAxBSA 
was	greater	with	APR	vs	PBO	(−48.1%	vs	−10.2%;	P < 0.0001); 
more pts achieved sPGA 0 or 1 and PGAxBSA-75 with APR vs 
PBO (30.4% vs 9.6% and 35.1% vs 12.3%). At Wk16 achievement 
of	DLQI	response	(≥5-point	decrease	in	pts	with	BL	DLQI	 > 5) 
was greater with APR vs PBO (63.8% vs 34.5%), as were pruritus 
VAS	response	(improvement	≥20%:	62.8%	vs	45.2%)	and	TSQM	
global satisfaction (63.2 vs 48.7) and effectiveness (57.3 vs 38.8). 
More pts had PtGA  ≤ 1 with APR vs PBO (33.8% vs 20.5%). At 
Wk52,	PGAxBSA	changes	were	−42.2%	(PBO/APR)	and	−55.5%	
(APR/APR); 45.3% (PBO/APR) and 42.1% (APR/APR) of pts 
achieved PGAxBSA-75, 35.9% (PBO/APR) and 33.1% (APR/
APR) achieved sPGA response, 55.6% (PBO/APR) and 59.4% 
(APR/APR) achieved DLQI response, and 68.8% (PBO/APR) and 
66.9% (APR/APR) achieved pruritus VAS response. TSQM global 
satisfaction (PBO/APR 59.2; APR/APR 59.9) and effectiveness 
(PBO/APR 57.7; APR/APR 54.1) were similar between groups at 
Wk52; 42.2% (PBO/APR) vs 37.2% (APR/APR) had PtGA  ≤ 1.
Conclusion: Physician and pt assessments improved with APR 
up to 52wks in biologic- and systemic-naive pts with moderate 
psoriasis.
Prior Presentation: AAD 2018
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HEMOGLOBIN A1C AND WEIGHT CHANGES WITH 
APREMILAST IN PATIENTS WITH PSORIASIS AND 
PSORIATIC ARTHRITIS: POOLED LABORATORY 
ANALYSIS OF THE PHASE 3 ESTEEM AND PALACE 
TRIALS
Luis Puig1, Neil Korman2, Chiara Greggio3, Joshua Cirulli3, Li-
chen Teng3, Vinod Chandran4, Majed Khraishi5, Nehal N. Mehta6
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Case Western 
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Introduction: Psoriasis and psoriatic arthritis (PsA) are associated 
with high prevalence of obesity and metabolic syndrome. In phase 
3	 trials,	 apremilast,	 an	oral	PDE4	 inhibitor,	was	 efficacious	 in	
patients (pts) with moderate to severe plaque psoriasis (ESTEEM 
1 and 2 [EST]) and active PsA (PALACE 1–3 [PAL]).
Objectives: To explore potential effects of apremilast on metabolic 
parameters, we assessed weight change and A1c in pts receiving 
placebo (PBO) or apremilast 30 mg twice daily (APR) in a pooled 
analysis of EST and PAL.
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Methods: Mean A1c change and mean percent weight change at 
Wk16 were compared among pts with baseline (BL) A1c  < 5.7%, 
5.7%	to	6.4%	(prediabetes),	and	≥6.5%	(diabetes)	and	between	pts	
reporting/not reporting concomitant insulin use. Spearman rank cor-
relations between percent change from BL in weight and change in 
A1c at Wk16 were calculated; p < 0.05	was	considered	significant.
Results: In the pooled EST-PAL population, 2,242 pts (PBO 
n = 913; APR n = 1,329) received study medication at BL. In all, 
230	pts	had	BL	A1c	≥6.5%.	At	Wk16,	A1c	change	in	pts	with	
BL A1c  < 5.7% was 0.02 with PBO and 0.04 with APR. In pts 
with BL A1c 5.7% to 6.4%, small changes were observed (PBO 
−0.07;	APR	−0.12).	Greatest	A1c	changes	were	in	pts	with	BL	
A1c	≥6.5%	(PBO	−0.08;	APR	−0.31).	At	Wk16,	mean	weight	
change	was	0.11%	(PBO)	and	−1.32%	(APR).	In	pts	reporting	
and not reporting concomitant insulin use, mean weight change 
was	0.05%	and	0.12%	with	PBO,	respectively,	and	−1.83%	and	
−1.31%	with	APR.	Weight	change	in	pts	with	BL	A1c	 < 5.7%, 
5.7%	to	6.4%,	and	≥6.5%	was	0.02%,	0.26%,	and	0.11%	with	
PBO,	respectively,	and	−1.24%,	−1.35%,	and	−1.68%	with	APR.	
Correlations between changes in weight and A1c were generally 
low, with greater correlation in APR pts with higher BL A1c. Corre-
lation	was	statistically	significant	in	APR	pts	with	BL	A1c	≥6.5%.
Conclusion: With APR, decreases in weight and A1c were greater 
in pts with higher BL A1c. Pts receiving APR and insulin had 
weight loss despite the association between insulin use and weight 
gain. Future studies may be warranted to determine whether re-
ductions in A1c with APR are independent of weight loss.
Prior presentation: AAD 2018
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CANADIAN HUMIRA POST­MARKETING 
OBSERVATIONAL EPIDEMIOLOGICAL STUDY 
ASSESSING THE EFFECTIVENESS OF ADALIMUMAB 
VS NON­BIOLOGIC DMARDS IN PSORIATIC 
ARTHRITIS (COMPLETE­PSA): 12­MONTH 
EFFECTIVENESS DATA
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raouil4, Viktoria Pavlova5, Jacqueline Stewart6, Valencia Remple7
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Background: Observational studies comparing the effectiveness 
of adalimumab (ADA) to non-biologic DMARDs (nbDMARD) in 
PsA patients failing prior treatment are scarce. COMPLETE-PSA 
is a Canadian observational study which assessed effectiveness 
of ADA and non-biological therapies (NSAIDs and DMARDs) 
among PsA patients failing previous therapy.
Objectives: To describe the baseline (BL) demographic and disease 
parameters and to compare 12-month real-life effectiveness of 
patients initiating nbDMARD or ADA. 
Methods: Eligible	patients	eligible	are	anti-TNFα	naïve	adults,	
with active PsA requiring a treatment regimen change, per the 
treating physician’s judgment. This analysis included patients 
enrolled during Jul/2011–Jun/2016. Outcome measures analyzed 
were: DAS28, SF-12, DLQI, presence of extra-articular manifesta-
tions (EAMs; enthesitis & dactylitis), psoriasis BSA, achievement 
of	modified	MDA	(achievement	of	[i]	4/6	(MDA	1)	and	[ii]	5/6	
following criteria (MDA 2): TJC ≤ 1, SJC ≤ 1, BSA ≤ 3%, pain 
VAS ≤ 15mm, PtGA ≤ 20 and HAQ ≤ 0.5),	modified	 remission	
(SJC = 0, TJC = 0, absence of enthesitis and dactylitis, BSA ≤ 3% 
and HAQ ≤ 0.5), DAPSA LDA ( ≤ 14), and DAPSA remission 
(REM;  ≤ 4). Analyses were conducted by initial group assignment 
(intent-to-treat approach). 
Results: 406 patients were included (nbDMARD n = 146, ADA 
n = 260). BL demographics were comparable between treatment 
groups. However, patients initiating ADA were more likely to be 
unemployed (47.3% ADA vs 34.9% nbDMARD, p = 0.015), had 
higher DAS28 (4.8 vs 4.4, p = 0.002) and total DLQI score (6.1 
vs 4.3, p = 0.007),	and	were	more	likely	to	have	BSA≥3%	(44.6%	
vs 35.0%, p = 0.063) and high DAPSA disease activity (50.8% 
vs 32.3%, p = 0.015). A higher proportion of nbDMARD patients 
had dactylitis (36.1% vs 25.3%, p = 0.023). No differences were 
observed between groups in enthesitis, overall EAMs, or QoL 
at BL. Following 12 months, mean adjusted DAS28 (2.6 vs 3.4, 
p < 0.001) and DLQI (2.2 vs 2.9, p = 0.530) scores, but not SF-12, 
were lower in the ADA group. Furthermore, even though statistical 
significance	was	not	always	met,	ADA	patients	had	lower	DAPSA	
score (p = 0.025) (LDA/REM: 64.9% vs 58.6%; REM: 37.7% vs 
17.1%),	were	more	likely	to	be	in	modified	remission	(14.7%	vs	
9.7%, p = 0.311), and to have mMDA (mMDA 1: 15.6% vs 12.6%, 
p = 0.529; mMDA 2: 17% vs 11.5%, p = 0.253) and BSA < 3% 
(89.3% vs 83.9%, p = 0.207). Also, EAM prevalence decreased in 
both	groups	but	was	significantly	lower	in	the	ADA	group	(17.4%	
vs 35.8%, p < 0.001). Over time, 9.6% of ADA patients initiated 
another biologic and 32.2% of patients in the nbDMARD group 
initiated biologic treatment (p < 0.001). 
Conclusions: PsA patients initiating ADA in Canadian routine 
clinical	care	have	significantly	greater	BL	disease	severity	com-
pared with those initiating nbDMARDs. However, 12-month 
ADA treatment resulted in improved disease control and EAMs. 
DAPSA-REM evaluation seems more sensitive than mMDA in 
differentiating both populations. 
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SECUKINUMAB EFFICACY IN PATIENTS WITH 
ACTIVE PSORIATIC ARTHRITIS: META­ANALYSIS OF 
4 PHASE 3 TRIALS
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Introduction: Secukinumab	(SEC)	has	exhibited	rapid,	significant	
and sustained improvement in the signs and symptoms of psoriatic 
arthritis (PsA) in 4 Phase 3 studies.1–4 
Objective:	To	report	meta-analyzed	efficacy	results	for	SEC	ver-
sus placebo at Week (Wk) 16 in PsA patients (pts) by prior TNF 
inhibitor (TNFi) use and with/without concomitant methotrexate 
(MTX) use from 4 Phase 3 studies: FUTURE 2,3,4,5. 
Methods: A total of 2148 pts with active PsA were randomised in 
FUTURE 2, 3, 4 and 5 studies (397, 414, 341 and 996, respecti-
vely). Study designs were described elsewhere.1–4 Assessments 
included	ACR20/50	by	prior	TNFi	use	(naïve/inadequate	response	
or intolerance [-IR]) and with/without MTX use. 
Results: Out of 2049 pts in analysis, 461, 572, 335, and 681 pts 
received SEC 300mg, 150mg, 150mg without load (NL) and pla-
cebo (PBO), respectively. ACR 20/50 responses were improved 
with SEC vs PBO at Wk 16 in both TNFi-naive/-IR pts and pts 
with/without concomitant MTX use (Table); improvements were 
also observed with SEC vs PBO for all other secondary endpoints. 
Conclusions: SEC provided improvement in the signs and 
symptoms of active PsA regardless of previous TNFi therapy or 
concomitant MTX use. Higher response rates were observed in 
TNFi-naïve	pts	compared	to	TNFi-IR	pts.	SEC	300mg	was	as-
sociated with higher responses compared to 150mg in pts with 
TNFi-IR and no concomitant MTX use. 
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Table: ACR20/50 responses at Week 16 by TNFi status and concomitant MTX use
 ACR20/50 Response [Treatment Effect vs. PBO at Week 16 (%)]
Pts subgroup SEC 300mg SEC 150mg SEC 150mg (NL)
TNFi	naïve 34.6/30.1 31.6/25.1 34.5/22.6
TNFi-IR 29.3/18.1 24.5/14.7 17.8/8.3
With MTX 23.1/20.1 28.1/20.1 23.5/11.3
Without MTX 41.6/29.1 29.7/20.6 34.5/22.6
P031
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Background: Previous	studies	have	shown	the	efficacy	of	anti-
TNFα	agents	in	improving	nail,	skin	and	joint	manifestations	of	
psoriatic arthritis (PsA). However, real-world data on the com-
parative effectiveness of switching to or adding these agents vs. 
continuing non-biologic treatments in patients having failed prior 
non-biologic treatment are necessary to support the integration of 
treatment algorithms into routine care.
Objectives: The aim of this analysis was to compare the effect 
of adalimumab (ADA) vs. non-biologic treatments (nbDMARD: 
NSAIDs and DMARDs) on skin outcomes and patient reported 
outcomes following initial treatment failure. In addition, the im-
pact of the extent of baseline skin disease on treatment outcomes 
was examined.
Methods: Patients	eligible	 for	COMPLETE	PsA	are	anti-TNFα	
naïve	adults,	with	active	PsA	who	require	change	in	their	treatment	
regimen, per the judgment of the treating physician. In the current 
analysis patients enrolled between July/2011 – Jun/2016 who had 
available information on baseline psoriasis body surface area (BSA) 
were included. Outcome measures analyzed were: BSA, Derma-
tology Life Quality Index (DLQI), Short Form Health Survey 
(SF-12), and the Beck Depression Inventory (BDI). Analyses were 
conducted by initial group assignment (intent-to-treat approach).
Results: A total of 392 patients were included (ADA n = 249, 
nbDMARD n = 143). Baseline demographics and disease duration 
were comparable between treatment groups. However, patients 
initiating	ADA	were	more	 likely	 to	have	BSA≥3%	(44.6%	vs.	
35%, p = 0.063) and had higher DLQI (6.2 vs. 4.3, p = 0.006) 
scores. No differences were observed in SF-12 physical (PCS) 
and mental (MCS) component scores at baseline.
During	 treatment,	BSA	 levels	 significantly	 improved	 in	 both	
groups but more patients achieved a BSA < 3% when treated 
with ADA vs. nbDMARD both at 6 months (89.7% vs. 80.2%, 
p = 0.027) and 12 months (89.0% vs. 83.7%, p = 0.222). Further-
more, upon adjusting for baseline scores, patients in the ADA 
group	experienced	greater	improvements	in	DLQI	(ΔLSM = -1.62, 
p = 0.004), particularly in the daily activities, leisure, and work/
school	domains,	and	SF-12	PCS	(ΔLSM = 0.36, p < 0.001). These 
differences between groups in BSA levels and DLQI improvement 
were	more	profound	among	patients	with	BSA≥3%	at	baseline.
During follow-up, 9.2% of ADA patients initiated another biologic 
and 32.2% of patients in the nbDMARD group initiated biologic 
treatment (p < 0.001).
Conclusions: PsA patients starting ADA following initial fai-
lure of non-biologic treatment in Canadian routine clinical care 
experience	greater	benefits	in	skin	outcomes	and	quality	of	life	
compared to switching to different non-biologic treatment. These 
benefits	are	particularly	evident	among	patients	with	more	severe	
skin disease at baseline. 
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Introduction: Ixekizumab (IXE), a high-affinity monoclonal 
antibody that selectively targets interleukin-17A, is approved for 
treatment of patients (pts) with active psoriatic arthritis (PsA) and 
provides	persistent	efficacy	through	52	weeks	(wks)	of	treatment.
Objective:To	evaluate	the	efficacy	of	IXE	treatment	over	52	wks	on	
nail and skin psoriasis in biologic disease-modifying anti-rheuma-
tic	drug	(bDMARD)-naïve	and	-experienced	pts	with	active	PsA.
Methods: Adult	pts	with	active	PsA	were	bDMARD-naïve	(SPI-
RIT-P1) or -experienced (SPIRIT-P2, TNF inhibitor inadequate 
responders [TNFi-IR] or intolerant). Pts were randomized to IXE 
80 mg every 2 (Q2W) or 4 wks (Q4W), placebo, or (in SPIRIT-
P1)	40	mg	adalimumab	Q2W.	Efficacy	of	IXE	on	nail	and	skin	
psoriasis in patients randomized to IXE was measured by the Nail 
Psoriasis Severity Index (NAPSI), Psoriasis Area and Severity 
Index (PASI), and static Physician Global Assessment (sPGA). 
Missing data were imputed using nonresponder imputation for 
categorical	variables	and	modified	baseline	observation	carried	
forward for continuous variables.
Results: IXE provided high clinical response in skin and nail 
psoriasis that persisted through 52 wks of treatment, regardless 
of IXE dosing or prior bDMARD use (Table).
 
SPIRIT-P1
(bDMARD	Naïve)
SPIRIT-P2
(TNFi-IR or Intolerant)
IXE Q4W
n = 107
IXE Q2W
n = 103
IXE Q4W
n = 122
IXE Q2W
n = 123
PASI 75a 52/73 (71.2) 45/59 (76.3) 41/68 (60.3) 37/68 (54.4)
PASI 90a 44/73 (60.3) 43/59 (72.9) 34/68 (50.0) 27/68 (39.7)
PASI 100a 37/73 (50.7) 37/59 (62.7) 27/68 (39.7) 24/68 (35.3)
sPGA 0/1b 39/52 (75.0) 29/41 (70.7) 37/60 (61.7) 41/62 (66.1)
sPGA 0b 29/52 (55.8) 23/41 (56.1) 26/60 (43.3) 27/62 (43.5)
NAPSI  = 0c 30/69 (43.5) 28/74 (37.8) 41/89 (46.1) 24/74 (32.4)
NAPSI mean (SD) change from 
baselinec
-15.9 (18.3) -20.0 (20.8) -15.2 (19.7) -14.4 (19.0)
Unless otherwise indicated, values are presented as: n/Nx (%), where Nx is apts with baseline 
BSA≥3%,	bpts	with	baseline	sPGA≥3,	or	cpts	with	baseline	fingernail	psoriasis
Conclusions: In these two phase 3 clinical trials in patients with 
active PsA, ixekizumab provided persistent high clinical response 
for improvement or clearance of nail and skin psoriasis through 
52 wks of treatment. 
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IXEKIZUMAB MAKES THERAPEUTIC THRESHOLDS 
POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS 
PATIENTS: RESULTS FROM SPIRIT TRIALS
Laura C Coates1, M. Elaine Husni2, Eric Lespessailles3, Lisa Kerr4, 
Gaia Gallo4
1University of Oxford, Leeds, UK, 2Cleveland Clinic, Cleveland, OH, USA, 
3Université d’Orléans, Orléans, EA, France, 4Eli Lilly and Company, In-
dianapolis, IN, USA
Introduction: Treatment goals in psoriatic arthritis (PsA) are mo-
ving toward attainment of absolute therapeutic thresholds rather 
than relative improvement.
Objective:To explore the effect of ixekizumab (IXE), an anti-IL-
17A monoclonal antibody, as assessed by composite endpoints, 
up to 52 weeks (wks) for the SPIRIT-P1 and SPIRIT-P2 trials.
17Poster abstracts
Acta Derm Venereol 2018
Methods: Data were analyzed from 2 double-blind, phase 3 trials 
investigating	the	efficacy	and	safety	of	IXE	in	active	PsA	patients	
(pts). For SPIRIT-1 [1] biologic disease-modifying antirheumatic 
drug-naïve	 pts	were	 randomized	 to	 placebo	 (PBO,	n = 106) or 
80 mg IXE every 4 wks (Q4W, n = 107) or every 2 wks (Q2W, 
n = 103) post 160 mg starting dose. For SPIRIT-2 [2] (inadequate 
responders to tumor necrosis factor inhibitors [TNFi]) pts were 
randomized to PBO (n = 118) or 80 mg IXE Q4W (n = 122) or 
Q2W (n = 123) post 160 mg starting dose. Minimal disease ac-
tivity (MDA), MDA very low disease activity (VLDA), Disease 
Activity in Psoriatic Arthritis (DAPSA) LDA, DAPSA remission, 
Psoriatic Arthritis Disease Activity Score (PASDAS) LDA, and 
PASDAS VLDA composite endpoints were evaluated. Imputa-
tion for categorical responses was non-responder imputation. 
Treatment comparisons (with placebo up to Wk 24) based on the 
intent-to-treat population were made using a logistic regression 
model. Data up to Wk52 are summarized.
Results: At Wk 24, percentage of pts achieving MDA (SPIRIT-P1 
Q4W: 29.9; Q2W: 40.8; PBO: 15.1; SPIRIT-P2 Q4W: 27.9; Q2W: 
31.9; PBO: 3.4), MDA VLDA (SPIRIT-P1 Q4W: 10.3; Q2W: 
11.7; PBO: 0.9; SPIRIT-P2 Q4W: 12.3; IXEQ2W: 3.3; PBO: 0.8), 
DAPSA LDA (SPIRIT-P1 Q4W: 31.8; Q2W: 34.0; PBO: 17.9; 
SPIRIT-P2 Q4W: 25.4; Q2W: 27.6; PBO: 11.1), DAPSA remission 
(SPIRIT-P1 Q4W: 15.9; Q2W: 24.3; PBO: 4.7; SPIRIT-P2 Q4W: 
14.8; Q2W: 7.3; PBO: 0.8), PASDAS LDA (SPIRIT-P1 Q4W: 
42.1; Q2W: 50.5; PBO: 18.9; SPIRIT-P2 Q4W: 39.3; Q2W: 35.0; 
PBO: 6.8), and PASDAS VLDA (SPIRIT-P1 Q4W: 11.2; Q2W: 
20.4; PBO: 1.9; SPIRIT-P2 Q4W: 13.1; Q2W: 7.3; PBO: 0.0) was 
greater with Q4W and Q2W versus placebo.
Similarly, at Wk 52 the response rates were either sustained or 
improved: MDA (SPIRIT-P1 Q4W: 39.3; Q2W: 36.9; SPIRIT-P2 
Q4W: 34.4; Q2W: 23.6), MDA VLDA (SPIRIT-P1 Q4W: 14.0; 
Q2W: 15.5; SPIRIT-P2 Q4W: 12.3; Q2W: 6.5), DAPSA LDA 
(SPIRIT-P1 Q4W: 30.8; Q2W: 29.1; SPIRIT-P2 Q4W: 34.4; Q2W: 
26.0), DAPSA remission (SPIRIT-P1 Q4W: 22.4; Q2W: 29.1; 
SPIRIT-P2 Q4W: 18.9; Q2W: 11.4), PASDAS LDA (SPIRIT-P1 
Q4W: 43.0; Q2W: 50.5; SPIRIT-P2 Q4W: 45.1; Q2W: 30.9), and 
PASDAS VLDA (SPIRIT-P1 Q4W: 17.8; Q2W: 26.2; SPIRIT-P2 
Q4W: 17.2; Q2W: 11.4).
Conclusions: Regardless of previous TNFi exposure, a higher 
proportion of IXE-treated pts achieved MDA and MDA VLDA, 
DAPSA LDA and DAPSA remission, and PASDAS LDA and 
PASDAS VLDA at Wk 24 versus placebo. At Wk 52, the extent 
of IXE clinical response sustained or further improved.
Reference:
1. Mease PJ et al. Ann Rheum Dis. 2017;76(1):79-87. 2. Nash P et al. 
Lancet. 2017;389(10086):2317-2327.
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THE MACROPHAGE MODULATOR MP1032 SHOWS 
SAFETY AND EFFICACY IN A HUMAN PHASE IIA 
STUDY FOR THE TREATMENT OF MODERATE­TO­
SEVERE PLAQUE PSORIASIS
Petra Schulz, Astrid Kaiser, David Kosel, Sara Schumann, Wolf-
gang Brysch
MetrioPharm GmbH, Berlin, Germany
Introduction: MP1032	belongs	to	a	new	class	of	anti-inflammatory	
drugs that modulate the redox state of activated macrophages. 
MP1032	attenuates	pro-inflammatory	cytokine	secretion	in vivo 
and in vitro and has pronounced disease-modifying effects in 
various preclinical models.
Objectives: This randomized, double-blind, parallel, and placebo-
controlled trial aimed to evaluate pharmacokinetics, safety, and 
efficacy	of	orally	administered	MP1032	in	patients	with	moderate-
to-severe plaque psoriasis.
Methods: Forty-six patients with chronic plaque psoriasis (PASI  > 
10;	 disease	 duration	≥	6	months)	were	 equally	 randomized	 to	
receive either 100 mg MP1032 or placebo by twice daily oral 
administration. The study design consisted of a 42 day treatment 
period with a follow-up of 28 days. Pharmacokinetic sampling 
occurred on day 1 at 15, 30, 60, and 120 min post-dose. Adverse 
events were coded according to the Medical Dictionary for Regu-
latory	Activities.	Efficacy	parameters	were	assessed	at	screening	
and on day 1, 15, 29, 43, 57, and 71.
Results: Enrolled patients had an average age of 40 years (21–65 
years) and a median baseline PASI of 13.6 (ranging from 10.1 to 
40.8). Pharmacokinetic evaluation demonstrated that MP1032 
was rapidly absorbed, reaching maximum plasma concentrations 
within 15 min after administration. Then, MP1032 plasma levels 
were quickly declining, indicating a fast elimination. Safety 
analysis did not reveal any clinically important safety issues. No 
serious adverse events or deaths were reported and the incidence 
of treatment emergent adverse events (TEAEs) between placebo 
and the MP1032 treatment group was comparable. The majority 
of TEAEs were mild to moderate in nature (mostly common cold, 
headache, and itching). Analysis of clinical laboratory data and 
vital signs did also not reveal any adverse effects of MP1032. After 
only six weeks of treatment, MP1032 led to a PASI reduction of 
about 25% in patients who entered the study with a PASI of 10–15. 
In contrast, placebo administration reduced the respective PASI 
only about 12%. During the four-week follow-up period, median 
PASI scores in the MP1032 group trended back upward while the 
placebo group remained unchanged, suggesting a positive thera-
peutic effect of MP1032. Since, patients with a lower basal PASI 
had greater improvements during therapy than those with higher 
scores, MP1032 seems to be a treatment option for patients with 
mainly moderate psoriasis.
Conclusion: After six weeks of treatment, there was a clinically 
relevant response in patients who entered the study with PASI 
scores of 10–15. Overall, MP1032 demonstrated an excellent 
safety	profile	and	was	well	tolerated.	Hence,	redox	modulation	
targeted at the innate immune response represents a promising 
new therapeutic mechanism for psoriasis and other chronic in-
flammatory	diseases.	
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SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS 
OF PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 
STUDY, FUTURE 5
Philip J. Mease1, D van der Heijde2, R Landewé3, S Mpofu4, P Rah-
man5, H Tahir6, A Singhal7, S Navarra8, E Boettcher8, X Zhu10, A 
Readie10, L Pricop10, K Abrams10
1Swedish Medical Center and University of Washington, Seattle, WA, USA, 
2Leiden University Medical Center, Leiden, 3University of Amsterdam and 
Atrium Medical Center, Amsterdam, the Netherlands, 4Novartis, Pharma 
AG, Basel, Switzerland, 5Memorial University, Newfoundland and Labra-
dor, Canada, 6Whipps, Cross Hospital, London, UK, 7Southwest Rheu-
matology, Dallas, TX, USA, 8Rheumazentrum Favoriten, Vienna, Austria, 
9University of Santo Tomas Hospital, Manila, Philippines, 10Novartis Phar-
maceuticals Corporation, East Hanover, NJ, USA
Introduction/Objectives: Secukinumab (SEC), a fully human mAb 
to	IL-17A,	has	shown	efficacy	in	psoriatic	arthritis	(PsA).	Here	
we	present	the	primary	results	of	FUTURE	5,	assessing	efficacy,	
including inhibition of radiographic progression of subcutaneous 
(sc) SEC 300 and 150mg in patients (pts) with PsA (1). 
Methods: Pts (n = 996) with active PsA, were randomized (2:2:2:3) 
to sc SEC 300mg with loading dosage (LD; n = 222), 150mg with 
LD (n = 220), 150mg without LD (n = 222), or placebo (PBO; 
n = 332). All groups received SEC or PBO at baseline (BL), Weeks 
(Wks) 1, 2, 3, and 4, and then every 4 wks. Primary endpoint 
was ACR20 at Wk16. Key secondary endpoint was radiographic 
structural	 progression,	 as	measured	 by	modified	 total	 van	 der	
Heijde Sharp score (mTSS). 
Results: SEC	significantly	 improved	ACR20	at	Wk16	vs	PBO	
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(Table).	 Radiographic	 progression	 (mTSS)	was	 significantly	
inhibited at Wk24 in all SEC arms vs PBO (Table). A greater pro-
portion of pts had no radiographic progression (change from BL 
in mTSS  ≤ 0.5) with SEC vs PBO: 88% (300mg), 79% (150mg), 
83% (150mg without LD), and 73% (PBO). Results for other 
secondary endpoints are shown in Table. No unexpected safety 
signals were reported.
Conclusions: Subcutaneous SEC 300 mg with LD and 150 mg 
with	 and	without	LD	provided	 rapid	 and	 clinically	 significant	
improvements in the signs and symptoms of PsA and inhibited 
radiographic	progression.	Safety	profile	was	consistent	with	that	
previously reported. 
Reference:
1. Mease PJ, et al. Arthritis Rheumatol.2017;69(suppl 10).
Table
Wk 16 data(a)
ACR20(b)
mTSS(c)
PASI 75/90(b,d)
HAQ-DI(c)
Enthesitis resolution(b,e)
Dactylitis resolution(b,e)
DLQI(c,d)
mNAPSI(c,f)
300 mg
62.6***
0.08*
70***/53.6***
–0.6***
55.7**
65.9***
–8.5***
–9.2***
150 mg
55.5***
0.17^
60***/36.8***
–0.4***
54.6**
57.5**
–7.4***
–9.3***
150 mg without LD
59.5***
–0.09*
58.1***/31.6***
–0.5***
41.9
56.3
–7.0***
–7.7***
PBO
27.4
0.5
12.3/9.3
–0.2
35.4
32.3
–2.4
–2.5
***P < 0.0001; **P < 0.001; *P < 0.01; ^P < 0.05 un-adjusted P-values vs PBO. (a)Wk24 data 
for	mTSS;	(b)%	responders;	(c)mean	change	from	BL;	(d)Data	from	pts	with	BL	psoriasis	≥3%	
body surface area; (e)Data from pts with dactylitis or enthesitis at BL; (f)Data from pts with 
nail psoriasis at BL
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INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN 
PATIENTS TREATED WITH SECUKINUMAB: POOLED 
ANALYSIS OF 21 RANDOMISED CONTROLLED PHASE 
3/4 CLINICAL TRIALS OF PSORIASIS, PSORIATIC 
ARTHRITIS, AND ANKYLOSING SPONDYLITIS
Stefan Schreiber1, Jean-Frederic Colombel2, Brian G Feagan3, 
Kristian Reich4, Atul Deodhar5, Iain B McInnes6, Brian Porter7, 
Ayan Das Gupta8, Luminita Pricop7, Todd Fox9
1Department of Internal Medicine, University Hospital Schleswig-Holstein, 
Kiel, Germany, 2Division of Gastroenterology, Icahn School of Medicine at 
Mount Sinai, New York, USA, 3Robarts Clinical Trials Inc., Department of 
Epidemiology and Biostatistics, Department of Medicine, Division of Gas-
troenterology, University of Western Ontario, London, Ontario, Canada, 
4Dermatologikum Hamburg and Georg-August-University, Göttingen, Ger-
many, 5Oregon Health & Science University, Portland, OR, USA, 6Institute 
of Infection Immunity and Inflammation, University of Glasgow, Glasgow, 
UK, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
8Novartis Healthcare Pvt. Ltd., Hyderabad, India, 9Novartis Pharma AG, 
Basel, Switzerland
Introduction: Inflammatory	bowel	disease	(IBD)	including	Crohn’s	
disease (CD) and ulcerative colitis (UC) are common comor-
bidities associated with psoriasis, psoriatic arthritis (PsA), and 
ankylosing spondylitis (AS). Compared with the general popula-
tion, epidemiological studies have shown that patients (pts) with 
psoriasis or PsA are at a 2–4-fold increased risk of developing CD 
and a 2–3-fold increased risk of developing UC.1–5 Additionally, 
in pts with AS, there is a 3–5-fold increased risk of IBD compared 
with the general population.6 Secukinumab is a fully human mo-
noclonal antibody that neutralizes interleukin-17A and is approved 
for the treatment of psoriasis, PsA, and AS.
Objectives: To evaluate the incidence of IBD, CD, and UC in pts 
with psoriasis, PsA, or AS who received IL-17A-inhibition with 
secukinumab from 21 phase 3/4 clinical trials of secukinumab for 
psoriasis, PsA, or AS. 
Methods: This analysis evaluated pooled data from fourteen phase 
3 and one phase 4 psoriasis trials, three phase 3 PsA trials, and 
three phase 3 AS trials. Pts with a history of IBD, but not active 
ongoing IBD, were eligible for enrollment in these trials. Data 
from all pts that received at least one dose of secukinumab were 
included in this analysis. IBD reporting includes cases of CD, UC, 
and	IBD	not	otherwise	specified	(NOS).
Results: A total of 7355 pts receiving secukinumab were asses-
sed for the presence of IBD: 5181 with psoriasis, 1380 with PsA, 
and 794 with AS. Over the entire treatment period, the mean total 
exposure to secukinumab was 10,416.9 patient-years (pt-yrs) in 
pts with psoriasis, 3866.9 pt-yrs in pts with PsA, and 1943.1 pt-yrs 
in pts with AS. The exposure-adjusted incidence rate (EAIR) per 
100	pt-yrs	(95%	confidence	interval)	of	CD,	UC,	and	IBD	NOS	in	
secukinumab-treated pts were 0.05 [0.02, 0.11], 0.13 [0.07, 0.23], 
and 0.01 [0.00, 0.05], respectively in the psoriasis studies; 0.08 
[0.02, 0.23], 0.08 [0.02, 0.23], and 0.05 [0.01, 0.19], respectively 
in the PsA studies; and 0.4 [0.2, 0.8], 0.2 [0.1, 0.5], and 0.1 [0.0, 
0.3], respectively in the AS studies. Additionally, the incidence 
of IBD, CD, and UC did not increase over time.
Conclusion: Pooled data from 21 studies indicated that the obser-
ved exposure- adjusted incidence rates of IBD, CD, and UC with 
secukinumab were low and did not increase over time in pts with 
moderate to severe plaque psoriasis, PsA, or AS.
References:
1. Augustin M, et al. Acta Derm Venereol. 2010;90(2):147-51
2. Cohen AD, et al. J Eur Acad Dermatol Venereol 2009;23:561-5.
3. Egeberg A, et al. Br J Dermatol. 2016;175(3):487-92. 4. Li WQ, et al. 
Ann Rheum Dis. 2013;72(7):1200-5.
4. Makredes M, et al. J Am Acad Dermatol. 2009;61(3):405-10.
5. Stolwijk C, et al. Ann Rheum Dis. 2015;74(7):1373-8; 6. Stolwijk C, 
et al. Ann Rheum Dis. 2015;74(7):1373-8. 
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ANALYSIS OF THE POSITION OF THE FUMARIC 
ACID ESTERS IN CURRENT EUROPEAN PSORIASIS 
GUIDELINES
Cecilia Dietrich1, Adria Gual2, Laura Padulles2
1Dermatologikum Hamburg, Germany, 2Almirall S.A., Barcelona, Spain
Introduction: Since 1994 a combination of fumaric acid esters 
(FAEs) (dimethylfumarate [DMF] plus three salts of monoethyl-
fumarate [MEF]) has been approved in Germany for moderate-
to-severe psoriasis, however is not widely licensed elsewhere. 
While a new formulation of DMF has been recently approved by 
the European Commission (June 2017) as monotherapy for adults 
with moderate-to-severe psoriasis, only UK (NICE) guidelines 
mention DMF to date.[1]
Method: Current treatment guidelines for plaque psoriasis in 
several European countries are reviewed to determine if these 
guidelines include therapy with FAEs and how these may guide 
the use of DMF monotherapy in the future.
Results: FAE status varies across Europe. Current European gui-
delines recommend FAEs for the initial and long-term treatment 
of psoriasis. These guidelines (based on consensus/expert opinion) 
also	recommend	a	gradual	increase	in	dose.[2]	Country-specific	
guidelines vary in their individual recommendations. German 
guidelines endorse FAEs as 1st-line treatment for moderate-to-
severe psoriasis, based on BSA  > 10% or a PASI score of  > 10, 
and recommend clinical assessments after 16–24 weeks of treat-
ment.[3] UK guidelines approve FAEs only as a 2nd-line option 
for	severe	plaque	psoriasis	(PASI	≥10	or	DLQI≥	10),[1]	whilst	in	
the Netherlands FAEs are indicated only for initial treatment of 
moderate-to-severe disease.[4] Swiss guidelines also recommend 
the use of FAEs for moderate-to-severe psoriasis, but only in 
patients who are unresponsive to topical therapy.[5] In Sweden, 
FAEs can be considered as a 2nd-line treatment option.[6]
Other	country-specific	guidelines	are	 less	clear.	While	Spanish	
guidelines discuss FAEs as a slower-acting therapy requiring 
treatment	goals	to	be	set	at	week	16,	no	specific	guidance	on	the	
use of FAEs is given.[7] Likewise, while Italian guidelines men-
tion FAEs, they are not included in treatment recommendations as 
they are currently not licensed in Italy.[8] In contrast, there is no 
mention of FAEs in guidelines in Denmark, Portugal and Norway.
Conclusion: European guidelines recommend FAEs for both the 
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initial and long-term treatment of moderate-to-severe psoriasis. 
In Germany, FAEs have been licensed for > 20 years and are 
commonly used as 1st-line therapy. In the rest of Europe, there 
is growing acceptance of FAEs as a systemic therapy option in 
moderate-to-severe disease. Guidelines continue to evolve as ex-
perience grows outside Germany, and will need to be updated to 
guide the use of the newly approved DMF monotherapy in future.
References:
1. NICE 2017. https://www.nice.org.uk/guidance/TA475
2. Nast A, et al. JEADV 2015;29:2277-94
3. Nast A, et al. 2017 https://bit.ly/2ESJhv3
4. Zweegers J, et al. 2014 https://bit.ly/2GtvwA2
5. Kolios AG, et al. Dermatol 2016. 232:385-406
6. Krogstad A. Psoriasis 2017 https://bit.ly/2F05vbh
7. Dauden E, et al. JEADV 2016;30 Suppl 2:1-18
8. Gisondi P, et al. JEADV 2017;31(5):774-790
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SECUKINUMAB PROVIDES RAPID AND SUSTAINED 
RESOLUTION OF ENTHESITIS IN PSORIATIC 
ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO 
PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3
Laura C Coates1, Dennis McGonagle2, Georg Schett3, Philip J 
Mease4, Erhard Quebe-Fehling5, Darren L Asquith6, Lawrence Ra-
souliyan7, Shephard Mpofu5, Corine Gaillez5
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Introduction: Enthesitis, one of the key features of psoriatic 
arthritis (PsA), shows chronicity in 50–70% of affected patients 
(pts).1 Secukinumab (SEC), a fully human monoclonal antibody 
that	selectively	neutralises	IL-17A,	provided	significant	and	sus-
tained improvement in the signs and symptoms of active PsA, with 
sustained resolution of enthesitis in Phase 3 studies.2,3
Objectives: To evaluate the effect of SEC on resolution of enthesi-
tis	count	(EC;	defined	by	Leeds	Enthesitis	Index)	in	PsA	pts	using	
pooled data from two Phase 3 studies, FUTURE 2 (NCT01752634) 
and FUTURE 3 (NCT01989468).
Methods: SEC and placebo (PBO) were administered weekly 
during	the	first	4	weeks	(wks)	followed	by	subcutaneous	mainte-
nance dosing every 4 weeks thereafter (PBO until Wk 16/24). The 
results are reported only for SEC 300 and 150 mg (approved do-
ses). Pts with baseline (BL) enthesitis (BLE) or without BLE (No 
BLE) were included. Evaluation through Wk 104 included: time 
to	first	resolution	of	enthesitis	(i.e.	EC	 =  0); shift analysis of BL 
EC (1, 2 or 3–6) to full resolution (FR) and partial resolution (PR; 
reduction of EC) at Wks 24 and 104; and number of new enthesitis 
sites developed in No BLE pts. Data are as observed in the overall 
population;	time	to	first	resolution	of	enthesitis	was	analysed	in	
the overall population and by prior use of tumour necrosis factor 
inhibitor	(TNFi-naïve	and	-inadequate	responders	[IR]).
Results: A total of 466 pts had BLE with a mean EC of 3.1±1.6, 
and 246 pts had no BLE. Median days to resolution of EC in BLE 
pts for SEC 300, 150 mg and PBO groups were 57, 85 and 167 in 
overall	population;	57,	85	and	120	in	TNFi-naïve	pts;	and	92,	82	
and 169 in TNFi-IR pts, respectively. In pts with BL EC  =  1/2, 
72%/61% (SEC 300 mg), 71%/66% (SEC 150 mg) and 45%/44% 
(PBO), respectively, achieved FR at Wk 24, with FR in SEC groups 
sustained or increased to 77%/81% (SEC 300 mg) and 75%/88% 
(SEC 150 mg) at Wk 104. In BL EC  =  3–6, 81% (SEC 300 mg), 
73% (SEC 150 mg) and 71% (PBO) of pts achieved FR and PR 
at Wk 24, with an increase of FR and PR to 88% (in both SEC 
300 and 150 mg) at Wk 104. A total of 89% of pts with No BLE 
did not develop enthesitis by Wk 104.
Conclusions: Time to resolution of enthesitis was earlier with SEC 
than PBO in the overall population, with faster resolution observed 
in	TNFi-naïve	than	TNFi-IR	pts.	Majority	of	SEC-treated	pts	with	
BL EC  =  1/2 had FR by Wk 24, with further an improvement 
by Wk 104. In pts with BL EC  =  3–6, greater improvement was 
observed with SEC 300 mg vs PBO in the proportion of pts with 
FR and PR of enthesitis at Wk 24; further improvements were 
observed in both SEC groups at Wk 104.
References:
1. Schett G, et al. Nat Rev Rheumatol. 2017;13:731–41.
2. Mease PJ, et al. N Engl J Med. 2015;373:1329–39.
3. McInnes IB, et al. Lancet 2015;386:1137–46.
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ANALYSIS IN 29,987 PATIENTS REPRESENTING 56,951 
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mes Rosenbaum4, Dilek Arikan5, Winnie L. Lau5, Rita Tarzynski-
Potempa2
1Charité - University Medicine Berlin, Berlin, Germany, 2University of Cal-
gary, Calgary, AB, Canada, 3Medical College of Wisconsin, Milwaukee, 
WI, USA, 4Oregon Health & Science University and Legacy Devers Eye 
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Introduction: Adalimumab	 is	 an	 anti–tumor	 necrosis	 factor-α	
(TNF-α)	agent	indicated	for	the	treatment	of	immune-mediated	
diseases. The long-term safety of adalimumab was previously 
reported in 23,458 patients representing up to 12 years of clinical 
trial exposure in rheumatoid arthritis (RA), juvenile idiopathic 
arthritis, ankylosing spondylitis (AS), psoriatic arthritis (PsA), 
plaque psoriasis (Ps), and Crohn’s disease (CD).
Objectives: Here we report an updated analysis examining the 
long-term safety of adalimumab in adult patients with RA, AS, 
non-radiographic axial spondyloarthritis (nr-axSpA), peripheral 
SpA (pSpA), PsA, Ps, hidradenitis suppurativa (HS), CD, ulcera-
tive colitis (UC), and non-infectious uveitis (UV).
Methods: Safety data from 78 clinical trials of adalimumab (RA, 
33; AS, 5; nr-axSpA, 2; pSpA, 1; PsA, 3; Ps, 13; HS, 3; CD, 11; 
UC, 4; UV, 2; other, 1) were included in these analyses, including 
randomized controlled, open-label, and long-term extension stu-
dies conducted in Europe, North America, South America, Asia, 
Australia, New Zealand, and South Africa through December 
31, 2016. Adalimumab postmarketing surveillance data were not 
included in this analysis. Safety assessments included all adverse 
events	(AEs)	and	serious	AEs	(SAEs)	that	occurred	after	the	first	
adalimumab study dose and up to 70 days (5 half-lives) after the 
last study dose.
Results: This analysis included 29,987 patients, representing 56,951 
patient-years of exposure. The majority of adalimumab exposure 
was in RA studies (37,106 PYs). The most frequently reported SAE 
of interest was infection (highest incidences in CD: 6.9, UV: 4.1, 
RA: 3.9, and UC: 3.5). The overall standardized mortality ratio was 
0.65, 95% CI [0.5, 0.74]. For most of the adalimumab populations 
(AS, PsA, Ps, UC, CD, and RA), the observed number of deaths 
was below what would be expected in an age- and sexadjusted po-
pulation. For HS, nr-axSpA, pSpA, and UV studies, the small size 
of these trials precluded accurate assessment of the standardized 
mortality ratio, and the 95% CIs all included 1.0.
Conclusion: This analysis of data from clinical trials of adali-
mumab	demonstrated	 an	 overall	 safety	 profile	 consistent	with	
previous	findings	and	with	the	TNF	inhibitor	class.	No	new	safety	
signals or tolerability issues with adalimumab treatment were 
identified	and,	for	most	indications,	the	mortality	rate	was	below	
what would be expected in an age- and sexadjusted population. 
Efficacy	and	safety	data	continue	to	support	the	well-established	
benefits	of	adalimumab	for	the	approved	indications.
Previously Published Arthritis Rheumatol. 2017; 69 (suppl 10).
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CLINICAL RESPONSE AFTER GUSELKUMAB 
TREATMENT AMONG ADALIMUMAB PASI 90 NON­ 
RESPONDERS: RESULTS FROM THE VOYAGE 1 AND 2 
TRIALS 
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Robert Bissonnette4, Michael Song5, Yasmine Wasfi5, Bruce Ran-
dazzo5, Yin You5, Yaung-Kaung Shen5, Bruce Strober6
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Objective:To evaluate the levels of response to guselkumab 
(GUS) among adalimumab (ADA) PASI 90 non-responders in 
the VOYAGE 1 and VOYAGE 2 trials.
Materials/Methods: In VOYAGE 1 (n = 837), patients were ran-
domized to GUS 100 mg at Weeks (Wks) 0/4/12, then every 8 wks; 
placebo (PBO) at Wks 0/4/12 followed by GUS 100 mg at Wks 
16/20 and then every 8 wks; or ADA 80 mg at Wk 0, 40 mg at Wk 
1, and 40 mg every 2 wks through Wk 47. In VOYAGE 2 (n = 992), 
patients were randomized to GUS 100 mg at Wks 0/4/12/20; PBO 
at Wks 0/4/12 then GUS 100 mg at Wks 16/20; or ADA 80 mg at 
Wk 0, 40 mg at W1, and then every 2 wks through Wk 23. ADA 
PASI 90 non-responders initiated GUS at Wk 52 (VOYAGE 1) or 
at Wk 28 (VOYAGE 2) and continued GUS treatment through Wk 
100. Here we report PASI 100, PASI 90, IGA 0 (cleared) and IGA 
0/1 (cleared/minimal disease), Dermatology Quality of Life Index 
(DLQI), and Psoriasis Symptom and Sign Diary (PSSD) outcomes 
among these ADA PASI 90 non-responders after initiating GUS 
treatment through Wk 100.
Results: In VOYAGE 1, among 138 ADA-treated PASI 90 non-
responders who initiated GUS treatment at Wk 52, a PASI 90 
response was achieved by 75.0% of patients at Wk 76, and 72.6% 
of patients at Wk 100. At Wk 100, 78.5% of patients achieved an 
IGA 0/1 response, 74.8% of patients reported a DLQI 0/1 score, 
33.3% of patients reported a PSSD symptom score of 0, and 
18.9% reported a PSSD sign score of 0. In VOYAGE 2, among 
112 ADA-treated PASI 90 non-responders who initiated GUS at 
Wk 28, a PASI 90 response was achieved by 66.1% of patients 
at Wk 48 and 75.5% of patients at Wk 100. At Wk 100, 81.0% of 
patients achieved an IGA 0/1 response, 65.3% of patients reported 
a DLQI 0/1 score, 32.6% of patients reported a PSSD symptom 
score of 0, and patients 18.0% reported a PSSD sign score of 0.
Conclusions: Among ADA PASI 90 non-responders, GUS treat-
ment	provided	robust	levels	of	efficacy,	which	were	maintained	
through Wk 100.
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CONSISTENCY OF RESPONSE BY WEIGHT ACROSS 
SUBGROUPS OF PATIENTS WITH PSORIASIS TREATED 
WITH GUSELKUMAB: RESULTS FROM THE VOYAGE 1 
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Objective:To evaluate the consistency of response of guselku-
mab (GUS) across predetermined weight quartile subgroups of 
psoriasis patients.
Materials/Methods: In VOYAGE 1 (n = 837) and VOYAGE 2 
(n = 992), patients were randomized to GUS 100 mg at Weeks 
0/4/12/20; placebo (PBO) at Weeks 0/4/12 followed by GUS 100 
mg at Weeks 16/20; or ADA 80 mg at Week 0, 40 mg at Week 
1, and 40 mg every 2 weeks through Week 23. The co-primary 
endpoints were the proportions of GUS vs PBO patients achieving: 
1)	≥90%	improvement	in	PASI	score	(PASI	90),	and	2)	cleared/
minimal disease (IGA 0/1) responses at Week 16. Response rates 
across endpoints were evaluated for predetermined subgroups by 
baseline weight quartiles.
Results: Pooled data from the two studies at Week 16 and Week 24 
demonstrated that patients in the guselkumab group achieved sub-
stantially higher clinical responses compared with placebo at Week 
16 and ADA at Week 24 across all quartiles of weight as cutoffs. 
At	Week	16,	for	each	quartile,	defined	by	 < 74.6,	≥74.6– < 86.4, 
≥86.4– < 100,	and	≥100	kg,	the	proportions	of	GUS	patients	with	
a PASI 90 response were 76.0%, 78.6%, 66.2%, and 65.2%, 
respectively and the proportions with an IGA 0/1 response were 
89.1%, 88.6%, 78.7%, and 82.6%, respectively. The proportions 
of PBO patients with a PASI 90 response by these quartiles were 
5.0%, 2.9%, 1.2%, and 0.9%, respectively and the proportions 
with an IGA 0/1 response were 11.6%, 10.5%, 4.9%, and 3.5%, 
respectively. 
At Week 24, the proportions of GUS patients with a PASI 90 re-
sponse by weight quartile were 79.7%, 81.1%, 75.1%, and 73.4%, 
respectively and the proportions with an IGA 0/1 response were 
85.9%, 88.1%, 83.1%, and 78.3%, respectively. The proportions 
of ADA patients with a PASI 90 response by these quartiles were 
62.4%, 66.0%, 52.7%, and 35.5%, respectively and the propor-
tions with an IGA 0/1 response were 70.9%, 76.5%, 61.1%, and 
45.2%, respectively.
Conclusions: The	efficacy	of	GUS	treatment	was	demonstrated	
across	all	predefined	weight	quartiles	and	high	efficacy	responses	
were observed in psoriasis patients without regard to weight.
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Introduction: Evidence suggests that timely and effective mana-
gement can improve long-term outcomes in patients (pts) with 
psoriatic	arthritis	 (PsA);	however	 factors	 influencing	 treatment	
management decisions are not well understood.
Objective:To evaluate the association between the clinical speci-
alty	setting	and	time	from	inflammatory	musculoskeletal	symptom	
onset to PsA diagnosis and to different management steps in pts 
with a diagnosis of PsA.
Methods: LOOP is a large cross-sectional, multi-center, observa-
tional study conducted in 17 countries across Western and Eastern 
Europe,	Latin	America,	and	Asia.	Adult	pts	(≥18	years)	with	a	
suspected or an established diagnosis of PsA routinely visiting a 
rheumatologist (rheum), dermatologist (derm) or non-rheum/non-
derm site were eligible to participate in this study. Each enrolled 
patient in the study was assessed by both rheum and derm. Main 
endpoints	assessed	were	time	from	inflammatory	musculoskeletal	
symptom	onset	to	PsA	diagnosis,	time	from	PsA	diagnosis	to	first	
csDMARD	and	to	first	bDMARD,	and	time	from	first	csDMARD	
to	first	bDMARD.
Results: Of the 1483 pts enrolled in this study, 1273 pts with a 
confirmed	diagnosis	of	PsA	were	included	in	this	analysis.	A	ma-
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jority of pts were recruited by rheums (671, 52.7%), followed by 
derms (541, 42.5%), physiatrists (36, 2.8%), and other specialties 
(25,	2.0%).	PsA	was	first	suspected	by	a	rheum	in	726	(57.0%)	pts	
and by a derm in 541 pts (42.5%). Pt demographics and disease 
characteristics were mostly comparable between rheum and derm 
settings. Disease activity was higher in PsA pts in derm setting 
compared with rheum setting. The mean time from symptom onset 
to PsA diagnosis was 24 months (mo) in rheum setting and 1 mo 
longer for derms. In rheum and derm settings, the mean time from 
PsA	diagnosis	to	first	csDMARD	were	11	and	25	mo,	respectively;	
whereas	the	mean	time	to	first	bDMARD	were	52	and	55	mo,	re-
spectively.	The	mean	time	from	first	csDMARD	to	first	bDMARD	
was 42 mo for rheums; while it was 3 months shorter for derms.
Conclusion: Although the duration from symptom onset to PsA 
diagnosis was similar between rheum and derm setting, there were 
differences in the timing of introduction of different DMARD 
classes.	Notably,	mean	time	to	first	csDMARD	was	significantly	
shorter	in	rheum	setting.	PsA	pts	in	derm	setting	had	significantly	
higher disease activity. These data lend further support to the need 
for rheum-derm collaborative approach to optimize management 
of pts with PsA.
P045
SPEED OF RESPONSE OF GUSELKUMAB COMPARED 
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MODERATE­TO­SEVERE PSORIASIS: RESULTS 
THROUGH WEEK 24 FROM THE PHASE 3, DOUBLE­
BLINDED, PLACEBO­ AND ACTIVE COMPARATOR­
CONTROLLED VOYAGE 1 AND VOYAGE 2 TRIALS 
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Background: VOYAGE 1 and 2 were two phase 3 double-blinded, 
placebo/active comparator-controlled trials evaluating guselkumab 
(GUS), a fully human monoclonal antibody targeting interleukin 
(IL)-23, compared with adalimumab (ADA) in the treatment of 
patients with moderate-to-severe plaque psoriasis. Here, we report 
speed of response results based on Psoriasis Area and Severity 
Index (PASI) outcomes through Week 24 from pooled VOYAGE 
1 and 2 data.
Methods: In VOYAGE 1 and 2, patients with plaque psoriasis 
were randomized at baseline to GUS 100 mg (Weeks 0 and 4, then 
every 8 weeks [q8w]; pooled n = 825), ADA (80 mg Week 0, 40 
mg Week 1, then 40 mg every 2 weeks [q2w]; pooled n = 582), or 
placebo (Weeks 0, 4, and 12, then GUS 100 mg at Weeks 16 and 
20; pooled n = 422).	Efficacy	was	evaluated	using	PASI	75,	PASI	
90,	and	PASI	100	responses	(patients	achieving	≥75%,	≥90%,	and	
100% PASI improvement from baseline, respectively) through 
Week	24.	Median	time	to	achieve	a	response	was	defined	as	the	
time	taken	for	≥50%	of	the	patients	to	ever	achieve	a	response.
Results: Based on the pooled VOYAGE 1 and 2 data, median 
time to achieve a PASI 75 response was  ≤ 8 weeks for both the 
GUS and ADA groups. However, median time to achieve a PASI 
90 response was  ≤ 12 weeks for GUS and  ≤ 16 weeks for ADA. 
Median time to achieve a PASI 100 response was  ≤ 24 weeks for 
GUS, but was not achieved for ADA. Median time to achieve any 
defined	endpoint	was	not	achieved	for	the	placebo	group.
Conclusions: Taken together, these results demonstrate that pa-
tients with moderate-to-severe psoriasis treated with GUS rapidly 
achieved	high	levels	of	response,	and	more	efficiently	and	more	
quickly than with ADA. 
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Introduction: The Fc-free, PEGylated, anti-tumor necrosis factor 
certolizumab	pegol	(CZP)	has	shown	efficacy	in	chronic	plaque	
psoriasis (PSO) over 48 weeks’ treatment.[1,2] 
Objectives: To report 48-week safety data for CZP in PSO.
Methods: Data were pooled from ongoing phase 3 trials of CZP 
in adults with PSO (n = 962): CIMPASI-1 (NCT02326298), CIM-
PASI-2 (NCT02326272), CIMPACT (NCT02346240). Patients 
(pts)	 had	PSO	≥6	months	 (Psoriasis	Area	Severity	 Index	≥12,	
≥10%	body	surface	area	affected,	physician’s	global	assessment	
≥3/5)	and	were	randomized	to	CZP	400	mg	every	2	weeks	(Q2W)	
or 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), placebo 
(PBO) for 16 weeks, or etanercept for 12 weeks (CIMPACT 
only).	We	present	data	for	pts	receiving	≥1	CZP	dose	during	initial	
and/or maintenance periods with up to 48 weeks’ exposure as of 
20Oct2016 (CIMPASI-1), 16Aug2016 (CIMPASI-2), 05Dec2016 
(CIMPACT).	Adverse	events	(AEs)	were	classified	using	Med-
DRAv18.1. Incidence rates (IR) are the incidence of new cases 
per 100 patient-years (PY).
Results: Total CZP exposure was 730PY. 709 pts (73.7%) ex-
perienced	≥1	AE;	IRs	were	similar	between	pts	 receiving	CZP	
200 mg Q2W and 400 mg Q2W (Table 1). Rates of serious AEs 
were low, including infections and infestations (Table 1). There 
were 4 malignancies (1 anaplastic oligodendroglioma, 2 basal 
cell carcinoma, 1 keratoacanthoma), 1 congestive heart failure, 1 
death (motor vehicle accident) and 1 case of primary progressive 
multiple sclerosis, all reported in patients receiving CZP 400 mg 
Q2W. AE IR did not increase with exposure duration, and at Week 
16 was comparable for CZP and PBO pts (Table 2).
Conclusion: CZP safety was as expected for this therapeutic class 
in PSO and there were no new safety signals.
References:
1. Reich K, (2017). Skin,1;24; 2. Augustin M, (2017). Skin,1;s24 
Table 1 AEs and Serious AEs to Week 48
IR/100 PY (95% CI)
 
All CZP
(n = 962)
CZP 400 mg 
Q2W (n = 627)
CZP 200 mg 
Q2W (n = 460)
AEs 219.6 (203.7–236.4) 228.6 (207.8–250.9) 221.2 (197.6–246.7)
Serious AEs 9.1 (7.0–11.6) 10.1 (7.3–13.8) 7.6 (4.8–11.4)
Serious infections and 
infestations
1.5 (0.8–2.7) 1.9 (0.8–3.8) 1.0 (0.2–2.8)
Active tuberculosis 0.1 (0.0–0.8) 0.2 (0.0–1.3) 0
Table 2 AEs to Week 16
IR/100 PY (95% CI)
 
PBO
(n = 157)
All CZP
(n = 692)
CZP 400 mg Q2W 
(n = 342)
CZP 200 mg Q2W 
(n = 350)
AEs 342.6 (277.8–417.9) 319.1 (289.1–351.4) 348.3 (303.5–397.9) 292.1 (252.8–335.9)
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Introduction: DAPSA and MDA are validated composite indices 
used in psoriatic arthritis (PsA) to measure disease activity states (1).
Objectives: To assess the proportion of pts treated with secukinu-
mab (SEC) reaching DAPSA remission (REM) or low disease 
activity (LDA) and those who reached either MDA or very low 
disease activity (VLDA) at Weeks (wks) 16 and 104 in the FU-
TURE 2 study (2).
Methods: DAPSA-REM, DAPSA-REM/LDA, MDA, and VLDA 
and their core components were assessed in the overall population 
and	in	pts	stratified	by	prior	anti-TNF	use	(TNF-Naïve/IR)	and	time	
since	first	PsA	diagnosis	( ≤ 2/ > 2 years) using as observed data.
Results: At Wk16, in the overall population, the proportion of pts 
treated with SEC 300/150 mg achieving remission was 14%/10% 
(DAPSA-REM) and 8%/6% (VLDA) and achieving LDA was 
42%/44% (DAPSA-REM/LDA) and 28%/23% (MDA). A higher 
proportion	of	anti-TNF-naïve	pts	and	pts	with	early	diagnosis	( ≤ 2 
years) treated with SEC achieved and sustained DAPSA-REM/
LDA and MDA than in the overall population (Table). DAPSA-
REM/LDA and MDA responses with SEC were sustained through 
Wk104.
Conclusions: In the overall population, a higher proportion 
of SEC treated pts at Wk16 achieved DAPSA-REM, VLDA, 
DAPSA-REM/LDA, and MDA than those treated with placebo 
with a greater number of pts achieving DAPSA-REM or LDA than 
VLDA or MDA, respectively. These responses were sustained 
through Wk104. 
References:
1.Coates, Helliwell.Ann Rheum Dis 2016;75:640-43.
2.McInnes et al. Rheumatol.2017;56:1993-2003.
Table.
% Response
DAPSA-REM/
LDA
TNF-Naïve/IR
MDA
TNF-Naïve/IR
DAPSA-REM/
LDA
 ≤ 2/ > 2 years
MDA ≤  2 /  >  2 
years
Wk16
Wk104
300 mg
150 mg
Placebo
300 mg
150 mg
52/22
54/27
23/10
75/46
62/33
34/15
32/8
14/3
49/25
37/10
52/40
42/45
17/19
63/66
46/57
43/23
21/24
7/12
33/43
20/33
Total number of pts providing data to the analysis: secukinumab 300 mg (n = 100), 150 mg 
(n = 100) and placebo (n = 98). 
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Introduction: Efficacy	 of	 tildrakizumab	 (TIL),	 a	 high	 affinity,	
humanized,	immunoglobulin	G1κ	monoclonal	antibody	against	
interleukin-23p19, has been evaluated for chronic plaque psoriasis 
(PsO) in 2 phase 3 randomized controlled trials.
Objective:The aim of our analysis was to determine predictors of 
response to TIL treatment in the 2 trials.
Methods: Patients (pts) with moderate to severe PsO were 
randomized in reSURFACE 1 (phase 3; NCT01722331) and 
reSURFACE 2 (phase 3; NCT01729754) [1]. In Part 1 (Week 
[W]1–W12), pts received subcutaneous TIL 200 mg, TIL 100 mg, 
or placebo (PBO) at W0 and W4. Pts receiving PBO in Part 1 were 
rerandomized to TIL 200 mg or 100 mg in Part 2 (W12–W28). For 
each trial, continuous variables of mean baseline Psoriasis Area 
and Severity Index (PASI), body mass index (BMI), Physician’s 
Global Assessment (PGA), and PASI component for head region 
as well as dichotomous variables of baseline PASI  > 20 or  ≤ 20 
and PASI 50 response or nonresponse at W8 were evaluated as 
predictors	of	response.	Response	was	defined	in	this	analysis	as	
PASI 50 or PASI 90 at W12 and W28.
Results: None of the continuous variables appeared to be consis-
tently predictive of PASI 50 or PASI 90 response, nor were baseline 
PASI  > 20 or  ≤ 20	definitive	predictors	of	response.	PASI	50	re-
sponse vs nonresponse at W8 with TIL 200 mg appeared to be pre-
dictive of a PASI 50 response at W12 (percentage of patients±SD: 
98%±0.9% vs 59%±6.1%, respectively, in reSURFACE 1, and 
99%±0.8% vs 57%±5.7%, respectively, in reSURFACE 2) and of 
a PASI 90 response at W12 (47%±3.3% vs 0%±0%, respectively, 
in reSURFACE 1, and 50%±3.3% vs 5%±2.6%, respectively, in 
reSURFACE 2). The percentage of patients with PASI 50 response 
vs nonresponse at W8 with TIL 200 mg who achieved PASI 50 by 
W28 was 99%±0.6% vs 90%±3.8%, respectively, in reSURFACE 
1, and 99%±0.8% vs 86%±4.0%, respectively, in reSURFACE 2; 
the percentage who achieved PASI 90 by W28 was 70%±3.1% 
vs 23%±5.4%, respectively, in reSURFACE 1, and 70%±3.1% 
vs 21%±4.7%, respectively, in reSURFACE 2. Similar trends in 
predictive responses were observed with TIL 100-mg treatment.
Conclusions: Achievement of PASI 50 by W8 was predictive of 
a PASI 50 and PASI 90 response at W12 and W28. Most of the 
patients who had not achieved PASI 50 by W8 were able to achieve 
a PASI 50 response by W28. Baseline PASI score, PGA, and BMI 
were not predictive of PASI 50 or PASI 90 response.
Reference:
1. Reich K, et al. Lancet. 2017;390:276–288.
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TREATMENT AFTER DRUG WITHDRAWAL AND 
RETREATMENT IN PATIENTS WITH MODERATE­
SEVERE PLAQUE PSORIASIS: RESULTS FROM 
VOYAGE 2
Kenneth Gordon1, April Armstrong2, Peter Foley3, Yasmine Wasfi4, 
Michael Song4, Yaung-Kaung Shen4, Shu Li4, Ernesto J Muñoz-
Elías4, Bruce Randazzo4, Kristian Reich5
1Medical College of Wisconsin, Milwaukee, WI, 2University of Southern 
California, Los Angeles, CA, USA, 3The University of Melbourne, St. 
Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc., Carl-
ton, VIC, Australia, 4Janssen Research & Development, LLC, 5Dermato-
logikum Hamburg and SCIderm Research Institute, Hamburg, Germany
Objective:To	report	long-term	efficacy	of	guselkumab	(GUS)	after	
drug withdrawal and retreatment in patients with moderate-severe 
psoriasis (PsO) in the Phase 3 VOYAGE 2 study.
Methods: At Wk28, patients initially randomized to GUS who 
achieved a PASI90 response were re-randomized to either PBO/
withdrawal	(with	retreatment	upon	loss	of	≥50%	PASI	improve-
ment achieved at Wk28 or at Wk72 if retreatment criteria were 
not met) or continued GUS treatment through Wk72.
Results: Among 375 patients initially randomized to GUS who 
achieved a PASI90 response at Wk28, 182 were re-randomized 
to PBO/withdrawal and 193 to GUS/maintenance treatment. Ef-
ficacy	 for	 the	continued	GUS	 treatment	group	was	maintained	
through Wk72, while responses for the withdrawal group dimi-
nished, with PASI90 responses of 86.0% vs 11.5% respectively at 
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Wk72. Among the 182 patients in the withdrawal arm, 117 were 
retreated with GUS prior to Wk72; 56 did not meet retreatment 
criteria and initiated retreatment at Wk72 per protocol. Of 173 
patients retreated, 87.6% achieved PASI90 within 6 months of 
commencing retreatment. No new safety signals were observed 
with GUS withdrawal and retreatment through Wk100. Mainte-
nance of PASI90 response after drug withdrawal was associated 
with continued suppression of IL-17A, IL-17F, & IL-22, while 
loss of response was associated with increased levels of these 
circulating cytokines.
Conclusion: Superior	maintenance	of	high	efficacy	response	rates	
was achieved with continuous GUS treatment vs withdrawal, and 
the majority of retreated patients achieved PASI90. Maintenance 
of PASI90 after drug withdrawal was associated with continued 
suppression of IL-17A, IL-17F, and IL-22. 
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Background: Various instruments are currently used for disease 
activity and outcome assessment in psoriatic arthritis (PsA). Some 
measures attempt to incorporate the total spectrum of psoriatic 
disease manifestations [eg, minimal disease activity (MDA)] while 
others focus on arthritis assessments [eg, disease activity index 
for PsA (DAPSA)]. Whether in patients (pts) with PsA it is suf-
ficient	to	primarily	consider	joint	disease	aspects	remains	unclear.	
Objective:To compare DAPSA remission and low disease activity 
(LDA) with MDA and very low disease activity (VLDA) for the 
presence of residual abnormalities of the respective composing 
variables. 
Methods: This post hoc analysis included pts with PsA receiving 
adalimumab (ADA) in one of two multicenter studies: ADEPT was 
a 24-week (wk), randomized, double-blind, placebo-controlled 
trial; ACCLAIM was a 12-wk, open-label study conducted in 
Canada	in	care	settings	that	reflected	usual	practice.	Frequencies	
of DAPSA remission/LDA and MDA/VLDA were summarized, 
and the individual PsA manifestations within these states were 
assessed. DAPSA was summed from the following continuous 
variables: swollen (66) and tender (68) joints, pt global assess-
ment (PtGA, cm), pt pain (PP, cm), and C-reactive protein (CRP, 
mg/dL).	DAPSA	remission	was	defined	as	 ≤ 4 and DAPSA LDA 
as  > 4 and  ≤ 14. MDA criteria were as follows: ≤ 1 tender,  ≤ 1 
swollen joint,  ≤ 1 entheseal point, PP  ≤ 15mm, PtGA  ≤ 20mm, 
HAQ  ≤ 0.5, and PASI  ≤ 3.	MDA	was	calculated	as	 fulfilling	5	
of	the	7	criteria,	and	VLDA	calculated	as	fulfilling	all	7	criteria.	
Data were as observed. 
Results: Among 151 pts receiving ADA in ADEPT, 33 (22%) each 
achieved DAPSA remission and LDA at wk 24, and 20 (14%) and 
11 (7%) achieved MDA and VLDA, respectively. Pts achieving 
DAPSA LDA appeared to mirror those in MDA, with the exception 
of experiencing numerically higher PP, PtGA, and PASI scores 
at wk 24. Pts in DAPSA LDA did experience numerically lower 
SJC when compared with the MDA achievers, and, like MDA 
achievers, displayed little residual enthesitis. Only VLDA, but not 
MDA,	could	match	the	stringency	of	DAPSA	remission,	a	finding	
that	was	confirmed	 through	analysis	of	 the	ACCLAIM	cohort.	
However, VLDA allowed for numerically higher residual PP and 
PtGA levels when compared with DAPSA remission. Importantly, 
residual enthesitis did not differ among pts achieving DAPSA 
remission or VLDA. Irrespective of disease activity assessment, 
pts receiving ADA displayed little to no radiographic progression. 
Conclusions: In the ADEPT and ACCLAIM cohorts, pts who 
achieved DAPSA remission or VLDA demonstrated similar 
outcomes with respect to the individual components of both sco-
res, despite the omission of several of these within the DAPSA. 
Given the DAPSA’s continuous nature, its use may offer a good 
alternative	to	fulfillment	of	the	VLDA	criteria,	but	these	results	
require	confirmation	in	different	pt	populations.
Previously published Ann Rheum Dis 2017. 
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Introduction: Ixekizumab (IXE), an interleukin-17A antagonist, 
was superior to placebo (PBO) in improving the signs and symp-
toms	of	 psoriatic	 arthritis	 (PsA)	 at	Week	24	 in	 biologic-naïve	
patients (pts). 
Objective:To	determine	the	efficacy	and	safety	of	IXE	treatment	
up	 to	3	years	 in	biologic-naïve	pts	with	PsA.	Methods: In the 
SPIRIT-P1 Phase 3 trial (NCT01695239), 210 pts were randomi-
zed to IXE (80 mg every 4 [Q4W] or 2 [Q2W] weeks), 101 pts to 
adalimumab (active reference arm), and 106 pts to PBO at Week 
0. ADA and PBO patients were re-randomized to IXE at the end 
of	the	double-blind	treatment	period.	Ad-hoc	efficacy	for	all	pts	
initially randomized to IXE (intent-to-treat [ITT]) is presented. 
Modified	non-responder	imputation	(missing	data	considered	non-
response	for	pts	discontinued	due	to	lack	of	efficacy	or	adverse	
events [AEs]; multiple imputation for all other missing data) was 
applied	to	efficacy	response	outcomes.	Ad	hoc	safety	data,	for	all	
pts who received at least one IXE dose during the trial (n = 386), 
are presented as exposure-adjusted incidence rates (IRs; number 
of pts with events*100 /total pt years [PY]). 
Results: Efficacy	results	are	summarized	for	ITT	IXE-treated	pts	
(Table 1). Improvements in ACR (American College of Rheu-
matology) responses, enthesitis, dactylitis, PASI (Psoriasis Area 
and Severity Index), and NAPSI (Nail Psoriasis Severity Index) 
persisted up to 3 years. Safety assessments for all pts initially 
randomized to IXE or re-randomized to IXE during SPIRIT-P1 are 
summarized (Table 2). IRs of treatment-emergent AEs (TEAEs) 
were similar between IXE Q4W and Q2W treatment groups.
Table	1.	Efficacy	Outcome	Measures	at	Week	156	(ITT	IXE-Treated	Population)	
 IXE Q4W (n = 107) IXE Q2W (n = 103)
ACR20 69% 62%
ACR50 51% 56%
ACR70 33% 44%
LEI = 0a 47% 40%
LDI-B = 0b 62% 69%
PASI75c 63% 69%
PASI90c 51% 65%
PASI100c 44% 61%
NAPSI = 0d 54% 57%
aPts with Leeds Enthesitis Index (LEI) > 0 at baseline. bPts with Leeds Dactylitis Index-Basic 
(LDI-B) > 0 at baseline. cPts with psoriatic lesions ³3% of body surface area at baseline. dPts with 
fingernail	psoriasis	at	baseline.
Table 2.
 
Total IXE Q4W 
(n = 195;Total PY = 450.4)
Total IXE Q2W 
(n = 191; Total PY = 442.1)
TEAEs 169 (37.5) 168 (38.0)
Serious AEs 38 (8.4) 23 (5.2)
Serious Infections 8 (1.8) 2 (0.5)
Discontinued due to AE 17 (3.8) 23 (5.2)
Death 1a (0.2) 0
Infections 111 (24.6) 112 (25.3)
Injection-Site Reactions 40 (8.9) 43 (9.7)
Hypersensitivities 10 (2.2) 21 (4.7)
n = pts	with	≥1	designated	AE.	Data	presented	as	n	(IR).	For	safety	analyses,	baseline	was	defined	
as	the	time	of	the	first	IXE	injection.	Total	PYs	is	the	total	time	pts	were	in	the	treatment	period	
following	the	first	IXE	injection.	aPt	experienced	a	cerebrocardiovascular	accident.
24
www.medicaljournals.se/acta
5th World Psoriasis & Psoriatic Arthritis Conference 2018
Conclusion: In pts treated with IXE, improvements in the signs 
and	symptoms	of	PsA	persisted	up	to	3	years.	The	safety	profile	
was consistent with previous studies of IXE.
Previously presented as Chandran et al. 2018 EULAR Congress. June 
13-16th
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Introduction: Tildrakizumab	is	a	high-affinity,	humanized,	immu-
noglobulin	G1κ	monoclonal	antibody	against	interleukin-23p19	
for the treatment of chronic plaque psoriasis.
Objectives: We evaluated gastrointestinal (GI) adverse events (AE) 
and,	specifically,	cases	of	inflammatory	bowel	disease	(IBD;	ie,	
Crohn’s disease or ulcerative colitis) in the clinical development 
program for tildrakizumab.
Methods: Patients with moderate to severe plaque psoriasis 
were randomized in 3 large clinical trials: P05495 (phase 2; 
NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and 
reSURFACE 2 (phase 3; NCT01729754) [1,2]. In this post hoc 
analysis, we sought to identify serious GI AEs and new-onset 
or exacerbation of pre-existing IBD from a pooled dataset of 
tildrakizumab-treated patients from these 3 trials, which followed 
patients up to 52 (reSURFACE 2) or 64 (reSURFACE 1) weeks. 
This analysis evaluated patients who received tildrakizumab 100 
mg and 200 mg in P05495 and the reSURFACE trials.
Results: In this analysis, we pooled 1911 patients from the 3 trials 
who received either tildrakizumab 100 or 200 mg. There were no 
new cases of IBD reported; among 6 patients with a history of IBD 
randomized to tildrakizumab, none experienced an exacerbation. 
The numbers (rate per 100 patient-years) of patients with serious 
GI AEs in the pooled dataset were 8 (0.80) for tildrakizumab 100 
mg and 4 (0.43) for tildrakizumab 200 mg. These serious GI AEs 
included abdominal pain, constipation, diverticulum, dyspepsia, 
gastritis, thrombosed hemorrhoids, esophageal polyp, pancreatitis 
(1 patient each) among patients treated with tildrakizumab 100 mg, 
and abdominal hernia, upper abdominal pain, acute pancreatitis, 
and salivary gland enlargement (1 patient each) among patients 
treated with tildrakizumab 200 mg.
Conclusion: In this post hoc analysis of patients from 3 large, 
randomized clinical trials, serious GI AEs were infrequent and 
there were no new cases of IBD or exacerbations of IBD.
Acknowledgements: The studies were funded by Merck Sharp & 
Dohme, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, 
NJ, USA. 
Reference:
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Lancet. 2017;390:276–288.
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Introduction: Certolizumab pegol (CZP), an Fc-free, PEGylated, 
anti-tumor	necrosis	factor,	has	shown	efficacy	in	chronic	plaque	
psoriasis (PSO).[1,2]
Objectives: To assess the proportions of patients (pts) achieving 
selected PASI thresholds over 48 weeks of CZP treatment.
Methods: Data were pooled from CIMPASI-1 (NCT02326298) 
and CIMPASI-2 (NCT02326272), ongoing phase 3 trials in adults 
with	moderate	to	severe	PSO	≥6	months	(Psoriasis	Area	Severity	
Index	[PASI]	≥12,	≥10%	body	surface	area	affected,	physician’s	
global	assessment	≥3/5).	Pts	were	randomized	2:2:1	to	CZP	400	
mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose 
[LD] at Weeks 0/2/4), or placebo (PBO). Week 16 PASI 50 re-
sponders receiving CZP continued the same dose to Week 48. We 
present the proportions of patients reaching PASI  ≤ 1, 2, 3 and 5 at 
Weeks 16 and 48. Responder rate estimates were calculated using 
a logistic regression model. Pts not achieving PASI 50 at Weeks 
16/32/40/48 were subsequently classed as non-responders. Other 
missing data were imputed using multiple imputation (Markov 
Chain Monte Carlo method).
Results: At Week 0, 175, 186 and 100 pts were randomized to 
CZP 400 mg Q2W, CZP 200 mg Q2W, and PBO. Baseline mean 
PASI was comparable across CZP 400 mg Q2W/CZP 200 mg 
Q2W/PBO pts: 19.6 (SD:7.3)/19.2 (7.2)/18.6 (6.6). At Week 16, 
PASI  ≤ 1 was achieved by 39.9% pts receiving CZP 400 mg Q2W 
and 36.2% CZP 200 mg pts, vs 2.6% PBO pts. Similarly, a higher 
proportion of CZP vs PBO pts achieved PASI  ≤ 2, PASI  ≤ 3 and 
PASI  ≤ 5 (Table). In CZP-treated pts, PASI was maintained or 
further reduced to Week 48, with 48.2% CZP 400 mg Q2W pts 
and 39.9% CZP 200 mg Q2W pts achieving PASI  ≤ 1 after 48 
weeks’ treatment (Table).
Conclusions: Higher proportions of CZP vs PBO pts met abso-
lute PASI cut-offs over 16 weeks and response was maintained 
or further improved to Week 48. Although durability of response 
was observed with both doses, higher proportions of pts treated 
with CZP 400 mg Q2W than 200 mg Q2W were able to reach the 
most stringent cut-offs at Week 48.
Reference:
1. Reich K, (2017). Skin,1;s23; 2. Augustin M, (2017). Skin,1;s24
Table. Pts achieving absolute PASI cut-offs at Weeks 16 and 48
PASI Week
PBO 
(n = 100)
% (95% CI)
CZP 400 mg Q2W 
(n = 175)
% (95% CI)
CZP 200 mg Q2Wa 
(n = 186)
% (95% CI)
 ≤ 1 16 2.6% (0.0–6.2) 39.9% (29.3–50.4) 36.2% (26.5–45.9)
48 - 48.2% (37.4–59.0) 39.9% (29.8–50.0)
 ≤ 2 16 3.3% (0.0–7.0) 54.5% (43.9–65.1) 46.7% (36.5–56.8)
48 - 70.5% (60.2–80.8) 55.9% (44.6–67.3)
 ≤ 3 16 6.8% (1.0–12.5) 70.5% (59.3–81.6) 65.1% (53.4–76.7)
48 - 75.2% (65.5–85.0) 63.7% (52.6–74.8)
 ≤ 5 16 12.2% (4.3–20.1) 83.0% (74.9–91.1) 77.6% (68.4–86.9)
48 - 82.3% (74.4–90.3) 73.1% (63.4–82.7)
aPts	received	CZP	400	mg	Q2W	LD	at	Weeks	0/2/4.	CI:	Confidence	interval.	
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Introduction: Tildrakizumab	(TIL)	is	a	high-affinity,	humanized,	
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anti–interleukin-23p19 monoclonal antibody that demonstrated 
efficacy	in	phase	3	trials	in	moderate	to	severe	chronic	plaque	pso-
riasis (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]) [1].
Objective:Here we investigated the relationship between TIL 
serum	concentration,	 and	 efficacy	 and	 safety	 outcomes,	 in	 re-
SURFACE 1 and 2.
Methods: Placebo or TIL 100 mg or 200 mg was administered at 
Weeks 0 and 4, then every 12 weeks. Endpoints included propor-
tion of patients achieving 75% Psoriasis Area and Severity Index 
(PASI 75) improvement from baseline (PASI 75 responders). 
Pooled	 efficacy	data	 for	 each	dose	 from	 reSURFACE	1	 and	2	
were grouped into quartiles based on average (mean) serum TIL 
concentration during Weeks 0–12 (Cav12). Associations between 
median Cav12 for each quartile (Q) and TIL dose were analyzed 
for PASI 75 response at Week 12 and adverse events (AEs).
Results: TIL steady-state concentrations were achieved by Week 
16 and were proportional to the dose administered. Median Cav12 
(range) for TIL Q1–Q4, respectively, were 4.4 (2.1–5.2), 5.7 
(5.2–6.4), 7.0 (6.4–7.8), and 8.7 (7.8–16.1) µg/mL for TIL 100 mg 
(n = 616) and 8.7 (4.2–10.4), 11.5 (10.4–12.5), 14.1 (12.5–15.5), 
and 17.3 (15.5–30.6) µg/mL for TIL 200 mg (n = 622). PASI 
responses were similar for corresponding quartiles across doses, 
with no relationship between serum concentration and patient 
response for Q1–Q3. Greater PASI 75 responses were associated 
with the highest Cav12 (Q4), particularly for TIL 100 mg where 
PASI	 75	 response	 rates	 (95%	confidence	 intervals	 [CI])	were	
58.4% (54.6, 62.3), 62.3% (58.4, 66.1), 59.2% (55.3, 63.1), and 
73.7% (70.1, 77.0) for Q1–Q4, respectively. Corresponding PASI 
75 rates (95% CIs) for patients receiving 200 mg were 52.9% (49.0, 
56.8), 68.6% (64.9, 72.2), 64.5% (60.6, 68.1), and 74.8% (71.2, 
78.0) over Q1–Q4. There were no associations between AE rates 
and serum concentrations, and incidence rates of any AE, any 
infections, serious infections, upper respiratory tract infections, 
malignancies,	 non-melanoma	 skin	 cancer,	 confirmed	 extended	
major cardiovascular events, and drug-related hypersensitivity 
for TIL-treated patients were similar to, or less than, for placebo-
treated patients.
Conclusions: No relationship was apparent between TIL dose or 
Cav12 and PASI response, although the greatest response was 
seen for the highest serum concentration. Importantly, there were 
no associations between serum concentration and AE incidence.
Study sponsored by Merck Sharp & Dohme Corp., a subsidiary 
of Merck & Co., Inc., Kenilworth, NJ, USA; analyses funded by 
Sun Pharmaceutical Industries, Inc.
Reference:
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Introduction: We evaluated long-term (up to 52 weeks) safety and 
efficacy	of	 originator	 adalimumab	 every-other-week	 treatment	
(ADA	eow)	 for	 fingernail	 psoriasis	 (Ps)	 in	 patients	 (pts)	with	
moderate-to-severe Ps with substantial, clinically impactful, 
moderate-to-severe	fingernail	Ps.
Methods: In 26-week Period A, pts were randomized 1:1 to 40 mg 
ADA after initial 80 mg dose, or matching placebo (pbo). Period 
B (open-label, 26 weeks) entry criteria: completion of Period A, 
or	≥25%	 increase	 from	baseline	 in	 affected	 body	 surface	 area	
(BSA) at week 16. At Period B entry (week 26), Period-A pbo pts 
received an initial blinded dose of 80 mg ADA; all received ADA 
eow from weeks 27 through 51. We analyzed all pts who received 
ADA	throughout	the	52	weeks.	Efficacy	is	reported	using	multiple	
imputation (MI) for missing data, and as observed results.
Results: Of	the	217	randomized	pts,	203	received	at	≥1	dose	of	
ADA, 188 entered Period B, and 168 completed the trial. Of those 
receiving continuous ADA treatment through 52 weeks (n = 109), 
response	rates	(MI)	for	key	efficacy	outcomes	at	weeks	26	and	52,	
respectively,	were	as	follows.	≥75%	improvement	from	baseline	in	
modified	Nail	Ps	Severity	Index	(mNAPSI	75):	47.4%	and	54.5%.	
Physician’s	Global	Assessment	of	fingernail	Ps	of	0	(clear)	or	1	
(minimal)	with	≥2	grades	 improvement	 from	baseline	 (PGA-F	
0/1): 51.1% and 55.6%. Mean change (improvement) from base-
line in nail Ps pain (numerical rating scale [NRS]): 3.6 and 3.8. 
Mean change (improvement) from baseline in Nail Ps Physical 
Functioning Severity score (NPPFS): 3.4 and 3.9. Mean change 
(improvement) from baseline in Dermatology Life Quality Index 
score (DLQI): 9.1 and 9.0 (n = 94).
As observed response rates at weeks 26 and 52 respectively, were 
as follows. mNAPSI 75: 47/88 (53.4%) and 52/80 (65.0%). PGA-F 
0/1: 48/88 (54.5%) and 49/80 (61.3%). Mean change (improve-
ment) from baseline in nail Ps pain (NRS): 3.8 (n = 92) and 4.4 
(n = 80). Mean change (improvement) from baseline in NPPFS: 
3.9 (n = 92) and 4.4 (n = 80). Mean change (improvement) from 
baseline in DLQI: 9.3 (n = 69) and 9.7 (n = 65).
Adverse events (AEs) per 100 pt years (E/100PYs; in 140.3 PYs) 
were: any event, 352 (250.9), serious AEs, 21 (15.0); and serious 
infections, 9 (6.4). AE’s were similar to those observed in phase 
3 clinical trials of ADA for Ps. 
Conclusion: ADA treatment of nail Ps across 52 weeks demon-
strated	short-	and	long-term	efficacy.	No	new	safety	signals	were	
identified	in	these	pts	receiving	≥1	dose	of	ADA.
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Introduction: ESPRIT is a 10-year (y) international prospective 
observational registry evaluating the long-term safety and effec-
tiveness of originator adalimumab (ADA) in adult patients (pts) 
with moderate to severe chronic plaque psoriasis.
Objectives: To determine safety, effectiveness, and pt-reported 
outcomes (PROs) over an 8-y period from an interim analysis of 
data collected from the ESPRIT registry.
Methods: ESPRIT enrolled pts who were continuing ADA treat-
ment from a current prescription or previous study participation, or 
initiating ADA  ≤ 4 weeks of entering the registry. The All-Treated 
pt population (All-Rx) received at least 1 ADA dose in this registry. 
Pts were evaluated at 3 and 6 months (mos) post-enrollment, and 
then every 6 mos for up to 10 ys. This interim analysis includes 
data collected from 26 Sep 2008 through 30 Nov 2016. Incidence 
rates (IR) for all treatment-emergent adverse events (All-TEAEs) 
in All-Rx pts are reported as events per 100 pt-ys (E/100PY) of 
overall exposure to ADA. Physician’s Global Assessment (PGA) 
and PROs (US only) were evaluated in as-observed population 
(pt numbers were small at 96 mos).
Results: For the 6045 All-Rx pts enrolled and dosed in ESPRIT, 
median duration of overall exposure to ADA was 3.9 ys. Registry 
discontinuation rate in All-Rx pts was 39.4%; with the most 
common reason being lost to follow up (18.2%). IR (E/100PY) 
for All-TEAEs was: overall 22.0; serious AEs 4.5; malignancies 
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1.1, serious infections 1.0; non-melanoma skin cancer 0.7; active 
TB  < 0.1; and All-TEAEs leading to death 0.2. Standardized 
mortality ratio was 0.34 (95% CI, 0.25–0.46), indicating the ob-
served number of deaths was below expected in an age-, sex- and 
country-matched population. PGA clear/minimal was achieved by 
57.0%, 58.7%, 59.1%, 62.6%, 61.9%, 63.8%, 65.5%, and 45.0% of 
pts at 12, 24, 36, 48, 60, 72, 84, and 96 mos, respectively. In 4202 
US pts, mean change from baseline in Dermatology Quality of 
Life Index, total work productivity impairment, and total activity 
impairment at 12-mo intervals were -3.1/-5.5/-8.3, -3.2/-5.4/-9.1, 
-3.3/-5.3/-8.4, -3.5/-5.6/-8.7, -3.9/-5.8/-9.3, -3.7/-6.3/-8.7, -5.1/-
9.1/-11.4, and -5.9/-7.5/-13.8.
Conclusions: In this 8-y interim analysis, no new safety signals 
were observed and safety was consistent with the known safety 
profile	of	ADA.	The	number	of	TE	deaths	 in	 the	 registry	was	
below the expected rate. As-observed effectiveness of ADA and 
improvement from baseline in PROs were maintained through 
96 mos.
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Introduction: Certolizumab pegol (CZP), the only Fc-free, PE-
Gylated, anti-tumor necrosis factor biologic, has shown clinical 
improvements	 and	 a	 safety	profile	 consistent	with	 the	 class	 in	
adults with chronic plaque psoriasis (PSO).[1,2,3]
Objectives: To assess durability to Week 48 of the initial Week 16 
clinical response with CZP in PSO patients (pts) in two identical 
phase 3 trials. 
Methods: Data were pooled from CIMPASI-1 (NCT02326298) and 
CIMPASI-2 (NCT02326272), ongoing CZP phase 3 trials in adults 
with	PSO	≥6	months	(Psoriasis	Area	Severity	Index	[PASI]	≥12,	
≥10%	body	surface	area	affected,	physician’s	global	assessment	
[PGA]	≥3/5).	Pts	were	randomized	2:2:1	to	CZP	400	mg	every	
two weeks (Q2W), 200 mg Q2W (400 mg loading dose [LD] at 
Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders 
receiving CZP continued the same dose through the maintenance 
period to Week 48. PASI 50 non-responders at Weeks 32/40/48 
were classed as non-responders at subsequent time points. These 
analyses do not include PBO pts or Week 16 PASI 50 non-respon-
ders. We report number needed to treat (NNT) to achieve PASI 75 
at Week 16, and PASI 75 at Week 48 in pts who achieved PASI 75 
at	Week	16.	Week	16	NNT,	95%	confidence	intervals	(95%	CI)	and	
Week 48 PASI 75 responder rates were estimated using logistic 
regression in which missing data and patients withdrawn due to 
relapse ( < PASI 50 during the maintenance period) were imputed 
using multiple imputation (Markov Chain Monte Carlo [MCMC] 
method). Sensitivity analyses on PASI 75 were conducted using 
non-responder imputation (NRI). 
Results: At Week 16, NNT to achieve a PASI 75 response was 1.41 
(95% CI: 1.26–1.60) for the CZP 400 mg Q2W dose group and 
1.53 (1.35–1.77) for the CZP 200 mg Q2W dose group.
Of the pts randomized to CZP 400 mg Q2W and CZP 200 mg Q2W 
at Week 0 who entered the blinded maintenance phase, 132/149 and 
130/150 achieved PASI 75, respectively. Out of Week 16 PASI 75 
responders, 98.0% of patients treated with CZP 400 mg Q2W and 
87.5% of patients treated with CZP 200 mq Q2W also reported a 
PASI 75 response at Week 48 (Table). Sensitivity analyses using 
NRI showed similar trends with both doses, and similar trends 
were seen in PASI 90 response rates.
Conclusions: These analyses show that patients in both CZP dose 
groups demonstrate durability of their initial Week 16 high-level 
response to Week 48, with greatest durability seen in the CZP 
400 mg Q2W dose group (98.0% maintenance between Weeks 
16 and 48).
Reference:
1. Blauvelt A (2018). Skin, 2:s16; 2. Reich K (2017). Skin,1;s23; 3. Au-
gustin M (2017). Skin,1;s24
Table: Pts achieving PASI 75 at Week 48 among Week 16 PASI 75 responders pooled 
for CIMPASI-1 and CIMPASI-2
 CZP 400 mg Q2W CZP 200 mg Q2Wa
Week 16 responders, n  132 130
Week 48 responders
MCMC, % (95% CI)
NRI, % of Week 16 (n)
98.0% (95.6–100)
88.6% (117)
87.5% (79.7–95.4)
78.5% (102)
aPts received 400 mg CZP LD at Weeks 0/2/4. 
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Introduction: Psoriasis (Ps) disease burden for patients with pso-
riasis	(Ps)	and	concomitant	fingernail	Ps	plus	psoriatic	arthritis	
(PsA) is higher compared with patients with Ps alone.
Objective:We	report	safety	and	efficacy	of	originator	adalimumab	
(ADA)	in	patients	with	fingernail	Ps,	and	also	for	patients	with	or	
without concomitant PsA.
Methods: Results are reported from the double-blind PBO-
controlled, Period A in which 217 patients with moderate to 
severe	plaque	Ps	and	fingernail	Ps	were	included	and	randomized	
1:1 to receive 40 mg ADA every other week (eow) from week 1 
(initial 80mg dose at week 0), or matching PBO, for 26 weeks. 
The	primary	endpoints	were	the	proportion	of	patients	with	≥75%	
improvement	in	modified	Nail	Ps	Severity	Index	(mNAPSI	75)	
and the proportion of patients with Physician’s Global Assess-
ment of Fingernail Psoriasis (PGA-F) of clear (0) or minimal 
(1)	with	≥2-grade	reduction	from	baseline	(primary	in	US	only;	
for regulatory purposes). Missing data were handled by multi-
ple imputation. Safety was assessed using treatment-emergent 
adverse events (AEs).
Results: Of the 217 randomized patients (108 PBO, 109 ADA), 
84.3% were male; mean age was 46.7 years; 188 (86.6%) comple-
ted 26 weeks of treatment or early escaped to Period B according 
to protocol. At baseline, 28.6% had PsA (29.6% PBO, 27.5% 
ADA)	with	mean	duration	7.91	years	[SD	8.314].	Total	fingernail	
mNAPSI 75 was achieved by 0.5% PBO vs 61.5% ADA of patients 
with PsA and 4.6% PBO vs 40.9% ADA without PsA (p < 0.001 
for	 both	 groups).	 PGA-F	0	 or	 1	with	≥2-grade	 reduction	was	
achieved by 4.4% PBO vs 59.3% ADA with PsA and 7.9% PBO 
vs 44.9% ADA without PsA (p < 0.001 for both groups). Adverse 
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events (AEs) in Period A were reported by 55.6% PBO vs 56.9% 
ADA (with PsA: 56.3% PBO vs 56.7% ADA; without PsA: 55.3% 
PBO vs 57.0% ADA without PsA); serious AEs by 4.6% PBO vs 
7.3% ADA (with PsA: 9.4% PBO vs 10.0% ADA; without PsA: 
2.6% PBO vs 6.3% ADA).
Conclusions: The results demonstrated that in this population, 
ADA	was	more	effective	than	PBO	for	the	treatment	of	fingernail	
Ps,	and	significantly	improved	signs	and	symptoms,	both	overall	
and regardless of the presence or abscense of PsA; no new safety 
risks	were	identified	with	ADA	eow	treatment	for	26	weeks.
Previously published J Am Acad Derm. 2017. 76(6 suppl 1): AB204.
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Introduction: The Fc-free, PEGylated, anti-tumor necrosis factor 
certolizumab	pegol	(CZP)	has	shown	efficacy	in	chronic	plaque	
psoriasis (PSO). [1,2]
Objectives: To	 assess	 the	 efficacy	of	CZP	 to	 48	weeks	 across	
patient (pt) demographic and baseline disease characteristic sub-
groups in phase 3 trials.
Methods: In	 this	 prespecified,	 pooled	 subgroup	 analysis,	 data	
were pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 
(NCT02326272), ongoing phase 3 trials in adults with moderate 
to	severe	PSO	≥6	months	(psoriasis	area	and	severity	index	[PASI]	
≥12,	affected	body	surface	area	[BSA]	≥10%,	physician’s	global	
assessment	[PGA]	≥3/5).	Pts	were	randomized	2:2:1	to	CZP	400	
mg every 2 weeks (Q2W), 200 mg Q2W (400 mg loading dose at 
Weeks 0/2/4), or placebo (PBO). At Week 16, PASI 50 responders 
receiving CZP continued the same dose through the maintenance 
period to Week 48. PASI 50 nonresponders at Weeks 32/40/48 were 
classed as nonresponders at subsequent time points. Subgroups 
included age, weight, body mass index (BMI), baseline PASI, BSA 
and PSO duration. PASI 75, PGA 0/1, and PASI 90 responder rates 
were summarized at Week 16 using a logistic regression model 
with multiple imputation (overall population) and descriptively at 
Week 48 based on nonresponse imputation (subgroups).
Results: 175/186/100 pts received CZP 400 mg Q2W/CZP 200 
mg	Q2W/PBO.	Efficacy	was	observed	across	all	subgroups	for	
both CZP 400 mg Q2W and 200 mg Q2W, with higher Week 48 
PASI 75 responder rates in CZP 400 mg Q2W vs CZP 200 mg 
Q2W treated pts (Table). Similar trends were observed for PGA 
0/1 and PASI 90.
Conclusions: Treatment with either dose of CZP resulted in 
clinically meaningful improvements in signs and symptoms of 
PSO at Week 16 maintained at Week 48. Similar to the overall 
population, PASI 75, PGA 0/1, and PASI 90 responder rates were 
greater for CZP 400 mg Q2W versus 200 mg Q2W across most 
subgroups at Week 48.
References:
1. Reich K (2017). Skin,1;s23; 2. Augustin M (2017). Skin,1;s24
Table: Week 48 PASI 75 subgroup responder rates
 
CZP 400 mg Q2W
(n = 175
CZP 200 mg Q2W
(n = 186) 
N
PASI 75 responders
n (%) N
PASI 75 responders
n (%)
Baseline demographics
Weight (kg)
 ≤ 74.00 40 32 (80.0) 32 23 (71.9)
 > 74.00– ≤ 85.00 36 28 (77.8) 35 24 (68.6)
 > 85.00– ≤ 95.40 36 26 (72.2) 34 23 (67.6)
 > 95.40– ≤ 109.00 28 18 (64.3) 45 26 (57.8)
 > 109.00 35 24 (68.6) 40 21 (52.5)
BMI (kg/m2)
 ≤ 25.44 37 30 (81.1) 35 25 (71.4)
 > 25.44– ≤ 28.68 39 36 (92.3) 33 25 (75.8)
 > 28.68– ≤ 31.92 39 26 (66.7) 32 20 (62.5)
 > 31.92– ≤ 37.16 25 16 (64.0) 48 30 (62.5)
 > 37.16 35 20 (57.1) 38 17 (44.7)
Age (years)
 < 40 65 54 (83.1) 67 45 (67.2)
≥40– < 64 97 66 (68.0) 107 65 (60.7)
≥65 13 8 (61.5) 12 7 (58.3)
Baseline disease characteristics
PSO duration (years, median)
 ≤ 15.00 84 61 (72.6) 96 64 (66.7)
 > 15.00 91 67 (73.6) 90 53 (58.9)
PASI (median)
 ≤ 17.00 79 55 (69.6) 97 59 (60.8)
 > 17.00 96 73 (76.0) 89 58 (65.2)
BSA (%, median)
 ≤ 19.0 88 67 (76.1) 97 60 (61.9)
 > 19.0 87 61 (70.1) 89 57 (64.0)
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DISCONTINUATION OF BIOLOGIC THERAPIES IN 
CHRONIC PLAQUE PSORIASIS: A RETROSPECTIVE 
COHORT
Susanne Gulliver, Wayne Gulliver, Shane Randell
NewLab Clinical Research
Introduction: Psoriasis is a chronic debilitating auto immune 
disease which manifests on the skin through red scaly plaques. 
Biologic treatment have been very successful in controlling mode-
rate to severe psoriasis, however they are quite expensive and not 
all treatments work for all patients. This study looks to understand 
the demographics, treatment patterns, treatment failures, number 
of therapies and time to switching. A cohort of 459 patients treated 
with biologics was examined
Objectives: 1. To understand the demographics, treatment patterns, 
treatment failures, number of therapies and time to switching.
2. To decipher patterns in biologic use in order to prescribe more 
efficiently	and	optimize	health	care	resources.
Methods: This was a retrospective cohort of all patients exposed 
to biologic or PD-4 inhibitors within a single Dermatologist’s 
private practice. A simple summary of patient demographics 
including gender, treatment patterns, reasons and length of time 
before discontinuation was compiled. Reasons for discontinuation 
included	lack	of	efficacy	(primary	or	secondary),	adverse	events	
(AEs), patient choice or other.
Results: There were 189 females (41.2%) and 270 males (58.8%) 
with 914 incidences of biologic or PD-4 inhibitor treatment. The 
mean age was 53.48±12.6 and the mean treatment duration was 
37.3 months±39.5 (approx. 3000 treatment years). 
39.2%	of	patients	(180)	remained	on	the	first	biologic	(range	0.5	
to 15 years). The mean number of therapies was 1.99 (range 1–8), 
but increased to 2.63 if patients were not biologic naive.
More male patients stayed on their first biologic (74.2% in 
ustekinumab-treated patients and in the Apremilast group 32.3%).
Reasons for discontinuation: AEs (14.69%) and non-response 
(30%);	highest	rates	were	in	etanercept	(78.0%),	and	infliximab	
(75.4%); lowest rates was in etanercept 12.8% (14 of 109 patients), 
highest	in	infliximab	34.9%,	(44	of	126	patients.
Conclusions: The most common cause for discontinuation of 
biologics was an AE and non-responsiveness (45.69%). Women 
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were more likely to discontinue therapy than men. Males were 
more	likely	to	remain	on	the	first	biologic	therapy.	Adalimumab	
and ustekinumab had lowest rates of discontinuation. Etanercept, 
infliximab	and	apremilast	had	the	highest.
References:
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Introduction: Risk of infections is a concern with cytokine inhi-
bitor treatments. 
Objectives: This analysis assessed infections during phase 2 and 
3	trials	of	tildrakizumab	(TIL),	a	high-affinity,	humanized,	IgG1κ	
monoclonal antibody against IL-23p19 under development for 
moderate to severe chronic plaque psoriasis. 
Methods: Patients (Pts) were randomized in P05495 (phase 2; 
NCT01225731), reSURFACE 1 (phase 3; NCT01722331), and 
reSURFACE 2 (phase 3; NCT01729754) [1,2]. In Part 1 (Week 
([W]1–16) of P05495, pts received subcutaneous (SC) TIL 5, 
25, 100, or 200 mg or placebo (PBO) at W0 and W4 and were 
rerandomized to various TIL doses in Part 2 (W16–52). In Part 1 
(W1–12) of reSURFACE 1 and 2, pts received SC TIL 200 mg, TIL 
100 mg, or PBO at W0 and W4. Pts were rerandomized in Part 2 
(W12–28) and Part 3 (W28–64 or W28–52 in reSURFACE 1 and 
2, respectively). Etanercept (ETN) 50 mg was an active control in 
Parts 1–2 of reSURFACE 2. Treatment-emergent adverse event 
data pools (n = 2081) for the PBO-controlled and full trial periods 
(52 weeks for P05495/reSURFACE 2; 64 weeks for reSURFACE 
1)	were	analyzed.	Severe	infections	met	the	regulatory	definition	
of a serious adverse event or required intravenous antibiotics. 
Results: In the PBO-controlled period, incidences of infections 
were comparable for TIL 100 mg and 200 mg (23% and 22%, 
respectively) and PBO (23%); all were comparable with ETN 
(24%). Incidences of severe infections were low for all treatment 
groups	(range,	0.0%-0.3%;	TIL	P≥0.6	vs	PBO).	In	the	full	trial	pe-
riod, exposure-adjusted rates (pts/100 pt-years) for infections with 
TIL 100 mg and 200 mg (48.9 and 52.6, respectively) were lower 
than with PBO and ETN (79.5 and 86.0, respectively). Exposure-
adjusted rates for severe infections were 1.10, 1.61, 1.96, and 0.91 
for TIL 100 mg, TIL 200 mg, ETN, and PBO, respectively. In all, 
33	severe	infections	were	identified	(respiratory:	TIL	100	mg,	4	
events; TIL 200 mg, 2 events; ETN and PBO, 0 events; skin: TIL 
100 mg, 3 events; TIL 200 mg, 6 events; ETN, 2 events; PBO, 
3 events; gastrointestinal: TIL 100 mg, 4 events; TIL 200 mg, 5 
events; ETN and PBO, 0 events; urinary tract: TIL 200 mg, 1 event; 
ETN, 1 event; TIL 100 mg and PBO, 0 events). One pt had bone 
tuberculosis	(TIL	200	mg;	original	purified	protein	derivative	test	
was negative); 1 sepsis event (TIL 200 mg) occurred months after 
ending TIL treatment.
Conclusion: Infection rates with TIL treatment were low and 
comparable to PBO and ETN during the PBO-controlled period. 
By W52/64, exposure-adjusted rates remained low for all groups.
Reference:
1. Papp K, et al. Br J Dermatol. 2015;173:930-939. 2. Reich K, et al. 
Lancet. 2017;390:276-288.
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Introduction: Interleukin-23 is a key cytokine in the development 
and maintenance of psoriatic lesions. Risankizumab is a humani-
zed IgG1 monoclonal antibody that binds to IL-23’s p19 subunit, 
selectively inhibiting this critical cytokine and its role in psoriatic 
inflammation.
Methods: UltIMMa-1 (n = 506) and UltIMMa-2 (n = 491) were 
replicate, randomized, double-blind, placebo- and active compara-
tor-controlled	studies	that	evaluated	efficacy	and	safety	of	risanki-
zumab in adult patients with moderate-to-severe plaque psoriasis. 
Patients	were	stratified	by	weight	and	prior	TNFi-exposure	and	
randomized 3:1:1 to receive 150 mg risankizumab, 45/90 mg us-
tekinumab (weight-based per label) or matching placebo. Patients 
were dosed at weeks 0, 4, 16, 28, and 40, with placebo crossover 
to risankizumab at week 16. Co-primary endpoints were PASI 90 
and sPGA0/1 at week 16 versus placebo with comparisons between 
risankizumab and ustekinumab as ranked secondary endpoints. 
Missing data were imputed as non-response.
Results: All primary and ranked secondary endpoints were met 
for both trials (p < 0.001). At week 16 of UltIMMa-1&2 trials, 
risankizumab-treated	patients	achieved	significantly	higher	PASI	
90 (75.3%/74.8%) and sPGA0/1 (87.8%/83.7%) response rates 
versus placebo- (4.9%/2.0%; 7.8%/5.1%) or ustekinumab-treated 
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patients (42.0%/47.5%; 63.0%/61.6%). At week 52, risankizumab-
treated	patients	achieved	significantly	higher	response	rates	versus	
ustekinumab. In both trials, treatment-emergent adverse event 
(TEAE) rates were comparable across treatment groups throughout 
the study duration. The most frequently reported TEAE was upper 
respiratory tract infection.
Conclusion: Risankizumab was consistently superior to both pla-
cebo and ustekinumab in the treatment of moderate-to-severe pla-
que	psoriasis.	TEAE	profiles	were	similar	between	risankizumab	
and	ustekinumab,	and	there	were	no	unexpected	safety	findings.	
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Objective:To	 evaluate	 the	 efficacy	 and	 safety	 of	 guselkumab	
(GUS) administered using a novel, self-injection device in adult 
patients with moderate-severe plaque psoriasis (PsO).
Methods: ORION is a Phase 3, multicenter, randomized, double-
blind, PBO-controlled study evaluating GUS administered using 
a	self-SC	injection	device	that	delivers	the	contents	of	a	pre-filled	
syringe.	Patients	of	age≥18	years	with	moderate-severe	PsO	for	
at	least	6	months,	IGA	score	≥3,	PASI	score	≥12,	and	BSA	≥10%,	
and were candidates for/or may have previously received systemic 
therapy or phototherapy, were eligible for the study. At baseline, 
78 patients were randomized to PBO (n = 16) at wks 0, 4, and 
12 with crossover to GUS 100mg at wks 16, 20, and28 or GUS 
(n = 62) at wks 0, 4, 12, 20, and 28. The co-primary endpoints were 
the proportions of patients achieving 1) an IGA score of cleared 
(0) or minimal (1) and 2) a PASI 90 response at wk16 (GUS vs 
PBO). Major secondary endpoints were the proportions of patients 
achieving an IGA score of 0 and a PASI 100 response at wk16. 
Results through wk16 are presented. 
Results: Baseline demographics and PsO disease characteristics 
were generally similar between the PBO and GUS-treatment 
groups.	At	wk16,	significantly	higher	proportions	of	GUS	vs	PBO	
patients achieved an IGA score of 0/1 (80.6% vs. 0.0%, p < 0.001) 
and a PASI 90 response (75.8% vs. 0.0%, p < 0.001). In addition, 
significantly	higher	proportions	of	GUS	vs	PBO	patients	achie-
ved an IGA score of 0 (56.5% vs 0.0, p < 0.001) and a PASI 100 
response (50.0% vs 0.0, p < 0.001) at wk16.
Through	wk16,	 the	 proportions	 of	 patients	with	 ≥1	AE	were	
comparable between the treatment groups (GUS: 62.9%, PBO: 
68.8%; respectively). Discontinuation rates due to AEs were 1.6% 
for GUS patients and 6.3% for PBO patients. Two patients in the 
GUS group had SAEs (1 chest discomfort and 1 atypical chest 
pain). There were no serious infections, malignancies, or deaths.
Conclusion: GUS administered using a novel self-injection device 
was	efficacious	and	well-tolerated	in	patients	with	moderate-severe	
PsO.	The	efficacy	and	safety	profile	of	GUS	administered	with	
this	device	was	consistent	with	previously	reported	findings	from	
the pivotal phase 3 studies in which GUS was administered using 
a different self-injection device.
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Introduction: Etanercept (ETN) is an anti-tumor necrosis fac-
tor	medication	that	was	among	the	first	biologics	approved	for	
psoriasis. Additional medications have been developed or are in 
development for psoriasis, and patients who do not adequately 
respond	to	ETN	may	benefit	from	these	more	recent	biologics.	
Objectives: To	 evaluate	 the	 efficacy	of	 tildrakizumab	 (TIL),	 a	
high-affinity,	 humanized,	 anti-interleukin-23p19	 antibody	 in	
patients (pts) with moderate to severe chronic plaque psoriasis 
who were partial responders (Psoriasis Area and Severity Index 
[PASI]	≥50– < 75) or nonresponders (PASI  < 50) to ETN and were 
subsequently rerandomized to TIL in a phase 3 trial. 
Methods: Pts	with	psoriasis	(≥10%	body	surface	area,	Physician’s	
Global	Assessment	[PGA]	≥3,	and	PASI	score	≥12)	participated	
in a 3-part, 52-week, randomized controlled trial (reSURFACE 
2; NCT01729754) [1]. In Part 1 (Week [W]0–W12), pts were 
randomized to subcutaneous TIL 200 mg, TIL 100 mg, or placebo 
(PBO) administered at W0 and W4, or ETN 50 mg administered 
2x/week. In Part 2 (W12–W28), TIL- and ETN-treated pts remai-
ned on the same treatment (TIL administered at W16; ETN 1x/
week), whereas PBO-treated pts were rerandomized to TIL 100 
or	200	mg.	In	Part	3	(W28–W52),	ETN	responders	(PASI	≥75)	
were discontinued, partial and nonresponders were switched to 
TIL 200 mg (administered at W32, W36, W48). For this post hoc 
analysis, the percentages of pts (±SD) with PASI responses and 
PGA response (score of 0 [clear] or 1 [minimal] with at least a 
2-grade score reduction from baseline) were determined at W52. 
Primary results from the trial have been previously reported. 
Results: In all, 1090 pts were randomized. Of the 313 pts ran-
domized to ETN, by W28 there were 83 partial responders and 39 
nonresponders. At W52 (after 20 weeks of TIL treatment) for ETN 
partial responders, 75%±5%, 34%±5%, 15%±4%, and 58%±5% 
had achieved PASI 75, 90, 100, and PGA responses, respectively, 
with TIL 200-mg treatment. At W52 for ETN nonresponders, 
54%±6%, 31%±5%, 10%±3%, and 56%±5% had achieved PASI 
75, 90, 100, and PGA responses, respectively, with TIL 200-mg 
treatment. Adverse events were similar in pts switched from ETN 
to TIL at W28, compared with the pts who were maintained on 
TIL through W52. 
Conclusions: A substantial portion of patients with moderate to 
severe chronic plaque psoriasis who were partial responders or 
nonresponders to ETN may respond after switching to treatment 
with TIL 200 mg. TIL may be a reasonable option for those who 
do not achieve adequate response to ETN.
Reference:
1. Reich K, et al. Lancet. 2017;390:276-288.
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Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. 
Analyses were presented at the American Academy of Dermatology Annual 
Meeting, February 16–20, 2018, San Diego, CA, USA. 
P065
EFFICACY OF TILDRAKIZUMAB IN MODERATE 
TO SEVERE PSORIASIS PATIENTS WITH PRIOR 
EXPOSURE TO APREMILAST
Kenneth Gordon1, Kristian Reich2, David Pariser3, Alan Menter4, 
Stephen Tyring5, Howard Sofen6, Stephen Rozzo7, Jeffrey Parno7, 
Qing Li8, Carmen La Rosa8
1Medical College of Wisconsin, Milwaukee, WI, USA, 2SCIderm Research 
Institute and Dermatologikum Hamburg, Hamburg, Germany, 3Eastern 
Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, 
4Division of Dermatology, Baylor University Medical Center, Dallas, TX, 
30
www.medicaljournals.se/acta
5th World Psoriasis & Psoriatic Arthritis Conference 2018
5Department of Dermatology, University of Texas, Houston, TX, 6Depart-
ment of Medicine (Dermatology) UCLA, Los Angeles, CA, 7Sun Pharma-
ceutical Industries, Inc., Princeton, NJ, 8Merck & Co., Inc., Kenilworth, 
NJ, USA
Introduction: Tildrakizumab	(TIL)	is	a	high-affinity,	anti–inter-
leukin-23p19 monoclonal antibody for the treatment of chronic 
plaque psoriasis.
Objectives: We assessed a subgroup of patients with chronic plaque 
psoriasis who reported prior treatment with apremilast (APT), a 
phosphodiesterase	4	inhibitor,	to	evaluate	its	potential	influence	
on	efficacy	in	2	large	phase	3	clinical	studies	of	tildrakizumab.
Methods: The reSURFACE studies were 3-part, double-blind, 
randomized	controlled	studies	in	patients	(≥18	years	of	age)	with	
moderate to severe chronic plaque psoriasis [1]. TIL 100 and 200 
mg were evaluated for 64 weeks (reSURFACE 1; NCT01722331) 
and 52 weeks (reSURFACE 2; NCT01729754). Part 1 (0–12 
weeks) was placebo (PBO)-controlled, whereas Part 2 (12–28 
weeks) rerandomized PBO patients to TIL. The washout period 
for discontinuation of APT before randomization in these studies 
was	4	weeks.	In	this	post	hoc	analysis,	we	analyzed	the	efficacy	
responses to TIL in patients who reported prior exposure to APT. 
Physicians’ Global Assessment (PGA) (0 or 1) and Psoriasis Area 
and Severity Index (PASI) 75, 90, and 100 responses were assessed 
at Weeks 12 and 28 in this cohort. One patient with missing data 
at Weeks 12 and 28 was considered to be a nonresponder at these 
visits. The TIL groups were pooled owing to the small numbers 
reporting prior APT exposure.
Results: The pooled reSURFACE 1 and 2 dataset includes 1238 
patients randomized to TIL; of these, prior APT exposure was 
reported by 35 patients (n = 21 for 100 mg and n = 14 for 200 mg). 
In the overall pooled population of TIL-treated patients, PASI 75, 
PASI 90, PASI 100, and PGA (0.1) responses were achieved by 
783 (63%), 450 (36%), 161 (13%), and 715 (58%) at Week 12 
and 898 (73%), 647 (52%), 303 (25%), and 784 (63%) at Week 
28, respectively. In the population of TIL-treated patients with 
prior APT exposure, PASI 75, PASI 90, PASI 100, and PGA (0.1) 
responses were achieved by 21 (60%), 9 (26%), 5 (14%), and 22 
(63%) at Week 12 and 27 (77%), 16 (46%), 7 (20%), and 22 (63%) 
at Week 28, respectively. There were no discontinuations due to 
adverse events (AEs) among patients with prior APT exposure.
Conclusions: Efficacy	 responses	with	TIL	were	similar	 for	 the	
small sample of patients with prior exposure to APT and the overall 
pooled population from reSURFACE 1 and reSURFACE 2. These 
results were consistent with the notion that no adverse effect on ef-
ficacy	or	discontinuations	due	to	AEs	are	expected	when	initiating	
treatment with TIL among patients with prior exposure to APT.
Reference:
1. Reich K, et al. Lancet. 2017;390:276–288.
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Introduction: Interleukin-23 (IL-23), a key regulator of multiple 
effector cytokines (including IL-17, IL-22, and TNF), is thought 
to drive the development and maintenance of psoriatic lesions. 
Risankizumab is a potent humanized IgG1 monoclonal antibody 
that	inhibits	IL-23	by	specifically	binding	its	p19	subunit.
Objectives: To	report	efficacy	and	safety	results	of	risankizumab	
from initial 16-week (wk) placebo (PBO)-controlled period of 
IMMhance trial in patients (pts) with moderate-to-severe chronic 
plaque psoriasis (PsO).
Methods: IMMhance (NCT02672852) is a phase 3 multicenter, 
randomized, double-blind, PBO-controlled trial, evaluating the 
efficacy	 and	 safety	 of	 risankizumab	 versus	 PBO	 in	 pts	with	
moderate-to-severe chronic plaque PsO. The initial 16-wk PBO-
controlled	period	(507	pts,	stratified	by	weight	and	prior	TNFi-
exposure, randomized 4:1 to receive either risankizumab [150 mg 
at wks 0 and 4] or PBO) was followed by randomized withdrawal 
and subsequent re-treatment with risankizumab. Co-primary end-
points were PASI 90 and sPGA 0/1 responses at wk 16; missing 
data were imputed as non-responders.
Results: At baseline, the mean age and weight were 49.2 years 
and 92.0 kg, respectively; 70.2% of pts were male. A history of 
diagnosed or suspected psoriatic arthritis was reported in 34.7% 
of pts and prior TNFi therapy was reported in 36.5% of pts. Mean 
baseline PASI and BSA were 20.2 and 26.1%, respectively. At 
wk 16, all primary and ranked secondary endpoints were met 
(p < 0.001). At Wk 16, risankizumab -treated pts achieved signi-
ficantly	higher	PASI	90	(73.2%)	and	sPGA	0/1	(83.5%)	response	
rates versus PBO-treated pts (2.0%; 7.0%). Treatment-emergent 
adverse events (TEAEs) and serious AEs were reported in 45.5% 
and 2.0% of risankizumab-treated pts, respectively. Through 16 
wks, there were no deaths, major adverse cardiovascular events, 
or cases of tuberculosis in risankizumab-treated pts.
Conclusions: Risankizumab was superior to PBO in the treatment 
of	adult	pts	with	moderate-to-severe	plaque	PsO.	The	safety	profile	
was consistent with previously reported risankizumab trials with 
no	new	or	unexpected	safety	findings.
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Introduction: Tildrakizumab	(TIL)	is	a	high-affinity	anti–IL-23p19	
antibody	that	showed	efficacy	in	2	phase	3	chronic	plaque	psoriasis	
studies (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]) 
[1].	Some	dichotomous	efficacy	measures,	eg,	proportions	of	pa-
tients achieving a 75% Psoriasis Area and Severity Index (PASI) 
response,	provide	limited	efficacy	and	disease	severity	informa-
tion at a patient level. Analysis of patient-level PASI data could 
address these limitations.
Objective:To	identify	potential	insights	into	efficacy	assessment	
31Poster abstracts
Acta Derm Venereol 2018
and disease severity using a post hoc analysis of patient-level 
PASI data.
Methods: ReSURFACE 1 and 2 methods have been described pre-
viously [1]. Patients who participated in either TIL phase 3 study 
received TIL 100 mg or TIL 200 mg at Week (W)0 and W4, and 
every 12 weeks thereafter, or placebo (PBO) at W0 and W4 then 
TIL 100 mg or 200 mg at W12 and W16. PASI score distributions 
were analyzed using descriptive statistics.
Results: Numbers of patients and mean and median PASI scores 
are shown in the Table. By W4 (1 dose), 55% of patients in both 
TIL arms had PASI  < 12, and would no longer meet clinical trial 
entry criteria. The percentage of patients with PASI  < 12 increased 
during TIL treatment: 87% at W12, 93% at W28 (100 mg); 90% 
at W12, 97% at W28 (200 mg). At W12, 32% (TIL 100 mg), 
29% (TIL 200 mg), and 2% (PBO) of patients had PASI  ≤ 1.0. 
By W28, 48% (TIL 100 mg) and 52% (TIL 200 mg) of patients 
had PASI  ≤ 1.0. Median PASI scores at W28 were 2.0 (TIL 100 
mg) and 1.0 (TIL 200 mg).
Conclusions: These results suggest that PASI scores may provide 
additional information about disease severity, and resolution with 
treatment, that might not otherwise be available using dichoto-
mous PASI assessments. Most TIL-treated patients had clinical 
improvement	 by	W4,	 and	≈50%	had	nominal	 disease	 severity	
(PASI  ≤ 1.0) by W28.
Reference:
1. Reich K, et al. Lancet. 2017;390:276–288. 
Study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck 
& Co., Inc., Kenilworth, NJ, USA; analyses funded by Sun Pharmaceutical 
Industries, Inc.
Table. PASI Scores
 
TIL 100 mg
(n = 616)
TIL 200 mg
(n = 622)
PBO
(n = 309)
W0
 Patients with PASI data, n
 Mean (95% CI)
 Median (range)
616
20.2 (19.6, 20.9)
18.0 (8.0–59.0)
622
20.3 (19.7, 20.9)
18.0 (5.0–66.0)
309
19.7 (18.8, 20.5)
18.0 (12.0–56.0)
W4
 Patients with PASI data, n
 Mean (95% CI)
 Median (range)
 PASI  < 12, n (%)
 PASI  ≤ 1.0, n (%)
610
12.1 (11.5, 12.8)
11.0 (0.0–53.0)
337 (55)
8 (1)
611
12.0 (11.4, 12.6)
11.0 (0.0–54.0)
335 (55)
11 (2)
302
18.0 (17.0, 19.0)
16.0 (2.0–59.0)
60 (20)
0 (0)
W12
 Patients with PASI data, n
 Mean (95% CI)
 Median (range)
 PASI  < 12, n (%)
 PASI  ≤ 1.0, n (%)
598
5.2 (4.7, 5.7)
3.0 (0.0–38.0)
521 (87)
189 (32)
602
4.6 (4.2, 5.1)
3.0 (0.0–36.0)
539 (90)
175 (29)
288
16.6 (15.6, 17.7)
15.5 (0.0–57.0)
73 (25)
5 (2)
W28
 Patients with PASI data, n
 Mean (95% CI)
 Median (range)
 PASI  < 12, n (%)
 PASI  ≤ 1.0, n (%)
575
3.4 (3.0, 3.8)
2.0 (0.0–26.0)
533 (93)
278 (48)
581
2.7 (2.4, 3.0)
1.0 (0.0–24.0)
561 (97)
303 (52)
-
-
-
-
-
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Introduction: Two phase-3, double-blind, randomized control-
led trials (reSURFACE 1: NCT01722331; reSURFACE 2: 
NCT01729754)	have	demonstrated	the	efficacy	and	safety	of	tild-
rakizumab,	a	high	affinity,	humanized,	IgG1	κ,	anti-interleukin–23	
monoclonal antibody, in the treatment of adult patients with 
moderate-to-severe plaque psoriasis over 28 weeks1.
Objective:This	analysis	evaluated	whether	the	efficacy	is	sustained	
or improved from week 28 through week 52.
Methods: Both trials randomized adult patients with moderate-to-
severe plaque psoriasis to receive tildrakizumab 100 mg or 200 
mg at weeks 0, 4, then every 12 weeks. At week 28, patients with 
Psoriasis	Area	and	Severity	Index	(PASI)	response	≥50%	were	
re-randomized, based on their week-28 PASI response, to receive 
the same, a higher or a lower dose of tildrakizumab or placebo 
(randomized withdrawal in reSURFACE 1 per the trial designs). 
The current analysis evaluated only patients treated with the same 
dose	of	tildrakizumab	(100	mg	or	200	mg)	throughout	the	first	
52 weeks. Four mutually exclusive groups were created based 
on week-28 PASI response: PASI 100, PASI 90–99, PASI 75–89 
and PASI 50–74. PASI responses at week 52 (observed data) were 
analyzed for each week-28 PASI-response group.
Results: This analysis included 352 patients on tildrakizumab 100 
mg (male: 69.9%; mean baseline age: 44.9 years) and 313 on tild-
rakizumab 200 mg (male: 67.1%; mean baseline age: 46.4 years). 
The proportions of patients achieving PASI 100, PASI 90–99, PASI 
75–89 and PASI 50–74 at week 28 were 25.9%, 38.4%, 25.3% 
and 10.5% respectively for those on the 100 mg dose, and 24.6%, 
24.3%, 19.5% and 31.6% respectively for those on the 200 mg 
dose.	Among	patients	who	achieved	week-28	PASI≥90	with	either	
dose	of	tildrakizumab,	88.9–89.4%	maintained	PASI≥90	at	week	
52. Overall, 91.1% patients on the 100 mg dose and 93.9% on the 
200	mg	dose	with	week-28	PASI≥75	maintained	PASI≥75	at	week	
52. In addition, 39.3–40.4% of patients with week-28 PASI 75–89 
remained PASI 75–89 at week 52 and 33.7%-41.0% improved to 
PASI≥90.	Among	patients	with	week-28	PASI	50–74,	20.2–29.7%	
achieved	PASI≥90	and	52.5–64.9%	achieved	PASI≥75	at	week	
52. Overall, only 2.6% of patients on the 100 mg (9 out of 352) 
or 200 mg (8 out of 313) dose had week-52 PASI < 50.
Conclusions: Among patients with moderate-to-severe plaque 
psoriasis treated with tildrakizumab 100 or 200 mg at weeks 0, 
4,	then	every	12	weeks,	those	who	achieved	week-28	PASI≥50	
and continued on the same dose had sustained or improved ef-
ficacy	from	week	28	through	week	52.	The	majority	patients	who	
achieved	week-28	PASI≥75	or	PASI≥90	maintained	PASI≥75	or	
PASI≥90	at	week	52.	More	than	half	of	partial	responders	(PASI	
50–74)	at	week	28	eventually	achieved	PASI≥75	and	at	least	1	in	
5	achieved	PASI≥90	at	week	52.
Reference:
1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo 
or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-
FACE 2): results from two randomised controlled, phase 3 trials. Lancet. 
2017;390(10091):276-288.
This abstract was presented at 2018 Winter Clinical Dermatology 
Conference-Hawaii. 
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BETTER SKIN CLEARANCE IS ASSOCIATED WITH 
IMPROVED QUALITY OF LIFE IN MODERATE­TO­
SEVERE PSORIASIS PATIENTS TREATED WITH 
TILDRAKIZUMAB
Andrew Blauvelt1, Stephen Tyring2, Melinda Gooderham3, John 
Koo4, Yang Zhao5, Simon Lowry5, Stephen Rozzo5, Alan Mendel-
sohn5, Jeffrey Parno5, Kristian Reich6
1Oregon Medical Research Center, Portland, OR, 2Department of Der-
matology, University of Texas Health Science Center, Houston, TX, 3Skin 
Centre for Dermatology, Peterborough, ON, Canada, 4Department of Der-
matology, University of California at San Francisco, CA, 5Sun Pharmaceu-
ticals, Princeton, NJ, USA, 6SCIderm Research Institute and Dermatologi-
kum Hamburg, Hamburg, Germany
Introduction: Tildrakizumab,	a	high	affinity,	humanized,	IgG1	κ,	
anti-interleukin–23	monoclonal	antibody,	has	demonstrated	effica-
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cy and safety in patients with moderate-to-severe plaque psoriasis 
in two phase 3, double-blinded, randomized controlled trials (re-
SURFACE 1: NCT01722331; reSURFACE 2: NCT01729754)1. 
Objective:The analysis examined the association between quality-
of-life improvements and the degree of skin clearance in patients 
enrolled in the two phase 3 trials and treated with tildrakizumab 
100 mg or 200 mg at weeks 0, 4, then every 12 weeks.
Methods: Both trials used a three-part design: Part 1 (weeks 0–12) 
was placebo-controlled; Part 2 (weeks 12–28) re-randomized 
placebo patients to receive tildrakizumab 100 or 200 mg; Part 3 
(weeks 28–64, reSURFACE 1; weeks 28–52, reSURFACE 2) re-
randomized patients from the tildrakizumab arms with Psoriasis 
Area	and	Severity	Index	(PASI)	response	≥50	at	week	28	to	receive	
the same, a higher, or a lower dose of tildrakizumab, or placebo 
(randomized withdrawal in reSURFACE 1). The Dermatology Life 
Quality Index (DLQI) questionnaire was administered at weeks 
0, 12, 28, 40, and 52. Tildrakizumab-treated patients were pooled 
from	the	two	trials	and	classified	into	5	mutually	exclusive	groups	
based on their week-28 PASI response: PASI  < 50, PASI 50–74, 
PASI 75–89, PASI 90–99, and PASI 100. Baseline characteristics, 
the proportion of patients with DLQI 0/1, and mean DLQI chan-
ges from baseline were examined for each PASI response group.
Results: Overall, 575 patients on tildrakizumab 100 mg (male: 
69.6%; mean baseline age: 45.6 years) and 581 on tildrakizumab 
200 mg (male: 73.0%; mean baseline age: 45.9 years) were inclu-
ded. At week 28, 8.3%, 22.0%, 40.9%, 66.3%, and 86.5% (8.7%, 
35.2%, 43.9%, 70.4%, and 85.9%) of patients with PASI  < 50, 
50–74, 75–89, 90–99, and 100 achieved DLQI 0/1 for those on 
100 mg (200 mg), respectively. Patients with higher week-28 PASI 
response also had greater mean DLQI reductions from baseline 
at week 28 (100 mg: 5.7-13.4; 200 mg: 5.4–12.9). Similar pat-
terns were observed among patients continuously treated with 
tildrakizumab 100 mg or 200 mg from baseline to week 52, with 
better PASI-response patients having greater proportions achieving 
DLQI 0/1 and greater DLQI reductions sustained from week 28 
through week 52.
Conclusion: Tildrakizumab-treated patients with higher levels of 
PASI response also demonstrated better quality-of-life improve-
ments. Achieving PASI 100 was not necessarily associated with 
achieving	DLQI	0/1,	therefore	both	efficacy	and	quality-of-life	
improvements need to be evaluated separately to provide a com-
plete picture of treatment success.
Reference:
1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo 
or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-
FACE 2): results from two randomised controlled, phase 3 trials. Lancet. 
2017;390(10091):276-288.
This abstract has been accepted by 2018 EADV Spring Symposium. 
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STATISTIC REVIEW OF PSORIASIS SYSTEMATIC 
THERAPIES IN NORTH GREECE
Konstantinos Efthimiadis, Florentina-Silvia Delli
State Clinical for Skin and Venereal Diseases Thessaloniki, Greece
Introduction: Psoriasis is a chronic disease that can have a 
significant	 effect	 on	quality	 of	 life.	Therefore,	management	 of	
psoriasis involves both psychosocial and physical aspects of 
this disease, lately generally admitted as systemic. Numerous 
topical and systemic therapies are available for the treatment of 
the cutaneous manifestations of psoriasis. In our daily clinical 
practice, treatment modalities are chosen on the basis of disease 
severity estimated with PASI and DLQI, relevant comorbidities, 
and patient preference.
Objective:To assess the frequencies of each systemic drug, clas-
sical or biological, used for the treatment of mild, moderate to 
severe psoriasis in our hospital care unit from January 2016 since 
December 2016.
Methods: Moderate	to	severe	psoriasis	was	defined	by	PASI > 10 
and/or DLQI > 10 and/or any PASI in a patient with psoriatic 
arthritis.
Results: Most of our patients with mild to moderate psoriasis are 
using	topical	and	classical	therapies.	A	significant	number	of	pa-
tients with severe psoriasis are using biological therapies and about 
a half of them were already used a classical or other biologic drug.
Conclusion: Despite the fact that new biological drugs are avai-
lable for psoriasis treatment, it seems that the patients with mild 
psoriasis are still treating with topical products. At least as far as it 
concerns our Mediterranean country, it seems that our patients dif-
ficult	accept	the	biological	therapies	as	first	choice	line	treatment.
P073
PHARMAKOVIGILANCE OF SYSTEMIC ANTIPSORITIC 
DRUGS: AN UPDATE FROM ROUTINE CARE 
Christina Sorbe1, Laura Kühl1, Stephan Jeff Rustenbach1, Ralph 
von Kiedrowski2, Marc Alexander Radtke1, Matthias Augustin1
1University Medical Center Hamburg-Eppendorf, 2Dermatological office, 
Selters
Introduction & Objectives: The spectrum of antipsoriatic systemic 
therapies	 is	 constantly	 changing.	The	 short-term	 efficacy	 and	
safety of the various therapies are demonstrated in controlled 
clinical studies. The German Psoriasis Registry PsoBest aims to 
gain long-term evidence of safety and effectiveness in routine 
care. Updated interim data of long-term safety of biological and 
non-biological treatment of psoriasis is presented.
Materials & Methods: The non-interventional German Psoriasis 
Registry PsoBest observes adult patients with moderate to severe 
psoriasis	and/or	psoriatic	arthritis.	Patients	are	registered	at	naïve	
systemic treatment start and are observed for 10 years in routine 
care. The registry aims to gain long-term evidence of safety and 
effectiveness of systemic antipsoriatic drugs. Data is collected 
in dermatological practices and walk-in clinics. Presented are 
standardised patient rates per 100 patient years (py) of exposure 
classified	by	system	organ	classes	of	MedDRA®	(SOC,	Medical	
Dictionary for Regulatory Activities).
Results: Until June 2017, 5,825 patients were registered and 
sufficient	for	analyses.	They	were	predominantly	male	(58.8%),	
had a mean age of 47.7 years (SD 14.5) and 30.0% of patients 
suffered psoriatic arthritis. 4,729 patient years (py) were observed 
on biologic treatments and 6,583 py on other systemic treatments.
For all cause death, malignancies and other serious adverse events 
(SAE),	there	were	no	significant	differences	between	the	treatment	
cohorts. Highest SAE rates were observed in the SOCs Surgical 
and medical procedures (3.5 and 2.6 patients/ 100 py on biologics 
and non-biologics, respectively), General disorders and adminis-
tration site conditions (2.0 and 1.8 patients/ 100 py), Infections 
and infestations (1.6 and 1.1 patients/ 100 py) and Neoplasms (1.4 
and 1.3 patients/ 100 py). Events from other SOCs were observed 
for less than 1 patient/ 100 py.
Non-serious adverse events (AE) within the SOCs Skin and sub-
cutaneous tissue disorders, Renal and urinary disorders, Blood 
and lymphatic system disorders, Gastrointestinal disorders, 
Nervous system disorders, Vascular disorders as well as Investi-
gations were less frequent in biologic treatment compared to 
non-biologics (2.2 vs. 5.3, 0.3 vs. 0.7, 0.4 vs. 2.3, 2.4 vs. 11.3, 1.3 
vs. 2.7, 1.2 vs. 2.1 and 2.0 vs. 3.4 patients/ 100 py, respectively, 
p ≤ 0.05). Non-serious infections were observed more often in 
biologics (7.0 vs. 4.8 0 patients/ 100 py, p ≤ 0.05). For the lately 
authorized treatments secukinumab and apremilast 253 and 111 
py were observed, for biosimilar treatment 5 py. They showed no 
deviations	from	the	previously	observed	safety	profile	of	other	
systemic therapies.
Conclusions: In the general, no increased risk of biological or 
non-biological	treatments	was	observed.	The	specific	differences	
in non-serious events will be evaluated in more detail in future 
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analyses. For robust data on recently authorised therapeutics, more 
observation time is needed, especially with a constantly changing 
spectrum of treatments.
P074
THE IMPACT OF PATIENT REQUESTS ON PSORIATIC 
ARTHRITIS TREATMENT
Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights
Introduction: As a result of direct to consumer advertising, pa-
tients frequently request well-known brands for the treatment of 
psoriatic arthritis, and these patients tend to be highly involved 
in their therapy decisions. Patient requests commonly relate to 
formulation preferences, and in an indication dominated by bio-
logics administered either subcutaneously or intravenously, oral 
small molecules are in high demand. 
Objectives: One of the objectives of this study was to gain further 
insight into patient requests as a main driver for switching to and 
from biologics/apremilast.
Methods: An	 independent	market	 analytics	 firm	 collaborated	
with US rheumatologists (n = 200) to conduct a retrospective 
chart review of patients diagnosed with psoriatic arthritis (PsA) 
(n = 1,008), who had switched from one biologic therapy or 
apremilast to another in the prior twelve weeks. Rheumatologists 
were able to submit up to seven PsA patient charts. Data were col-
lected in April 2017 and included clinical and non-clinical patient 
demographics, as well as physician demographics and attitudinal 
survey responses. 
Results: PsA patients tend to be very involved when it comes to 
treatment	decisions	as	60	percent	of	patients	had	significant	input	
or were the primary driver behind the recent decision to switch 
agents. Of those patient driven switches, only 36 percent of treating 
rheumatologists felt there was strong clinical rationale behind the 
switch; despite this, nearly half of rheumatologists state they tend 
to	approve	specific	patient	requests.
Two-thirds of collaborating rheumatologists believe patients would 
choose an oral agent over one that administered subcutaneously, 
thus switching to apremilast is particularly common when patients 
are involved in the decision. Patient requests were the primary 
driver behind 24 percent of all switches to apremilast, compared 
to just 12 percent when switching to a biologic. Furthermore, for 
rheumatologists who are not in favor of an “apremilast before 
biologics”	treatment	approach,	patient	requests	are	significantly	
more of a driver for the brand than those who have adopted an 
“apremilast before biologics” approach.
Conclusion: PsA patients are highly involved in the decision to 
initiate and switch biologic/apremilast therapies, and treating rheu-
matologists tend to be open to granting such requests, regardless 
of clinical rationale. When patient requests are a primary driver 
for	switching,	apremilast	benefits	the	most;	largely	due	to	the	oral	
formulation.	With	the	new	approval	of	the	first	JAK	inhibitor	and	
second	oral	option	in	the	PsA	market,	tofacitinib	will	likely	fill	a	
gap	for	both	physicians	and	patients	by	introducing	a	high	efficacy	
oral option, warranting follow-up analysis on the evolution and 
impact of patient requests in PsA.
P075
THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING 
BIOLOGICS COMPARED TO CONVENTIONAL 
SYSTEMIC THERAPIES
Kayleigh Mason
The University of Manchester, Manchester, UK
Introduction: Whether psoriasis patients exposed to biologic 
therapies have an elevated risk of keratinocyte carcinoma (KC), 
including basal cell carcinoma (BCC) or cutaneous squamous cell 
carcinoma (cSCC) remains uncertain.
Objective:The aim of the present study was to determine whether 
such patients were at higher risk of developing a KC compared to 
those on conventional therapy.
Methods: The British Association of Dermatologists Biologic 
Interventions Register (BADBIR), a pharmacovigilance register 
of psoriasis patients, explores the long-term safety of systemic 
therapies. Patients with chronic plaque psoriasis registering to 
BADBIR	on	their	first	biologic	or	a	conventional	therapy,	who	had	
at least one follow-up completed were included in analyses if they 
were of white ethnicity, Fitzpatrick skin types 1–4 and reported 
no previous cancers. Confounding factors included: age; sex; 
smoking; and previous exposure to acitretin, psoralen ultraviolet-
A (PUVA), ciclosporin, and/or PUVA and ciclosporin. Propensity 
score-weighted Cox-proportional hazard models estimated the 
hazard	 ratio	 (HR)	 for	developing	a	first	KC	or	separately,	first	
BCC or cSCC.
Results: In total, 5672 patients initiating biologic therapy and 3188 
patients on conventional therapy who met the entry criteria were 
identified	with	20558	and	7829	person-years	of	follow-up,	respec-
tively. During follow-up, 74 (1.3%) patients initiating a biologic 
therapy	were	diagnosed	with	their	first	KC	(43	BCC;	34	cSCC	
first)	and	22	(0.7%)	patients	receiving	conventional	therapy	with	
their	first	KC	(15	BCC;	10	cSCC	first).	No	significant	difference	
in risk was observed for developing a KC (adjusted HR 1.05; 95% 
CI 0.64, 1.73), BCC (0.84; 95% CI 0.45, 1.54) or cSCC (1.20; 
95% CI 0.57, 2.50) on biologic compared to conventional therapy.
Conclusion: Biologic therapy does not appear to confer a higher 
risk	of	developing	a	first	KC	as	compared	to	conventional	therapy	
in psoriasis patients. These data will help inform clinical decision 
making in psoriasis patients at risk of KC in whom biologic or 
conventional therapy is being considered. 
On behalf of the BADBIR Study Group, British Association of Derma-
tologists, London, UK
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PATIENT PERCEPTIONS OF PSORIASIS SEVERITY IN 
SWEDEN, NORWAY, AND DENMARK
Kjersti Danielsen1, Albert Duvetorp2, Lars Iversen3, Mikkel 
Østergaard4, Oliver Seifert5, Kåre Steinar Tveit6, Lone Skov7
1UiT The Arctic University of Norway, Tromsø, Norway; University Hos-
pital of North Norway, Tromsø, Norway, 2Linköping University, Linköping, 
Sweden; Skånes Universitetssjukhus, Malmö, Sweden, 3Aarhus University 
Hospital, Aarhus, Denmark, 4Copenhagen Center for Arthritis Research, 
Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, 
University of Copenhagen, Copenhagen, Denmark, 5Linköping University, 
Linköping, Sweden; Ryhov Hospital, Jönköping, Sweden, 6Haukeland Uni-
versity Hospital, Bergen, Norway, 7Herlev and Gentofte Hospital, Univer-
sity of Copenhagen, Copenhagen, Denmark
Introduction: Optimal clinical management of psoriasis (PsO) and 
psoriatic arthritis (PsA) requires understanding of their impact 
on patients.
Objectives: NORPAPP aimed to evaluate disease prevalence and 
patient perceptions of severity in Sweden, Denmark, and Norway.
Methods: NORPAPP was an on-line survey carried out during 
November and December 2015 using YouGov panels in Sweden, 
Denmark, and Norway. The survey included 44 questions covering 
self-perceived disease severity/symptoms, quality of life, contact 
with the healthcare system, and treatment. The initial survey 
population was randomly selected using framing quotas based 
on population census data to ensure inclusion of a representative 
sample of adults (aged 18–74 years) from each country. Partici-
pants were asked if they had PsO or PsA and if it was physician 
diagnosed: those diagnosed by a physician were invited to partici-
pate in the full survey. Final survey data were weighted to match 
national sex and age distributions. Self-perceived disease severity 
was expressed by a 5-level score. Severity of PsO based on the % 
body surface area (BSA, mild ≤ 3%; moderate 4–9%; and severe 
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≥10%)	was	based	on	the	respondent’s	estimate	of	palms	of	affected	
skin (1 palm  =  1% BSA).
Results: Among 22,050 individuals questioned, reported preva-
lence of PsO and/or PsA was 9.7% (9.4% in Sweden, 9.2% in Den-
mark, and 11.9% in Norway); 1264 (5.7%) individuals reported 
physician diagnosis and 1221 of these completed the full survey. 
Among survey participants, 74.6% reported PsO alone, 10.3% PsA 
alone, and 15.1% both. There was a limited correlation between 
self-perceived disease severity and estimates of % BSA for PsO 
(Spearman’s rho 0.42). Self-perceived PsO severity was related 
to	the	most	common	symptoms	(itching	and	flaking/scales)	but	%	
BSA-based clinical severity was not. Respondents with PsA+PsO 
reported	significantly	worse	self-perceived	severity	and	%	BSA	
of PsO than those with PsO alone. Overall, PsA symptoms were 
self-perceived to be more severe than PsO symptoms.
Conclusion: Patient perceptions of PsO severity differ from their 
estimates of %BSA and should be considered in the assessment 
and management of PsO. 
P077
PATIENT EXPECTATIONS AND SATISFACTION IN 
PSORIASIS TREATMENT: A SURVEY FROM EUROPE 
AND CANADA
Jonathan Barker1, Robert McKenzie2, Daniel Saure2, Stefan Wil-
helm2, Kunal Gulati2, Ronald Vender3
1Guy’s Hospital, St. John’s Institute of Dermatology, London, UK, 2Eli Lilly 
and Company, 3Dermatrials Research INC, Hamilton, Ontario, Canada
Introduction: Psoriasis is a chronic immune-mediated disease that 
negatively affects the quality of life of patients.1 Despite recent 
advancements in treatment, patient expectations may differ from 
the treatment outcome, potentially leading to dissatisfaction.
Objective:To evaluate patient expectations on psoriasis treatment 
outcomes and to what extent these were met by the treatment.
Methods: Data were collected from patients with moderate-to-
severe	psoriasis	with	≥	3%	skin	involvement.	Patients	were	inclu-
ded from 17 European countries and Canada through a structured, 
web-based interview in their local language. Patients were on 
topical, PUVA/phototherapy, conventional systemic or biological 
treatment. Descriptive statistical analyses were conducted.
Results: Overall, 1946 patients (mean [SD] age: 42 [13] years, 
43% male) with psoriasis were surveyed between 6 July 2016 and 
5 May 2017. The vast majority of patients currently on treatment 
reported	 reduced	 itchiness	 (69%),	 reduced	flaking	 (62%),	 and	
clearer skin/skin that looked better generally (61%) as the main 
expectations of their treatment. In addition, these patients reported 
duration of effect (41%), extent of overall skin clearance (36%), 
and	speed	of	onset	(34%)	as	the	main	influences	for	changing	their	
current treatment. Furthermore, patients were asked whether their 
achieved results matched with their initial treatment expectations. 
Patients reported that the convenience of dosing (68%) and admi-
nistration method (68%) completely met, or even exceeded their 
initial expectations for the treatment. Conversely, expectations for 
reduced	itchiness	(62%),	reduced	flaking	(62%),	clearer	skin/	skin	
that looked better generally (63%) were only partially met or not 
met	at	all.	Approximately,	two-third	of	patients	were	dissatisfied	
or	only	partially	satisfied	with	the	extent	of	their	skin	clearance	
and	improvement	in	at	least	one	specific	area.	Specifically,	scalp	
(48%), legs (42%), and arms (41%) were the highest rated areas 
if	asked	for	insufficient	satisfaction	for	clearance.
Conclusion: Data from this international survey indicate that 
efficacy	and	maintenance	of	response	are	 the	patients’	primary	
expectations	of	psoriasis	treatment	whereas,	insufficient	response	
to	therapy	in	difficult-to-treat	areas	appears	to	be	a	major	reason	
for patient dissatisfaction.
Reference:
1. Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus beta-
methasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: 
rationale	for	development	and	clinical	profile.	Expert	Opin	Pharmacother.	
2017 Jan;18(1):115-121.
This survey was sponsored by Eli Lilly and Company, Indianapolis, USA.
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SOCIOECONOMIC DETERMINANTS OF PAEDIATRIC 
PSORIASIS
Jonathan Groot1, Anne-Marie Nybo Andersen2, Abdulfatah Adam2, 
Tilde Elkjær Tind Nielsen2,3, Christoffer Blegvad3, Lone Skov3
1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, 
University of Copenhagen, Hellerup, Denmark, 2Section for Epidemiology, 
Department of Public Health, University of Copenhagen, Copenhagen, 
Department of Dermatology and Allergy, Herlev and Gentofte Hospital, 
University of Copenhagen, Hellerup, Denmark
Introduction: Psoriatic comorbidities have been shown to be 
inversely associated with socioeconomic position (SEP). We hy-
pothesized that the social patterning of paediatric psoriasis would 
be similar to that observed for several psoriatic comorbidities, such 
as cardiovascular disease and type 2 diabetes mellitus.
Objectives: Our aim was to investigate whether maternal SEP is 
a determinant of paediatric psoriasis.
Methods: Data on paediatric psoriasis from 36,003 offspring of a 
national birth cohort were cross-linked with nation-wide registry 
data on maternal educational attainment, maternal labour market 
attachment and equivalised household income. We performed lo-
gistic regression analyses to test for associations between measures 
of maternal SEP and paediatric psoriasis. Cohort analyses were 
conducted,	estimating	the	odds	ratios	(OR)	and	95%	confidence	
intervals (CI) of offspring psoriasis. We included maternal age at 
birth and maternal psoriasis as covariates in adjusted analyses.
Results: Maternal educational attainment and equivalised hous-
ehold income were inversely associated with offspring psoriasis. 
Offspring of mothers with a low educational attainment had an OR 
1.62 (95% CI: 1.20–2.18; p < 0.01) of paediatric psoriasis, after 
adjusting for maternal psoriasis and age, compared to offspring 
of mothers with a medium educational attainment. Offspring of 
mothers in the highest quartile compared to mothers in the lowest 
quartile of equivalised maternal household income had an OR 
0.59 (95% CI: 0.44–0.80; p < 0.001) of paediatric psoriasis, after 
adjusting for maternal psoriasis and age.
Conclusion: Lifetime prevalence of paediatric psoriasis was inver-
sely associated with maternal SEP in our study population. Early 
life	exposure	to	modifiable	risk	factors	associated	with	SEP	may	
play an important role in the development of paediatric psoriasis. 
Future studies are warranted to clarify the role of mediating factors.
P079
OBESITY AND THE RISK OF PSORIASIS: A KOREAN 
NATIONWIDE, POPULATION­BASED STUDY
Ju Hee Han1, Kyung Do Han2, Chul Hwan Bang1, Young Min 
Park1, Jun Young Lee1, Yong Gyu Park2, Ji Hyun Lee1
Department of Dermatology, Seoul St. Mary’s Hospital, College of Medici-
ne, The Catholic University of Korea, Department of Biostatistics, College 
of Medicine, The Catholic University of Korea, Seoul, Korea
Introduction: Psoriasis is a T-helper-1 and -17 cell-mediated, 
chronic,	inflammatory	skin	disease	affecting	approximately	1–3%	
of the general population. Psoriasis is currently considered as a 
chronic	 low-grade	 inflammatory	condition	 that	plays	 an	 active	
role in the development of the pathophysiologic phenomena 
responsible for metabolic syndrome and cardiovascular disease. 
Obesity, as a component of the metabolic syndrome, represents a 
major comorbidity and possibly contributes to reduced treatment 
response.
Objective:This nationwide, population-based study investigated 
the impact of body mass index (BMI) and waist circumference 
(WC) on the psoriasis in the Korean population.
Methods: We used the health check-up database, which is sub-
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dataset of the Korean National Health Insurance Service database. 
Study population includes subjects who had undergone health 
screenings between January 2009 and December 2012. Patients 
who were diagnosed with psoriasis prior to the health screening 
or who were less than 20 years of age were excluded. This study 
investigated newly diagnosed patients with psoriasis (ICD-10 
code, L40) by dermatologists among subjects during the follow-up 
period through the claim data.
Result: Total 22,633,536 subjects were included and psoriasis 
newly developed in 399,461 subjects. Mean BMI among newly de-
veloped psoriasis group (23.9±3.25) was higher than non-psoriasis 
group (23.68±3.27)(p < 0.0001). Mean WC of newly developed 
psoriasis group (81.21±9.27) was higher than non-psoriasis group 
(79.99±9.26) (p < 0.0001). BMI showed J-shaped association with 
the risk of psoriasis. Subjects with BMI over 30 had higher risk 
of psoriasis (HR 1.118, 95% CI 1.1–1.137). The risk of psoriasis 
increased in proportion to WC. Subjects with WC over 105 cm 
showed highest risk of psoriasis (HR 1.305, 95% CI 1.261–1.349) 
after adjusting confounding factors including BMI. The risk of 
psoriasis increased most in the male group with normal weight, 
abdominal obesity (HR 1.175, 95% CI 1.15–1.2).
Conclusion: According to our study, the WC is more likely to affect 
the risk of psoriasis than obesity. Our study supports the associa-
tion between abdominal obesity and psoriasis, which increases 
awareness of the role of abdominal obesity in the pathogenesis 
and comorbidities of psoriasis.
P080 
CLINICAL CHARACTERIZATION OF PSORIATIC 
ARTHRITIS IN A MULTIDISCIPLINARY CARE MODEL 
OF PATIENTS WITH PSORIASIS
Dalila Alejandra Lopez-Rodriguez
Dermatologico Country
Introduction: Psoriatic	arthritis	(PsA)	is	an	inflammatory	arthro-
pathy that occurs in patients with Psoriasis (PsO). The frequency 
of PsA in patients with PsO has been estimated between 10–40%. 
The presentation and clinical course are variable, therefore, it is 
necessary to understand the clinical behavior, severity and as-
sociated factors that condition functional impairment, disability 
and lost quality of life.
Objective:To describe the clinical features of the ApS, in a mul-
tidisciplinary PsO clinic.
Methods: Prospective study, August 2016-february 2018, patients 
attending to Multidisciplinary Clinic for psoriasis in Dermatolo-
gico Country were included.
Results: A	total	of	53	participants	were	included,	finding	a	preva-
lence of psoriatic arthropathy of 58.5%.
The median age was 42 years and 71% were female. Patients with 
ApS have higher frequency of DM2, metabolic syndrome and 
hepatic steatosis. However, the differences are not statistically 
significant,	which	could	be	a	result	of	the	sample	size.	According	
to the activity of PsO the most frequent presentation was plaque 
psoriasis in 67.7%. Median PASI was 5.4 (1.5, 16.4). Axial pre-
sentation of ApS was observed in 51.6% and peripheral disease 
in 71%, enthesitis was found in 54.8% and dactylitis 16.1%. 
To determine the severity of PsA according DAS 28 score, we 
found 45.2% of patients presented severe activity. One hundred 
percent of the subjects with peripheral disease did not achieve 
low activity criteria of the disease measured by MDA. When 
calculating the tertiles of the HAQ instrument, it is possible to 
observe that 51.6% of patients presented severe deterioration 
in the quality of life. In the logistic regression model without 
adjustment, the presence of a severe DAS 28 is associated with 
an increase in the risk of deterioration in quality of life, with OR 
of 6.24 (1.74, 22.2). The presence of BMI >  27 is associated with 
an increase in the risk of deterioration in quality of life with OR 
of 6.53 (1.59, 26.8). When performing the adjusted multivariate 
model, the only variables that were associated with severe de-
terioration of quality of life were the presence of BMI >  27 and 
on the other side, pain, with BMI >  27 is the factor that mostly 
impairs the quality of life.
Conclusions: Prevalence of PsA in this series of patients with skin 
or nail psoriasis was 58.3%. The 45.2% of patients showed severe 
activity and 51.6% severe deterioration in their quality of life, that 
leads to disability and limitation performing daily activities. An 
early diagnosis provides the possibility of appropriate treatment 
to improve function, quality of life and decrease the progression 
and complications of the disease.
P081 
TRIGGERING FACTORS IN CHILDHOOD PSORIASIS
Iveta Dencheva1, Ivan Botev2, Lyubka Miteva1
1Dermatology clinic “Persenk”, 2Department of Dermatology and Venere-
ology, Medical University, Sofia, Bulgaria; Dermatology clinic “Persenk”, 
Sofia, Bulgaria
Introduction: Psoriasis	is	a	chronic	multisystem,	inflammatory	di-
sease that occurs at any age. It represents about 4% of all dermato-
sis observed in children. Approximately one third of all patients 
have onset of the disease under the age of 16. The most common 
triggering factors in children are stress, Koebner phenomenon, 
infections and seasonal change.
Objectives: The aim of this study was to assess the most common 
triggering and precipitating factors of psoriasis among Bulgarien 
children.
Materials and Methods: This study included 42 consecutively 
diagnosed children with psoriasis who presented in the Department 
of Dermatology and Venereology at Alexandrovska University 
Hospital,	in	Sofia,	Bulgaria.	The	inclusion	criteria	were	a	clinical	
diagnosis of psoriasis and age under 18 years.
Results: A total of 42 children with psoriasis were examined, 18 
(42.85%) males and 24 (57.15%) females. The most frequent fac-
tors precipitating psoriasis in our group of children were psycho-
emotional stress in 16 (38.09%) cases. Koebner`s phenomenon 
was observed in 3 (7.14%) patients. In only two (4.76%) children 
triggering factors associated with psoriasis were infections. In 17 
(40.47%)	cases	aggravating	factors	could	not	be	identified.	The	
influence	of	the	season	on	disease	activity	could	be	determined	
in 25 (59.52%) patients. All of them showed worsening in winter 
and improvement in summer.
Conclusion: The most frequent factors precipitating psoriasis in 
children revealed in this study, were stressful life events, Koebner 
phenomenon and infectious disease. Among patients who reported 
triggering factors, stress was the most common cause. The study 
showed that psoriasis in children relapses and worsens mainly in 
winter season.
P082
QUALITY OF CARE FOR PSORIASIS IN THE PAST 12 
YEARS – RESULTS FROM A SERIES OF NATIONWIDE 
HEALTH CARE STUDIES IN GERMANY
Matthias Augustin
Institute for Health Services Research in Dermatology
Introduction: In Germany, the quality of health care for psoriasis 
was	very	critical	in	2005.	Most	patients	lacked	of	sufficient	care	
and there was only a minor proportion receiving systemic drugs. 
In the mean time, there has been conducted a national psoriasis 
program in order to improve the quality of psoriasis care, inclu-
ding development of an evidence-based guideline, a consensus of 
treatment goals, the invention of a “culture of measurement” and 
consented national goals for psoriasis care. These measures were 
supported by the establishment of 30 regional psoriasis networks 
involving more than 800 dermatologists.
Objectives: (1) Presentation of the very recent results on the health 
care situation of patients with psoriasis vulgaris in dermatological 
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treatment in Germany 2016/17 (2) Comparison of health care 
quality indicators between the surveys 2004/05, 2007, 2013/14 
and 2016/17.
Methods: Nationwide, non-interventional, cross-sectional studies. 
In each survey between 71 and 130 centers included patients 
and data from patients and dermatologists were obtained from a 
minimum of 1500 patients per survey. Quality of care indicators 
were severity of the psoriasis (PASI and proportion of patients 
with PASI > 20, indicating high severity), quality of life (DLQI 
and proportion of patients with DLQI > 10, indicating strong 
impairments in quality of life), previous systemic therapy and 
inpatient	treatment	in	the	last	five	years.
Results: Between January 2016 and December 2017 n = 1827 
patients from 93 dermatological centers were included in the re-
cent survey (mean age 51 years, 45.2% female). 7.5% had severe 
psoriasis (PASI > 20) compared to 9.2% in 2013/14, 11.6% in 2007 
and 17.8% in 2004/05. The mean PASI was 7.3 compared to 8.1 in 
2013/14, 10.1 in 2007 and 11.4 in 2005. The mean DLQI was 6.1 
compared to 5.9 in 2013/14, 7.5 in 2007 and 8.6 in 2005. 21.4% 
reported a strongly impaired quality of life (DLQI > 10) compared 
to 21.3% in 2013/14, 28.2% in 2007 and 34.0% in 2005. 59.5% of 
all participants stated that they had received systemic therapy at 
least	once	within	the	last	five	years	compared	to	59.5%	in	2013/14,	
47.3% in 2007 and 32.9% in 2005. 18% received inpatient hospi-
tal	treatment	within	the	last	five	years	at	least	once,	compared	to	
20.1% in 2013/14, 20.1% in 2007 and 26.9% in 2005.
Conclusions: It can be assumed that health care quality for pso-
riasis patients in Germany has improved within the last 12 years.
P083
GLOBAL PSORIASIS ATLAS – WORK STREAM 2
Matthias Augustin, Nirohshah Suthakharan
University Medical Center Hamburg, Institute for Health Services Re-
search in Dermatology and Nursing (IVDP)
Introduction: Psoriasis is a common, chronic and non-com-
municable skin disease with an immensely negative impact on 
people’s	lives.	There	is	a	lack	of	standardized	case-definition	or	
methodology leading to a wide variation in the prevalence estimate 
between	0.09%	and	11.43%.	To	tackle	this	knowledge	deficit	and	
in response to the WHO Global report on Psoriasis (2016), the 
Global	Psoriasis	Atlas	(GPA)	will	be	a	first-ever	online	leading	
epidemiological database on psoriasis. It will inform research, 
policy and health care provision worldwide. GPA provides a 
detailed disease prevalence and incidence as well as information 
on access to treatment, comorbidities and cost to society which 
will enable extensive comparisons between countries over time. 
Furthermore, it will provide accurate health data for decision 
makers, stakeholders and patients worldwide. 
Objectives: The GPA includes two Work Streams (WS) Teams. 
WS1 is conducting extensive literature review on psoriasis. In this 
paper the WS2 is explaining the development of methodology 
to serve the framework for compiling the GPA data. Methods: 
Currently, data sources are being collected in two phases and 
for the selection of data sources an in-/exclusion criteria were 
developed and followed. Firstly, a global online survey on data 
source	identification	is	being	conducted	in	 > 150 countries world-
wide addressed to dermatologists and non-dermatologists. The 
questionnaire	identifies	local,	regional	and	national	data	sources	
including registries, research institutes, projects, publications and 
other relevant sources supporting the GPA project. Secondly, Desk 
research on the same data sources is being conducted. Discussion 
on	the	following	aspects:	identification	of	non-published	sources,	
integration of different sources, solving interpolation issues of 
hard-to-reach areas and creating database. 
Results:	Desk	research	has	identified	potential	data	sources	from	
199 countries which includes 194 ministries of health, 97 registries, 
84 patient associations, 32 statistic institutes, 25 Public Health 
organizations,	230	research	institutes	(general/psoriasis	specific),	
13 claim data sources and 261 publications on psoriasis. The in-
ternal pilot for the global online surveys has been completed by 
an international expert team for further improvement. Currently, 
the surveys are being sent out to dermatologists and non-dermato-
logists. On a monthly base, both work streams are updating each 
other about their achievements and issues. 
Conclusion: In the next steps of Work Stream 2, a database will 
be	created	in	order	to	insert	all	identified	data	sources.	Informa-
tion	 from	 identified	 data	 sources	will	 be	 used	 to	 contact	 (via	
email) the responsible persons to access this data. Additionally, 
survey responses will be analyzed and added in the database. 
This database will be updated regularly and extended to include 
comorbidities in future.
P084
GLOBAL BURDEN OF DISEASE: A SYSTEMATIC 
LITERATURE REVIEW ON DISABILITY WEIGHTS FOR 
SKIN DISEASES
Nirohshah Suthakharan, Matthias Augustin
University Medical Center Hamburg, Institute for Health Services Re-
search in Dermatology and Nursing (IVDP)
Introduction: Skin diseases account for one of the most common 
human illnesses globally but in the recent Global Burden of Di-
sease (GBD) study, psoriasis, for example, ranked 144 out of 174 
conditions in the DALY rankings. Two components of DALY cal-
culation are prevalence of the disease and disability weight factor. 
The derivation of disability weight (DW) factor depends on many 
factors which can lead to wide range of results. GBD methodology 
can	significantly	underestimate	the	skin	disease	burden.	
Objective:To understand the currently used DWs of skin diseases 
in-depth and if these current records of DWs can be solely based 
on a survey that was conducted on the general population.
Methodology: A systematic literature review was performed to 
answer the research questions. Comprehensive search of eligible 
scientific	and	grey	publication	in	English,	from	2007	to	2017,	were	
conducted in PubMed and EMBASE (Ovid). The studies included 
were based on 16 skin condition and other diseases indicating a 
re-estimation, alternative approach (also besides DALY) to DWs. 
20 relevant studies were included and have been elaborated in the 
review based on a ‘conceptual model of assessing DWs and its 
design choices’ by Haagsma et al., 2014. The health state descrip-
tions, panel composition, and valuation methods used to derive 
DWs in these studies is discussed in detail.
Results: There was scarce literature available for skin diseases 
in particular. DW value depends on and can vary with the panel 
composition: general public, health experts or patients. The health 
state	 description	whether	 disease	 specific	 or	 generic,	with	 or	
without label, describing the course of condition over a period or 
only	temporarily,	can	all	influence	the	panel	members’	decision.	
The valuation methods paired comparison, population health 
equivalence, visual analogue scale, standard gambling or person/
time trade-off can alter the results to a great extent. The contextual 
differences across the countries can also make a difference in the 
calculation. The inclusion of certain skin conditions/health states 
under other medical specialties can be a major factor leading to 
underestimation of overall skin disease burden worldwide.
P085
MIR­499 POLYMORPHISM IS ASSOCIATED WITH 
SUSCEPTIBILITY TO PSORIATIC ARTHRITIS – 
PRELIMINARY STUDY
Renata Sokolik1, Jerzy Świerkot1, Milena Iwaszko2, Mikołaj 
Kozłowski1, Lucyna Korman1, Piotr Wiland1, Katarzyna Bogunia-
Kubik2
1Department and Clinic of Rheumatology and Internal Medicine of Wro-
claw Medical University, 2Laboratory of Clinical Immunogenetics and 
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Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental 
Therapy, Polish Academy of Sciences, Wroclaw, Poland
Introduction: Polymorphism within the miR-499 has been reported 
to be associated with susceptibility to rheumatoid arthritis (RA) 
in various populations.
Objectives: Our	study	aimed	to	find	out	whether	similar	associa-
tion could be observed also in Polish population in both RA and 
psoriatic arthritis (PsA) patients.
Methods: For this purpose 359 individuals were studied, including 
111 RA patients, 86 patients with PsA and 162 healthy blood 
donors that served as a control group. Genotyping for miR-499 
rs3746444 T/C was performed using a LightSNiP assay.
Results: Distribution of the miRNA-499 alleles and genotypes 
was similar in RA patients and controls. Among RA patients 
those carrying the CC homozygous genotype presented with 
lower DAS28 at diagnosis (0.027) but higher CRP levels after 12 
weeks of anti-TNF treatment (p = 0.042). Interestingly, the TT 
genotype (rs3746444) was overexpressed in patients with PsA 
as compared to controls (OR = 1.85, p = 0.034) but its frequency 
was	not	significantly	different	when	compared	to	RA	cases.	This	
polymorphism was also not found to be associated with clinical 
parameters in PsA patients.
Conclusions: These results show that miR-499 rs3746444 T/C 
polymorphism may constitute a risk factor for psoriatic arthritis 
development.
P086
ASSOCIATION BETWEEN INFLAMMASOME­RELATED 
POLYMORPHISMS AND CLINICAL PHENOTYPES OF 
PSORIATIC ARTHRITIS
Kristina Juneblad, Gerd-Marie Alenius
Department of Public Health and Clinical Mediciine, Rheumatology, Uni-
versity Hospital, Umeå
Introduction: Psoriatic Arthritis (PsA) disease expression can 
vary from mild mono-/oligoarthritis to severe erosive polyarthritis 
comparable with Rheumatoid Arthritis (RA), with or without axial 
involvement, and manifestations such as dactylitis and enthesitis 
are	common.	Markers	of	systemic	inflammation	(ESR	or	CRP)	are	
generally unhelpful as markers of disease severity since elevated 
in only 50% of cases.
In	recent	years,	research	on	the	interleukin	1β	(IL1	β)–regulating	
protein	complex,	called	the	inflammasome,	has	shown	interesting	
associations	with	various	inflammatory	diseases.	E.g.	for	RA	(1)	
and psoriasis (Pso) (2,3) associations with genetic polymorphisms 
in	genes	 related	 to	 the	 inflammasome	has	been	discovered.	So	
far,	 no	 studies	 investigating	 genetic	 polymorphisms	 in	 inflam-
masome genes in patients with Psoriatic Arthritis (PsA) have 
been published.
Aim: To analyse different single nucleotide polymorphisms 
(SNP:s)	in	genes	related	to	the	inflammasome	in	relation	to	dif-
ferent disease phenotypes of Psoriatic Arthritis (PsA).
Methods: DNA from 771 PsA patients from Northern Sweden were 
analyzed for different single nucleotide polymorphisms (SNPs) in 
NLRP3 ( rs35829419 (NLRP3-Q750K), rs10733113, rs4353135), 
CARD8 (CARD8-C10X, rs 2043211) and NLRP1 (rs8079034, 
rs878329) in relation to different phenotypes of PsA.
Results:	A	significant	association	was	seen	with	NLRP1 rs878329C 
and patients with axial involvement of disease. When different 
genotypes	were	compared,	significantly	higher	frequency	of	ge-
notype CC were detected in the subgroup with axial involvement 
of disease. In addition, NLRP1	 rs8079034T	was	 significantly	
associated with prescription of a csDMARD. Also, the NLRP3 
rs10733113 showed association with the G-allele in patients with 
a skin disease with an early onset (Pso type1, onset  < 40 years) 
and in the subgroup of PsA with destructive-/deforming disease 
significant	 association	was	 found	with	 the	major	 allele,	C,	 of	
NLRP3 Q705K rs35829419. (Table 1)
Conclusions: In the study, we found association with different 
phenotypes	of	PsA	and	different	polymorphisms	in	inflammasome	
genes.	The	results	could	indicate	a	possible	role	of	inflammasomes	
in different disease phenotypes of PsA and make further studies 
in the area of interest.
References:
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Table 1. Genotype and allele frequencies in different PsA disease expressions#
NLRP1 rs878329
 Genotype   
OR 
(95% CI)*
p-
value
n G/G 
n (%)
G/C
n (%)
C/C
n (%)
C allele χ2
Axial disease 107 30 (28) 51 (48) 26 (24) 48% 4.44 1.37 
(1.02–1.84)
0.035
Peripheral disease 539 184 (34) 275 (51) 80 (15) 41%    
NLRP3 Q705K 
rs35829419
 C/C C/A A/A C allele    
Destructive disease 314 282 (90) 32 (10) 0 (0) 95% 4.7 1.61 
(1.05–2.57)
0.03
No destructive disease 360 304 (84) 54 (15) 2 (0.6) 92%    
NLRP3 rs10733113  G/G G/A A/A G allele    
Pso type1 439 347 (79) 87 (20) 5 (1) 89% 7.4 1.58 
(1.13–2.21)
0.007
Not Pso type1 210 149 (71) 53 (25) 8 (4) 84%    
NLRP1 rs8079034  C/C C/T T/T T allele    
csDMARD ever 499 320 (64) 169 (32) 19 (4) 20% 9.1 1.63 
(1.19–2.25)
0.003
Never csDMARD 216 164 (76) 47 (22) 5 (2) 13%    
*Calculated	with	χ2 test comparing variant allele frequencies between patients and controls.
#Only	significant	association	are	shown.
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FREQUENCY OF INADEQUATE RESPONSE TO 
TREATMENT AMONG PSORIASIS PATIENTS ON FIRST­
LINE BIOLOGICS
Anna Sheahan1, Edward Lee2, Lisa Pisenti2, Mohamed Yassine2, 
Robert Suruki3
1UCB Pharma, Raleigh, NC, 2UCB Pharma, Smyrna, GA, 3UCB Pharma, 
Raleigh, NC
Introduction: Studies describing the occurrence of inadequate 
response (IR) to biologic treatments in psoriasis (PSO) in the real-
world setting are currently lacking. Thus an understanding of IR, 
due to the lack of treatment durability, persistence, or access, to 
1st line biologics in PSO may help to identify and address unmet 
treatment needs.
Objectives: To assess the frequency of IR in the year after initiation 
of	1st	line	biologic	treatment	for	PSO.	IR	was	defined	as	biologic	
dose increase, biologic discontinuation, or add-on treatment.
Methods: Retrospective analysis of commercial US healthcare 
claims (2012–2016) was conducted. Patients initiating a biologic 
(PSO approved anti-TNF, secukinumab, ustekinumab, apremilast) 
with	≥	1	year	 of	 database	 enrolment	 before	 and	 after	 biologic	
initiation (index date) who had a qualifying PSO ICD 9/10 code 
and no previous biologic exposure in the year prior to the index 
date were included. Patients experiencing any of the following 
were	classified	as	experiencing	an	IR	event:	1)	≥	1	claim	with	a	
biologic dose  > 110%	of	 the	 label-recommended	dose	 for	≥30	
days, 2) cessation of 1st line biologic ( > 2 months with no tre-
atment)	(‘non-switch	discontinuation’),	3)	cessation	of	first	line	
biologic followed by initiation of a new biologic within 2 months, 
or 4) addition of a corticosteroid, immunosuppressant, or biologic 
(‘add-on treatment’) with any days’ supply overlap.
Results: Of the 13,995 patients meeting inclusion criteria, 9,520 
(68.0%) experienced an IR event in the 12-month follow-up period 
(53.2% female; mean age: 46.2 yrs) and 4,475 (32.0%) did not 
experience an IR event (45.2% female; mean age: 46.9 yrs). The 
most frequently used 1st line biologics were adalimumab (42.5%) 
and etanercept (26.5%); the proportion of IR patients was 60.4% 
in adalimumab and 75.8% in etanercept. Among all IR patients, 
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non-switch discontinuation was experienced by 63.8% of patients, 
switch to another biologic by 15.1%, above label dosing by 11.5%, 
and add-on treatment by 9.7%. Overall, the mean time from initia-
tion of 1st line treatment to IR event was 4.7 months, ranging from 
4.3 months to add-on therapy and 5.7 months for patients switching 
to another biologic. Among patients switching to another biologic, 
70.3% of patients were persistent on the new biologic after three 
months versus 54.0% after 6 months. The most frequent add-on 
therapies were immunosuppressive drugs (63.8%) followed by 
systemic corticosteroids (20.6%), and biologics (15.5%).
Conclusions: IR in 1st line PSO biologic treatment is common 
with non-switch discontinuation being the most frequent. This 
highlights an opportunity to optimize treatment options currently 
available and better understand patients’ needs for successful th-
erapy. Therapeutic options with improved durability may provide 
a clinically meaningful path to optimizing psoriasis management. 
Further analysis is necessary to identify underlying causes of IR 
and to guide more effective approaches to treatment.
Acknowledgements: This study was supported by UCB Pharma.
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BARRIERS OF GUIDELINE­COMPLIANT CARE 
FOR PSORIASIS IN GERMANY – RESULTS OF THE 
EUROPEAN STUDY PSOBARRIER
Matthias Augustin, Anna Langenbruch, Marc Radtke, Nicole Zander
University Medical Center Hamburg-Eppendorf
Introduction & Objectives: A series of nation-wide studies in 
Germany over the last years has focused on the quality of psoriasis 
care.	It	was	found	that	a	significant	proportion	of	psoriasis	patients	
is not treated according to the national guideline1. Similar under-
provision	of	care	has	been	identified	in	other	countries	as	well,	
reflected	by	patients’	dissatisfaction	with	the	management	of	their	
disease2. This study aims to identify these barriers of guideline-
compliant healthcare for psoriasis in Europe.
Materials & Methods: The study assesses barriers and quality of 
health care in a multi-centre, cross-sectional study design. Par-
ticipating	centres	in	five	European	countries	(Denmark,	Poland,	
Spain, United Kingdom, and Germany) aim to represent the range 
of dermatological health care-providing outpatient facilities of the 
respective country. The current analysis includes the data collected 
in Germany from January 2016 to May 2017.
Results: Data of n = 497 patients were analysed. Mean age was 49.7 
years, 41.4% were female. Mean PASI was 7.2 ± 9.2, 20.9% had a 
PASI > 10. The mean DLQI was 6.2 ± 6.7. 27.0% were currently 
treated with systemics (excluding biologics), 22.3% with biolo-
gics. Since the diagnosis of psoriasis, the participants consulted 
on average 3.0 ± 2.3 different dermatologists (min 0/max 27) and 
had 3.5 ± 3.7 therapy changes. For 32.0% of the patients the time 
between	the	first	skin	changes	and	the	first	diagnosis	of	psoriasis	
was one year or longer. 7.6% stated that their health insurance 
turned down a therapy, treatment or referral that was recommended 
by a physician at least once.
Conclusions: The quite high numbers of consultations of different 
dermatologists, therapy changes and therapies turned down indi-
cate that there might be barriers in psoriasis care. The generated 
data facilitate measures for an improved patient access to systemic 
drugs and biologics. The European comparison will allow for 
the	first	 time	 the	direct	 description	of	psoriasis	 care	 in	 a	wide	
variety of European countries. The matching of patient-reported 
outcomes with data of the health care system and barriers from 
the physician’s perspective is a novelty worldwide and the results 
will contribute to developing strategies to overcome these barriers.
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INDIVIDUALISED THERAPY FOR PSORIASIS ­ CASE 
SERIES
Seema Mahesh1, Viraj Shah2, Mahesh Mallappa1, George Vithoul-
kas3
1Centre For Classical Homeopathy, 2Shah Homeopathic Clinic, 3Interna-
tional Academy of Classical Homeopathy
Introduction: Psoriasis and its complications are still a challenge 
to clinicians. The autoimmune disorder though targeting the skin, 
involves	the	immune	system	as	a	whole.	The	inflammatory	com-
ponent in the pathogenesis of psoriasis has further established the 
role of aberrant immune system in the process [1, 2, 3]. 
Homeopathy addresses every individual’s peculiar combination 
of genetic and epigenetic causative factors in the development of 
such auto immune diseases [4, 5]. Therefore it may be considered 
as a therapy where integrated approach is indicated. 
Case series: 5 cases of psoriasis are presented, two of which 
were in erythrodermic state [one also with sepsis superimposed]. 
Through monitoring of blood markers and documenting on photos 
and videos the effect of individualised homeopathic therapy on 
psoriasis and its complications is demonstrated. 
The theory of Levels of Health can explain the variety in the 
presentation of psoriasis and response to treatment in terms of 
the time taken and number of remedies required. The same theory 
also helps to assess the prognosis and comprehend the response 
to treatment [LOH]. With the help of the evidence of these cases 
we may formulate a larger study to ascertain the extent to which 
classical homeopathy may be employed in psoriasis.
Conclusions: These cases depict the potential for homeopathy in 
alleviating the suffering of patients with psoriasis if applied as 
individualised therapy and give grounds to further conduct control-
led	studies	to	confirm	the	role	of	homeopathy	in	psoriatic	therapy.	
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A UNIQUE CLINICAL CASE OF PSORIATIC ARTHRITIS 
AND RELAPSING POLYCHONDRITIS 
Elena Gubar, Alla Godzenko, Tatiana Korotaeva
Nasonova Research Institute of Rheumatology, Moscow
Introduction: Relapsing polychondritis (RP) is a rare systemic 
autoimmune disorder affecting the cartilaginous structures of the 
body and resulting in their destruction. In the literature available 
we	didn’t	find	any	references	to	RP	occurring	together	with	pso-
riatic arthritis (PsA).
Objective:to demonstrate a rare clinical case of RP and PsA.
Methods: Patient (pt) (female), 29 y.o., complained of pain, swel-
ling, and hyperemia of both ears, pain in the joints, in heels and 
toes and pain in cervical spine. Scalp psoriasis (Ps) and Ps in the 
external ear canal occurred in April, 2017, nail Ps and dactilitis in 
October, 2017; in November, asymmetrical polyarthritis, pain in 
heels, pain and limitation of movement in cervical spine develo-
ped. Besides the pt noticed redness, swelling and pain in pinnas 
of both ears and impairment of hearing; conjunctivitis, stomatitis 
and subfebrile temperature developed.
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At presentation: plaque Ps on the face and scalp, nail Ps, palmo-
plantar feet pustulosis (BSA–4%, PASI –2.1); both pinnas of the 
ears were swollen, painful and red; ear lobes were not involved. 
The pt suffered from conjunctivitis. The pt had asymmetrical 
polyarthritis, dactylitis, achillobursitis. Painful movements at 
cervical spine, rotation 30°-35°. ESR 54 mm/h, CRP 99 mg/l, 
RF negative, positive HLA B27, HLA B5 not detected. PET-CT 
imaging did not reveal any pathological changes besides bilateral 
auricular	inflammation.
Results: PsA diagnosis was determined according to CASPAR 
criteria. RP diagnosis was based on the McAdams criteria. The 
diagnosis	 is	definite	when	no	less	 than	three	out	of	six	criteria	
are present: bilateral auricular chondritis, nonerosive serone-
gative	 arthritis,	 nasal	 septum	 chondritis,	 ocular	 inflammation,	
respiratory tract chondritis, and cochlear disorder. Our pt had 
bilateral auricular chondritis, conjunctivitis, cochlear disorder. 
The	diagnosis	was	confirmed	by	ear-auricles	biopsy	which	sho-
wed	perichondrial	inflammation	and	granulocyte	infiltration.	The	
therapy delivered: methotrexate s/c 10 mg pw; Solu-Medrol i/v 
(750 mg cumulatively); methylprednisolone per os 16 mg per day. 
Within days, there was normalization of temperature, ear-auricle 
swelling, redness and pain had regressed; hearing was restored, 
conjunctivitis passed, the intensity of arthritises, dactylitis and 
spondylitis had decreased; the reduction in ESR, CRP was to 14 
mm/h, to 7.0 mg/l accordingly.
Conclusion: As is known, when a pt has PsO, he is twice as 
likely to develop additional autoimmune diseases. It is of great 
importance to properly diagnose and treat cross autoimmune di-
seases. Early diagnosis (within 3 months) and adequate treatment 
resulted	in	rapidly	decreased	inflammatory	process	and	in	escaping	
nonreversible changes in cartilage tissues.
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SPINY FOLLICULAR HYPERKERATOSIS IN A PSO RIA­
SIS PATIENT TREATED WITH USTEKINUMAB
Antoanela Carija, Adela Markota Cagalj, Neira Puizina Ivic
University Hospital Centre Split
Introduction: We present a psoriasis patient developing asymp-
tomatic white spiny follicular hyperkeratoses (SFH) after being 
treated with ustekinumab for 3 months.
Objectives: This type of eruption has been described under several 
names including spiny follicular keratoderma, hyperkeratotic spi-
cules,	filiform	hyperkeratoses,	parakeratotic	horns,	and	follicular	
hyperkeratoses (1). Facial hyperkeratotic spicule eruption was re-
ported in association with monoclonal gammopathy. Drug-induced 
filiform	hyperkeratosis	has	been	reported	with	cyclosporine,	with	
BRAF inhibitors (vemurafenib), with acitretin and with vismo-
degib and sorafenib.
Methods: Our patient started ustekinumab treatment in June 
2015. At the same time he was treated with metothrexate, folic 
acid, metformin and lisinopril/hydrochlorothiazide. Three months 
after ustekinumab introduction patient noticed growth of tiny skin 
projections located on the face, scalp, upper trunk and upper arms. 
Each spiny lesion was approximately 0.5 to 1 mm in diameter and 
up to 5 mm high. A biopsy of a white spiny keratotic projection sho-
wed orthokeratosis, achantosis and mild spongiosis in epidermis, 
inflammatory	infiltrate	in	chorium	and	dilatated	acrotrichiums.
Condition resolved in several weeks without any treatment and 
without ustekinumab cessation.
Results: A similar condition viral-associated trichodysplasia (TS) 
was originally described in 1999 as a folliculocentric viral infec-
tion in a patient who was receiving cyclosporine after kidney and 
pancreas transplantation. Trichodysplasia spinulosa associated 
polyomavirus	(TSPyV)	was	identified	in	TS	lesions	and	shown	
to be the probable cause of this disease (2). Pathogenesis both of 
viral-associated TS and BRAF inhibitor-induced SFH is based on 
the paradoxical activation of MAPK (mitogen-activated protein 
kinase) pathway, which regulates a variety of cellular processes 
including cell division, differentiation and apoptosis. 
Conclusions: Our patient developed SFH possibly due to use of 
ustekinumab, IL-12 and IL-23 inhibitor. The latter has a role in 
differentiation process of the skin (12), suggesting that inhibition of 
IL-23 might explain the imperfect keratinization process observed 
in SFH. Considering that in our patient drug was not stopped and 
the condition resolved in several weeks without any treatment, 
possible cause could be ustekinumab-induced immunosupression 
and consequent viral infection.
References:
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COMBINATION THERAPY OF APREMILAST AND 
BIOLOGICAL PRODUCT IN A PATIENT WITH 
PSORIASIS
Koji Masuda, Fuminao Kanehisa, Norito Katoh
Department of dermatology, Kyoto Prefectural University of Medicine
Apremilast was approved in March 2017 in Japan for the treat-
ment of psoriasis and psoriatic arthritis. Apremilast appears to 
have	 lower	efficacy	 than	biological	product.	However,	 its	ease	
of administration as an oral agent coupled with a mild side ef-
fect	profile	makes	it	an	attractive	option	for	psoriasis	treatment.	
While monotherapy with biological products is effective for 
many	patients	with	psoriasis,	some	patients	are	not	satisfied	by	
the outcome. There are few data or reports about the safety and 
efficacy	of	apremilast	in	combination	of	biological	product	in	the	
treatment of psoriasis.
We report a 46-year-old man with about a twenty-year history of 
plaque psoriasis and psoriatic arthritis who failed several therapies 
including topical therapy, phototherapy and etretinate. At the time 
of presentation, the patient was using secukinumab for 9 months, 
which had controlled his arthritis. However, the patient noted 
plaque remained mainly on his lower legs. Apremilast was added 
and up-titrated to 30 mg twice per day along with his secukinumab 
therapy. After two months of combination therapy, the patient’s 
disease has improved and stabilized with only a few scattered 
erythematous mildly scaly plaques on his lower legs. The patient 
denied side effects of nausea, diarrhea or headache. Laboratory-
work was within normal limits.
However, we also experienced two other cases who failed apre-
milast	add	on	therapy	to	biological	product	because	of	efficacy	or	
side effects. So, this method may be useful for uncontrolled patient 
for psoriasis, more studies are needed to determine the safety and 
efficacy	of	using	these	drugs	together.
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PSORIASIS WORST­CASE SCENARIOS: A SERIES OF 3 
CASE REPORTS
Elena Popa1, Persa Ghitulescu2, Patricia Cristodor1, Caius So-
lovan1
1Department of Dermatology and Venereology, Clinical Emergency Muni-
cipal Hospital Timisoara; University of Medicine and Pharmacy “Victor 
Babes” Timisoara, Romania, 2Department of Dermatology and Venereo-
logy, Clinical Emergency Municipal Hospital Timisoara
Introduction: Psoriasis	 is	a	chronic,	 immune,	 inflammatory	di-
sease, that can occur at any time and it is most common in the age 
group 50–69. The reported prevalence of psoriasis in countries 
ranges between 0.09% and 11.4%, making psoriasis a serious 
global problem.
Objectives: We present a series of 3 case reports that stand for some 
of the worst-case scenarios a Psoriasis patient could end up in.
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We won’t be insisting on the treatment nor the outcomes of these 
patients whereas the aim of this presentation is to emphasize the 
importance of patient’s education, prevention, but also of an early 
and correct treatment.
Materials And Methods: 
Case report no.1:
-Patient characteristics: 49-years-old white Caucasian male;
-Clinical	presentation:	widespread,	confluent	erythema	of	the	skin,	
large scales, malaise, intense joint pain, shivers, oliguria, marked 
onychodystrophy	of	fingernails	and	toenails	with	an	evolution	of	
about 1 week;
-Physical examination: fever, tachycardia, generalized nontender 
adenopathy;
-Patients history: Psoriasis vulgaris and Psoriatic arthritis since 
2003 treated with 8 months Methotrexate switched (due to diges-
tive symptoms) to oral Acitretinum for about 2 months prior the 
current presentation;
-Possible	cause	of	the	flare-up:	lack	of	compliance	to	treatment,	
but mostly because of disorderly lifestyle.
Case report no.2:
-Patient characteristics: 64-years-old white Caucasian male;
-Clinical	presentation:	widespread,	confluent	erythema	of	the	skin,	
large scales, malaise, loss of appetite, marked onychodystrophy 
of	fingernails	and	toenails	with	an	evolution	of	about	2	weeks;
-Physical examination: fever, tachycardia;
-Patients history: Psoriasis vulgaris since 1992 treated with Ada-
limumb (discontinued after 2 years) and Methotrexate;
-Possible	cause	of	the	flare-up:	voluntarily	discontinuation	of	the	
treatment (Methotrexate) 3 weeks prior to current presentation.
Case report no.3:
-Patient characteristics: 38-years-old white Caucasian female;
-Clinical presentation: pustular lesions spread throughout an 
erythematous background intercalated with skin atrophies and 
subepidermal pseudocysts disseminated throughout the body, 
erythematous, scaly plaque on the scalp;
-Physical examination: vital signs within normal limits;
-Patients history: Pustular Psoriasis from the age of 7 treated with 
Prednisone, Acitretinum and topical steroids;
-Possible	 cause	 of	 the	flare-up:	 voluntarily	 discontinuation	 of	
the treatment (Acitretinum) 7 months prior to current presenta-
tion (the patient wishes to conceive) and long-term use of potent 
topical steroids.
Results: All three cases were treated considering the Psoriasis 
type, clinical presentation and symptoms, each of them having a 
positive evolution during the hospitalization and follow-up visits.
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SUCCESSFUL SWITCHING TO BIOSIMILAR IN 
PSORIATIC PATIENT WITH SEVERE DRUG REACTION 
TO INFLIXIMAB. A CASE REPORT
Maria Politou1, Maria Pompou1, Dimitrios Rigopoulos1, Nikolaos 
Fekkas2, Anastasios Giannoukos1
11st Department of Dermatology-Venereology "Andreas Syggros" Hospital, 
UOA, 2Department of Dermatology-venereology, 401 Military Hospital, 
Greece
Introduction: Biosimilar medicines are drugs which are highly 
similar to other biological medicines already licensed and that do 
not have any clinically meaningful difference to the originator 
drug	in	structure,	pharmacokinetics,	quality,	safety	or	efficacy.
Objectives: Many clinical and observational studies involving a 
switch	between	reference	infliximab	and	its	biosimilars	have	been	
conducted or are ongoing. Switching between reference biologics 
and biosimilars should be performed by the prescriber for clinical 
reasons	such	as	optimizing	efficacy	or	minimizing	AES.	Efficacy	
and clinical measures of safety were similar in the switched and 
not switched groups at studies end. Differences in the type of AES 
upon switching must also be considered. Because biosimilars are 
structurally distinct from innovator biologic, they may produce 
significantly	different	side	effects.	Although,	data	in	the	literature	
suggest that if a patient experience a severe allergic reaction to 
the originator drug it is most possible the same reaction to happen 
with the biosimilar this may not always be the case.
Methods/Results: We present a case of a 60 years old female patient 
with	severe	plaque	psoriasis	from	25	years	treated	with	infliximab	
every	eight	weeks	for	the	last	five	years	with	great	therapeutic	ef-
ficacy.	During	the	last	five	infusions	she	presented	mild	reaction	
with itching and facial redness which was treated successfully 
with antihistamines without the need of interrupting the infusion. 
Patient was also administered pretreatment therapy with a three day 
course of corticosteroids to minimize these reactions. During the 
last infusion patient presented severe body rash and hypotension 
which led to the discontinuation of the infusion. Due to the great 
therapeutic response and because patient had undergone several 
therapies in the past which either hadn’t tolerated or hadn’t re-
sponded to, she was reluctant to change therapy so we decided to 
switch to a biosimilar. Patient is currently through the eight month 
of treatment with the biosimilar with no sign of reaction and with 
maintenance of the therapeutic response.
Conclusion: Biologics are much more complex than conventional 
chemical drugs because they are larger and have more complicated 
structures, so it is impossible to produce biosimilars that are iden-
tical	to	the	originator	drug.	As	a	result,	the	therapeutic	efficacy	and	
safety of a biosimilar could vary from the originator because the 
end product is highly dependent on a proprietary manufacturing 
process that differs for each manufacturer. Our case suggests that 
we may try a switch between reference biologic and its biosimilar 
even when an allergic reaction to the originator drug had occurred, 
especially	when	we	have	a	great	therapeutic	efficacy.	However,	
more data is needed.
P096
SAFETY OF APREMILAST IN THE TREATMENT OF A 
PSORIASIS PATIENT WITH CHRONIC HEPATITIS B
Christina Fotiadou, Myrto Trakatelli, Despina Papathemeli, Eli-
zabeth Lazaridou
Second Department of Dermatology-Venereology, Aristotle University 
Medical School
Introduction: The treatment of patients with moderate-to-severe 
psoriasis in an everyday clinical setting, sometimes, poses serious 
challenges. The presence of hepatitis B Virus Infection (HBV) in 
these patients complicates the therapeutic choices.
Objectives: We report the case of a female patient, 52 years old, 
suffering from moderate-to- severe plaque psoriasis and chronic 
hepatitis B.
Methods: She was referred to our outpatient psoriasis clinic with 
a Psoriasis Area and Severity Index (PASI) score of 13.2. The 
patient’s condition has deteriorated the past year but she had not 
received any kind of systemic treatment. During our pre-treatment 
screening tests she was found HBsAg positive although the liver 
function tests were within normal rates. The HBV serological 
status of the patient (HBsAg, HBeAg, anti-HBc, anti-HBs and 
anti-HBe) was estimated. HBV DNA load was measured with the 
Polymerase	Chain	Reaction	(PCR)	method,	in	order	to	confirm	
that the disease was not active, and it was undetectable.
Results: At that point it was decided to treat the patient with 
Apremilast using the standard titration dosing schedule (10mg on 
day one and increasing the dose by 10 mg daily) until reaching 
the maintenance dose of 30mg twice daily on day 6. Antiviral 
treatment was not given to the patient but liver function tests were 
performed at a monthly basis and HBV load every three months 
during treatment. All these test from the baseline until last obser-
vation (12 months after) were within normal rates. The patient 
exhibited an amelioration of her condition from the beginning 
which	was	confirmed	by	the	significant	reduction	of	her	PASI	score	
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which reached PSI75 at week 12 and PASI90 at week 24. At the 
time of this writing, one year after the initiation of treatment, the 
patient remains almost clear from her psoriatic lesions. Apremilast 
was well-tolerated by the patient.
Conclusions: The treatment of moderate-to-severe psoriasis in the 
background of chronic HBV limits the therapeutic options due 
to the possibility of HBV reactivation when the psoriasis patient 
is treated with immunosuppressive or even immunomodulatory 
drugs. Apremilast is an oral small-molecule PDE-inhibitor, appro-
ved by the Food and Drug Administration for the treatment of 
moderate-to-severe- plaque psoriasis in 2014. It does not target 
any	one	cytokine	but	restores	a	balance	of	pro-inflammatory	and	
anti-inflammatory	mediators.	The	 pharmacokinetics	 of	Apre-
milast is not affected by hepatic impairment and the drug is not 
hepatotoxic. Moreover, it is not contraindicated in patients with 
active	infection.	To	our	knowledge,	this	is	the	first	reported	case	
of Apremilast psoriasis patient with chronic inactive Hepatitis B. 
It	proved	to	be	both	safe	and	efficacious	but	large,	well-organized	
studies	are	needed	in	order	to	confirm	this	conclusion.
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IL­22 INDUCES KERATINOCYTES 
HYPERPROLIFERATION IN PSORIASIS VIA MIR­21 
AND MIR­31 UPREGULATION
Florence Abdallah
Centre de Biophysique Moléculaire, CNRS UPR4301, Orléans, France
Psoriasis	 is	 a	 chronic	 inflammatory	 skin	 disease	 that	 affects	
people of all ages with an estimated 3% prevalence worldwide. 
It manifests as thick red irritated skin lesions due to imbalanced 
keratinocytes hyperproliferation and differentiation caused mainly 
by increased activation of IL-22 pathway in keratinocytes. Emer-
ging	 studies	 showed	a	 specific	psoriatic	miRs	 signature	where	
miR-21 and miR-31 are one of the most upregulated miRs. The 
latters	 act	 by	 favoring	 cellular	 proliferation	 and	 inflammation.	
Hence, re-conciliating the microRNAs and the immunopathogenic 
occasions responsible for psoriasis development can be a new 
approach for developing effective mechanism and target-based 
agents to treat psoriasis.
The common hyper-proliferation effect of IL-22, miR-21 and 
miR-31 prompted us to look after a potential interaction between 
these actors. The expression levels of those 2 microRNAs and that 
of their targets were evaluated both in vitro and in vivo studies in 
presence or absence of IL-22.
We	first	exploited	different	skin	models	to	investigate	a	potential	
connection between IL-22 and miR-21 or miR-31. The qPCR 
analysis	showed	a	significant	increase	in	the	relative	expression	
(RE) of both miRs in the different models upon IL-22 stimula-
tion during 24h compared to untreated cells. These observations 
indicate the implication of miR-21 and miR-31 in proliferation-
differentiation processes in the different layers of the epidermis. 
We also examined the miR-21 target RE PTEN involved in cell 
growth and apoptosis control and the miR-31 target RE ppp6c 
involved in G1 to S phase transition restriction. In line with the 
upregulation of miR-21 and miR-31, IL-22 stimulation resulted 
in	significant	downregulation	of	both	targets	at	the	genomic	and	
proteomic levels.
We next investigated the in vivo correlation between IL-22 and 
miR-21 or miR-31 respectively in the development of psoriatic 
lesion.	We	used	the	imiquimod-induced	psoriasiform	skin	inflam-
mation	in	Wild	type	and	IL-22	deficient	mice	(known	to	be	almost	
protected from IMQ). Mice displaying a less severe disease form 
had less miR-21 expression. By contrast, WT mice treated with 
IMQ	exhibited	significantly	higher	miR-21	RE	than	IL-22-/-	mice.	
Furthermore, miR-31 expression in IL-22-/- mice was identical to 
miR-31 expression in WT control mice. These results suggest a 
direct correlation between IL-22 pathway and miR-31 epidermal 
expression. In line with these observations, the miR targets (PTEN 
and ppp6c) were contrariwise proportional to miRs expression 
confirming	by	that	the	specificity	of	the	IL-22/miR-21	and	IL-22/
miR-31 correlation.
These	findings	identify	IL-22	as	a	key	regulator	of	miRs	implica-
ted in multiple signaling pathways that coordinate keratinocytes 
proliferation activity
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SERUM CONCENTRACION OF IFN­GAMMA IN 
PATIENTS WITH PSORIASIS: CORRELATION WITH 
CLINICAL TYPE AND SEVERITY OF DISEASE
Nermina Ovčina-Kurtović, Emina Kasumagić-Halilović, Jasmina 
Muhović
Dermatovenerology Department Clinical center University of Sarajevo, 
Bosnia and Herzegovina
Introduction: Psoriasis	is	a	multifactorial	chronic	inflammatory	
disease. The etiopathogenesis of the disease is still unclear but 
there is evidence that many of cytokines released by keratinocytes 
and	inflammatory	leukocytes	may	contribute	to	the	induction	or	
persistence	of	the	inflammatory	process	in	psoriasis.
Objectives: The aim of the study was to evaluate serum concen-
trations of INF-gamma in patients with psoriasis and the healthy 
subjects and also to assess a possible association between IFN-
gamma, clinical type and severity of disease.
Methods: The study included a total of 60 patients with psoriasis, 
both genders and all of ages. There were 20 healthy subjects in the 
control group. According to the clinical type of disease, patients 
with psoriasis were divided into four groups: psoriasis vulgaris, 
psoriasis pustulosa, psoriasis erythrodermica and psoriasis arth-
ropatica. Blood samples were collected from all psoriasis patients 
and from healthy control subjects. Serum IFN-gamma levels were 
measured by an enzyme-linked immunosorbent assay (ELISA) 
technique. The severity of psoriasis vulgaris was assessed by 
Psoriasis Area and Severity Index (PASI) score.
Results: Of the total number of patients suffering from psoriasis 
42 (70%) had psoriasis vulgaris. The second most frequent was 
psoriasis erythrodermica 9 (15%), while 6 (10%) patients had 
psoriasis pustulosa and 3 (5%) psoriasis arthropatica. The serum 
concentartion of IFN-gamma in patients with psoriasis was sig-
nificialy	higher	than	that	in	the	control	group	(1.91+1.79	pg/ml	
vs	0.91+0.38	pg/ml,	respectively).	Significantly	elevated	serum	
IFN-gamma concentrations were noticed in patients with psoriasis 
vulgaris (2.15+0.30 pg/ml), compared with patients suffering from 
psoriasis erythrodermica (1.57+0.68 pg/ml), psoriasis arthropa-
tica (1.33+0.53 pg/ml), and in particular patients suffering from 
psoriasis pustulosa (1.08+0.21 pg/ml) who had the lowest mean 
serum concentration of IFN-gamma. There was no statistically 
significant	difference	between	 the	mean	values	of	 IFN-gamma	
compared to the clinical type of psoriasis (p > 0.05). In the group of 
patients with psoriasis vulgaris 36 (85.71%) patients had mild form 
of disease with PASI  < 50, and 6 (14.29%) patients had severe 
disease with PASI  > 50.	It	was	not	found	statistically	significant	
correlation between IFN-gamma and PASI score.
Conclusions: The results of this study showed that psoriasis is 
associated	with	significant	changes	in	serum	concentracion	of	IFN-
gamma.	There	was	no	statistically	significant	correlation	between	
serum IFN-gamma concentracions, clinical type of psoriasis, and 
also severity of psoriasis vulgaris evaluated by PASI score.
References:
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IMMUNOLOGICAL MEMORY EXISTS IN THE 
RECURRENT LESION AND NONRECURRENT SKIN 
AFTER REMISSION IN PSORIATIC PATIENTS
Zhu Shen
Institute of Dermatology and Venereology, Sichuan Academy of Medical 
Sciences & Sichuan Provincial People’s Hospital
Introduction: Psoriasis usually recurs in previously affected areas, 
so a pathogenic memory has been proposed, but the nature of such 
site-specific	recurrent	memory	is	not	completely	known.	Tissue-
resident memory T (TRM) cells are non-recirculating memory T 
cells that persist long-term in epithelial tissues, including the skin. 
Because they can localize in the skin for many months, we spe-
culate that TRM may contribute to recurrent pathology of psoriasis.
Objectives: The aim of the present study is to compare the dif-
ferences of quantity proportion and secretion ability of cytokines 
of the TRM cells between recurrent and nonrecurrent lesions 
following remission, as well as to explicit the possible survival 
signal for these TRM cells in psoriatic lesion.
Methods: RNA-Seq, Gene Ontology and KEGG analysis, real-time 
PCR,	flow	cytometer	analysis/sorting,	cell	stimulation	assay,	and	
western blot were used to explore the immunological memory.
Results: Compared with normal skin, there are common shared 
genes	significantly	upregulated	( > 2 folds, p < 0.001) by recurrent 
and nonrecurrent lesions, including CD69. CD69 mRNA transcrip-
tion level in nonrecurrent lesions after remission remains as high 
as in neighboring recurrent lesions. CD8+CD69+ TRM cells exist 
in both lesions, and they can secret almost same amount of IL-17A 
and IL-22 after stimulation. Levels of IL-15, secreted by kerati-
nocytes in psoriasis epidermis, in nonrecurrent lesions remain as 
high as in neighboring recurrent lesions, and recombinant human 
IL-15 can induce CD69 on TRM cells.
Conclusions: Our preliminary study shows that CD8+CD69+ 
TRM cells persist in clinically resolved psoriatic lesions whether it 
recurs or not, and they can produce IL-17A and IL-22 with critical 
effect on psoriatic recurrence and development. Furthermore, we 
have indicated the IL-15 may play crucial role in the survival of 
CD8+CD69+ TRM cells in psoriatic lesions.
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INVESTIGATING SYSTEMIC INFLAMMATION AS THE 
COMMON LINK BETWEEN DEPRESSION, PSORIASIS, 
AND PSORIATIC ARTHRITIS IN US VETERANS
Samar Gupta1, Alicja Wasilewski2
University of Michigan1, MI State2
Introduction: Psychosocial factors are important in the onset and/
or exacerbation of psoriasis in 40% to 80% of cases. Psoriasis 
has been associated with suicide, and an increased prevalence of 
alcoholism and a range of personality characteristics.
A recent systematic meta-analysis of 98 eligible studies with a total 
of 401,703 psoriasis patients showed that patients with psoriasis 
were approximately one and a half times more likely to exhibit 
signs of depression compared with healthy controls. [1].
Emerging evidence suggests that depression, like psoriasis, is 
associated	with	systemic	inflammation,	and	the	systemic	inflam-
matory	profile	of	the	two	conditions	show	similar	traits.	Depression	
is	considered	to	have	a	strong	inflammatory	component,	similar	to	
psoriasis, e.g. interleukin (IL)-2, IL-6, IL-12, and tumour necrosis 
factor	(TNF)-α	[2–5].
US Veteran population has increased incidence of mental health 
issue as compared to general population. making Veteran group 
a unique population that warrants investigation.
Objectives: Hypotheses - 1/ Veterans with concomitant depres-
sion	and	psoriasis/PsA	may	have	elevated	inflammatory	markers	
like CRP, ESR, and SPEP. 2/ Depression may improve with the 
treatment of psoriasis/psoriatic arthritis without antidepressant use. 
Methods: A 36-month retrospective chart review of 100 veterans 
with diagnosis of depression and psoriasis/psoriatic arthritis. 
Elevated	 inflammatory	markers,	 including	 sedimentation	 rate,	
C-reactive protein (CRP) and serum protein electrophoresis 
(SPEP), as well as longitudinal disease course of depression 
(PHQ-8)	and	psoriasis/psoriatic	arthritis	(HAQ-DI);	specifically	
disease activity, and depression symptoms will be assessed. We 
then aim to draw a correlation between disease activity and active 
depressive symptoms.
Results: to be available
Conclusions: to be available
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THE IMMUNE­PHENOTYPE OF SMALL PLAQUE 
PSORIASIS
Touraj Khosravi-Hafshejani1, Mehran Ghoreishi2, Cristian Vera 
Kellet3, Magdalena Martinka4, Jan Dutz1
1Department of Undergraduate Medical Program, Faculty of Medicine, 
2Department of Dermatology, and Skin Science and 4Department of Pat-
hology and Laboratory Medicine, University of British Columbia, 3Depart-
ment of Dermatology, Pontifical Catholic University of Chile
Introduction: Small plaque psoriasis (SPP) is a subtype of pso-
riasis	first	described	by	Griffiths	et	al	(2007).	It	resembles	guttate	
psoriasis but lesions are larger, are chronic, and are not associated 
with streptococcal infection. We have observed SPP develop in 
four	different	population	groups;	patients	under	TNFα-inhibitor	
therapy, patients under immune checkpoint inhibitor (ICI) th-
erapy, and patients with concurrent SLE or ANA positivity and 
psoriasis. Subtypes of psoriasis develop on a spectrum between 
autoimmune	and	auto-inflammatory	responses	and	an	interplay	
between three signalling pathways are involved in their distinct 
pathogenesis. Chronic plaque psoriasis lesions are on the autoim-
mune	spectrum,	dominated	by	a	T-cell	mediated	TNFα/IL-23/
IL-17/IL-22	axis.	Pustular	psoriasis	is	a	neutrophilic	infiltrative	
inflammatory	skin	disease	resulting	from	dysregulation	of	the	
IL-36/IL-1	axis.	Lastly,	TNFα-inhibitor	(TNFi)	induced	lesions	
have a SPP morphology and demonstrate increased expression 
of LL37 by keratinocytes, activated plasmacytoid dendritic cells 
and upregulated type-1 interferons (IFN). These lesions express 
fewer epidermal CD8 T cells.
Objectives: Our aim is to characterize the immune-phenotype 
of SPP in multiple clinical scenarios. We hypothesize that SPP 
develops as a result of increased expression of cytokines and 
antimicrobial peptides involved in the type-1 IFN pathway.
Methods: Skin biopsies were obtained from three patients with 
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TNFi-induced psoriasis, three patients with SLE and psoriasis, 
three patients with positive ANA and psoriasis, two patients with 
ICI-induced psoriasis and two patients with chronic plaque psoria-
sis as control. Immunohistochemistry was performed using anti-
bodies against type-1 IFN induced MXA, LL37, IL-36 and CD8 T 
cells. The intensity and the area of positively stained samples were 
each	graded	from	0–4	and	then	multiplied	to	provide	a	final	score.	
Results: Small plaque lesions in various clinical scenarios had his-
tologic changes consistent with psoriasis.. Immunohistochemical 
evaluation revealed an increased expression of MXA (TNFi = 14, 
SLE = 13.3, ANA = 11.3, ICI = 16 vs. control = 6, t-test p < 0.05), 
LL37 (TNFi = 10.8, SLE = 6, ANA = 9.7, ICI = 12 vs. control = 2, 
t-test p < 0.05) and IL-36 (TNFi = 10.5, SLE = 13.3, ANA = 11, 
ICI = 7, control = 0.25, t-test p < 0.05) in the keratinocytes of 
SPP patients. There was decreased CD8 T cell migration to the 
epidermis in SPP compared to control.
Conclusion: This is the first study to describe the immune-
phenotype of SPP and to extend the phenotype observed in TNFi 
induced psoriasis to varying clinical scenarios. There was an 
increased expression of MXA, LL-37 and IL-36 as well as fewer 
epidermal CD8 T cells than in chronic plaque psoriasis consis-
tent with the type-1 IFN pathway of psoriasis pathogenesis. This 
immune-phenotypic analysis may suggest tailored therapy for 
this form of psoriasis.
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SERUM GLUCOCORTICOID­INDUCIBLE KINASE­
1(SGK1) LEVELS IN PATIENTS WITH PSORIATIC 
ARTHRITIS
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partment of Immunology, Medical School of Baskent University, 3Depart-
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Introduction: Psoriatic	arthritis	(PsA)	is	an	inflammatory	rheuma-
tic disorder that occurs in patients with psoriasis. The etiology of 
PsA is not well understood but evidence supports an interplay of 
genetic, immunologic, and environmental factors which promote 
pathological bone remodeling and joint damage in PsA. The 
glucocorticoid-inducible kinase-1(SGK1) is genomically upre-
gulated by cell stress. However, excessive SGK1 expression and 
activity participates in the pathophysiology of several disorders, 
such	as	inflammation,	autoimmune	disease,	fibrosis,	hypertension,	
thrombosis and tumor growth. 
Objectives: In this study, we analyzed the possible role of serum 
SGK-1 levels in the pathogenesis of psoriatic arthritis.
Methods: 56 patients with psoriasis (40 patients with psoriatic 
arthritis; 16 female, 24 male, mean age; 46.7 ± 6.5 years, mean 
disease duration 17.7 ± 4.3 years and 16 patients without arthritis; 8 
female, 8 male, mean age; 43.2 ± 1.9 years, mean disease duration; 
14.1 ± 3.9 years) and 19 healthy controls (11 female, 8 male; mean 
age 41.3 ± 4.7 years) were enrolled in this study. Oligoarthritis was 
the commonest clinical presentation (76.4 %). Dactylitis (73.4%) 
and enthesitis (48.1%) were frequent extra-articular features. 
All patients were negative for rheumatoid factor. HLA-B27 was 
negative in 14 patients. Serum SGK-1 levels were determined 
by ELISA.
Results: The mean serum SGK-1 levels were 58.4 ± 18.1 pg/ml in 
healthy controls, 163.7 ± 27.8 pg/ml in patients without arthritis 
and 443.9 ± 32.1 pg/ml in patients with arthritis. Serum SGK-1 
levels	were	significantly	high	in	patients	with	psoriasis	compared	
with healthy controls (p < 0.001). Serum SGK-1 levels were sig-
nificantly	high	in	patients	with	psoriatic	arthritis	compared	with	
in patients without psoriatic arthritis (p < 0.001).
Conclusions: The evidence is strong that immunological mecha-
nisms are involved in the pathogenesis of psoriasis. In this study, 
we	demonstrated	 that	 serum	SGK-1	 levels	were	 significantly	
elevated in patients with psoriasis and psoriatic arthritis.
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DIFFERENTIAL NH2­TERMINAL AUTOANTIGEN 
TRIMMING MAY EXPLAIN EPISTASIS BETWEEN 
HLA­C*06:02 AND ERAP1 VARIANTS IN PSORIASIS 
RISK 
Akiko Arakawa1, Emma Reeves2, Sigrid Vollmer1, Yukiyasu Ara-
kawa1, Edd James2, Jörg Prinz1
1Ludwig-Maximilian-University, 2Southampton General Hospital 
Introduction: NH2-terminal trimming by endoplasmic reticulum 
aminopeptidase 1 (ERAP1) generates the appropriate length of 
antigenic peptides for binding to and presentation by HLA-class 
I molecules. Genetic interaction between ERAP1 variants and 
HLA-class I alleles determines the genetic risk for various HLA-
class	I-associated	inflammatory	diseases.	Epistasis	between	HLA-
C*06:02 and ERAP1 variants affects also psoriasis risk but the 
mechanisms of these gene interactions remained unknown. Using 
a	pathogenic	Vα3S1/Vβ13S1-TCR	from	a	psoriatic	CD8+	T-cell	
clone we had shown that in psoriasis, HLA-C*06:02 mediates an 
autoimmune response against melanocytes through autoantigen 
presentation	and	we	had	identified	a	peptide	from	ADAMTS-like	
protein 5 (ADAMTSL5) as HLA-C*06:02-presented melanocyte 
autoantigen.
Objectives: To determine the role of ERAP1 variants in psoriasis 
pathogenesis. 
Methods: We established ERAP1 knockout cells using CRISPR/
Cas9 system. ERAP1 knockout cells transfected with plasmids 
coding for HLA-C*06:02, ERAP1 variants, and antigenic pep-
tides were co-cultured with the TCR hybridoma to determine 
the	 levels	 of	TCR	 ligation	which	 reflect	 the	 generation	 of	 the	
antigenic	ADAMTSL5	peptide	and	other	Vα3S1/Vβ13S1-TCR	
ligands from precursors.
Results: Our data show that NH2-terminal trimming by ERPA1 
is required to generate the actual antigenic ADAMTSL5 peptide 
from NH2-terminally elongated precursors. An ERAP1 variant 
protecting from psoriasis reduced the immunogenicity of the 
antigenic ADAMTSL5 peptide presumably through overtrimming 
and peptide destruction, whereas a psoriasis risk variant of ERAP1 
highly kept the antigenicity of the autoantigen. This effect was 
specific	 for	ADAMTSL5.	Precursors	of	other	Vα3S1/Vβ13S1-
TCR self-ligands were not substrates of ERAP1. 
Conclusions: Using a proven psoriatic autoantigen and a cognate 
psoriatic TCR, these experiments provide direct evidence that 
gene-gene interaction between ERAP1 and HLA-C*06:02 affects 
the risk for psoriasis through differential autoantigen trimming 
from precursors. These data furthermore propose a model where 
ERAP1 function essentially controls the autoantigenic potential 
of self-peptides in HLA-class I associated CD8+ T-cell mediated 
autoimmune diseases.
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ENVIRONMENTAL TRIGGERS OF AN HLA­C*06:02­
RESTRICTED AUTOIMMUNE RESPONSE IN PSORIASIS
Secil Vural, Yukiyasu Arakawa, Adrian Galinski, Sigrid Vollmer, 
Akiko Arakawa, Jörg Prinz
Ludwig Maximilian University
Introduction: Psoriasis vulgaris is a multifactorial disease. While 
the major psoriasis risk gene HLA-C*06:02 accounts for up to 
50% of disease onset, environmental factors are considered to 
contribute to approximately 30% of disease risk. Psoriatic skin 
inflammation	is	driven	by	an	HLA-C*06:02-mediated	autoimmune	
response	against	melanocytes.	A	pathogenic	Vα3S1/Vβ13S1	T-cell	
receptor (TCR), which we had reconstituted from a lesional epi-
dermal CD8+ T-cell clone of an HLA-C*06:02–positive psoriasis 
patient	in	a	mouse	reporter	hybridoma	cell	line,	specifically	reacts	
against melanocytes through HLA-C*06:02 restricted recognition 
of a psoriatic melanocyte autoantigen, ADAMTS-like protein 5 
(ADAMTSL5). However, it is unknown whether and how environ-
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mental factors may contribute to autoimmunity in psoriasis. TCRs 
are	known	to	be	polyspecific,	recognizing	multiple	peptide	ligands	
which	share	a	conserved	amino	acid	pattern	specific	for	each	TCR.
Objectives: To examine the potential role of environmental factors 
in the psoriatic autoimmune response.
Methods:	We	first	 determined	 the	particular	 amino	 acid	motif	
which	 is	 recognized	 by	 the	 psoriatic	Vα3S1/Vβ13S1	TCR	 in	
the context of HLA-C*06:02. By homology searches using this 
conserved amino acid pattern, we selected 57 peptides from 
food, bacterial, fungal and viral pathogens and from the skin and 
intestinal microbiomes as candidate environmental antigens that 
may trigger the psoriatic autoimmune response. We cloned the 
peptides into expression plasmids, co-transfected them with HLA-
C*06:02	into	Cos7	cells	and	used	them	to	stimulate	the	Vα3S1/
Vβ13S1	TCR.	TCR	ligation	was	determined	by	GFP	induction	
of TCR hybridoma in FACS analysis. We then stimulated blood 
lymphocytes with the candidate peptides that had ligated the 
Vα3S1/Vβ13S1	TCR.	Lymphocyte	activation	was	assessed	by	
induction of activation markers and proliferation assays using 
thymidine incorporation.
Results: We	identified	a	variety	of	peptides	contained	in	proteins	
from food (wheat, coffee, apple, and spinach), microbiota of hu-
man skin or gut, and infectious pathogens including Chlamydia 
trachomatis,	which	 ligated	 the	psoriatic	TCR	 in	a	polyspecific	
manner. Stimulation of blood lymphocytes with particular candi-
date	antigens	resulted	in	significant	activation	in	psoriasis	patients,	
as compared to healthy individuals. Interindividual-correlation 
analyses demonstrated cross-reactive immune responses between 
environmental antigens and the melanocyte autoantigen presen-
ted by HLA-C*06:02 in psoriasis patients. Among the candidate 
antigens, wheat peptides induced most robust lymphocyte activa-
tions	in	psoriasis	patients.	Moreover,	psoriasis	was	significantly	
improved by wheat-free diet in several patients with lymphocytes 
responding to wheat, indicating potential pathogenic contribution 
of wheat antigens in psoriasis.
Conclusions: Our results provide unbiased evidence that several 
environmental antigens may trigger the melanocyte-specific 
autoimmune response in psoriasis. By identifying and avoiding 
those triggers at the molecular level which translate the genetic 
predisposition into disease manifestation, we may develop stra-
tegies to prevent disease onset and exacerbation.
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A SKEWED POOL OF RESIDENT T CELLS TRIGGERS 
DISEASE­ASSOCIATED TISSUE RESPONSES IN NEVER­ 
LESIONAL PSORIASIS
Irène Gallais Sérézal1, Elena Hoffer1, Borislav Ignatov1, Elisa 
Martini1, Beatrice Zitti2, Marcus Ehrström3, Liv Eidsmo1
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Institutet, Karolinska University Hospital Huddinge, 3Department of Re-
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holm, Sweden
Background: Psoriasis lesions evolve as a result of cytokine driven 
interactions between intralesional immune cells and keratinocytes 
in genetically predisposed individuals. Skin resident T cells are 
implicated in maintenance and recurrence of psoriasis plaques 
but their composition and function in never-lesional psoriasis 
skin is less known. 
Objective:Characterisation of T cell driven tissue responses and 
subsets of resident T cells in never-lesional psoriasis. 
Methods: T cell driven tissue responses were assessed in explanted 
skin biopsies using Nanostring and Multiplex analysis. Epidermal 
and	dermal	T	cells	were	characterised	using	flow	cytometry	 in	
never-lesional skin from patients with mild disease.
Results: T cell activation induced epidermal psoriasiform- and 
type-1 interferon tissue responses in explants from never-lesi-
onal skin. Skin resident T cells were skewed with enrichment 
of epidermal IL-17 and IL-22 producing CD4+CCR6+ and 
CD8+CD103+CD49a-	T	cells	and	IFN-γ	producing	CD4	T	cells	
in never-lesional skin compared to healthy skin. Keratinocytes 
from	never-lesional	psoriasis	responded	to	IFN-γ	activation	with	
IFN-α	secretion	and	MX1	upregulation	and	skin	explants	exposed	
to common fungal antigens produced the CCR6-attractant CCL20.
Conclusion: Resident T cells poised to induce psoriasiform tissue 
responses	accumulate	in	never-lesional	skin	of	psoriasis-afflicted	
individuals. Additionally our data suggest that microbial interplay 
with genetically predisposed keratinocytes may shape the local 
pool of resident T cells.
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NAIL INVOLVEMENT IN PSORIASIS; IS IT A 
PREDICTOR OF PSORIATIC ARTHRITIS?
Omid Zargari1, Ehsan Kazemnejad2, Seyyede Zeinab Azimi3
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Introduction: Psoriatic Arthritis (PsA) arises in an increased burden 
of psoriasis and impairments in both quality of life and functional 
capacity. The relationship between nail involvement and PsA in 
psoriasis is not fully characterized. 
Objective:To evaluate the frequency and characteristics of nail 
involvement in psoriatic patients and to assess the relationship 
with joint involvement.
Methods: A total of 197 patients with moderate-to-severe psoriasis, 
were consecutively selected to participate in this cross-sectional 
study. The patients divided into two groups; with and without 
psoriatic arthritis. 
Results: 69.5% of psoriatic (137 out of 197) patients had nail in-
volvement. The most common nail abnormality was onycholysis, 
followed by pitting and oil drop. Nail changes were more common 
in patients with psoriatic arthritis (82.1% vs. 57.8%).
Limitations: Our study had certain limitations. One of them was 
lack of information about the subtypes of PsA. Also, we have not 
recorded the severity of nail involvements. Furthermore, previous 
medications may have interfered with the degree of nail changes 
in our patients.
Conclusion: Nail involvement is associated with PsA. Onycho-
lysis,	splinter	hemorrhage,	and	oil	drop	were	significantly	more	
common in PsA group. In general, psoriatic patients with arthritis 
had the more severe disease. 
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ABSOLUTE AND RELATIVE PASI IMPROVEMENTS 
WITH IXEKIZUMAB TREATMENT: RESULTS AT WEEK 
12 FROM IXORA­P
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Introduction and Objectives: Ixekizumab (IXE), an interleukin-
17A	antagonist,	has	shown	superior	efficacy	in	psoriasis	compa-
red to placebo,1 etanercept,1 and ustekinumab.2 This post hoc 
analysis intended to evaluate absolute and relative Psoriasis Area 
and Severity Index (PASI) improvements with IXE treatment in 
a phase 3 trial (IXORAP).
Methods: In IXORA-P, patients with moderate-to-severe psoriasis 
were randomized (2:1:1) to receive any of the 3 dosing regimens 
of IXE 80 mg: every 2 weeks (Q2W; n = 611), every 4 weeks 
(Q4W; n = 310), or Q4W/Q2W step-up (n = 306), for 52 weeks. 
Randomization	was	stratified	by	country	and	weight	( < 80	kg,	≥80	
to  < 100	kg,	or	≥100	kg).	The	percentage	of	patients	achieving	a	
75%, 90% or 100% improvement from baseline in PASI (PASI 
75, 90, and 100) was evaluated using logistic regression with 
dosing regimen, country, and baseline weight as factors. Fisher’s 
exact test with nonresponder imputation was used to compare the 
response rates between treatment groups. Here, we present results 
at 12 weeks for Q2W (label dose) and Q4W groups; results from 
Q4W/Q2W group will be discussed separately.
Results: Mean (standard deviation) PASI score at baseline was 
20.3	(8.25).	Response	rates	were	significantly	higher	(p < 0.001) 
for Q2W group compared to Q4W group across all cut-off points 
for absolute PASI: absolute PASI ≤ 1, 2, 3, and 5 response rates at 
Week 12 were 61.4%, 76.1%, 84.5%, and 89.4%, respectively, for 
Q2W group, and 49.7%, 64.5%, 72.6%, and 83.9%, respectively, 
for Q4W group. At Week 12, PASI 75 response rates in Q2W and 
Q4W groups were 89.2% and 83.2%, respectively (p = 0.012). 
For Q2W and Q4W groups, PASI 90 response rates were 75.3% 
and 63.2%, respectively (p < 0.001), and PASI 100 response rates 
were 46.0% and 32.6%, respectively (p < 0.001).
Conclusion: As reported in psoriasis registration trials, induction 
with IXE Q2W, the labeled dosing regimen, provides better clinical 
outcomes at Week 12.
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PREVALENCE AND SEX DIFFERENCES OF PSORIATIC 
ARTHRITIS IN PATIENTS WITH SEVERE PLAQUE 
PSORIASIS. 
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Background: Prevalence of psoriatic arthritis in patients with 
psoriasis	 has	 conflicting	 data	 in	 different	 population.	But	 no	
study has been performed in Russian population of prevalence 
and sex differences of psoriatic arthritis in patients with severe 
plaque psoriasis.
Objectives: to evaluate the prevalence PsA in patients (pts) with 
PsO in a dermatological hospital cohort.
Methods: 890 pts (Male-516/Female-374) with severy plaque 
PsO, mean age 50.4±17.6 years, mean PsO duration 21.5±14.7, 
mean PASI 49.4±0.5 were included. 374 female were divided into 
groups by age. 113 young F. pts with age less than 49 years (mean 
age 36.1±11.0 years), 261 old F. pts with age more than 50 years 
(mean age 63.7±9.6 years). 516 male were divided into groups 
by age. 304 young M. pts with age less than 54 years (mean age 
38.5±11.3 years), 212 old M. pts with age more than 55 years 
(mean age 38.5±11.3 years) were included. PsO and PsA pts were 
identify in hospital Database reporting and coding by International 
Statistical	Classification	of	Disease	and	Related	Health	Problems	
(ICD-10) between 2010 - 2015 years. PSA was diagnosed after 
appointment with a rheumatologist and an X-ray examination. 
Diagnosis was carried out according to the criteria of CASPAR. 
M±m, t-test, x2, (%) were calculated. All p < 0.05 were considered 
to	indicate	statistical	significance.
Results: 303 out of 890 pts (34.0%) had psoriatic arthritis (PsA). 
PsA pts were older then PsO pts without arthritis – 55.3±13.7 years 
and 50.4±17.6 years accordingly (p < 0.001). PsA was found sig-
nificantly	often	in	F.	pts	compare	to	M.	pts	–	in	143	out	of	374	pts	
(38.2%) and in 129 out of 516 pts (25.0%) accordingly (p < 0.05). 
PsA	was	found	significantly	often	in	F.	pts	over	50	years	old	(y.o.)	
compare to F. pts under 50 y.o. – in 134 out of 261 pts (51.3%) and 
in 9 out of 113 pts (7.9%) accordingly (p < 0.05). In old M. and 
young M. PsA was found in the same cases - in 58 out of 212 pts 
(27.3%) and in 71 out of 304 pts (23.3%) accordingly (p > 0.05).
Conclusions: PsA was detected in more than a third of patients 
with severe plaque psoriasis. PSA was found predominantly often 
in F. pts over 50 years of age with severe plaque psoriasis. Future 
investigation	in	this	field	is	needed	to	determine	the	causes	of	high	
risks PSA in this age group.
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SKIN LESION SEVERITY IN EARLY AXIAL AND 
PERIPHERAL PSORIATIC ARTHRITIS PATIENTS
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taeva
Nasonova Research Institute of Rheumatology, Moscow
Introduction: Comparative analysis of skin lesion severity in early 
PsA patients with and without axial involvement hadn’t been suf-
ficiently	studied.
Objective:to compare skin lesion severity of two early peripheral 
PsA patient populations – with and without axial involvement.
Methods: 95 patients (pts) (M/F–47 /48) with early PsA according 
to CASPAR criteria were included; all pts had peripheral arthritis 
for ≤ 2	years;	no	inflammatory	back	pain	(IBP)	pts	were	specially	
selected. Mean age 36.5±10.7 yrs, disease duration 12.2±10.3 
mo, disease activity indexes DAS = 4.0±1.4, DAS28 = 4.2± 1.1, 
BASDAI = 4.5±1.6. Skin lesion severity was evaluated in terms 
of body surface area (BSA) affected and Psoriasis Area Severity 
Index	(PASI).	When	BSA	was	≥3%,	PASI	was	calculated.	PASI	
≥11	indicates	moderate	and	severe	psoriasis.
All	pts	were	evaluated	for	the	presence	of	inflammatory	back	pain	
(IBP) by ASAS criteria. IBP was observed in 63 (66.3%) cases. 
Magnetic resonance imaging (MRI) of SIJs was performed in 79 
pts, regardless of the presence of IBP, on Signa Ovation 0,35T. MRI 
results were evaluated by an independent reader. Bone marrow 
edema on MRI (STIR) was considered as active MRI sacroiliitis 
(MRI-SI). MRI-SI was detected in 28 of 79 (35.4%) examined 
cases. The examination also included X-ray of sacroiliac joints 
(SIJs) (pelvic radiographs). Radiographic sacroiliitis (R-SI) was 
considered	according	to	New	York	criteria	(unilateral	grade≥3	or	
bilateral	grade≥2).	R-SI	was	found	in	29	(30.5%)	cases.	Pts	were	
split into two groups: those with axial involvement (axPsA), that 
is with IBP and/or MRI-SI and/or R-SI; and those without axial 
involvement (having only peripheral PsA [pPsA]). The axPsA 
group included 65 (68.4%) cases, the pPsA one 30 (31.6%) cases. 
Results: skin lesions’ severity was higher in the axPsA group than 
in the pPsA group: in axPsA pts BSA median was 3.0 [1.0 – 9.0] 
and	in	pPsA	pts	it	was	1.0	[0.2	–	3.0]	(р = 0.007); in the axPsA 
group PASI median was 15.6 [6.6 – 55.2] and in the pPsA group 
it	was	6.0	[0.0	–	7.2]	(р = 0.006).
Conclusion: Axial involvement in early PsA patients is associated 
with	skin	 lesions’	severity.	These	findings	may	have	a	positive	
impact on the selection of the best therapeutic strategy. 
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U.S. PATIENTS WITH MODERATE­SEVERE PSORIASIS 
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Background/Objective:Patients with moderate-to-severe plaque 
psoriasis	(PsO)	are	at	increased	risk	of	developing	inflammatory	
bowel disease (IBD). A survey was conducted to evaluate the 
prevalence of gastrointestinal symptoms in PsO patients.
Methods: An electronic survey was available to U.S. PsO patients 
with data collected from Jan-Feb. 2017. Patients with moderate-
to-severe plaque PsO and healthy controls (HC), with common 
co-morbidities	allowed	in	both	groups	qualified	for	inclusion	in	
the survey. Psoriasis patients were further categorized as those 
without recent exposure to biologic therapy (PsO-) vs those with 
recent (within 4 months) biologic exposure (PsO+). GI symptoms 
and signs, including frequency and severity, were compared across 
groups. CalproQuest (CPQ) scores, which have recently been pro-
posed as a tool to identify patients with elevated fecal calprotectin 
levels and increased risk for IBD, were also calculated. Patients 
with	 inflammatory	 bowel	 disease	 (IBD),	 inflammatory	 bowel	
syndrome (IBS), or other gastrointestinal (GI) diagnoses with 
symptoms that overlap with IBD were excluded.
Results: Overall, 915 patients with self-reported moderate-severe 
PsO and 1,411 healthy controls participated. Demographics were 
generally comparable between groups. GI symptoms and signs 
were	significantly	more	prevalent	in	the	PsO-	and	PsO+	groups	
vs the HC group, respectively: pain- 20.6% and 36.9% vs 10.5%; 
fullness/bloating- 37.2% and 48.4% vs 25.3%; and diarrhea (16.3% 
and 29.3% vs 12.2% (all p-values = 0.002 except diarrhea for 
PsO- vs HC, p = 0.023). Mucous and blood in the stool followed 
a	similar	pattern.	A	significantly	greater	percentage	of	PsO-	and	
PsO+ patients had positive CPQ scores vs HCs, with the greatest 
percentage of positive CPQ scores in the PsO+ group. 
Conclusion: GI symptoms and signs are common in patients with 
moderate-to-severe PsO, more so than in healthy controls. This 
suggests that physicians caring for patients with PsO may consider 
assessing for GI symptoms and signs, and monitoring for their 
progression with treatment of PsO to identify patients potentially 
at risk for developing IBD. 
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SECUKINUMAB’S LONG­TERM SAFETY REMAINS 
FAVORABLE UP TO 5 YEARS OF TREATMENT
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Introduction and Objectives: Psoriasis is a condition typically 
requiring long-term treatment, thus longitudinal data establishing 
the safety of approved therapies are required. We report exposure 
adjusted incidence rates (IRs per 100 patient years) for treatment-
emergent adverse events (AEs) per year of treatment from a pooled 
analysis of all secukinumab psoriasis trials to date (19 studies, 
4,674 patients, 10,061 patient-years exposure; secukinumab 
exposure up to 5 years).
Methods: AE IRs were examined per year for subjects receiving 
secukinumab, and for 52 weeks only for those receiving etanercept 
(ETN), ustekinumab (UST), or placebo (PBO).
Results: Duration of exposure through 52 weeks of secukinumab 
treatment 300 mg, ETN 50 mg, UST 45/90 mg, and PBO was 
1467.4, 296.9, 318.1, and 301 patient-years, respectively. Expo-
sure duration through 2, 3, 4, and 5 years of secukinumab 300 mg 
treatment was 859.6, 423, 377.5, and 90 patient-years. 
Over 52 weeks for secukinumab, ETN, UST, and PBO, respectively, 
exposure adjusted IRs were overall comparable across treatments: 
total AEs (275.6, 245.7, 252.2, 355.8); nasopharyngitis (28.4, 35.9, 
31.2, 35.9); headache (12.6, 15, 14.6, 23.7); upper respiratory 
infections [URI] (9.1, 5.9, 9.9, 8.8); opportunistic infections (0.2, 
0.3, 0.3, 0.3); Candida infections (4.7, 1.4, 1.6, 1.7); neutropenia 
(0.5, 1.4, 0, 0); major adverse cardiovascular events [MACE] (0.5, 
0.3, 0.3, 1.3); Crohn’s disease (0.1, 0, 0, 0); ulcerative colitis (0.1, 
0.3,	0,	0);	and	malignant	or	unspecified	tumors	[excluding	non-
melanoma skin cancer [NMSC]] (0.4, 0.3, 0.3, 0.3).
Secukinumab 300 mg pooled safety remained favorable over time 
with no increases in AEs (exposure adjusted IRs for up to Year 
1 to Year 5, respectively): total AEs (275.6, 168.1, 160.2, 111.9, 
13.9); nasopharyngitis (28.4, 21.2, 24.1, 11.8, 3.4); headache 
(12.6, 5.4, 4.3, 4.9, 0); URI (9.1, 7.3, 6.1, 5.5, 0); opportunistic 
infections (0.2, 0.1, 0, 0, 0); Candida infections (4.7, 3.6, 1.9, 1.3, 
1.1); neutropenia (0.5, 0.1, 0, 0, 0); MACE (0.5, 0.1, 0.5, 0, 0); 
Crohn’s disease (0.1, 0, 0, 0, 0); ulcerative colitis (0.1, 0.4, 0.2, 
0.3,	0);	and	malignant	or	unspecified	tumors	[excluding	NMSC]	
(0.4, 0.4, 0.2, 0, 0).
Conclusions: This comprehensive pooled analysis supports the 
favorable	long-term	safety	profile	of	secukinumab	in	patients	with	
psoriasis;	no	new	safety	signals	were	identified	for	up	to	5	years	
of	treatment	and	secukinumab’s	safety	profile	was	consistent	with	
that established in a large phase 3 program. 
Findings previously published at the AAD Annual Meeting, February 
16–20, 2018, San-Diego, California. 
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PATIENTS
Arthur Kavanaugh1, Alice Gottlieb2, Akimichi Morita3, Joseph F 
Merola4, Julie Birt5, Chen-Yen Lin5, Catherine L Shuler5, Diamant 
Thaçi6
1University of California, San Diego, CA, 2Department of Dermatology, 
New York Medical College at Metropolitan Hospital, New York, NY, USA, 
3Nagoya City University Medical School, Nagoya, Japan, 4Harvard Medi-
cal School, Brigham and Women’s Hospital, Boston, MA, 5Eli Lilly and 
Company, Indianapolis, IN, USA, 6University Hospital Schleswig Holstein 
Campus Luebeck, Ratzeburger Allee, Germany
Introduction: Psoriatic arthritis (PsA) is a chronic immune-
mediated	 inflammatory	 disease	 affecting	 peripheral	 and	 axial	
joints. For patients with active psoriasis, the added burden of skin 
disease can further reduce health-related quality of life (HRQoL) 
of patients with joint disease.
Objective:To determine the contribution of joint and skin impro-
vements in HRQoL of patients with active PsA during Phase 3 
clinical trials investigating ixekizumab (IXE) treatment.
Methods: The double-blind Phase 3 trials (SPIRIT) investigated 
the	treatment	of	IXE,	a	high-affinity	monoclonal	antibody	selec-
tively targeting interleukin-17A, for patients with active PsA. 
The integrated database of 2 SPIRIT trials consisted of biologic 
disease-modifying	antirheumatic	drug	(DMARD)-naïve	patients	
(SPIRIT-P1, NCT01695239) or inadequate responders to tumor 
necrosis factor (TNF)-inhibitors (SPIRIT-P2, NCT02349295). 
Patients were randomized to 80mg IXE every 4 weeks (Q4W, 
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n = 229) or 2 weeks (Q2W, n = 226) after a 160mg starting dose or 
placebo (PBO, n = 224). At baseline and Week 24, joint and skin 
diseases were measured by the Disease Activity index for PSo-
riatic Arthritis (DAPSA; calculated post-hoc) and Psoriasis Area 
and Severity Index (PASI), respectively. HRQoL was measured 
by EuroQoL 5 Dimensions Visual Analog Scale (EQ-5D VAS), 
Short Form-36 Health Survey (SF-36), and Work Productivity 
and	Activity	Impairment-Specific	Health	Problem	(WPAI).	The	
synergistic contribution of skin and joint improvements to HRQoL 
was modeled using smoothing spline method and depicted with 
response surface. Missing data were imputed using last observa-
tion carried forward.
Results: Of 679 PBO- and IXE-treated patients in the SPIRIT 
trials,	402	(65%)	and	224	(36%)	patients	had	≥3%	body	surface	
area	(BSA)	and	≥10%	BSA	psoriasis	at	baseline,	respectively.	In	
these patients, we applied response surface modeling to investigate 
the relationship among DAPSA, PASI, and change from baseline 
in EQ-5D VAS at Week 24. The greatest improvement in EQ-5D 
VAS was associated with the largest percent improvements in 
both DAPSA and PASI together, rather than DAPSA or PASI 
alone.	Similar	observations,	regardless	of	≥3%	or	≥10%	BSA	ba-
seline psoriasis, were made in domains of SF-36 (General Health, 
Physical Functioning, Social Functioning, and Vitality; data not 
shown) and WPAI (Activity Impairment; data not shown).
Conclusion: For PsA patients with psoriasis, optimal improve-
ments in patients’ HRQoL, as measured by select domains of 
patient-reported outcomes, were dependent on successful treatment 
of both joint and skin symptoms.
Kavanaugh A, Gottlieb A, Morita A, Merola J, Birt J, Lin C-Y, Shuler 
CL, Thaci D. The Contribution of Skin and Joint Improvements to the 
Health-Related Quality of Life of Patients with Active Psoriatic Arthritis. 
Arthritis Rheumatol. 2017;69(Suppl 10).
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Introduction: Palmoplantar psoriasis (ppPsO) occurs in up to 40% 
of plaque psoriasis subjects and is often resistant to treatment. It 
is associated with pain, functional limitations, and greater impair-
ment of health related quality of life compared with plaque pso-
riasis on other parts of the body (1). Secukinumab, a fully human 
monoclonal antibody which selectively neutralises IL-17A, has 
shown	long	lasting	efficacy	and	safety	in	the	complete	spectrum	
of psoriasis manifestations, including nails, scalp, palms and soles 
and psoriatic arthritis.
Objectives: Here	we	report,	the	long-term	follow-up	efficacy	and	
safety	results	from	the	GESTURE	study,	the	first	robust	(2.5-year)	
data reported in subjects with moderate to severe ppPsO treated 
with secukinumab.
Methods: GESTURE is a double blind, randomised, placebo-con-
trolled, parallel-group, multicentre phase 3b study to investigate 
safety	and	efficacy	of	secukinumab	150	and	300	mg	s.c.	in	205	
subjects with moderate to severe ppPsO.
Results: As previously reported, after 16 weeks placebo-controlled 
treatment, the primary endpoint palmoplantar Investigator’s Global 
Assessment (ppIGA) 0/1 and all secondary endpoints of this study 
were met, demonstrating superiority of secukinumab to placebo 
at week 16 (2). An interim analysis at week 80 established the 
continuation	 improvement	of	palmoplantar	disease	 for	 all	 effi-
cacy parameters. The effect was sustained through 2.5 years with 
59.2% and 52.5% of subjects in secukinumab 300 and 150 mg 
groups, respectively [multiple imputation (MI)] achieving clear 
or almost clear palms and soles (ppIGA 0/1). Consistent with this 
observation, the mean palmoplantar Psoriasis Area and Severity 
Index % change from baseline reached –74.7% and –61.6% for 
secukinumab 300 and 150 mg, respectively, at 2.5 years (MI). 
The Dermatology Life Quality Index 0/1 response, was achieved 
in 45.5% vs. 23.9% of subjects for secukinumab 300 and 150 
mg groups respectively (LOCF). Pain and function of palms and 
soles	was	markedly	improved	with	secukinumab;	as	reflected	by	
the Palmoplantar Quality of Life Instrument overall scores with 
16.7%	and	17.9%	subjects	experiencing	no	difficulty	in	hand	and	
feet functionality in secukinumab 300 mg and 150 mg groups 
respectively	(LOCF).	The	safety	profile	was	consistent	with	that	
seen in secukinumab phase 3 trials. The most common adverse 
events across all treatment arms were nasopharyngitis, upper 
respiratory tract infection and headache.
Conclusions: GESTURE, the largest and longest duration rando-
mised controlled trial to date, revealed that secukinumab provides 
a novel treatment option for the challenging and infrequently 
studied ppPsO population by providing a strong and sustained 
response through 2.5 years.
References:
1. Kumar B, et al. Acta Dermatol Venereol. 2002; 82:192–5.
2. Gottlieb A, et al. J Am Acad Dermatol. 2017; 76:70–80.
This investigation was sponsored by Novartis Pharma AG, Basel, Swit-
zerland.
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Introduction: Nail	psoriasis	 is	associated	with	decreased	finger	
mobility, functional impairment, pain and reduced quality of life 
(QoL) and is often challenging to treat. It correlates with more 
severe psoriatic disease and is an important predictor of psoriatic 
arthritis (PsA). Nails are affected in up to 50% of psoriasis patients, 
with a lifetime incidence as high as 90%1. Secukinumab, a fully 
human monoclonal antibody that selectively neutralises IL-17A, 
has	shown	long	lasting	efficacy	and	safety	in	the	complete	spec-
trum of psoriasis manifestations, including nails, scalp, palms and 
soles and psoriatic arthritis.
Objectives: Here,	we	report	the	long-term	follow-up	efficacy	and	
safety	 results	 from	 the	TRANSFIGURE	 study,	 the	first	 robust	
(2.5-year) data reported in subjects with nail psoriasis treated 
with secukinumab.
Methods: TRANSFIGURE is a double blind, randomised, 
placebo-controlled, parallel group, multi-centre phase 3b study, 
to	investigate	safety	and	efficacy	of	secukinumab	150	and	300	mg	
s.c. in moderate to severe nail psoriasis, involving 198 subjects.
Results: As previously reported, at week 16 the primary end-
point NAPSI (NAil Psoriasis Severity Index) and all secondary 
endpoints of this study was met, demonstrating superiority of 
secukinumab to placebo after 16 weeks placebo-controlled treat-
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ment2. An interim analysis at week 80 demonstrated the continua-
tion	of	improvement	in	nail	psoriasis	for	all	efficacy	parameters.	
The effect was sustained through 2.5 years with a large mean 
NAPSI	improvement	from	baseline	(BL)	of	−73.3%	and	−63.6%	
with secukinumab 300 and 150 mg, respectively (as observed). 
Secukinumab demonstrated sustained reductions (improvements) 
in total mean NAPPA (Nail Assessment in Psoriasis and Psoria-
tic	Arthritis)	QoL	scores	 from	BL	to	2.5	years	by	−52.4%	and	
−18.1%,	and	70.2%	and	71.0%	of	subjects	achieved	a	weighted	
NAPPA-PBI	(Patient	Benefit	Index)	global	score	of	≥2	(at	least	
moderate	benefits)	with	secukinumab	300	and	150	mg,	respec-
tively (LOCF). Subjects showed considerable improvements in 
EQ-5D (EuroQOL 5-Dimension Health Status Questionnaire) 
compared with BL reporting decreased pain and discomfort. The 
safety	profile	was	consistent	with	that	observed	in	previous	phase	
3 trials of psoriasis and PsA.
Conclusions: TRANSFIGURE	is	the	first	large,	randomised	con-
trolled trial to report long-term results in subjects with nail psoria-
sis. Secukinumab demonstrated strong sustainability of clinically 
meaningful	 efficacy,	 large	QoL	 improvement	 and	a	 favourable	
safety	profile	up	to	2.5	years	in	this	challenging	form	of	psoriasis.
This investigation was sponsored by Novartis Pharma AG, Basel, 
Switzerland.
References:
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THE OBESITY AND PREVALENCE PSORIATIC 
ARTHRITIS IN PATIENTS WITH PLAQUE PSORIA SIS: 
DERMATOLOGICAL REAL­SETTING DATA
Maria Chamurlieva, Tatiana Korotaeva
N.A.Nasonova Research Institute of Rheumatology
Background: Psoriasis	(PsO)	is	a	chronic	inflammatory	disease,	
which can be associated with the obesity. A link between body 
mass index (BMI) and psoriatic arthritis (PsA) has been found 
recently. But there is limited data about this association in Russian 
population and from real-world data.
Objective:To study the incidence of PsA in PsO patients (pts) 
with/without obesity.
Methods: 103 pts (male-47/female-56) with different forms of 
plaque PsO, mean age 44±13.69 years (yrs.), mean PsO duration 
10.7±10.2 yrs., mean PASI 15.39±12.51 were included. 61 out of 
103 pts with PsO (59.2%) had psoriatic arthritis (PsA) by CASPAR 
criteria. In all pts BMI was calculated. If the BMI was more than 
30 it was regarded as obesity. M±m, %, t-test were peformed. All 
p < 0.05	were	considered	to	indicate	statistical	significance.
Results: The overweight in both groups of pts with PsO and PsA 
was	not	significantly	different:	in	30	pts	without	PsA	and	in	48	
with PsA, 71.4% and 78.7% respectively. However, there was a 
significant	difference	in	the	frequency	of	PsA	in	the	group	of	pts	
with a BMI  =  30–35 (obesity 1 degree). Thus, it was more than 4 
times higher the pts with PsA, compared with pts without PsA - 19 
and 4 pts (31.2% vs. 9.5%) respectively (p = 0.06).
Conclusion: There is a higher incidence of PsA in PsO pts with 
obesity. It should be taken into account during choice of treatment 
and	evaluation	of	efficiency	of	therapy	in	real-world	dermatologi-
cal setting. Russian population – based studies are needed. 
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Introduction: Secukinumab (SEC) is a fully human monoclonal 
antibody that selectively neutralizes IL-17A, a key cytokine 
involved in the development of psoriasis (PsO). SEC has shown 
long	lasting	efficacy	and	safety	in	the	complete	spectrum	of	PsO	
manifestations, including nails, scalp, palms and soles and psoriatic 
arthritis (PsA). PURE is an international registry of adult patients 
(pts) from Canada and Latin America with moderate to severe PsO 
treated with SEC vs other approved therapies (other Tx).
Objectives: To describe and compare the baseline demographic, 
disease,	and	clinical	characteristics	–	specifically,	the	history	of	
a PsA diagnosis among PsO pts treated with SEC vs other Tx. 
Methods: Approximately 2,500 adult pts (1:1 ratio, SEC: other Tx) 
will be recruited. A decision regarding treatment must have been 
reached prior to enrollment. The independent-samples and Chi-
square tests were used for continuous and categorical variables, 
respectively, for treatment group comparison. 
Results: As of Nov 27, 2017, 1032 pts (397 SEC vs 635 other Tx) 
had been enrolled. Mean age (50.5 vs 49.4 years), time since diag-
nosis (18.5 vs 16.9 years), duration since symptom onset (20.5 vs 
19 years), and race (78.6% vs 83.8% Caucasian) were comparable 
between groups. The percentage of females was lower in the SEC 
group (38.0%) vs other Tx (45.5%; p = 0.037). At baseline, the 
majority of SEC-treated pts (66.2%) were employed, and 23.7% 
vs 34.8% vs 34.3% had public vs private vs combined coverage, 
respectively. There was no difference between cohorts. A higher 
proportion of SEC pts had a history of PsA (23.2% vs 15.0%; 
p = 0.001) or diabetes (18.1% vs 13.4%; p = 0.072) compared to pts 
on other Tx. About 87.9% pts with PsA history and 34.1% pts wit-
hout had a Psoriasis Epidemiology Screening Tool (PEST) score 
≥3	at	baseline;	however,	the	diagnosis	of	PsA	in	these	pts	needs	to	
be	confirmed.	In	terms	of	prior	PsO	treatments,	52.4%	vs	29.9%	
(p < 0.001) of SEC vs other Tx pts had been previously treated 
with methotrexate, and 50.6% vs 18.0% (p < 0.001) with a biolo-
gic. Prior to enrollment, 4.7%, 13.2% and 4.7% pts in the other 
Tx	group	received	anti-IL-12/23,	anti-TNF-α,	and	anti-IL-17A,	
respectively. Pts treated with SEC had a higher historical Psoriasis 
Area and Severity Index (PASI) score (16.5 vs 14.2; p = 0.005), 
baseline PASI (13.6 vs 12.0; p = 0.001) and Investigator’s Global 
Assessment score (severe disease [score = 4]: 25.4% vs 20.1%) 
at enrollment compared to pts on other Tx. 
Conclusions: Pts with moderate to severe PsO selected for treat-
ment with SEC were more likely to have been previously exposed 
to another biologic, have comorbid PsA and had more severe 
skin	disease,	compared	to	pts	treated	with	other	Tx.	A	significant	
proportion of PsO pts may have their PsA undiagnosed in routine 
clinical care. 
References:
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EFFICACY AND SAFETY RESULTS OF GUSELKUMAB 
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Introduction/Objective:To	evaluate	the	efficacy,	safety	&	tolera-
bility of guselkumab (GUS) in patients (pts) w/ PsA.
Methods: In this double-blind, PBO-controlled study, pts w/active 
PsA	&	≥3%	BSA	of	PsO	despite	treatment	were	randomized	2:1	
to SC GUS 100mg or PBO at wks0, 4, & q8w thereafter through 
wk44. At wk16, pts w/ < 5% improvement from baseline (BL) 
in swollen & tender joint counts were eligible for early escape 
(EE) to open-label ustekinumab. At wk24, PBO pts crossed-over 
to GUS 100mg (PBO to GUS). The primary endpoint was ACR 
20 at wk24. Major secondary endpoints were PASI 75 & ACR 
50 responses, change from BL in HAQ-DI, & improvement in 
enthesitis (Leeds enthesitis index [LEI]) & dactylitis score (by 
a 0–3 scoring system) at wk24; & ACR 20 response at wk16. 
Through	wk24,	efficacy	analyses	were	performed	in	a	modified	
Intent-to-Treat (mITT) population. Pts who met treatment failure 
criteria, EE or had missing data at wk24 were considered non-
responders	for	ACR/MDA	endpoints	at	wk24.	Efficacy	post	wk24	
was evaluated in pts who did not EE & continued treatment at 
wk24 based on observed data.
Results: Of 149 pts (PBO:49, GUS:100), BL demographics & ACR 
component measures were generally similar between the 2 groups. 
4	PBO	&	9	GUS	pts	were	previously	exposed	to	anti-TNFα	agents.	
At	wk24,	significantly	more	GUS	pts	achieved	ACR	20	(58.0%	vs	
18.4%, p < 0.001), PASI 75 (78.6% vs 12.5%, p < 0.001), & ACR 
50 (34.0% vs 10.2%, p = 0.002) responses vs PBO. At wk24, mean 
decrease in HAQ-DI score from BL (-0.42 vs. -0.06, p < 0.001), 
& median percent improvement in enthesitis (100% vs 33.33%, 
p = 0.009) & dactylitis (100% vs 33.33%, p < 0.001) scores (among 
pts	w/	BL	enthesitis	and	dactylitis)	were	significantly	greater	in	
GUS	group	vs.	PBO.	Significantly	more	GUS	pts	achieved	ACR	
20 at wk16 (60.0% vs 16.3%, p < 0.001) and MDA at wk24 (23.0% 
vs. 2.0%, p = 0.001)	vs.	PBO.	Post	wk24,	efficacy	improved	in	
PBO to GUS crossover pts as expected and were well-maintained 
in GUS pts through wk56.
Through wk24, the frequencies of AEs & infections were compa-
rable (AEs: PBO 32.7%; GUS 36.0%; infections: PBO: 20.4%; 
GUS: 16.0%). Post wk24, there was no disproportional increase 
in AE frequency or infections among GUS pts w/ longer exposure. 
Through wk56, there was 1 malignancy (basal cell carcinoma), 6 
SAEs (myocardial infarction, osteoarthritis, pupils unequal, radius 
fracture, pneumonia, ulcerative keratitis), 2 pts discontinued treat-
ment due to AEs, 1 grade 3 neutropenia, & 6 pts were positive for 
antibodies to GUS. No deaths occurred through wk56.
Conclusions: GUS	demonstrated	significant	improvement	on	joint	
symptoms, physical function, PsO, enthesitis, dactylitis & quality 
of	life;	efficacy	was	well-maintained	through	wk56.	GUS	was	well	
tolerated in this population after ~1 year of exposure.
Data has been previously presented at EULAR 2017 & ACR 2017
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TILDRAKIZUMAB EFFICACY OVER TIME BY WEEK 
28 RESPONSE LEVELS IN TWO PHASE 3 CLINICAL 
TRIALS IN PATIENTS WITH CHRONIC PLAQUE 
PSORIASIS
Andrew Blauvelt1, Howard Sofen3, Kim Papp3, Melinda Gooder-
ham4, Yang Zhao5, Simon Lowry5, Jeff Parno5, Qing Li6, Carmen 
La Rosa6, Kristian Reich7
1Oregon Medical Research Center, Portland, OR, 2Department of Medicine 
(Dermatology) UCLA, Los Angeles, CA, USA, 3Probity Medical Research, 
Waterloo, ON, 4Skin Centre for Dermatology, Peterborough, ON, Canada, 
5Sun Pharmaceuticals, Princeton, NJ, 6Merck & Co., Inc., Kenilworth, NJ, 
USA, 7SCIderm Research Institute and Dermatologikum Hamburg, Ham-
burg, Germany
Introduction: Tildrakizumab	(TIL),	a	humanized,	IgG1/κ	mono-
clonal	antibody	for	IL-23p19,	recently	demonstrated	its	efficacy	
in subjects with chronic plaque psoriasis in two, phase 3 clinical 
studies1.
Objective:In	this	analysis,	we	examined	efficacy	from	baseline	
to week 52 among TIL patients achieving various Psoriasis Area 
and Severity Index (PASI) responses at week 28.
Methods: ReSURFACE 1 (NCT01722331) and reSURFACE 2 
(NCT01729754) were double-blind, randomized controlled studies 
in subjects with moderate-to-severe chronic plaque psoriasis. Part 
1 (0–12 weeks) was placebo controlled; Part 2 (12–28 weeks) 
re-randomized placebo patients to TIL; Part 3 (28–64 weeks, 
reSURFACE 1; 28–52 weeks, reSURFACE 2) re-randomized pa-
tients	with	≥PASI	50	to	continue	or	increase	TIL	dose	or	to	placebo	
based on their PASI response at week 28. In this post-hoc pooled 
analysis, patients consistently on TIL 100 mg and 200 mg from 
baseline	to	week	52	were	classified	in	5	mutually	exclusive	groups	
based on their week-28 PASI response: PASI  < 50, PASI 50–74, 
PASI 75–89, PASI 90–99, and PASI 100. Baseline characteristics 
and % PASI improvement from baseline up to week 52 (observed 
data) were examined for each group.
Results: This analysis included 575 (TIL 100 mg) and 581 (TIL 
200 mg) patients; the proportions of patients with week-28 PASI 
75/90/100 responses were 77%/54%/23% (TIL 100 mg) and 
78%/58%/29% (TIL 200 mg). At week 28, 133 (23.1%), 175 
(30.4%), 137 (23.8%), 82 (14.3%), and 48 (8.3%) TIL 100 mg 
patients and 170 (29.3%), 169 (29.1%), 114 (19.6%), 105 (18.1%), 
and 23 (4.0%) TIL 200mg achieved PASI 100, PASI 90–99, PASI 
75–89, PASI 50–74, and PASI  < 50, respectively. On average, 
PASI 100 patients were younger, lighter, and had shorter disease 
duration at baseline compared to other response groups. For TIL 
100 mg, % PASI improvement was highest for PASI 100 and least 
for PASI < 50 patients on all visits up to week 28 (week 4: 53%, 
46%, 38%, 30%, and 16%; week 28: 100%, 95%, 83%, 64%, and 
33% for PASI 100, PASI 90–99, PASI 75–89, PASI 50–74, and 
PASI  < 50 categories, respectively). Among patients achieving 
PASI  > 50 at week 28 and continued up to 52 weeks, % PASI 
improvement maintained or improved from week 28 to week 52. 
Similar results were observed for TIL 200 mg as well as a subgroup 
analysis with bio-naive and bio-experienced patients respectively.
Conclusions: The majority of TIL 100 and 200 mg patients achie-
ved PASI > 50 response at week 28, and PASI improvement was 
maintained from week 28 to week 52. Among patients achieving 
PASI  > 90 at week 28, TIL 100 and 200 mg were associated with 
a rapid PASI improvement by week 4.
Reference:
1. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo 
or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-
FACE 2): results from two randomised controlled, phase 3 trials. Lancet. 
2017;390(10091):276-288.
This abstract was presented at 2018 Annual Meeting of American Academy 
of Dermatology.Note: This abstract was presented at 2018 Annual Meeting 
of American Academy of Dermatology. 
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POTENTIAL DISCONNECT: CO­MANAGEMENT OF 
PATIENTS WITH PSORIATIC ARTHRITIS BETWEEN 
RHEUMATOLOGISTS AND DERMATOLOGISTS
Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights
Introduction: On average, the majority of psoriasis (PSO) patients 
are diagnosed a year prior to a psoriatic arthritis (PsA) diagnosis, 
making the referral patterns and co-management between derma-
50
www.medicaljournals.se/acta
5th World Psoriasis & Psoriatic Arthritis Conference 2018
tologists and rheumatologists an important aspect to understanding 
the management of these diseases. Dermatologists represent an 
important referral-base for rheumatologists, accounting for over 
one-quarter of all new PsA patients. However, there are discrepan-
cies between the specialists regarding the timing in which these 
referrals take place.
Objectives: One objective of the study was to gain further insight 
into rheumatologist and dermatologist co-management of patients 
with PsA.
Methods: An	independent	market	analytics	firm	collaborated	with	
US rheumatologists (n = 101) and US dermatologists (n = 101) to 
conduct analysis of both the PsA and PSO markets. Data were 
collected	via	 an	 online	 survey	fielded	 in	November/December	
2017 and included patient demographics, as well as physician 
demographics, and attitudinal survey responses.
Results: Rheumatologists indicate that 51 percent of referrals result 
from primary care physicians, 28 percent result from a dermato-
logist, and 13 percent are self-referred. The majority (73%) of 
PsA patients under the care of collaborating rheumatologists had 
previously been diagnosed with PSO prior to PsA. Dermatologists 
state that one-quarter of their patients with severe PSO also have 
PsA, with more than one-third of severe PSO patients also being 
co-managed with a rheumatologist. The majority of rheumatolo-
gists	believe	that	dermatologists	refer	patients	at	the	first	sign	of	
joint involvement and do not attempt to treat joint pain; however, 
31 percent of dermatologists report they do not refer PSO patients 
to rheumatologists until patients have failed biologics or are not 
improving on their current systemic regimen, while an additional 
35 percent report they refer only severe arthritis/patients with 
worsening disease. Furthermore, only 35 percent of dermatologists 
agree that they refer their PSO patients to a rheumatologists at the 
first	sign	of	joint	involvement.
 At the time of dermatologist referral, rheumatologists state that 
two-thirds	of	referred	patients	are	biologic/apremilast	naïve,	with	
only 6 percent having controlled PSO and joint pain. However, 
dermatologists state that 40 percent the patients that they referred 
to rheumatologists were treated with biologics and 15 percent of 
said referred patients were treated with apremilast. Indeed, 76 
percent of dermatologists agree with the statement, “I believe that 
starting my PSO patients earlier on biologic therapy will slow 
the development and progression of the arthritic component of 
the disease (PsA),” while 57 percent of dermatologists agree “I 
prefer to use biologics that are indicated in both PSO and PsA.” 
Conclusion: With many patients diagnosed with both PSO and 
PsA, co-management between dermatologists and rheumatolo-
gists is common. While rheumatologists appear to be under the 
impression that they are receiving the majority of dermatologist-
treated	patients	with	PsA	at	 the	first	sign	of	 joint	 involvement,	
dermatologists largely report that they are managing and treating 
PsA patients. Furthermore, most dermatologists believe early ag-
gressive use of biologic treatments will mitigate the development 
and/or progression of joint involvement, implying their willingness 
to manage their patients with PsA, particularly at early stages. 
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THE USE OF TUMOR NECROSIS FACTOR INHIBITORS 
(TNF) IN THE SECOND­LINE BIOLOGIC/SMALL 
MOLECULE SETTING: A CROSS­SPECIALTY 
COMPARISON
Lynn Price, Jennifer Robinson, Gianna Melendez
Spherix Global Insights
TNF therapy has been the standard of care for adult patients 
diagnosed with autoimmune conditions, resulting in familiarity, 
comfort, and satisfaction among physicians. TNFs are typically 
used	as	a	first-line	biologic/small	molecule	 in	 the	 treatment	of	
psoriasis (PSO) and psoriatic arthritis (PsA). However, the adop-
tion of agents with alternate mechanisms of action (AMOA) has 
increased in recent years across indications and the practice of 
sequential TNF prescribing after an initial TNF is less common. 
Though	TNFs	are	still	the	preferred	first-line	agent,	there	are	dis-
crepancies between specialists on the use of AMOA agents in the 
second-line setting. This research sought to understand the extent 
to which AMOA agents are prescribed after an initial TNF, and 
how this varies across PSO and PsA.
An	independent	market	analytics	firm	collaborated	with	US	der-
matologists (n = 201) and US rheumatologists (n = 200) to con-
duct a retrospective chart review of patients diagnosed with PSO 
(n = 950) and PsA (n = 1,008) who had switched from one biologic/
apremilast to another agent in the prior 12 weeks. Physicians were 
able to submit up to 7 patient charts. PSO data was collected in 
September 2017 and PsA data was collected in April 2017.
Analysis of patients recently switched from one biologic/apre-
milast to a different brand revealed the majority of patients were 
treated	with	a	TNF	in	the	first-line	biologic/small	molecule	set-
ting, though this varies by indication. Rheumatologists prescribe 
first-line	TNFs	 significantly	more	 than	dermatologists.	83%	of	
PsA	patients	are	prescribed	TNFs	first-line	compared	to	just	69%	
of	PSO	patients.	Furthermore,	rheumatologists	are	significantly	
more likely to practice TNF-sequencing than dermatologists. 
Indeed,	44%	of	PsA	patients	treated	with	a	first-line	TNF	were	
prescribed a second TNF, compared to 6% of PSO patients. Ad-
ditionally, certain TNF brands have experienced recent declines 
in	first	line	use,	though	this	varies	by	indication	as	well.	For	rheu-
matologists,	use	of	first-line	etanercept	has	declined,	38%	of	PsA	
patients were initiated on etanercept at least 24 months prior to 
the study, compared to just 28% initiated on etanercept within 12 
months	of	the	study.	For	dermatologists,	there	were	significantly	
more	PSO	patients	initiated	on	etanercept	in	the	first-line	setting	
24 months or more prior to the study compared to those initiated 
within 12 months of the study, (45% vs 31%.) This pattern also 
held	true	for	adalimumab,	where	42%	of	first-line	PSO	patients	
initiated more than 24 months prior to the study were prescribed 
adalimumab,	a	figure	that	drops	to	just	27%	for	patients	initiated	
within 12 months.
Though	the	position	of	TNFs	as	first-line	agents	remains	dominant,	
the	treating	specialist	and	indication	influence	how	widespread	and	
continuous	TNF	use	is.	Specifically,	dermatologists	are	less	likely	
to	prescribe	TNFs	as	first-line	agents	and	are	also	significantly	
less	likely	to	partake	in	the	sequencing	of	TNFs	in	the	first-	and	
second-line setting than rheumatologists. The introduction of 
several agents in PSO reporting substantially higher rates of skin 
clearance compared to TNFs could potentially be the source of 
increased switching to AMOAs compared to other specialties; 
whereas	 superior	efficacy	of	AMOA	agents	over	TNFs	 in	PsA	
may be less apparent. 
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IMPACT OF GUSELKUMAB VERSUS PLACEBO AND 
ADALIMUMAB ON PATIENT REPORTED OUTCOMES 
IN PATIENTS WITH AND WITHOUT PSORIATIC 
ARTHRITIS IN VOYAGE 2
Luis Puig1, Chenglong Han2, Ron Vender3, Michael Song2, Yin 
You2, Yaung-Kaung Shen2, Peter Foley4
1Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Bar-
celona Medical School, Barcelona, Spain, 2Janssen Research & Develop-
ment, LLC, Spring House, PA, USA, 3McMaster University, Hamilton, ON, 
Canada, 4University of Melbourne, St. Vincent’s Hospital, Melbourne and 
Skin & Cancer Foundation Inc., Carlton, Victoria, Australia
Introduction/Objective:VOYAGE 2 is a phase 3 double-blind, 
placebo/active comparator-controlled trial comparing guselkumab 
(GUS) with placebo (PBO) and adalimumab (ADA) in patients 
(pts) with moderate-to-severe PsO. The impact of treatment on 
patient-reported outcomes (PROs) was evaluated.
Methods: Pts were randomized to GUS 100mg (wks 0 & 4, then 
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q8wks), ADA (80 mg wk 0, 40 mg wk 1, then 40 mg q2 wks), 
or PBO (wks 0, 4, & 12, then GUS 100 mg wks 16 & 20). We 
evaluated PROs using the Work Limitations Questionnaire [WLQ; 
work productivity], the Hospital Anxiety & Depression Scale 
[HADS], and the Medical Outcomes Study 36-Item Short Form 
(SF-36; health related quality of life) at wk16 (GUS vs PBO) and 
wk24 (GUS vs ADA) in pts with and without PsA.
Results: In all, 18% of pts reported a history of PsA. At wk16, 
GUS pts had numerically greater improvements vs PBO in work 
productivity, anxiety and depression, and SF-36 PCS & MCS 
scores regardless of PsA status. The least square (LS) mean dif-
ferences (95% CI; adjusted for baseline value) for GUS vs PBO 
for all PROs were generally similar between pts with and without 
PsA. At wk24, GUS pts had numerically greater improvements 
vs ADA in all PROs regardless of PsA status. The LS mean dif-
ferences for GUS vs ADA were generally greater for pts with PsA 
vs pts without PsA (Table).
Conclusions: GUS showed better improvements in all PROs vs 
PBO at wk16 and vs ADA at wk24. Improvements vs PBO were 
similar regardless of PsA status, while improvements vs ADA 
were greater for pts with PsA.
Table: Summary of Change from Baseline in WLQ, HADS and SF-36 Scores from 
VOYAGE 2
Week 16 GUS vs PBO Week 24 GUS vs ADA
w/ PSA w/out PSA w/ PSA w/out PSA
N, 
LSMean 
Diff 
(95% 
CI) p-value
N, 
LSMean 
Diff 
(95% 
CI) p-value
N, 
LSMean 
Diff 
(95% 
CI)
p-
value
N, 
LSMean 
Diff 
(95% 
CI)
p-
value
WLQ Physical 
Demands
86, -7.1
(-13.21, 
-0.92)
0.0249 446, -7.7
(-10.56, 
-4.88)
< 0.0001 79, -1.6 
(-10.58, 
7.29)
0.7152 445, -2.6
(-5.39, 
0.28)
0.0769
WLQ Time 
Management
85, -6.6
(-15.35, 
2.06)
0.1326 419, -7.0
(-10.31, 
-3.79)
< 0.0001 79, -4.3 
(-14.40, 
5.81)
0.3996 420, -0.6
(-3.46, 
2.30)
0.6931
WLQ Mental-
Interpersonal
83, -3.8
(-11.03, 
3.35)
0.2913 439, -4.9
(-7.54, 
-2.35)
0.0002 78, -11.4 
(-19.37, 
-3.34)
0.0061 436, -1.5
(-4.16, 
1.11)
0.2569
WLQ Ouput 
Demands
84, -7.9
(-14.51, 
-1.21)
0.0211 440, -3.5
(-6.11, 
-0.88)
0.0089 79, -14.7 
(-24.29, 
-5.17)
0.0030 437, -1.2
(-3.94, 
1.62)
0.4136
Anxiety 
Score
135, -1.2
(-2.45, 
0.04)
0.0584 608, -1.6
(-2.05, 
-1.07)
< 0.0001 133, -2.1 
(-3.33, 
-0.83)
0.0012 608, -0.8
(-1.29, 
-0.28)
0.0025
Depression 
Score
135, -1.2
(-2.55, 
0.06)
0.0611 608, -1.5 
(-1.96, 
-0.98)
< 0.0001 133, -1.5 
(-2.85, 
-0.09)
0.0374 608, -0.4
(-0.91, 
0.10)
0.1158
SF-36 Physical 
Score
135, 5.7
(2.94, 
8.43)
< 0.0001 607, 4.4 
(3.31, 
5.39)
< 0.0001 132, 2.9
(0.21, 
5.57)
0.0346 608, 1.0
(-0.10, 
2.04)
0.0753
SF-36 Mental 
Score
135, 4.5
(1.61, 
7.48)
0.0026 607, 4.8 
(3.53, 
6.15)
< 0.0001 132, 3.2 
(-0.12, 
6.53)
0.0591 608, 1.8
(0.45, 
3.15)
0.0092
N is the sample size across two groups.
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THE DERMATOLOGY LIFE QUALITY INDEX IN 
RUSSIAN PATIENTS WITH PSORIASIS AND PSORIATIC 
ARTHRITIS.
Nadezhda Batkaeva, Edgem Batkaev, Muslimat Gitinova
Peoples' Friendship University of Russia (RUDN University)
Introduction: The most severe form of psoriasis is psoriatic arthritis 
(PsA), which belongs to the seronegative spondyloarthritis group, 
characterized	by	chronic	inflammation	of	the	joints,	spine,	enthe-
sis. The frequency of PsA in the population is 0.06–1.4%. PSA is 
comparable to rheumatoid arthritis (RA) in terms of progression, 
disability and quality of life (QOL) in patients.
Objectives: Compare the quality of life index of patients with 
severe forms of psoriasis (PsO) with psoriatic arthritis patients’ 
index.
Methods: 120 (100%) patients suffering from PsO and PsA 
(Male-87/female - 33) were analyzed. 70 (54.2%) patients were 
diagnosed PsO, 50 (41.7%) were diagnosed PsA. The average 
age of patients with skin manifestations PsO was 54.0±14.2 years 
(n = 70). The average age of patients with PsA was 49.1±15.9 years 
(n = 50). The group of patients with PsA was older than the group 
PsO patients by age. PASI  >  10. The quality of life was assessed 
using the Dermatology Life Quality Index (DLQI) questionnaire. 
The results were evaluated: from 0 to 1 score - cutaneous disease 
does not affect the patient's life, from 2 to 5 scores - the disease 
has a minor effect on the patient's life, from 6 to 10 scores - the 
disease has a moderate effect on the patient's life, from 11 to 20 
scores - the disease has a very strong effect on the patient's life, 
from 21 to 30 scores - the disease has an extremely strong effect 
on the patient's life. Statistical processing of the data was carried 
out using the Excel analysis package. All p < 0.05 were considered 
to	indicate	statistical	significance.
Results: 120 (100%) patients suffering from PsO were taken for 
analysis. The duration of PsO was: for more than 15 years - 25 
people (35.7%), 10–15 years - 18 people (25.7%); 3–10 years - 
15 people (21.4%), 1–3 years - 12 people (17.1%). The duration 
of PsA was: for more than 15 years – 5 people (10.0%), 10–15 
years – 7 people (14.0%); 3–10 years – 20 people (40.0%), 1–3 
years – 18 people (36.0%). Heredity was aggravated in 35 (29.1%) 
out of 120 patients. Comorbidity was presented in 112 (93.3%) out 
of 120 patients. Gastrointestinal and liver diseases were found in 
48 (42.8%) out of 120 patients. Type 2 diabetes was observed in 
45 (40.1%) out of 120 patients, cardiovascular diseases - in 100 
(89.2%) out of 120 patients, diseases of the nervous system - in 59 
(52.6%) out of 120 patients, and diseases of the urinary system - in 
20 (17.8%) out of 120 patients.
The total score DLQI in the psoriasis group was 15.8±5.2. The 
score DLQI in PsO patients was 12.5±3.4 and in PsA patients was 
20.4±3.7. The total score DLQI in PsO patients with comorbidity 
was 16.1±5.3.
Conclusions: The	 total	score	DLQI	was	significantly	higher	 in	
patients with PsA compare to PsO patients. This result revealed 
the existence of an inferior quality of life for the PsO patients with 
comorbidity disease, compared with pts without comorbidity di-
sease. The score of DLQI is affected the development and progress 
of the psoriasis and comorbidity pathology. Then higher DLQI 
value, the more it affects experience considerable physical and/
or	psychological	discomfort,	difficulties	in	social	and	professional	
adaptation,	which	subsequently	cause	significant	distress	and	even	
social phobia. All these conditions psoriasis are interrelated by 
genetic and immunopathogenetic mechanisms. Thus, patients with 
psoriasis require an integrated approach and dynamic observation 
by dermatologists and doctors of related specialties.
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EFFECTS OF MINDFULNESS­BASED COGNITIVE 
THERAPY ON SELF­REPORTED PSORIASIS AND 
PSYCHOLOGICAL SYMPTOMS
Alan Maddock, David Hevey
School of Psychology, Trinity College Dublin
Introduction: Psoriasis can have a profound impact on a patient’s 
life, with the prevalence of anxiety, depression, poor wellbeing 
and quality of life generally found to be high in psoriasis popula-
tions. Mindfulness based interventions have been shown to have 
positive impacts on anxiety, depression, wellbeing and quality of 
life in various populations.
Objectives: The aim of the present study was to investigate the ef-
fect of mindfulness-based cognitive therapy (MBCT) on psoriasis 
symptoms and psychological symptoms associated with psoriasis 
including anxiety, depression, reduced wellbeing and QoL. The 
study	also	aimed	to	investigate	if	MBCT	significantly	impacted	
the potential mediating variables of a new theory of mindfulness 
mechanisms	 the	 ‘Clinically	Modified	Buddhist	 Psychological	
Model (CBPM)’, these variables being acceptance, mindfulness, 
self-compassion, aversion, non-attachment, attention, rumination 
and worry.
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Methods: 101 participants were randomly allocated to a treatment 
arm (MBCT) or a TAU arm. Participants were measured pre, post-
treatment and after a 3-month follow up period. Data were analysed 
using intention-to-treat analysis and the ANCOVA method with 
baseline scores entered as covariates.
Results: There	was	a	significant	group×time	(pre	vs.	post)	interac-
tion	on	all	variables	except	QoL,	indicating	a	significant	reduction	
of each variable except QoL over time in the MBCT group, but not 
in the control group. When baseline variables were controlled for, 
the participants in the MBCT group achieved small statistically 
significant	changes	across	all	variables	post	intervention	versus	
the TAU group.
Conclusions: The results suggest that MBCT may be a useful ad-
junct therapy for those suffering from psoriasis and the associated 
psychological symptoms relating to the condition. The results 
also indicate that each of the mechanisms outlined in the CBPM 
change	significantly	for	patients	who	engage	in	the	intervention.	
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A MIXED METHODS STUDY EXPLORING THE 
IMPACT OF MINDFULNESS ON PSORIASIS, ANXIETY, 
DEPRESSION AND QOL
Alan Maddock, David Hevey
School of Psychology, Trinity College Dublin
Introduction: Psoriasis is a common condition with recognised 
psychological comorbidity. Psoriasis can have a profound impact 
on a patient’s life, with the prevalence of anxiety, depression, poor 
wellbeing and quality of life generally found to be high in psoriasis 
populations. Based on Buddhist psychology, mindfulness based 
interventions have been shown to have positive impacts on anxiety, 
depression, wellbeing and quality of life in various populations.
Methods: Mixed methods explored the impact of a mindfulness 
based cognitive therapy (MBCT) intervention on 10 psoriasis 
patients using a Buddhist Psychological Model (BPM) as a 
theoretical framework to understand changes in these variables. 
Quantitative measures of acceptance, attention regulation, at-
tachment, aversion, self-compassion, mindfulness, rumination, 
worry, wellbeing, anxiety, depression and psoriasis symptoms 
were completed pre and post intervention, and participants were 
interviewed about their experiences of MBCT.
Results: Statistically	significant	changes	in	attention,	mindfulness,	
attachment, aversion, rumination, quality of life, anxiety and 
psoriasis were found. The qualitative data provided support for 
the BPM as a theoretical lens with which to understand the way 
in which mindfulness impacts on patient quality of life, anxiety 
and psoriasis symptoms.
Conclusions: This study gives support to the promising potential 
of mindfulness interventions being implemented by mental health 
care professionals with psoriasis patients. 
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A LINK BETWEEN QUALITY OF PATIENT­PHYSICIAN 
COMMUNICATION AND PATIENT HEALTHCARE 
NEEDS IN PSA 
A-M Orbai1, L Coates2, VF Azevedo3, A Garg4, A Majjhoo5, CEM 
Griffiths6, P Young7, JC Cappelleri8, J Moser9, L Fallon10
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 
2University of Oxford, Oxford, UK, 3Universidade Federal do Paraná, 
Curitiba, Brazil, 4Donald and Barbara Zucker School of Medicine at 
Hofstra/Northwell, Hempstead, NY, 5Shores Rheumatology, MI, USA, 
6University of Manchester, Manchester, UK, 7Pfizer Inc, Collegeville, PA, 
8Pfizer Inc, Groton, CT, 9The Harris Poll, Rochester, NY, USA, 10Pfizer 
Canada, Montréal, QC, Canada
Introduction: Patient(pt)-physician(HCP) communication may 
influence	symptom	reporting	and	disease	control.
Objectives: To evaluate psoriatic arthritis (PsA) symptoms, life 
impact and treatment satisfaction in pts who report good commu-
nication with their HCP vs suboptimal communication.
Methods: An online pt-based survey was conducted in the US 
from 2 Nov–1 Dec 2017. Pts had reported having PsA for  > 1 
year,	taken	≥1	synthetic(s)	or	biologic(b)	DMARD	for	PsA.	Pts	
reported overall health, PsA severity/symptoms/life impact, tre-
atment satisfaction and communication experience. We evaluated 
differences by pt-HCP communication status.
Results: Overall, 301 pts with PsA responded, mean age 45 years, 
61% female, 89% self-reported moderate/severe PsA. Current PsA 
treatments included bDMARD (52%), sDMARD (25%), combi-
nation b/sDMARD (15%). Overall, 256 (85%) of PsA pts were 
managed by a rheumatologist and 15% by a dermatologist. Of the 
256,  > 40% reported suboptimal pt-HCP communication. Pts in 
the suboptimal vs good communication subgroups were typically 
younger, more likely to be Hispanic and reported greater life im-
pact and lower satisfaction with pt-HCP communication (Table). 
Table. Pts with PsA managed by rheumatologist (n = 256)
 
“I worry that if I ask too 
many questions my healt-
hcare professional will see 
me	as	a	difficult	patient	and	
it will affect the quality of 
care I receive”
“I often tell  my 
healthcare professi-
onal	I	am	fine	when	
I am really expe-
riencing symptoms”
 
Agree
n = 105 (41%)
%
Disagree
n = 151 
(59%)
%
Agree
n = 118 
(46%)
%
Disagree
n = 138 
(54%)
%
Mean age (years) 41.9 46.8* 41.6 47.5*
White
Hispanic
Black
66
20
10
73
15
7
58
26*
11
80*
9
7
Symptoms in past 12 months
Joint pain
Skin/nail symptoms
Stiffness
 Joint swelling
85
83
74
70
90
84
79
72
86
84
72
75
89
83
82
68
Moderate PsA 70* 55 58 64
Severe PsA 23 32 33 25
Reported impact on
-emotional well being
-work productivity
-romance/intimacy
-decision to start family
-education
76*
69*
67*
40*
35*
59
56
48
24
17
78*
69*
66*
42*
36*
56
54
46
21
15
Very	satisfied	with	HCP	communication 43 75* 52 71*
Very	satisfied	with	treatment 29 45* 36 40
Stopped taking treatment 22* 8 19* 9
*p < 0.05
Conclusions: Pts who reported suboptimal communication with 
their HCP may have greater healthcare needs for their PsA vs 
other pts.
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PSORIASIS PATIENTS POINT OF VIEW: WHAT ARE WE 
MISSING WHEN MANAGING THEM?
Elena Popa1, Alexandra Brahas2, Caius Solovan1
1Department of Dermatology and Venereology, Clinical Emergency City 
Hospital Timisoara; University of Medicine and Pharmacy “Victor Babes” 
Timisoara, Romania, 2University of Medicine and Pharmacy “Victor Ba-
bes” Timisoara, Romania
Introduction: Psoriasis is a skin disease that can occur at any 
time and it is most common in the age group 50–69. The reported 
prevalence of Psoriasis in countries ranges between 0.09% and 
11.4%, making it a serious global problem.
Psoriasis affects the quality of life and it is associated with many 
comorbidities such as depression, diabetes, cardiovascular disease 
and psoriatic arthritis.
To	evaluate	the	severity	and	the	efficiency	of	the	treatment	applied	
to patients with Psoriasis, in practice it is used PASI (Psoriasis 
Area and Severity Index). The value may vary, for example, in this 
study, PASI 75 represents the percentage (or number) of patients 
that have achieved a 75% or more reduction in their PASI score 
in 12 weeks from baseline.
Objectives: Aim of this study is to gain a better perspective on 
the Psoriasis patient’s point of view when seeking a physician’s 
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help, therefore, to try and minimize the gaps that exist when 
managing them.
Methods: This study was based on a custom questionnaire which 
included 14 questions for each patient. The responses were 
gathered from 20 patients (and it is still ongoing) diagnosed in 
our Department of Dermatology and Venereology Timisoara, each 
in	 different	 stages	 of	 disease.	All	 the	 answers	 are	 confidential	
and anonymous. An informed consent was signed prior to any 
taken actions. To achieve meaningful results, we asked patients 
to be honest and to present the situation in a real way. The most 
important question on the questionnaire was “Which of the three 
options represents the PASI score you would like to achieve? 
50/75/90?”. In addition to this question, we provided the patients 
with three pictures each of them showing a different PASI score, 
so they can choose the proper answer much easier.
Results: 80% of the patients chose PASI 90, 15% chose PASI 75 
and only 5% chose PASI 50.
In addition to this, the gender distribution showed us that 100% 
of the female patients chose PASI 90, proving how important 
appearance is for them, and how much of a weight it is for them 
to have disease that is in the limelight. On the other hand, the 
male patients were divided into three groups. 69% said that the 
efficiency	of	the	therapy	is	very	good,	choosing	PASI	90.	Only	
23% of male patients consider PASI 75 satisfying and the last 8% 
represents PASI 50.
Conclusions: Psoriasis	is	a	chronic	inflammatory	disease,	which	
is intensively studied at the cellular and molecular level. What is 
considered a good response to a treatment is sometimes different 
from the perception of a patient vs. a physician, therefore we must 
always keep a balance between aiming high (and maybe risking to 
over-treat some patients) and meeting the patient’s expectations. 
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THE IMPACT OF PSORIASIS AND PSORIATIC 
ARTHRITIS ON QUALITY OF LIFE AND CAREER IN 
SCANDINAVIA
Albert Duvetorp1, Mikkel Østergaard2, Lone Skov3, Oliver Seifert4, 
Kåre Steinar Tveit5, Kjersti Danielsen6, Lars Iversen7
1Skånes Universitetssjukhus, Malmö, Sweden; Linköping University, Lin-
köping, Sweden, 2Copenhagen Center for Arthritis Research, Center for 
Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, University 
of Copenhagen Copenhagen, 3Herlev and Gentofte Hospital, University of 
Copenhagen, Denmark, 4Linköping University, Linköping, Sweden; Ryhov 
Hospital, Jönköping, Sweden, 5Haukeland University Hospital, Bergen, 
6UiT The Arctic University of Norway; University Hospital of North Nor-
way, Tromsø, Norway, 7Aarhus University Hospital, Aarhus, Denmark
Introduction: Patients’ perspectives on the effects of psoriasis 
(PsO) and psoriatic arthritis (PsA) on health-related quality of 
life (HRQoL) are important in establishing better approaches to 
their care and treatment.
Objectives: To better understand the impact of PsO and PsA on 
daily life, education and work in Scandinavian countries.
Methods: The NORdic PAtient survey of PsOriasis and Psoriatic 
arthritis (NORPAPP) was an on-line survey carried out in Nov/
Dec 2015 using YouGov panels in Sweden, Denmark, and Norway. 
Adults (18–74 years old), with physician-diagnosed PsO or PsA 
(n = 1221), answered questions about the impact of disease on 10 
aspects of daily activity/mood and on work/education; 5-point 
Likert scale responses were dichotomised into “no/minor impact” 
(1–3 or “don’t know”) and “strong impact” (4–5).
Results: For the 10 aspects of activity/mood a “strong impact” was 
reported	for	≥4,	1–3	or	0	aspects	by	22.8%,	24.2%,	and	61.9%	of	
respondents with PsO alone and 44.5%, 63.0%, and 27.0% of those 
with PsA±PsO. The most commonly reported strong impacts were 
limitations on dress (22.6%), sleep disorders (16.3%) and depres-
sion and/or anxiety (16.2%) for respondents with PsO alone; and, 
daily routine (45.1%), leisure/sports (44.0%), sleeping disorders 
(44.5%), and limitations on clothing (41.8%) for respondents 
with PsA±PsO. Regarding the impacts on work/career or educa-
tion since development of symptoms, 6.4% of respondents with 
PsO alone and 30.3% of those with PsA±PsO reported a strong 
negative impact. Of the 82.2% of respondents who were working 
or studying, frequency of absences in the previous 12 months 
were	significantly	higher	(Bonferroni	corrected	z-tests,	total	α	 = 
0.05) among those who: had PsA±PsO vs PsO alone; perceived 
their symptoms to be severe vs non-severe; used systemic vs 
only topical treatments; were aged 18–44 years vs 45–74; were 
members of patient groups vs non-members; saw a dermatologist 
or rheumatologist at least annually vs those who did not.
Conclusion: PsO has a profound impact on the HRQoL and career/
education of individuals with these conditions in Scandinavia. The 
impact is greater among individuals with PsA±PsO.
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QUALITY OF LIFE OF PATIENTS WITH PSORIASIS IN 
KHARTOUM DERMATOLOGY HOSPITAL, DECEMBER 
2017
Hind Madani
University of Khartoum- faculty of medicine
Introduction: Psoriasis is a common chronic non-contagious skin 
disease, affecting 1–3% of the world population. Defects in the 
immune	regulation	and	the	control	of	inflammation	are	thought	
to play major roles. Quality of life (QOL) is increasingly recog-
nized as an important outcome measure in dermatology. Psoriasis 
although it doesn’t affect the survival it has a great impact on qua-
lity of life of patients, and has a strong effect on social relations, 
psychological status, daily activities and thought to be associated 
with depression.
Objectives: The aim of this study was to determine the impact of 
psoriasis on the quality of life(QOL) of the patients in Khartoum 
dermatology hospital, 2017.
Methods: Descriptive case series study, hospital based survey 
conducted among 70 participants from psoriasis patients aged 
above 18 years in Khartoum dermatology hospital, through self-
administered standard questionnaire, which was developed after 
extensive literature reviewing, comprised of Socio-demographic 
data, psoriasis life stress inventory(PLSI), psoriasis disability 
index(PDI) and depression assessment.
Results: 64.3% of the participants have a high psoriasis-related 
stress (PLSI) and 35.7% have a low psoriasis-related stress. 21.4% 
of the participants have a very large disability in daily activities 
(PDI), 37.1% have a large disability, 24.3% have a moderate disa-
bility, 14.3% have a mild disability and 2.9% have no disability at 
all.7.1% of the participants have a moderately severe depression, 
15.7% have a moderate depression, 35.7% have a mild depres-
sion, 41.4% have none or minimal depression and none of the 
participants has a severe depression.
Conclusion: the study concluded that psoriasis has impacts on 
the quality of life, causing high stress and high disability in daily 
activities with variable degrees of depression.
Key words: psoriasis, QOL, PLSI, PDI, depression.
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MIRIKIZUMAB SIGNIFICANTLY IMPROVES SELF­
REPORTED DISEASE SEVERITY AND GENERAL 
HEALTH STATUS IN PATIENTS WITH MODERATE­TO­
SEVERE PSORIASIS
Melinda Gooderham1, Paul Klekotka2, Emily Edson Heredia2, 
Joanne Li2, Baojin Zhu2, Jiaying Guo2, Jerry Bagel3
1SKiN Centre for Dermatology, 2Eli Lilly & Company, 3Windsor Derma-
tology
Introduction: In a randomized, placebo-controlled, phase 2 trial 
(NCT02899988),	mirikizumab	met	its	primary	efficacy	endpoint	
at Week 16.1
Objective:To determine if mirikizumab improves patient-reported 
disease severity and general health status in psoriasis patients at 
Week 16.
Methods: Adults with moderate-to-severe psoriasis were ran-
domized 1:1:1:1 to receive placebo (n = 52), mirikizumab 30 mg 
(n = 51), 100 mg (n = 51), or 300 mg (n = 51) at Weeks 0 and 8. 
At baseline and Weeks 2, 4, 8, 12, and 16, patients completed the 
Patient Global Assessment of psoriasis (PtGA) (0 = clear, 5 = se-
vere). At baseline and Week 16, patients completed the Medical 
Outcomes Study 36-Item Short Form Health Survey (SF-36; 
[range 0–100]) which measures 8 general health status domains 
that can be scored as mental component and physical component 
summaries. For continuous measures, comparisons were made 
by a mixed-effects for repeated measures model (PtGA) or an 
analysis of covariance model (SF-36). Comparisons of categorical 
efficacy	variables	were	conducted	by	logistic	regression	analysis	
with non-responder imputation (NRI).
Results: At Week 16, mirikizumab-treated patients reported greater 
improvements in psoriasis severity and aspects of physical functio-
ning versus placebo (Table).
Conclusion: Mirikizumab	treatment	at	various	doses	significantly	
improved psoriatic disease severity and physical health status.
Reference:
1. Reich K et al. Programme and abstracts of Psoriasis from Gene to Clinic; 
Nov. 30-Dec. 2, 2017; Abstract FC31.
Table. Patient-Reported Outcomes (Week 16)
Placebo
n = 51
Mirikizumab
30 mg
n = 48
100 mg
n = 51
300 mg
n = 51
PtGA, least squares mean(SE) 0.4 (0.16) 2.2 (0.16)*** 2.9 (0.16)*** 2.8 (0.16)***
Change from Baseline in SF-36 Domains, LSM (SE)
 Physical functioning 2.8 (1.9) 7.2 (2.0) 8.2 (1.9)* 7.2 (2.0)
 Role-physical 1.2 (2.4) 11.4 (2.5)** 11.5 (2.5)** 12.3 (2.5)**
 Bodily pain 5.7 (2.8) 17.6 (2.9)** 19.2 (2.9)*** 18.9 (2.9)**
 General health 1.4 (1.9) 5.8 (2.0) 3.2 (1.9) 5.4 (1.9)
 Vitality 1.0 (2.0) 6.9 (2.1)* 4.7 (2.0) 6.2 (2.0)
 Social functioning -0.2 (2.4) 10.5 (2.4)** 13.4 (2.4)*** 8.2 (2.4)*
 Role-emotional 1.3 (2.0) 5.2 (2.1) 6.1 (2.0) 6.0 (2.0)
 Mental health 1.7 (1.8) 5.5 (1.8) 6.6 (1.8) 3.2 (1.8)
≥2.5	point	improvement	in	SF-36	
MCS, % (NRI)
36.5 37.3 45.1 33.3
≥2.5	point	improvement	in	SF-36	
PCS, % (NRI)
42.3 52.9 56.9 62.7*
MCS, mental component summary; PtGa, Patient Global Assessment; PCS, physical component 
summary; SE, standard error; SF-36, 36-Item Short Form Health Survey.
*p <  .05 vs placebo; **p <  .01 vs placebo; ***p <  .001 vs placebo. 
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EFFECT OF TILDRAKIZUMAB ON PERSONAL 
RELATIONSHIPS IN PATIENTS WITH MODERATE­TO­
SEVERE CHRONIC PLAQUE PSORIASIS 
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Introduction: The negative impact of psoriasis extends beyond 
the patient, affecting his/her social interactions and the quality 
of life of cohabitants. Furthermore, patients with psoriasis often 
experience	sexual	difficulties	because	of	their	disease.
Objective:This analysis examined the effect of treatment with 
tildrakizumab (TIL) on personal relationships of patients with 
moderate-to-severe chronic plaque psoriasis.
Methods: Patients in two phase 3 trials reSURFACE 1 
(NCT01722331) and reSURFACE 2 (NCT01729754) were 
randomized to subcutaneous TIL 200 mg, 100 mg, or placebo 
(PBO) and received treatment at weeks 0 and 4. PBO patients 
were re-randomized at week 12 to either TIL 200 mg or 100 mg. 
Etanercept (ETN) 50 mg (semiweekly until week 12 then weekly 
until week 28) was also a treatment arm in reSURFACE 2. Data on 
personal relationships were collected at weeks 12 and 28 from the 
Dermatology Life Quality Index (DLQI) questionnaire question 
8 (Q8) “Over the last week, how much has your skin created pro-
blems with your partner or any of your close friends or relatives” 
and question 9 (Q9) “Over the last week, how much has your skin 
caused	any	sexual	difficulties”.	Each	question	was	scored	on	a	
scale of 0 (not affected at all) to 3 (very much affected). The data 
were pooled from reSURFACE 1 and 2.
Results: In all, 1,820 patients had DLQI data. All patients repor-
ted a negative effect for Q8 and Q9 at baseline. At week 12, the 
proportion of patients with no negative effect (score of 0) on per-
sonal relationships (Q8 and Q9) was higher for TIL 200 mg, TIL 
100 mg, and ETN than for PBO (76%, 72%, and 64% vs. 39%, 
respectively). A similar trend was observed for individual questions 
Q8 and Q9. At week 28, more patients on TIL 200 mg and TIL 
100 mg reported no negative effect on personal relationships than 
those on ETN (85% and 77% vs. 66%; respectively). More patients 
on TIL 200 mg and TIL 100 mg reported no negative effect than 
those on ETN for Q8 (89% and 81% vs. 70%; respectively) and 
for Q9 (89% and 84% vs. 75%, respectively). 
Conclusions: TIL	 had	 a	 beneficial	 effect	 on	 psoriasis-related	
personal	relationship	problems	and	sexual	difficulties,	compared	
to placebo and ETN.
This abstract was presented at 2018 Annual Meeting of American Academy 
of Dermatology.
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PRURITUS SEVERITY ASSESSMENT AND 
CORRELATION WITH BASELINE CHARACTERISTICS 
OF PATIENTS WITH PSORIASIS VULGARIS: AN 
EXPLORATORY ANALYSIS OF THE PHASE IIIB, 
PSORITUS STUDY
Sonja Ständer1, Sabine Steinke1, Matthias Augustin2, Dieter Me-
tze1, Karin Loser1, Daniel Baeumer3, Thomas Luger4
1Department of Dermatology and Competence Center Chronic Pruritus 
and 4Department of Dermatology, University hospital Münster, Münster, 
2Institute for Health Services Research in Dermatology and Nursing, Ham-
burg, and 3Novartis Pharma, Nuernberg, Germany
Introduction: Chronic pruritus lasts for at least 6 weeks and is a 
most common symptom in patients with psoriasis. Pruritus is a 
highly prevalent and troublesome symptom and has a negative 
impact upon patients’ health-related quality of life (QoL). The 
ItchyQoL	is	a	pruritus-specific	QoL	questionnaire	that	can	be	app-
lied to patients with pruritus independent of the underlying disease.
Objective:To assess the impact of pruritus on QoL in patients with 
psoriasis by an exploratory analysis of baseline characteristics of 
subjects from the PSORITUS study.
Methods: PSORITUS was an exploratory, randomized, double-
blind, placebo-controlled 16-week drug withdrawal study with a 
16-week open-label run-in phase, to assess the kinetics of psoriasis 
symptoms, pruritus intensity, and lesional biomarkers. Subjects 
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≥18	years	of	age	with	chronic	moderate-to-severe	psoriasis	at	least	
6 months prior to baseline, with a Psoriasis Area and Severity 
Index (PASI) score  > 10	at	baseline,	and	pruritus	intensity	≥30	on	
a 100-point Visual Analogue Scale (VAS, the worst itching within 
a recall period of 24 hours), were included. In an exploratory ba-
seline	analysis,	correlation	coefficients	were	calculated	between	
ItchyQoL outputs and individual baseline characteristics based 
on Spearman‘s (r) and Kendall rank correlations (t). A multiple 
linear regression model was performed to assess the effect of 
exploratory variables correlating with the ItchyQoL score and 
achieving	statistical	significance	(p-value  < 0.05).
Results: The study included 130 subjects with psoriasis. The 
subjects had a mean age of 46.8 years (standard deviation [SD], 
12.30) and majority (71.5%) were in the age group of 35–64 years. 
The	mean	(SD)	time	since	first	diagnosis	of	psoriasis	and	psoriatic	
arthritis (PsA) was 19.5 (13.81) and 17.2 (18.30) years, respectively; 
13.8% of subjects had PsA. The mean (SD) baseline PASI, patient 
benefit	index	(PBI),	and	ItchyQoL	score	was	23.9	(10.85),	84.2	
(24.17), and 78.7 (17.42) respectively, indicating severe disease 
activity and pruritus. The baseline ItchyQoL score showed moderate 
correlation with baseline VAS scores for average and worst pruritus 
(r: 0.542 [95% CI: 0.41, 0.65] and 0.547 [95% CI: 0.41, 0.66]; t: 
0.381 [95% CI: 0.22, 0.52] and 0.383, 95% CI: 0.23, 0.52]) and 
a strong correlation with baseline dermatology life quality index 
(DLQI) scores (r: 0.803 [95% CI: 0.73, 0.86]; t: 0.622 [95% CI: 
0.50, 0.72]. Furthermore the multiple linear regression analysis 
showed substantial dependency of QoL measured by ItchyQoL 
for VAS (average pruritus last 24 h), duration of psoriasis and 
health-related	patient	needs	as	measured	by	patient	benefit	index.
Conclusions: ItchyQoL assessment demonstrated that subjects 
with psoriasis are highly burdened by pruritus and show severely 
impaired quality of life. The correlation between pruritus intensity, 
ItchyQoL- and DLQI questionnaire results suggests the need for 
routine assessment of pruritus in clinical practice. 
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QUALITY OF LIFE AND PSYCHOSOCIAL 
IMPLICATIONS IN PATIENTS WITH PSORIASIS
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Georgios Kontochristopoulos1
1Andreas Sygros Skin Hospital, 2Attikon University Hospital, Athens, 
Greece
Introduction: Psoriasis is a common, long-term skin disease that 
affects approximately 1.5–3% of the population. The burden of 
living with psoriasis is equivalent to or greater than that seen in 
other long-term conditions, such as cardiac failure and chronic 
lung disease. The stigma provoked by the disease, often lead 
to the discontinuation of daily activities and social withdrawal. 
Nevertheless, these effects of psoriasis are seldom recognized and 
often undertreated.
Objectives: The aim of the study is to evaluate the quality of life, 
anxiety and depression, self-esteem and loneliness in patients 
with psoriasis.
Methods: Ninety-eight patients with psoriasis were enrolled in the 
study. The quality of life, depression and anxiety, loneliness and 
self-esteem of the patient were assessed using the Dermatology 
Life Quality Index, Hospital Anxiety and Depression Scale, the 
UCLA loneliness Scale (UCLA-Version 3) and Rosenberg’s Self-
esteem Scale, respectively.
Results: The Dermatology Quality of Life Index score among pso-
riasis patients was 13.52±4.58.	They	had	statistically	significantly	
higher scores according to the Hospital Anxiety and Depression 
Scale -anxiety subscale (p = 0.031)-compared with healthy volun-
teers.	Moreover,	a	statistically	significant	difference	was	found	
between the two groups concerning the UCLA-scale (p = 0.032) 
and RSES-scale (p < 0.0001). Female patients presented with lower 
self-esteem than male patients.
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THEIR DISEASE. RESULTS FROM AN OBSERVATIONAL 
PATIENT SURVEY
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Introduction: A global patient survey was adapted and implemen-
ted in Sweden, in order to explore and understand the patients’ view 
on their disease, as well as the personal and emotional impact of 
their psoriasis. The focus of the survey was the patient’s perception 
of the possibility to achieve clear skin, and how having clear skin 
could affect their quality of life. A publication based on earlier 
data is under review. 
Methods: The Swedish “Clear about Psoriasis” survey was conduc-
ted from June 16 2017 to August 8 2017. Recruitment was made 
via online panels and patient organizations. Validated methods 
were used to assess severity of disease and health-related quality 
of life. The survey consisted of multiple-choice questions, no 
definition	of	clear	skin	was	given,	and	spontaneous	feelings/per-
ceptions	were	reported.	Respondents	(≥18	years	old)	were	required	
to have current plaque psoriasis, for which they had received a 
medical diagnosis and should not have participated in an online 
survey about psoriasis in the preceding four weeks. The analysis 
included only patients with moderate-to-severe plaque psoriasis, 
defined	as	a	Psoriasis	Area	Severity	Index	(PASI)	score	≥10,	or	
a PASI score 5.0–9.9 with plaques in visible and/or in sensitive 
areas, such as the face and genitals. 
Results: In total, 54 patient responses were completed and analy-
zed. Mean age was 45 years and 80% were female. The average 
self-assessed PASI score was 16.0, 26% had PASI 5.0–9.9, 74% 
PASI  > 10 and 54% reported to have psoriatic arthritis. Current 
treatment allowed 44% of patients to achieve clear or almost clear 
skin. Clear or almost clear skin was believed to be achievable by 
30% of the patients. Of patients reaching clear or almost clear 
skin, 71% had talked to their physician about their aim for clear 
skin. Among patients who have not achieved clear or almost clear 
skin, 47% had spoken to their physician about their aim. 57% of 
the	patients	were	satisfied	with	their	current	treatment.	The	most	
important reasons for treatment satisfaction were less itching (81%), 
and the achievement of less pain and soreness (55%). Not achieving 
clear skin was the major reason for dissatisfaction. Discrimination 
or humiliation has been experienced by 98%. About 69% have 
been asked if they are contagious. Relationships were affected and 
52% avoided to have sex. Worklife was affected by 65% of the 
respondents. For 58% of patients it took more than 5 years to get 
a treatment that resulted in clear or almost clear skin. During the 
last 6 months, 24% of employed patients had taken at least one day 
off work due to their disease whilst 5% took more than 14 days.
Conclusions: This survey shows that a majority of patients do not 
believe achieving clear or almost clear skin is possible and they 
are not comfortable to talk to their physician about it. Furthermore, 
patients encounter a stigmatizing environment. Better treatment 
as well as improved patient information is needed. 
Novartis is grateful to Psoriasisförbundet for facilitating the survey.
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Introduction: Ixekizumab,	a	high-affinity	monoclonal	antibody	
that selectively targets IL-17A, was shown to be superior to uste-
kinumab, an IL-12/23 inhibitor, with respect to skin clearance and 
quality of life up to 24 wks in patients with moderate-to-severe 
psoriasis in IXORA-S1.
Objectives: The objective of this analysis was to compare the 
cumulative	benefits	of	ixekizumab	versus	ustekinumab	at	12	and	
24 weeks of treatment in IXORA-S, with respect to skin clearance, 
itching, health-related quality of life (HRQoL), and pain.
Methods: In the IXORA-S trial, patients were randomized (1:1) 
to receive either IXE (160-mg starting dose, then 80-mg every 2 
wks for 12 wks followed by 80-mg every 4 wks; n = 136) or UST 
(45–mg/90-mg weight-based dosing per label; n = 166) through 
52 wks. Data at week 12 and week 24 were used in this post-hoc 
analysis.	At	wks	2,	4,	and	every	4	wks	thereafter,	clinical	benefits	
were measured using percentage improvements in Psoriasis Area 
and Severity Index (PASI 75/90/100); the Itch Numeric Rating 
Scale (NRS; 0 = no itch, 10 = worst itch imaginable); and Skin Pain 
VAS (0 = no pain, 100 = maximum pain). Health-related quality 
of	life	(HRQoL)	benefit	was	measured	at	wks	2,	4,	12,	and	24	
using the Dermatology Life Quality Index (DLQI) [DLQI score  = 
0.1	 indicates	 no	 effect	 on	patient’s	 life].	Total	 benefits	 -	 PASI	
75/90/100; itch NRS = 0; DLQI = 0.1; Pain VAS 0 – were used to 
determine the area-under-the-curve (AUC) of responders for each 
outcome at 12 and 24 weeks. Missing values were imputed using 
non-responder imputation (NRI). AUC results, capturing the rapid 
and sustained treatment response, were normalized as a percentage 
of	maximum	possible	(0–100%)	AUC.	The	clinical	benefit	ratios	
between IXE vs UST were calculated for each outcome to show 
relative	cumulative	benefit.
Results: At	12	wks,	 the	normalized	cumulative	clinical	benefit	
with IXE vs UST, respectively, was 58.2% and 32.9% (PASI75); 
36.7% and 15.6% (PASI90); 14.2% and 4.0% (PASI100); 25.3% 
and 14.3% (itch); 36.0% and 23.7% (pain); and 44.9% and 25.2% 
(DLQI).	Cumulative	clinical	benefits	at	week	24	for	IXE	and	UST,	
respectively, were 74.3% and 54.3% (PASI75), 58.1% and 32.3% 
(PASI90), 29.0% and 12.2% (PASI100); 33.5% and 22.1% (itch); 
42.7% and 30.6% (pain); and 54.3% and 37.0% (DLQI). At 12 wks, 
clinical	benefit	ratios	(IXE/UST)	for	PASI	75/90/100	were	1.77,	
2.36, and 3.52; 1.51 for pain; and 1.78 for both itch and DLQI. At 
24 wks, the ratios were 1.37, 1.80, 2.38 (PASI 75/90/100), 1.52 
(itch), 1.39 (pain) and 1.47 (DLQI).
Conclusions: Cumulative	benefits	measured	by	PASI,	itch,	pain,	
and DLQI responders were greater for IXE vs. UST following 12 
and	24	wks	of	treatment.	Long-term	cumulative	benefits	will	be	
addressed upon publication of Week 52 results from the IXORA-S 
trial.
Reference:
Reich K, et al. Br J Dermatol. 2017;177(4):1014-1023.
Previously presented at AAD, San Diego, CA; February 16 – 20, 2018. 
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COACH@HOME: A SUPPORT PROGRAM FOR 
PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Nicolai Böhme1, Ann-Dörthe Holst2, Friedrich Dybowski3, Chris-
toph Volberg4, Hans-Georg Pott5, Udo Lendl6
1Healthcare at Home Deutschland GmbH, Weinheim, 2Rheumapraxis, Lud-
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Introduction: Coach@home (c@h) is a German support program 
for certolizumab pegol (CZP)-treated patients (pts) with rheumatic 
diseases, including psoriatic arthritis (PsA). Eight coaching calls 
are offered over one year, scheduled around critical milestones on 
the therapeutic journey. These are made by trained nurses, who 
offer support and information about both the pt’s disease and its 
treatment with CZP.
Objectives: To assess the baseline characteristics of PsA pts sub-
scribed to c@h, and the level of pt satisfaction with the program 
across indications (Sep 2017 data cut).
Methods: c@h was launched in Jun 2014, and is available to pts 
who are prescribed CZP according to the local product label. Pts 
must	be	CZP-naïve	when	subscribed	to	the	program,	and	pt	consent	
is required prior to subscription by the treating physician. There 
are no additional criteria for enrolment, although the program must 
be recommended to the pt by the treating physician. Pt satisfaction 
across indications (PsA, rheumatoid arthritis and axial spondylo-
arthritis) was measured at program completion or discontinuation 
using the net promoter score (NPS), which has previously been 
used for this purpose.1 The NPS is derived by asking pts to state 
the likelihood that they would recommend c@h to others (on a 
0–10 scale). Rankings of 9–10 are considered ‘promoters’, 7–8 
‘passives’, and 0–6 ‘detractors’. Subtracting the percentage of 
detractors from that of promoters yields the NPS.
Results: A cumulative total of 136 PsA pts had been registered to 
c@h by Sep 2017. Mean age at baseline was 52 years; the majority 
were female (69%). Prior biological DMARD exposure was 24%. 
The most common topics discussed on calls were treatment adhe-
rence (290 calls), CZP maintenance dose (284 calls) and syringe 
disposal (201 calls). The average length per call was 15.7 min 
(SD: 5.33) at the end of Week 0 (total: 135 calls), and 14.6 min 
(SD: 6.59) at the end of Week 52 (45 calls).
Across indications, a cumulative total of 272/655 pts had either 
completed the coaching period (n = 70) or discontinued (n = 202) 
by 28 Sep 2017, of whom 106 rated the program. Of these, 87.5% 
gave promoter scores, 10.4% passive, and 3.8% detractor, yiel-
ding an NPS of 83.7. The program was still ongoing at the time 
of this data cut.
Conclusions: c@h offers support and guidance to CZP-treated pts 
in Germany. Feedback from pts willing to provide a rating (39%) 
indicates a high level of satisfaction with the program.
References:
1. Hamilton DF. Bone Joint J 2014;96-B(5):622–8.
Acknowledgements: c@h is performed by Healthcare@home Deutschland 
GmbH, funded by UCB Pharma, led by Elke Zeise and managed by Karen 
Thiel and Manh Dan Nguyen. We thank the patients and their caregivers 
in addition to the investigators and their teams who contributed to this 
program. Editorial services were provided by Costello Medical. 
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A COMPREHENSIVE SURVEY ASSESSING THE FAMILY 
PLANNING NEEDS OF WOMEN WITH PSORIASIS
Mark Lebwohl1, Abby S Van Voorhees2, Michael Siegel3, Lindsey 
Shankle3, Lisa Pisenti4, Mohamed Yassine4
1Icahn School of Medicine at Mount Sinai, New York, NY, 2Eastern Virginia 
Medical School, Norfolk, VA, 3National Psoriasis Foundation, Portland, 
OR, 4UCB Pharma, Smyrna, GA, USA
Introduction: Psoriasis (PS) in women often overlaps with their 
peak reproductive years. Data on the family planning (FP) ex-
perience of patients (pts) are therefore needed to optimize PS 
management.
Objectives: To report the results of a survey evaluating the FP 
needs of women with PS.
Methods: Women of childbearing potential (WoCP; aged 18–45) 
diagnosed with PS (including pts with psoriatic arthritis), were 
recruited to complete a 96-question web-based survey on Sur-
veyGizmo®.	The	survey	included	questions	on	pts’	experience,	
concerns and educational needs, and was disseminated using e-
blasts (the National Psoriasis Foundation, Advance E-News, and 
TalkPsoriasis.org mailing lists) and social media (Facebook and 
Twitter). Responses were collected Dec 2017–Feb 2018.
Results: Of 141 pts completing the survey, 91 (65%) were plan-
ning to conceive (PTC), and 66 (47%) had experienced pregnancy 
(EP) within the last 5 years. Prescribed systemic medications were 
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being used by 40% of pts PTC and 12% of pts who had EP. Only 
41% pts who had EP informed the healthcare provider (HCP) 
treating their PS of their pregnancy right away, while 21% did 
not notify them at all.
While PTC, most pts who had not EP (88%), sought FP advice from 
the internet; only 21% had consulted the HCP treating their PS, 
compared to 55% of pts who had EP. Of the 96 pts who discussed 
FP with the HCP treating their PS, just 7% said this was initiated by 
the	HCP.	Pts	PTC	were	most	influenced	by	their	personal	network	
(e.g. family), but of pts who had EP, 41% said the HCP treating 
their	PS	was	one	of	the	most	influential	types	of	support	in	their	
FP decisions. Pts reported wanting information on the impact of 
PS	and	treatments	on	their	baby,	the	heritability	of	PS,	and	flare	
management during pregnancy. During pregnancy, 65% pts who 
had EP stopped treatment (of any type), 79% of whom did so out 
of fear of harming their baby. In 40% cases where pts had stopped 
all and any treatment for PSO, the decision was initiated by the pt, 
and in 47%, by their PS treatment provider. Of pts who stopped 
treatment, 44% experienced a worsening in the severity of their 
PS,	 yet	most	 pts	 do/did	not	 have	 a	plan	 for	flare	management	
during pregnancy (PTC: 69%; EP: 65%). Many pts stopping all 
treatment had not been advised on restarting treatment post-partum 
(PTC: 42%; EP: 23%).
Conclusions: Many WoCP with PS take systemic medications but 
many do not discuss FP with their PS treatment provider, and if 
they do, the discussion is rarely initiated by the HCP. PS treatment 
providers should prioritize discussing FP, and plan treatment 
around and during pregnancy. The educational needs of WoCP 
with	PS	include	the	impact	of	treatment	on	their	baby,	flare	ma-
nagement during pregnancy, and restarting treatment post-partum.
Acknowledgements: This study was funded by UCB Pharma. The survey 
was conducted by the National Psoriasis Foundation. We thank the pa-
tients who contributed to this study. Editorial services were provided by 
Costello Medical.
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THE PSYCHOSOCIAL IMPACT OF PSORIASIS: 
DIFFERENTIAL EXPERIENCES OF MEN AND WOMEN 
IN EARLY ADULTHOOD
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2UCB Pharma, Brussels, Belgium, 3Cello Health, London, UK
Introduction: Plaque psoriasis (PSO) can have a profound im-
pact on patients’ (pts’) psychosocial wellbeing, leading to self-
consciousness, embarrassment, depression, social isolation and 
stigmatization. However, little is known of how the impact of 
disease differs between genders. 
Objective:To evaluate differences in the psychosocial impact of 
PSO on quality of life in men and women in early adulthood. 
Methods: Pts	aged	≥18	in	the	US,	Canada,	France,	Germany	and	
Italy without a diagnosis of psoriatic arthritis were invited to 
complete a postal survey (Oct 2016–Jan 2017), in the ratio 3:1 
as being treated with advanced therapy (biologic/apremilast), 
or eligible for but not yet receiving advanced therapy. Answers 
were given on 5- or 7-point Likert Scale. Percentages shown are 
proportions of pts responding using either of the two responses 
indicating greatest impact of disease. Data are presented for pts in 
early	adulthood	(18–45	years),[1]	stratified	by	gender.	
Results: 63 women and 73 men completed the survey; mean age 
was 35 and 36 years, respectively, mean age at diagnosis was 28 for 
both genders. Disease distribution was similar between genders, 
although women reported more severe disease affecting their arms 
and males reported more severe scalp disease. Whilst physical 
impacts of disease were similar ( ≤ 2 pts reported severe problems 
with walking, washing/dressing, carrying out housework/family/
leisure activities or daily work), a higher proportion of women 
(14% vs 4%) reported severe/extreme pain or discomfort. Both 
genders were more concerned by appearance (women: 73%, men: 
63%) than pain (women: 43%, men: 34%). 
A higher proportion of women than men were concerned by their 
appearance (73% vs 63%), reported a greater impact on their 
choice of clothing (37% vs 21%), and always/usually tried to 
cover their skin (27% vs 16%). Similarly, psychosocial effects of 
disease tended to be greater in women: 16% women vs 8% men 
reported severe/extreme anxiety or depression; 29% women vs 
18% men suffered sexually/in achieving intimacy. Similar pro-
portions had suffered at work (women: 11%, men: 16%), while 
a higher proportion of women (6%) than men (3%) struggled to 
live	their	lives	as	they	did	prior	to	their	diagnosis.	These	findings	
have been corroborated by ethnography studies.
Conclusion: Despite similar clinical manifestations of PSO, 
women in early adulthood tended to report a greater impact of 
their disease on their lives, both physically, in terms of pain, and 
psychosocially, in terms of effects on relationships and impact on 
their daily lives. Physician awareness of such gender differences 
in the impact of the disease on patients’ lives would encourage 
a more holistic approach to discussing treatment options with 
their patients.
Reference:
1. A Conception of Adult Development. Daniel J. Levinson. 1986. Ame-
rican Psychologist vol. 41, No. 1, 3-13
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Introduction: Certolizumab pegol (CZP) is an Fc-free, PEGylated, 
anti-TNF biologic. Here we present patient (pt)-reported quality of 
life (QoL), work productivity and social activities over 48 weeks 
of CZP treatment.
Materials/Methods: Data were pooled from CIMPASI-1 
(NCT02326298) and CIMPASI-2 (NCT02326272) phase 3 trials 
of	adults	with	PSO	≥6	months	(psoriasis	area	and	severity	index	
[PASI]	≥12,	affected	body	surface	area	[BSA]	≥10%,	physician’s	
global	assessment	[PGA]	≥3/5).	Pts	were	randomized	to	CZP	400	
mg every 2 weeks (Q2W), CZP 200 mg Q2W (following 400 mg 
loading dose at Weeks 0, 2, 4), or placebo (PBO) Q2W for 16 
weeks. Week 16 CZP-treated PASI 50 responders continued initial 
blinded treatment to Week 48 (PBO-treated PASI 50 responders 
are not included). PASI 50 non-responders at Weeks 32, 40 and 
48 were discontinued.
Mean change from baseline (CFB) in Dermatology Life Quality 
Index (DLQI), rates for DLQI minimally clinically important diffe-
rence	(MCID;	≥4-point	improvement)	and	DLQI	remission	(score	
of 0/1), and CFB in Work Productivity and Activity Impairment 
(WPAI)	PSO-specific	at	Weeks	16	and	48	were	assessed.	Negative	
CFB	 for	DLQI	 and	WPAI	 signifies	 improvement.	CFB	DLQI	
analyses used last observation carried forward (LOCF) imputation 
for missing data, DLQI MCID and remission analyses used non-
responder imputation, WPAI analyses used last observation carried 
forward imputation at Week 16 and observed data at Week 48.
Results: At Week 16, CZP pts showed greater improvements in 
DLQI vs PBO, and higher proportions achieved DLQI MCID and 
DLQI remission (Table). Improvements were maintained to Week 
48 in CZP-treated pts who continued treatment (Table). Improve-
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ments in work productivity and reductions in activity impairment 
were seen with both CZP doses vs PBO; and were maintained to 
Week 48 in patients remaining in the trial. (Table).
Conclusions: Treatment with CZP was associated with improve-
ments in QoL, work productivity and social activities vs PBO at 
Week 16, which was maintained to Week 48 in patients remaining 
in the trials.
Table. Improvements in DLQI and WPAI at Weeks 16 and 48
PBO
(n = 100)
CZP 400 mg Q2W
(n = 175)
CZP 200 mg Q2W
(n = 186)
Week 16 Week 16 Week 48 Week 16 Week 48
DLQI
Mean CFB (SD) -3.1 (6.7) -9.8 (7.0) -10.3 (7.5) -10.0 (8.2) -9.7 (8.4)
MCID, n (%) 41 (41.0) 135 (77.5) 121 (69.1) 131 (70.4) 113 (60.8)
DLQI 0/1, n (%) 7 (7.0) 84 (48.0) 90 (51.4) 87 (46.8) 78 (41.9)
WPAI Domains, mean change from baseline (SD)
Absenteeism 2.9 (22.1) 4.7 (22.7) -0.1 (17.5)
[n = 96]
0.7 (21.7) 2.6 (15.6)
[n = 89]
Presenteeism 0.7 (21.8) -12.9 (25.2) -17.0 (26.1)
[n = 96]
-9.6 (25.3) -9.9 (27.1)
[n = 89]
Work productivity loss 4.8 (28.5) -9.0 (32.7) -16.4 (28.9)
[n = 96]
-9.0 (31.5) -8.0 (30.1)
[n = 89]
Activity impairment -1.5 (25.3) -23.9 (28.3) -28.6 (28.9)
[n = 129]
-21.0 (31.9) -23.9 (29.4)
[n = 132]
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Introduction: The WHO resolution 2014 raised fundamental 
demands for the health care system to increase the awareness for 
patients with chronic skin diseases such as psoriasis, including its 
fight	against	stigmatization.	Single	member	states	were	encouraged	
to take action on all levels, including public awareness campaigns. 
After a period of refusal, the German ministry of health approved 
a project submitted by German dermatologists, patient groups and 
further experts to develop interventions against stigmatization. 
Objectives- Aim of investigation: The project aims to develop and 
evaluate public interventions against stigmatization of people with 
visible skin diseases.
Methods: The project consist of three phases. Within a one-year 
period current research will be processed through a systematic 
literature search; recommendations for intervention formats will 
be derived. The consecutive 18 months involve the development 
of	defined	intervention	formats.	The	interventions	are	supposed	
to focus on locations of stigma and encounters of stigmatizing 
with stigmatized persons.
Results: The application has been approved and is funded by the 
German ministry of health for a period of three years throughout 
the years 2018 to 2021. The project group consists of 25 der-
matology-, science- and patient-experts who work in operative 
groups in order to develop the content and the intervention for-
mat. In doing so, different levels of the stigmatization process, 
namely stereotypes, prejudice, discrimination are considered as 
important aspects and will be accounted for in the development 
of the intervention. First results of the literature review imply that 
people with visible skin disease such as psoriasis are affected by 
stigmatization in several dimensions and strategies for reducing 
the stigma are required.
Conclusion: Following the WHO resolution, this project is an ex-
ample for successful project initiation of an interdisciplinary team 
to develop and implement an intervention against stigmatization. 
First outcomes will be a comprehensive review of papers derived 
from the systematic literature search in May 2018.
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Introduction: The Global Research on the Impact of Dermatolo-
gical	Diseases	(GRIDD)	project	will	be	the	first	global	patient-
initiated and patient-led impact research study in dermatology. 
By including the patient perspective stringently into the burden 
metrics,	this	will	be	the	first	program	to	systematically	challenge	
the current Global Burden of Disease concept, which markedly 
underestimates the patient burden of skin diseases. 
Objective:The objective of the GRIDD research project is to 
develop a comprehensive measure of the impact of living with 
skin diseases instruments by country, regionally and worldwide. 
The global instrument, developed with patient organisations, 
will capture patient experiences, including the extent of disease 
impact and burden for patients and their families, for generic (i.e. 
all	dermatological	diseases)	and	specific	dermatological	disease	
including psoriasis assessment worldwide. 
Materials + Methods: Development of the comprehensive mea-
sure of impact of disease will be based on a novel methodology 
with several phases. Phase 1 will systematically review existing 
measures of the life impact of skin diseases and conduct a patient-
centered	item	identification	exercise.	Phase	2	will	be	informed	by	
Phase 1 data and will focus on instrument development: develop 
the wording for items (i.e. impact categories) and appropriate 
item scaling. This measure will describe the impact on life which 
may include economic; psychological and social impacts. Phase 
3 describes the acquisition of real world data to further test the 
validity and acceptability of the new measure. Lastly, phase 4 and 
5 include dissemination and launch of data, the new measure and 
an implementation strategy to increase uptake of the measure.
Results: GRIDD	has	assembled	a	scientific	advisory	board	repre-
senting different regions worldwide. Currently, we are collabora-
ting with over 100 patient associations in 32 countries worldwide, 
with more than 26 disease areas. Industry funding has been secured 
from	five	different	companies	for	the	first	phase	and	a	portion	of	
phase 2. The GRIDD research team, including researcher from the 
University Medical Center in Hamburg and University of Cardiff, 
met in 2017 to start phases 1 and 2. The systematic literature review 
on “Existing patient-centred outcome measures currently used in 
dermatology” is currently underway.
Conclusion: This novel patient-centric methodology will com-
plement existing concepts of evaluating patient perspective in 
dermatology. GRIDD will provide an extended patient view for 
better decision making in dermatology on a global and country 
level. It supports local, regional and international attempts to create 
awareness, better position psoriasis and other skin diseases and 
encourage decision-makers and stakeholders to include dermato-
logical diseases in their policies. 
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TREATMENT OF NAIL PSORIASIS WITH DIFFE RENT 
PULSE DURATIONS OF PULSED DYE LASER
Mohamad Goldust1, Homan Alipour2
1Mazandaran University of Medical Sciences, 2Tabriz University of Medi-
cal Sciences
Background: There are different treatment modalities for nail 
psoriasis but the treatment of choice is still controversial. Laser 
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therapy opened new windows for treatment of nail psoriasis (1,2).
Objective:The	aim	of	this	study	was	to	evaluate	the	efficacy	of	
different pulse durations in the treatment of nail psoriasis with the 
595-nm PDL to determine the optimal pulse duration.
Methods: In	this	clinical	trial	study,	120	patients	with	bilateral	fing-
ernail psoriasis were evaluated. PDL was applied on the proximal 
and lateral nailfolds based on random assignment. 240 nails were 
treated with 6-millisecond pulse duration and 9 J/cm(2) whereas 
240 nails were treated with 0.45-millisecond pulse duration and 6 J/
cm(2). Nail Psoriasis Severity Index (NAPSI) was used to assess the 
clinical outcome from pretreatment and posttreatment photographs.
Results: After	 6	months	of	first	 treatment,	 there	was	 a	 signifi-
cant reduction in overall NAPSI, nail matrix NAPSI, and nail 
bed NAPSI scores from baseline in both groups; however, no 
significant	difference	was	found	between	the	two	pulse	duration	
groups. Side effects were mild including transient petechiae and 
hyperpigmentation.
Conclusion: PDL was found to be an effective and well-tolerated 
option in the treatment of nail psoriasis. This study demonstrated 
that both the longer 6-millisecond and shorter 0.45-millisecond 
pulses of PDL (595 nm) have been clinically proven to be effective 
for the treatment of nail matrix and nail bed psoriasis.
References:
1. Al-Mutairi N, Nour T, Al-Rqobah D. Onychomycosis in patients of 
nail psoriasis on biologic therapy: a randomized, prospective open label 
study	comparing	Etanercept,	Infliximab	and	Adalimumab.	Expert	Opin	
Biol Ther 2013;13(5):625-629.
2. Radtke MA, Beikert FC, Augustin M. Nail psoriasis - a treatment chal-
lenge. J Dtsch Dermatol Ges 2013;11(3):203-219.
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NEUTROPENIA IN A PSORIASIS PATIENT: SECU­
KINUMAB OR MICRONUTRIENT DEFICIENCY?
Maruska Marovt, Katarina Trcko, Pij B. Marko
University Medical Centre Maribor, Maribor, Slovenia
We report a case of severe neutropenia in a psoriasis patient, which 
developed three months after discontinuation of secukinumab. She 
had gastric bypass surgery a few years ago and was intermittently 
treated	due	to	iron	deficiency	anemia.	According	to	the	suggested	
approach to the adult with unexplained neutropenia (1) a range 
of diagnostic tests were performed and no abnormalities were 
noticed. Neutropenia still persists, however the patient hasn’t 
had any complications. Neutropenia was reported infrequently in 
subjects with moderate to severe psoriasis receiving secukinumab 
in a pooled analysis of 10 phase II and III clinical studies (2). Most 
were grades 1 or 2. Grade 3 neutropenia was uncommon and not 
associated with serious infections, and no grade 4 neutropenia was 
recorded.	Deficiencies	of	dietary	vitamins	and	minerals	typically	
cause neutropenia in association with other cytopenias. Patients 
who have undergone bariatric surgery require lifelong vitamin 
and mineral supplementation. Severe neutropenia in our patient 
could be due to combination of secukinumab and micronutrient 
deficiency,	however	exact	etiology	remains	unclear.
Berliner N (2018). Approach to the adult with unexplained neutropenia. In 
Newburger P (Ed.), UpToDate. Retrieved February 19, 2018, from https://
www.uptodate.com/contents/approach-to-the-adult-with-unexplained-
neutropenia
Van	de	Kerkhof	PC,	Griffiths	CE,	Reich	K,	Leonardi	CL,	Blauvelt	A,	Tsai	
TF, et al. Secukinumab long-term safety experience: A pooled analysis of 10 
phase II and III clinical studies in patients with moderate to severe plaque 
psoriasis. J Am Acad Dermatol 2016 Jul;75(1):83-98.e4. 
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Introduction: Psoriasis is on the indication list for therapy in radon 
galleries (1). Radon is a radioactive noble gas evaporating from 
rocks. It is absorbed through skin or lung epithelium during inha-
lation.	Radon	decays	in	the	tissue	under	emission	of	α-particles.	
The estimated dose received during a radon therapy is in the 
order of 1.2 mSv which corresponds to the annual background 
irradiation	caused	by	radon.	Chronic	inflammatory	diseases	such	
as rheumatoid arthritis are treated with radon and pain reduction 
and improvement of mobility are reported (2). Positive effects 
are also reported for psoriasis, but sparely documented. However, 
for	both	diseases	the	mechanisms	underlying	the	clinical	benefit	
are unknown.
Objectives: To investigate effects of radon treatment we have 
established a cellular model for psoriasis which can be used for 
irradiation	with	α-particles.	The	requirements	in	using	α-particles	
are	specific	due	to	their	short	range.
Methods: Special rings stringed with a 2 µm oxygen plasma 
treated	boPET	foil	are	used	to	facilitate	α-irradiation	and	growth	
of NHEK (normal human epidermal keratinocytes). Cells were 
cultured in rings or culture dishes for 24 hours and induced with 
IL-17,	IL-22	and	TNF-α.	Supernatants	and	cells	for	protein	and	
mRNA extraction were collected 24 hours after induction. ELISA, 
qPCR and Western Blot analysis was performed.
Results: We could show that it is possible to culture primary 
keratinocytes on plasma treated boPET foil with a similar morp-
hology to cells cultured in cell culture dishes. Furthermore, the 
selected	cytokines	are	able	to	significantly	induce	psoriasis-related	
markers like IL-19 and BDEF2 on mRNA level and the release 
of the cytokine IL-6. Testing if culturing of NHEK on the treated 
boPET	foil	alone	has	an	inflammatory	effect	revealed	no	significant	
differences in the expression or release of markers compared to 
cells cultured in cell culture dishes.
Conclusion: We conclude that the plasma treated boPET foil is a 
promising	tool	for	a	setup,	which	enables	α-irradiation	of	mono-
layer cell cultures. The induction of a psoriasis-like phenotype with 
cytokines leads to an enhancement of relevant markers.
References:
Gasteiner Kur- Reha- und Heilstollen-Betriebsges.m.b.H. www.gasteiner-
heilstollen.com
Cucu	et	al;	Front	Immunol.	2017;	8:	882.;	doi:	10.3389/fimmu.2017.00882
This work is supported by the Forschungsinstitut Bad Gastein (FOI-15/08-
031WIE), EURADON, the Radon Gallery of Bad Gastein and GREWIS 
(02NUK017A) 
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THE HISTORY OF PSORIASIS
Selma Poparic
Dermatology Department University Clinical Center of Sarajevo
Many	ancient	texts,	including	the	Bible,	mention	people	afflicted	
with diseases and symptoms very much like psoriasis. Ancient 
Egyptians wrote about a salve made with various herbs that would 
be	spread	on	the	skin,	after	which	the	afflicted	person	would	be	
instructed to sit in the sun to bring relief to symptoms that seem 
to	point	 to	psoriasis.	The	Arabian	physicians	perhaps	first	dis-
tinguished psoriasis from other skin diseases already in the 8th 
century	A.D.,	but	the	first	written	description	of	psoriasis	appears	
during the Roman Empire in the 1st century AD in the books of A. 
Cornelius Celsus » De re medica libri octo». Galen (131–201 AD) 
of	Pergamon,	physician	of	some	Roman	imperators,	was	the	first	
who used the term psoriasis, but only for an itchy, scaly eruption of 
the eyelids and scrotum, that was probably seborrheic dermatitis.
Unfortunately, little was known about the origin of the disease for 
hundreds of years, in the darkness of the Middle Age - a period of 
stagnation, and many psoriasis sufferers were thought at the time 
to have leprosy. Because so little was known about contraction 
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and treatment, psoriasis patients were often separated from the 
general population for fear of them contaminating others. People 
with psoriasis – thousands in medieval Europe – were forced to 
warn others of their arrival by ringing a clapper.
It wasn’t until the early 1800’s that psoriasis was determined to 
be a condition separate from leprosy. In the cultural movement of 
Renaissance some authors mentioned the diseases psora and lepra 
in their books. In the 18th century hospitals or dispensaries were 
opened only for treatment of skin or venereal diseases giving to 
the physicians the opportunity to study more cases of skin diseases 
and psoriasis as well, while the end of the 19th century psoriatic 
micro morphology was already described. In 20th century many 
authors studied the genetic alteration, and today there is undisputed 
evidence that the disease is multifactorial.
Psoriasis,	as	a	common	disease,	has	a	significant	socio-economic	
impact on the individual and on the society. Last decades numerous 
immunological researches accumulate evidence of presence of 
alteration of the innate and adaptive immune response in psoriatic 
patients. This imply a primary disregulation of the immune system 
and permitts a better understanding and new insight in the pathoge-
nesis and as well new possibilities in the management of psoriasis.
This article shows a retrospective view of development of our 
knowledge on psoriasis through history.
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COMORBIDITIES AND TREATMENTS IN PATIENTS 
WITH INVERSE PSORIASIS
Mia Schneeweiss, Joseph Merola
Brigham and Women’s Hospital
Introduction: Inverse (intertriginous) psoriasis is an underdiag-
nosed, often untreated phenotype of psoriasis (PsO) with a high 
burden of illness. Inverse PsO may occur in up to 23% of subjects 
with psoriasis, higher than previously reported.
Objectives: To characterize the frequency of inverse PsO and 
patient characteristics and their treatment in a large commercial 
insurance claims database.
Methods: We used longitudinal claims data from commercially 
insured patients in the US between 10/2015 and 12/2016 to identify 
adults	with	a	diagnosis	of	flexural	psoriasis	(ICD-10-CM:	L40.8,	
“other	psoriasis”	which	is	“recommended	to	be	used	for	flexural	
PsO”) associated with an outpatient or inpatient encounter. A 180-
day	enrollment	period	was	required	before	the	first	diagnosis	of	
AD. Among those diagnosed we computed the risk of initiating 
immunomodulating medications during the following 6 months. 
All analyses were conducted using the Aetion Evidence Platform.
Results: Of 1.5million patients with at least one code for PsO, after 
excluding patients with concomitant other autoimmune conditions, 
we	identified	5,310	patients	with	an	ICD-10	code	of	L40.8	used	for	
inverse PsO (4/1,000) with a median age of 52 years and an equal 
gender distribution. Half of the patients were 41–60 years old.
Of those, 0.3% generalized pustular, 0.5% guttate, and 0.2% 
pustulosis palmaris et plantaris. Prevalent comorbidities included 
depression (7%), anxiety (6.5%), and cardiovascular conditions 
(5%). 20% received antidepressants. Within 180 days after the 
diagnosis	of	flexural	PsO,	81%	were	using	high-potency	topical	
corticosteroids, 66% phototherapy, 8.6% calcipotriene, 5.6% uste-
kinumab, 7.2% methotrexate, 7.3% adalimumab, 3.3% etanercept, 
1.3%	acitretin,	0.8%	infliximab,	0.9%	Cyclosporine,	0.1%	Sulfa-
salazine, 0.02% topical tacrolimus, 0.5% topical pimecrolimus.
In patients 60+, 83% used high-potency topical corticosteroids, 
7.8% phototherapy, 8.8% calcipotriene, 3.1% ustekinumab, 6.9% 
methotrexate, 4.8% adalimumab, 2.9% etanercept, 1.5% acitretin, 
0.5%	infliximab,	0.9%	Cyclosporine,	0.6%	topical	pimecrolimus.
Limitations: Although the ICD-10-CM code L40.8 is recommen-
ded	for	flexural	PsO,	its	sensitivity/specificity	for	validating	cases	
of	flexural	PsO	has	not	been	established,	it	may	not	encompass	
all aspects of inverse/intertiginous disease and the code may be 
highly underutilized.
Conclusions: Using the code ICD-10-CM L40.8, which is re-
commended	to	be	used	for	inverse	“flexural”	PsO	leads	to	lower	
prevalence estimates of inverse PsO than previously reported; 
this underscores the known underreporting and underdiagnosis 
of this condition. Among those patients diagnosed and coded, 
most received topical corticosteroids and/or phototherapy, others 
received calcipotriene, ustekinumab, methotrexate, adalimumab, 
etanercept, and acitretin. Further work is needed to understand 
how	best	 to	capture	 inverse	 (intertriginous)	 /	flexural	psoriasis	
for clinical research work.
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DEVELOPMENT OF THE “PSO SLEEPY­Q” AND 
THE “PSA SLEEPY­Q”: TWO QUESTIONNAIRES 
TO CHARACTERIZE SLEEP IN PATIENTS WITH 
PSORIATIC DISEASE
Lourdes Perez-Chada
Harvard Medical School - Brigham and Women’s Hospital
Introduction: Substantial evidence suggests that psoriasis (PsO) 
and psoriatic arthritis (PsA) are independently associated with 
sleep disturbance, which may result in serious health consequen-
ces including cardiovascular events and mortality. However, the 
validity of the sleep measures used in these studies is unknown 
as they have not been validated in patients with psoriatic disease 
or included psoriatic patients during their development process. 
There	 is	 a	need	 for	validated	disease-specific	Patient-Reported	
Outcome Measures (PROMs) to accurately characterize sleep in 
this population and to measure the effect of psoriatic therapies on 
sleep disturbance. 
Objectives: This study aimed to develop and establish the content 
validity of 2 new sleep PROMs: the “PsO Sleepy-Q” and the 
“PsA Sleepy-Q”.
Methods: Following FDA PROM-development guidance, our 
study: (i)	 hypothesized	 a	 conceptual	 framework	 and	 identified	
domains through literature review and patient semi-structured 
interviews using a saturation model (n = 30); (ii) rated domains 
for importance by patients (n = 42) and an international expert 
panel including dermatologists, rheumatologists and sleep experts 
(n = 45); (iii)	selected	final	domains	based	of	the	patients’	prefe-
rence; (iv) generated item pools and the preliminary versions of 
the instruments. 
Results: Psoriatic patients reported that sleep maintenance, ade-
quacy, quantity and quality were the most important aspects of 
disordered sleep. Regarding causes of disturbed sleep: itch, skin 
and joint pain, stiffness, taking care of psoriatic lesions before 
bedtime, worsening of psoriatic symptoms at night, feeling un-
comfortable in bed due to PsA and sleep apneawere the most out-
standing factors selected. Finally, patients reported that disturbed 
sleep may increase psoriatic signs and symptomsas well as fatigue, 
cognitive impairment and psychological stress. Overall, patients 
with PsA expressed a higher burden of sleep disturbance compared 
to patients with PsO. Preliminary versions of the “PsO Sleepy-
Q” and “PsA Sleepy-Q” including 18 and 24 items, respectively, 
were created. These questionnaires intend to measure the degree 
of sleep disturbance, the potential causes of sleep disturbance and 
the impairment related to sleep disturbance.
Conclusion: This study establishes the content validity of the “PsO 
Sleepy-Q” and “PsA Sleepy-Q”, two patient-derived PROMs to 
characterize sleep in patients with psoriatic disease in research 
and clinical settings. These questionnaires will undergo cognitive 
debriefing	 and	 further	 psychometric	 testing	 to	 define	 the	final	
instrument forms.
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UNSTABLE FORMS OF PSORIASIS – INDICATOR OF AN 
INTERMEDIATE STATE OF SYSTEMIC DISEASE
Florentina-Silvia Delli
State Hospital for Skin and Venereal Diseases - Hippokratia General Hos-
pital, Thessaloniki, Greece
Introduction: Erytrodermic psoriasis, inverse psoriasis and gene-
ralized pustular psoriasis are considered three particular clinical 
forms of psoriasis.
Objectives: We present two clinical cases in which it is discussed 
the possibility of considering these clinical pictures as a manifesta-
tion of the immunological switch of psoriasis from an organ-target 
(skin or joint) disease, to a systemic form of psoriasis.
Methods: A 22-year-old-man with erythodermic psoriasis and a 
history of inverse psoriasis since childhood was successfully trea-
ted with 60 mg acitretin, until the diagnosis of psoriatic arthritis at 
the age of 26. The presence of arthritis determined us to change the 
therapy. Secukinumab at the classic therapeutic scheme is keeping 
the patient’s skin clean of psoriatic lesions, except from the arm-
pits, and without any arthritic symptoms. A 75-year-old-woman 
with psoriatic arthritis and hyperkeratotic palms and soles non-
specific	lesions,	under	infliximab	therapy	presented	generalized	
pustular psoriasis. After 3 months of acitretin 40mg and etanercept 
at the classic dose, the patient remains free of any symptoms. 
Conclusions: The majority of psoriasis studies focus on chronic 
plaque psoriasis. We sustain the opinion that the above unstable 
forms of psoriasis, usually impossible to diagnose by other spe-
cialities than Dermatology, should be consider the main step in 
multidisciplinary approach of psoriasis as a systemic disease.
References: 
1.Kivelevitch D et al. Pharmacotheraputic approaches for treating pso-
riasis	 in	 difficult-to	 treat	 areas.	ExpertOpinPharmacother	 2018	April;	
19(6); 561-575
2.Sano S et al. Guselkumab, a human interleukin-23 monoclonal antibody 
in	Japanise	patients	with	generalized	pustular	psoriasis:	efficacy	and	safety	
analyses of a 52-week, phase 3, multicentre, open-label study. JDermatol 
2018 May; 45(5): 529-539
3.Cafaro	G,	McInnes	IB.	Psoriatic	arthritis:	tissue-directed	inflammation?	
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COULD BIOLOGICAL AGENTS FOSTER SUICIDE 
THROUGH ITS POTENTIAL ANTIDEPRESSANT 
MECHANISM? A PSYCHODERMATOLOGICAL 
APPROACH
Estela M Malatesta
Dermatologist and Psychiatrist, Doctor. Arturo Ameghino Mental Health 
Centre, Buenos Aires, Argentina. President of ADEPSI, Academy of Der-
matology and Psychiatry
Introduction: Depression and Psoriasis are associated in up to 
60% of the cases, with an increased risk of attempted and com-
pleted suicide in patients with severe forms of the disease. Bipolar 
Disorder is a biological condition that affects between 2 and 5% 
of the population, being an important cause of disability in the 
world. In spite of this, Bipolar Disorder is often underdiagnosed as 
Unipolar Depression, which increases the possibility of prescribing 
errors, as it occurs when administering only antidepressant agents 
without accompanying them with mood stabilizers, fostering the 
appearance of episodes of inverse polarity (SWITCHING) which, 
in turn, raises the risk of suicide.
Objectives: The “Cytokine Hypothesis” as a cause of depression 
suggests the association between the immune system and depres-
sion through the induction of the indolamine 2, 3- dioxygenase 
enzyme. The objectives of the poster are:
•	To	raise	the	need	for	new	studies	to	confirm	this	hypothesis	as	
well as the antidepressant effect of biological agents and their 
potential ability to cause a shift into mania.
•	To	deepen	the	criteria	for	patient	selection	for	both	scientific	and	
therapeutic protocols.
Methods: This poster reviews the literature for evidence that while 
biological agents could improve the mood of patients with psoriasis 
treated with these drugs, this same favourable antidepressant effect 
on humor may trigger a switch of mood into mania, favouring 
attempted and completed suicide in undiagnosed bipolar patients 
treated for psoriasis with IL17-TNF alpha cytokine blockers.
Results:	Evidence	gathered	so	far	suggests	that	common	inflam-
matory processes could underpin both bipolar and psoriasis. 
The current literature is lacking of longitudinal and mechanistic 
studies, as well as comparison studies to explore the magnitude 
of this relation.
Conclusion: Considering both bipolar disorder and psoriasis as a 
multi-system disorder should help us understand the common phy-
siopathology of this comorbidity so as not to see them as separated 
disorders. Consequently, it is vital to emphasize the importance of 
the initial psychiatric evaluation for a correct psychiatric/ clinical 
diagnosis for patients with Psoriasis to be both admitted to a strict 
control protocol and treated with biological agents.
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TREATING THE PAIN, NOT THE PROBLEM? RESULTS 
FROM A SWEDISH ONLINE SURVEY ON PSORIATIC 
ARTHRITIS AND PSORIASIS WITH JOINT PAIN
T Norgren, B Bohannan
Psoriasisförbundet, Stockholm, Sweden
Introduction: Psoriatic	arthritis	(PsA)	is	a	chronic	inflammatory	
disease associated with psoriasis, that can cause pain, swelling and, 
if untreated, severe joint destruction and disability. The knowledge 
about PsA among both the public and healthcare providers is limi-
ted, leading to both underdiagnosis and undertreatment. To raise 
awareness of PsA and gather relevant data, the Swedish Psoriasis 
Association (Psoriasisförbundet) and the Swedish Rheumatism 
Association (Reumatikerförbundet) initiated an educational 
awareness campaign on a well-visited online health information 
platform, which also featured a survey on healthcare experiences 
and Quality of Life.
Objectives: The purpose of the survey was to identify gaps or 
discrepancies in the healthcare provided for individuals diagnosed 
with PsA and for individuals with psoriasis and joint pain consis-
tent with a PsA diagnosis, as well as understanding the impact on 
QoL for both groups.
Methods: The survey consisted of two questionnaires, one for 
individuals diagnosed with PsA, group A, and one for individu-
als diagnosed with psoriasis who have joint pain consistent with 
a PsA diagnosis (using CASPAR criteria as reference), group 
B. The survey was open from April 6 2017 to March 31 2018. 
The total number of respondents in group A was 5 201, and in 
group B 11 272. It was not mandatory to answer all questions 
in the survey. One section of the survey focussed on prescribed 
medication,	to	specifically	identify	discrepancies	in	the	treatment	
of the diagnosed (A) and undiagnosed (B) groups. Limitations: 
self-reported diagnosis, possible to take survey multiple times 
using different devices.
Results: In response to the question “Which medication has been 
prescribed for your joint pain during the past year?” 23.91% of 
group B (214 of 895) answered that they had been prescribed 
opioid pain medication for their joint pain. In group A only 4.61% 
of the respondents (73 out of 1 582) were prescribed opioid pain 
medication for their PsA.
Conclusions: The results show a large discrepancy between the 
groups in the prescription of opioid pain medication. The results 
suggest that individuals with psoriasis that have joint pain con-
sistent with a PsA diagnosis are being over-prescribed potentially 
addictive pain medication rather than receiving treatment for their 
underlying	condition	or	inflammatory	symptoms	apart	from	pain.	
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As early diagnosis and effective treatment is vital to slow down 
disease progression, individuals with psoriasis as well as healt-
hcare providers need to be educated on symptoms and diagnosis 
criteria of PsA to prevent undertreatment or treatment that may 
even be harmful.
Disclosure: Project platform and consultancy services were provided 
by health portal company Netdoktor. The project received funding from 
Novartis.
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AN INTERNATIONAL DELPHI SURVEY TO DEFINE 
SCREENING FOR PSORIATIC ARTHRITIS AND 
MEASUREMENT OF PSORIATIC ARTHRITIS 
SYMPTOMS IN PSORIASIS CLINICAL TRIALS
Lourdes Perez Chada
Harvard Medical School-Brigham and Women’s Hospital
Introduction: The International Dermatology Outcome Measures 
(IDEOM) group was established to standardize patient-centered 
outcome measures to improve the assessment of treatment respon-
se	and	disease	course	in	dermatology.	To	define	the	measurement	
set	for	psoriasis,	IDEOM	has	initially	defined	a	set	of	domains	to	
be measured in all psoriasis clinical trials representing a “Core Do-
main Set”. “Psoriatic arthritis (PsA) Symptoms” is part of this set.
Objectives: To achieve consensus on whether patients enrolling 
in	a	psoriasis	clinical	trial	should	first	be	screened	for	PsA	and	
then with which measure their PsA symptoms should be assessed.
Methods: Following the OMERACT (Outcome Measures in 
Rheumatology) Filter 2.0, the COSMIN guidelines, and based 
upon the feedback from a consensus meeting held at the IDEOM 
2017 Annual Meeting, we conducted an international, multidisci-
plinary and multi-stakeholder on-line Delphi survey. The survey 
was organized into 3 parts in which participants were asked to 
(1) vote on the role of PsA screening in psoriasis trials, (2) vote 
on the quality (measurement properties) of 4 patient-reported 
instruments: Patient Global (PG)-arthritis associated to a pain 
assessment tool, PG-Psoriatic Arthritis (PG-PsA) associated to a 
pain assessment tool, Routine Assessment of Patient Index Data-3 
(RAPID3), and Psoriatic Arthritis Impact of Disease 9 (PsAID9), 
and (3) rank these instruments in order of importance. Additionally, 
respondents were invited to provide feedback on the survey.
Results: A total of n = 293, n = 233 and n = 218 subjects completed 
the PsA screening, instrument quality assessment, and ranking 
sections of the survey, respectively. The group was comprised of 
rheumatologists (44.5%), dermatologists (26%), patients (7.5%), 
industry partners (8.9%), dermatologist-rheumatologists (5.1%), 
and patient association representatives (3.4%). Results showed that 
90%of participants agreed that all patients enrolling in a psoriasis 
trial should be screened for PsA. Regarding the quality of the 
instruments,	only	the	PsAID9reached	the	pre-specified	endpoint	
of  > 70% with agreement that the instrument has good-to-excellent 
validity, feasibility, reliability and responsiveness;  < 15% agreed 
that the quality of the instrument is poor or that there is not enough 
information to make an informed decision. In the ranking exercise, 
PsAID9	was	the	first	choice(voted	by	48%	of	respondents)	and	
RAPID3 represented an acceptable alternative second choice 
(voted by 33% of respondents).
Conclusion: In this Delphi study, most participants agreed that all 
psoriasis trial participants should be screened for PsA. Regarding 
the measurement set for “PsA Symptoms”, PsAID9 was selected 
as the most appropriate measure, while RAPID3 could be an ac-
ceptable alternative to PsAID9. This will be followed by a work-
shop at the IDEOM and GRAPPA 2018 annual meetings to review 
discussion points as well as any need for a second Delphi round. 
P155
THE IMPACT OF A DIAGNOSIS ON THE PATIENTS’ 
PERCEPTION OF TREATMENT AND CARE. RESULTS 
FROM AN ONLINE SURVEY ON PSORIATIC ARTHRITIS 
AND PSORIASIS WITH JOINT PAIN
T Norgren, B Bohannan
Psoriasisförbundet, Stockholm, Sweden
Introduction: Psoriatic	arthritis	(PsA)	is	a	chronic	inflammatory	
joint disease that, if untreated, can cause joint destruction and disa-
bility. The knowledge about PsA among both public and healthcare 
providers is limited, leading to underdiagnosis and undertreatment. 
To raise awareness of PsA and gather relevant data, the Swedish 
Psoriasis Association and the Swedish Rheumatism Association 
initiated a web-based educational campaign which also featured 
a survey on healthcare experiences and Quality of Life.
Objectives: The purpose of the survey was to identify the gaps in 
the healthcare provided for individuals diagnosed with PsA and 
individuals with psoriasis and joint pain consistent with a PsA diag-
nosis, as well as understanding the impact on QoL for both groups.
Method: The survey consisted of two questionnaires, one for 
individuals diagnosed with PsA, group A, and one for individuals 
diagnosed with psoriasis who have joint pain consistent with a PsA 
diagnosis (using CASPAR criteria), group B. The survey was open 
from April 6 2017 to March 31 2018. One section of the survey 
focussed on time to diagnosis and perception of healthcare. Limi-
tations: self-reported diagnosis, possible to take survey multiple 
times using different devices.
Results: Both groups had seen multiple doctors for their joint 
pain. In group A 60% (n = 1 132) had seen  > 4 doctors, with 11% 
reporting having seen  > 10. In group B 52.5% (n = 824) had 
seen  > 4 doctors, with 8% having seen  > 10. In group A nearly 
51% (n = 1 211) reported having had joint pain/symptoms for at 
least 1 year before receiving a diagnosis, with 12% waiting  > 10 
years. In group B 91% (n = 1 872) reported having had joint pain/
symptoms for at least 1 year, with 35% at  > 10 years.
Perception of healthcare differed greatly between the groups. In 
group A over half (n = 1 273) reported that their perception of 
healthcare improved or improved greatly after receiving their 
PsA diagnosis. In group B nearly 78% (n = 1 227) reported be-
ing	dissatisfied	or	 very	dissatisfied	with	 the	 care	 they	 receive. 
Conclusions: The results show that the group with a PsA diagnosis 
have a much more positive perception of the treatment and care 
they receive than the group without a diagnosis. Interestingly, in 
another part of the survey group B reported their psoriasis having a 
low to medium impact on their lives, indicating that their psoriasis 
may be mild enough to be treated in a primary care setting only. 
In the past few years there have been extensive efforts put into 
educating Swedish dermatologists on recognizing early signs of 
PsA, but steps should also be taken to raise awareness of psoriasis-
associated joint pain among general practitioners to ensure timely 
referral to specialist care.
Disclosure: Project platform and consultancy services were provided 
by health portal company Netdoktor. The project received funding from 
Novartis.
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